




CPDD 79th Annual Scientific Meeting Program

June 17-22, 2017

**HÔTEL BONAVENTURE
Montréal, Canada**





BOARD OF DIRECTORS

Leonard Howell, PhD, President
Sandra D. Comer, PhD, Past-President
Alan J. Budney, PhD, President-Elect
Linda B. Cottler, PhD, MPH, Treasurer
Patrick M. Beardsley, PhD
Jack Bergman, PhD
Kathleen M. Carroll, PhD
Marilyn E. Carroll, PhD
Howard D. Chilcoat, ScD
Timothy P. Condon, PhD

Toby K. Eisenstein, PhD
Margaret Haney, PhD
Sarah H. Heil, PhD
Marc J. Kaufman, PhD
Charles O’Keeffe, MBA
Thomas E. Prisinzano, PhD
Beatriz Rocha, MD, PhD
William Stoops, PhD
Jennifer Tidey, PhD
Elise Weerts, PhD

EXECUTIVE OFFICER

Loretta P. Finnegan, MD

DIRECTOR, EXECUTIVE OFFICE

Ellen B. Geller, MA

SCIENTIFIC PROGRAM COMMITTEE

William W. Stoops, PhD, Chair
Elise Weerts, PhD, Past Chair
Kelly Dunn, PhD
Michael Bardo, PhD
Ziva Cooper, PhD
Matthew W. Johnson, PhD
R. Kathryn McHugh, PhD
Howard D. Chilcoat, ScD
Danielle E. Ramo, PhD
Teresa Franklin, PhD
Sterling McPherson, PhD
Kevin B. Freeman, PhD
Loretta P. Finnegan, MD, ex officio
Ellen B. Geller, MA, ex officio

PRE- MEETING SATELLITES

10th Annual International Women's and Children's Health and Gender Group Conference
Chaired by Wendee Wechsberg

Friday, June 16, 2017
Fontaine A&B
9:00 AM – 5:30 PM

The 2017 NIDA International Forum: Building International Collaborative Research on Drug Abuse

- NIDA – Drug Flows Research Consortium
- NIDA-Special Issues Group Meeting
- NIDA-ISAJE Workshop & NIDA International Networking Session
- NIDA International Plenary

Friday, June 16, 2017
Montreal Ballroom – Verdun
1:45 PM – 3:45 PM

Friday, June 16, 2017
**Montreal Ballroom-
Mont-Royal**
3:00 PM – 5:00 PM

Friday, June 16, 2017
**Montreal Ballroom –
Lachine/Lasalle**
4:00 PM – 8:00 PM

Saturday, June 17, 2017
**Montreal Ballroom –
Westmount&Outremont**
8:30 AM – 4:45 PM

The International Study Group Investigating Drugs as Reinforcers (ISGIDAR)
Chaired by Mark Smith

Saturday, June 17, 2017
Montreal Ballroom – Verdun
8:00 AM – 5:00 PM

Saturday, June 17, 2017

REGISTRATION

Bottom of
escalator
1:00 - 5:30 PM

NIDA GRANT-WRITING (Pre-Registrants Only)

Fontaine A & B
1:00 - 5:30 PM

OPENING RECEPTION

Salon Bonaventure &
Ville-Marie
7:00 - 9:00 PM

Sunday, June 18, 2017

Plenary Program

Montreal Ballroom
8:30 - 11:30 AM

- 8:30 *Welcome*
 CPDD President Leonard Howell
- 8:40 *Report from the National Institute on Drug Abuse: Drug Abuse and Addiction
 Research: Progress, Priorities and Challenges*
 Nora D. Volkow, Director, NIDA
- 9:10 *Report from the National Institute on Alcohol Abuse and Alcoholism: NIAAA Update:
 Priorities Going Forward*
 George F. Koob, Director, NIAAA
- 9:40 *Presentation of the Stephen G. Holtzman Travel Award for Preclinical Investigators to
 Jibran Y. Khokhar*
 Introduction by Alan Budney
- 9:50 *Presentation of the CPDD/NIDA Media Award to Sam Quinones*
 Introduction by Meg Chisolm
- 10:05 *Presentation of the Joseph Cochin Young Investigator Award to Matthew Banks*
 Introduction by Steve Negus
- 10:15 *Presentation of the Mentorship Award to Stephen T. Higgins*
 Introduction by Alan J. Budney
- 10:25 *Presentation of the Nathan B. Eddy Award to Walter Ling*
 Introduction by Peggy Compton
- 10:40 *Nathan B. Eddy Lecture: Accidents and Angels: The Man Who Got His Life Philosophy
 from a Bottle Cap*
 Walter Ling, UCLA

Sunday, June 18, 2017

**CPDD Early Career Travel Awards
Luncheon**

(By Invitation Only)

**Salon Ville-Marie
11:30 - 1:00 PM**

President's Symposium

**Westmount/Outremont
1:00 - 2:30 PM**

**ENHANCING RESEARCH ON CONTROLLED
SUBSTANCES**

- 1:00 *Introduction*
 Leonard Howell, President of CPDD
- 1:05 William Dewey
 Public Policy Officer of CPDD
- 1:10 *Perspective from NIDA*
 Susan Weiss, Director of the Division of Extramural Research, NIDA, NIH,
 Rockville, MD
- 1:15 *Perspective from FDA*
 Dominic Chiapperino, Lead Chemist, FDA, Silver Spring, MD
- 1:20 *Perspective from DEA*
 Terrence Boos, Deputy Section Chief, DEA, Springfield, VA
- 1:25 *Perspective from a researcher*
 Martin W. Adler, Center for Substance Abuse Research, Lewis Katz School of
 Medicine at Temple University, Philadelphia, PA
- 1:30 *Questions and comments from audience*

Oral Communications 1

**Mont-Royal
2:45 - 4:45 PM**

**DISPARITÉS EN MATIÈRE DE SANTÉ:
HEALTH DISPARITIES**

Chairs: Qiana Brown and Anna Pagano

- 2:45 *The use of the Black Church to improve treatment access for Blacks with SUD*
 A. Jordan, Yale University, New Haven, CT
- 3:00 *Exploring factors related to uptake of oral pre-exposure prophylaxis among Black women
 with substance use problems*
 Keosha Bond¹, Alana Gunn², Porche Williams³, ¹NYU Rory Meyers College of Nursing,
 New York, NY, ²Binghamton University, Binghamton, NY, ³National Development and
 Research Institute, Inc., New York, NY
- 3:15 *Model minorities? Asian-American trauma and drug use*
 Tanya Saraiya¹, Denise Hien², Aimee Campbell³, ¹TRACC Program, Brooklyn,
 NY, ²Adelphi University, Garden City, NY, ³Columbia University and NYSPI, New York,
 NY

Sunday, June 18, 2017

- 3:30 *Prenatal marijuana use, psychiatric comorbidity, and vulnerable populations in the U.S.*
Qiana Brown¹, Aaron Sarvet², Deborah Hasin², ¹Columbia University Mailman School of Public Health, Newark, NJ, ²Columbia University, New York, NY
- 3:45 *Cannabis motives and social anxiety: Effects of race and gender in cannabis use and problems among young adults*
Dawn Foster¹, Ecker Anthony², Kraus Shane³, Stephanie O'Malley⁴, Kristin Dukes⁵, Gretchen Blycker⁶, Carolyn Sartor⁴, ¹Yale University, New Haven, CT, ²Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX, ³Edith Nourse Rogers Memorial Veterans Hospital, Bedford, MA, ⁴Yale School of Medicine, New Haven, CT, ⁵Simmons College, Boston, MA, ⁶University of Rhode Island, Kingston, RI
- 4:00 *Predictors of smoking behaviors among Latinos in substance abuse treatment*
Anna Pagano¹, Noah Gubner², Thao Le², Barbara Tajima³, Joseph Gudyish², ¹Prevention Research Center, Oakland, CA, ²UCSF, San Francisco, CA, ³UCSF, San Francisco, CA
- 4:15 *Cultural predictors of intimate partner violence perpetration and victimization in Latino emerging adults*
Carolina Villamil Grest¹, Hortensia Amaro², Jennifer Unger¹, ¹University of Southern California, Los Angeles, CA, ²ISC School of Social Work, Los Angeles, CA
- 4:30 *Racial and ethnic disparities in opioid agonist treatment for opioid use disorder in a U.S. national sample*
Noa Krawczyk¹, Kenneth Feder², Brendan Saloner², ¹Johns Hopkins Bloomberg School of Public Health, Department of Mental Health, Baltimore, MD, ²Johns Hopkins Bloomberg School of Public Health, Baltimore, MD

Oral Communications 2

Verdun
2:45 - 4:45 PM

THE ODD COUPLE: DRUG INTERACTIONS

Chairs: Sally Huskinson and Emily Jutkiewicz

- 2:45 *Ethanol reversal of prescription opioid tolerance*
Jacy Jacob¹, Hamid Akbarali¹, Graeme Henderson², William Dewey¹, ¹Virginia Commonwealth University, Richmond, VA, ²University of Bristol, Bristol, UK
- 3:00 *A sex comparison of morphine and delta-9-tetrahydrocannabinol interactions on inflammatory pain in rats*
Stevie Britch¹, Carlie Knox¹, Jenny Wiley², Rebecca Craft¹, ¹Washington State University, Pullman, WA, ²RTI International, Research Triangle Park, NC
- 3:15 *Adolescent delta(9)-tetrahydrocannabinol exposure enhances sensitivity to the reinforcing effects of cocaine*
Emily Jutkiewicz¹, Amy Friedman², ¹University of Michigan, Ann Arbor, MI, ²Wayne State University, Detroit, MI
- 3:30 *Abuse-related effects of mixtures of cocaine and caffeine in rats*
Brenda Gannon¹, Kayla Galindo¹, Melson Mesmin¹, Kenner Rice², Gregory Collins³, ¹University of Texas Health Science Center at San Antonio, San Antonio, TX, ²NIH, NIDA, Rockville, MD, ³University of Texas Health Science Center, San Antonio, TX

- 3:45 *Endorsing cannabis as drug of choice is associated with increased use of other illicit drugs: A longitudinal analysis*
Jesse Hinckley¹, Christian Hopfer², Michael Stallings³, John Hewitt³, Susan Young¹, ¹University of Colorado School of Medicine, Department of Psychiatry, Aurora, CO, ²University of Colorado School of Medicine, Aurora, CO, ³University of Colorado, Denver, CO
- 4:00 *Self-administration of benzodiazepine and cocaine combinations by monkeys in a choice procedure: Role of GABA-A receptor subtypes*
Sally Huskinson¹, Kevin Freeman¹, James Rowlett¹, ¹University of Mississippi Medical Center, Jackson, MS
- 4:15 *Cannabinoid modulation of the analgesic effects of opioids in humans*
Shanna Babalonis¹, Michelle Lofwall², Paul Sloan¹, Paul Nuzzo¹, Laura Fanucchi¹, Sharon Walsh¹, ¹University of Kentucky, Lexington, KY, ²University of Kentucky College of Medicine, Lexington, KY
- 4:30 *The influence of mentholation on usual brand and research cigarettes of varying nicotine content in vulnerable populations*
Danielle Davis¹, Cecilia Bergeria¹, Joanna Streck², Janice Bunn¹, Diann Gaalema³, Sarah Heil¹, Stacey Sigmon¹, Maxine Stitzer⁴, Jennifer Tidey⁵, Stephen Higgins¹, ¹University of Vermont, Burlington, VT, ²Vermont Center on Behavior and Health, Burlington, VT, ³University of Vermont UHC Campus, Burlington, VT, ⁴Johns Hopkins Bayview Medical Center, Baltimore, MD, ⁵Brown University School of Medicine, Providence, RI

Symposium I

**Westmount
2:45 - 4:45 PM**

WHAT IS THE ROLE OF SLEEP IN SUBSTANCE USE? EVIDENCE FROM STUDIES OF CANNABIS, ALCOHOL AND OPIOID USE

Chairs: Patrick Finan and Brant Hasler

- 2:45 *Mechanisms of sleep disturbance in individuals with opioid use disorder*
P. Finan, Johns Hopkins University, Baltimore, MD
- 3:10 *Sleep and circadian function in adolescents and young adults who use alcohol*
B. Hasler, University of Pittsburgh, Pittsburgh, PA
- 3:35 *Subjective and objective assessment of sleep in treatment-seeking cannabis users*
D. Lee, Johns Hopkins Medicine, Lexington, KY
- 4:00 *Sleep and substance use: Effects at varying frequencies of use among cannabis and alcohol users*
D. Conroy, University of Michigan, Ann Arbor, MI
- 4:25 *DISCUSSANT: Methodological considerations in sleep research among individuals with substance use disorder*
P. Morgan, Yale School of Medicine, New Haven, CT

Symposium II

Outremont
2:45 - 4:45 PM

TRANSLATIONAL APPROACHES TO UNCOVERING THE MECHANISMS UNDERLYING NEONATAL ABSTINENCE SYNDROME

Chairs: Lisa Brents and Jessica Coker

- 2:45 *The impact of antenatal buprenorphine use on fetal neurobehavioral profile, obstetrical course, and neonatal outcome*
J. Coker, University of Arkansas for Medical Sciences, Little Rock, AR
- 3:10 *The genetics and epigenetics of neonatal abstinence syndrome*
D. Nielsen, Baylor College of Medicine, Houston, TX
- 3:35 *Opioid addiction treatments during pregnancy and their potential effects on glial cell development and brain myelination*
C. Sato-Bigbee, Virginia Commonwealth University, Richmond, VA
- 4:00 *Preclinical modeling of opioid addiction during pregnancy using self-administration*
E. Byrne, Treatment Research Institute, Philadelphia, PA
- 4:25 *DISCUSSANT: Clinical and basic science partnerships: The key to future therapeutic breakthroughs in NAS research*
L. Brents, University of Arkansas for Medical Sciences, Little Rock, AR

Oral Communications 3

Outremont
5:00 - 6:00 PM

TRANSLATIONAL KAPPA-TILIZATION

Chairs: Drew Townsend and Thomas Prisinzano

- 5:00 *Development of salvinorin A-based kappa opioid receptor agonists for drug abuse therapy*
Rachel Crowley¹, Thomas Prisinzano², ¹University of Kansas, Lawrence, KS, ²University of Kansas School of Pharmacy, Lawrence, KS
- 5:15 *Analgesic effects of kappa opioid receptor agonist 16-ethynyl Salvinorin A in mice*
Kelly Paton¹, Samuel Williamson², Thomas Prisinzano³, Bronwyn Kivell¹, ¹Victoria University of Wellington, Wellington, New Zealand, ²University of Kansas, Department of Medicinal Chemistry, Lawrence, KS, ³University of Kansas School of Pharmacy, Lawrence, KS

Sunday, June 18, 2017

- 5:30 *Effects of nalfurafine on oxycodone reinforcement and thermal antinociception: Modeling a candidate abuse-deterrent opioid analgesic in male rats*
Drew Townsend¹, Jennifer Naylor², S. Stevens Negus³, Shelley Rae Edwards⁴, Hina Qureshi⁴, Hunter McLendon¹, Christopher McCurdy⁵, Kenneth Sufka⁵, Kevin Freeman¹, ¹University of Mississippi Medical Center, Jackson, MS, ²U.S. Food and Drug Administration, Silver Spring, MD, ³Virginia Commonwealth University, Richmond, VA, ⁴Millsaps College, Jackson, MS, ⁵University of Mississippi, Mississippi, MS
- 5:45 *A randomized, double-blind, placebo-controlled study of the selective kappa opioid receptor antagonist, cerc 501, in a human laboratory model of smoking behavior*
Jermaine Jones¹, Sandra Comer², Sharon Walsh³, Shanna Babalonis³, Brad Vince⁴, Suky Martinez⁵, Michelle Lofwall⁶, Debra Kelsh, Eileen McNulty⁷, Heather Fraser⁷, Ronald Marcus⁷, ¹Columbia University College of Physicians and Surgeons, New York, NY, ²Columbia University and NYSPI, New York, NY, ³University of Kentucky, Lexington, KY, ⁴Vince and Associates, Malvern, PA, ⁵Columbia University Medical Center, New York State Psychiatric Institute, New York, NY, ⁶University of Kentucky College of Medicine, Lexington, KY, ⁷Cerecor, Inc., Baltimore, MD

Oral Communications 4

**Mont-Royal
5:00 - 6:00 PM**

FEEDING FRENZY: DIET AND DRUGS

Chairs: Amanda Price and Eric Strain

- 5:00 *DREADD-induced activation of the insular cortex suppresses high fat food intake in a binge eating disorder paradigm*
Amanda Price¹, Sonja Stutz¹, Noelle Anastasio¹, Kathryn Cunningham¹, ¹University of Texas Medical Branch, Galveston, TX
- The role of the serotonin 5-HT_{2C} receptor in compulsive and addictive behaviors*
Maylen Perez Diaz¹, Leonard Howell¹, Mark Wilson², ¹Emory University, Atlanta, GA, ²Yerkes National Primate Research Center, Atlanta, GA
- 5:30 *Escalated intake of palatable food in rats with intermittent, extended access is associated with high corticotropin-releasing factor mRNA neuronal density in the ventral tegmental area*
Alison Kreisler¹, Candice Contet², Daniella Walter², Eric Zorrilla², ¹The Scripps Research Institute, La Jolla, CA, ²Scripps Research Institute, La Jolla, CA
- 5:45 *An exploration of the effect of acute morphine administration on taste acuity and feeding behavior*
Denis Antoine¹, Eric Strain¹, ¹Johns Hopkins University School of Medicine, Baltimore, MD

Sunday, June 18, 2017

Oral Communications 5

**Verdun
5:00 - 6:00 PM**

TECHNIQUES DE PSYCHOMÉTRIQUE

Chairs: Paul VanVeldhuisen and Lorra Garey

- 5:00 *Test characteristics of a 4-item screening instrument for non-alcohol substance use disorders in trauma inpatients*
David Gorelick¹, Zachary Dezman², Carl Soderstrom², ¹University of Maryland, College Park, MD, ²University of Maryland School of Medicine, Baltimore, MD
- 5:15 *Smoking consequences questionnaire: A reevaluation of the psychometric properties across two independent samples of smokers*
Lorra Garey¹, Kara Manning¹, Charles Jardin¹, Adam Leventhal², Matthew Stone², Amanda Raines³, Raina Pang², Clayton Neighbors¹, Norman Schmidt³, Michael Zvolensky¹, ¹University of Houston, Houston, TX, ²University of Southern California, Los Angeles, CA, ³Florida State University, Tallahassee, FL
- 5:30 *Concordance of tobacco, alcohol, prescription medications, and substance use tool for unhealthy substance use with timeline follow back*
Paul VanVeldhuisen¹, Gaurav Sharma¹, Jennifer McNeely², Robert Schwartz³, Li-Tzy Wu⁴, Geetha Subramaniam⁵, Jacqueline King¹, Aimee Wahle¹, ¹The Emmes Corporation, Rockville, MD, ²New York University School of Medicine, New York, NY, ³Friends Research Institute, Baltimore, MD, ⁴Duke University School of Medicine, Durham, NC, ⁵NIDA, Bethesda, MD
- 5:45 *Development of short, fixed forms of the IRT-based CAT versions of the seven ASI-MV® domains*
Stacey McCaffrey¹, Stephen Butler¹, Ryan Black¹, ¹Inflexxion, Inc, Waltham, MA

Sunday, June 18, 2017

Symposium III

**Westmount
5:00 - 6:00 PM**

DARK MINDS: NEURAL AND BIOBEHAVIORAL SUBSTRATES OF NEGATIVE AFFECT REGULATION IN ADDICTION

Chairs: Sarah Yip and Lora Cope

- 5:00 *Stress and negative emotion regulation in youth: FMRI findings from substance and behavioral addictions*
 S. Yip, Yale University, New Haven, CT
- 5:20 *Neural responses to negative affective cues in relation to future cannabis-use, negative emotionality and binge-drinking*
 J. Hardee, University of Michigan, Ann Arbor, MI
- 5:40 *Cognitive and emotion regulation in early abstinence from cocaine: A potential target for medication development*
 H. Fox, Stonybrook University, Department of Psychiatry, Stony Brook, NY

Workshop I

**Westmount
7:00 - 9:00 PM**

BIG DATA: ETHICAL CONSIDERATIONS IN HUMAN SUBJECT'S RESEARCH

Chairs: Jonathan Stoltman and H. Westley Clark

- Can electronic health record data be meaningfully used for SUD research?*
G. Bart, University of Minnesota, Minneapolis, MN
- Ethical and privacy expectations of the participant and researcher: What does "Harm" look like in a big data context?*
H. Clark, Public Health Program, Santa Clara University, Santa Clara, CA
- Using EHR data for research in the context of a learning health care system: Challenges and opportunities*
S. Sterling, Kaiser Permanente, Oakland, CA
- Can mobile assessment have stable ethics?*
W. Kowalczyk, NIH, Bethesda, MD

Sunday, June 18, 2017

Workshop II

**Outremont
7:00 - 9:00 PM**

**USING BEHAVIORAL AND IMPLEMENTATION
SCIENCE TO ACHIEVE AN AIDS-FREE GENERATION
AMONG PEOPLE WHO USE DRUGS**

Chairs: Wendee Wechsberg and Don Des Jarlais

Prospects for ending the HIV epidemic among people who inject drugs in Haiphong, Vietnam

D. Des Jarlais, Icahn School of Medicine at Mount Sinai, New York, NY

Adoption and sustainability in treatment of the Women's Health CoOp in South Africa: Real-world challenges in implementation science

W. Wechsberg, RTI International, Research Triangle Park, NC

Effects of marijuana use on neurobehavioral outcomes among persons living with HIV: Harmful or benign?

C. Meade, Duke University School of Medicine, Durham, NC

These genes don't lie: Associations of recent methamphetamine use with gene expression in treated HIV infection

A. Carrico, University of Miami, Miami, FL

What did we hear and where does this lead us? – Followed by Q&A

M. Iguchi, RAND Corporation, Arlington, VA

Please be advised that no photographing of presentations or data is permitted.
Badges must be worn at all times and are required for admission into all events and sessions.

Sunday, June 18, 2017

Workshop III

**Mont-Royal
7:00 - 9:00 PM**

ASSESSMENT OF ABUSE POTENTIAL IN CLINICAL TRIALS IN THE CONTEXT OF THE FINALIZED FDA GUIDANCE

Chairs: Jack Henningfield and Michael Klein

The process of documenting abuse-related signals from clinical trials

S. Calderon, U.S. Food and Drug Administration, Silver Spring, MD

Assessment of abuse potential in clinical trials to contribute to scheduling: Controlled substance act scheduling recommendations and abuse deterrent labeling introduction and issues

J. Henningfield, Pinney Associates, Bethesda, MD

Development of a standardized classification system for assessing abuse potential in clinical trials: ACTION recommended considerations

S. Smith, University of Rochester School of Medicine and Dentistry, Rochester, NY

Development and feasibility of the misuse, abuse, and diversion drug event reporting system (MADDERS®)

N. Katz, Analgesic Solutions, Natick, MA

Assessing abuse potential from soup to nuts: Nonclinical and clinical study data that inform label claims and CSA scheduling recommendations

K. Bonson, U.S. Food and Drug Administration, Silver Spring, MD

Workshop IV

**Verdun
7:00 - 9:00 PM**

ANNUAL CPDD DESIGN AND ANALYSIS WORKSHOP

Chairs: Sterling McPherson and Susan Mikulich-Gilbertson

Using count regression models to evaluate important population level events in quasi-natural experiments: Marijuana legalization and prescription opioid reformulation examples

J. Davis, University of Colorado School of Medicine, Aurora, CO

Understanding health utilities and QALYS in substance use research

S. Murphy, Weill Cornell Medicine, New York, NY

Overview of pharmacokinetics and pharmacodynamics in substance use research: Estimating drug exposure and understanding drug/metabolite values

S. Mikulich-Gilbertson, University of Colorado School of Medicine, Aurora, CO

Population PK/PD: What data you need to collect and what you can do with existing substance use data?

T. Henthorn, University of Colorado School of Medicine, Aurora, CO

Using novel methodologies to ask and answer new questions in substance abuse research

D. Feaster, University of Miami Miller School of Medicine, Miami, FL

Monday, June 19, 2017

Poster Session I (Breakfast)

Fontaine
8:00 - 10:00 AM

Odd numbered posters manned first hour
Even-numbered, second hour

Set up time begins Sunday, 1:00 PM
Must be removed by Monday, 12:00 noon

PERINATAL

- 1 *The detection of prenatal marijuana exposure using meconium and umbilical cord: A comparison using matched pairs*
Mary Jones¹, Joseph Jones¹, Jason Hulen¹, ¹United States Drug Testing Laboratories, Des Plaines, IL
- 2 *White-matter crossing-fiber microstructure in adolescents prenatally exposed to cocaine*
Kristen Morie¹, Sarah Yip¹, Zu Wei Zhai¹, Jiansong Xu¹, Rajita Sinha², Linda Mayes¹, Marc Potenza², ¹Yale University, New Haven, CT, ²Yale School of Medicine, New Haven, CT
- 3 *Receipt of antenatal steroids and respiratory support among substance-exposed premature infants*
Yukiko Washio¹, Neal Goldstein², Amy Mackley³, Matthew Hoffman³, Robert Locke³, David Paul³, ¹Christiana Care Health Services/University of Delaware, Media, PA, ²Christiana Care Health Services/Drexel University, Philadelphia, PA, ³Christiana Care Health Services, Wilmington, DE
- 4 *Fetal assessment measured with multi-sensor abdominal array in buprenorphine-maintained women compared to controls*
Jessica Coker¹, Diana Escalona-Vargas¹, Shona Ray-Griffith¹, Curtis Lowery¹, Hari Eswaran¹, Zachary Stowe¹, ¹University of Arkansas for Medical Sciences, Little Rock, AR
- 6 *Opioid-dependent pregnant women with higher engagement in methadone maintenance treatment and specialty programming have better maternal, neonatal and family outcomes*
Leslie Lundahl¹, Corissa Carlson¹, Dragana Ostojic², David Ledgerwood¹, Mark Greenwald¹, Deepti Challagolla³, ¹Wayne State University, Detroit, MI, ²University of Windsor, Windsor, ON, ³University of Mississippi Medical Center, Jackson, MI
- 7 *Does maternal drug treatment access affect the relationship between adult opioid misuse and neonatal abstinence syndrome?*
Sebastian Tong¹, Elizabeth Wolf¹, Roy Sabo¹, Alex Krist¹, James Pecsok¹, Kassie Abbinanti², Dace Svikis¹, ¹Virginia Commonwealth University, Richmond, VA, ²University of Virginia, Charlottesville, VA
- 8 *Increasing effective contraceptive use among opioid-maintained women at risk for unintended pregnancy*
Sarah Heil¹, Alexis Matusiewicz², Heidi Melbostad¹, Stacey Sigmon¹, Lauren Macafee¹, Stephen Higgins¹, ¹University of Vermont, Burlington, VT, ²University of Vermont, Ann Arbor, MI

Monday, June 19, 2017

- 9 *Delay discounting of pregnancy- and condom-protected sex among methadone-maintained women*
Dennis Hand¹, Lindsay Reid¹, Diane Abatemarco¹, ¹Thomas Jefferson University, Philadelphia, PA
- 10 *Knowledge and attitudes about pregnancy prevention among women who are opioid-maintained*
Heidi Melbostad¹, Alexis Matusiewicz², Sarah Heil¹, ¹University of Vermont, Burlington, VT, ²University of Vermont, Ann Arbor, MI
- 11 *The utility of a cigarette purchase task in detecting differences in the reinforcing efficacy of cigarettes between opioid-maintained and non-dependent pregnant cigarette smokers*
Ivori Zvorsky¹, Joan Skelly¹, Stephen Higgins², ¹Vermont Center on Behavior and Health, Burlington, VT, ²University of Vermont, Burlington, VT
- 12 *Cannabis use in pregnant and recently postpartum cigarette smokers and nonsmokers*
Cecilia Bergeria¹, Sarah Heil¹, Allison Kurti¹, Taylor Ochalek¹, Stephen Higgins¹, ¹University of Vermont, Burlington, VT
- 13 *Examining patterns of tobacco product use among pregnant women*
Allison Kurti¹, Ryan Redner², Alexa Lopez¹, Diana Keith¹, Cassandra Stanton³, Diann Gaalema⁴, Janice Bunn¹, Nathan Doogan⁵, Megan Roberts⁵, Antonio Cepeda-Benita¹, Julip Phillips¹, Stephen Higgins¹, ¹University of Vermont, Burlington, VT, ²Southern Illinois University, Carbondale, IL, ³Westat, Rockville, MD, ⁴University of Vermont UHC Campus, Burlington, VT, ⁵Ohio State University, Columbus, OH
- 15 *The association between medical marijuana law and maternal marijuana use*
J. Jones, United States Drug Testing Laboratories, Des Plaines, IL
- 16 *Characteristics of marijuana-using pregnant women entering and leaving treatment*
Mishka Terplan¹, Yukiko Washio², ¹Virginia Commonwealth University, Richmond, VA, ²Christiana Care Health Services/University of Delaware, Media, PA
- 17 *Predictors of risk of illicit drug use during pregnancy among women attending midwife obstetric units in the Cape Metropole, South Africa*
Petal Petersen¹, Catherine Mathews², Esme Jordaan², Charles Parry³, ¹South African Medical Research Council, Tygerberg, South Africa, ²University of Cape Town, Western Cape, South Africa, ³South African Medical Research Council, Tygerberg, South Africa

NICOTINE I

- 18 *Separate and combined effects of the nicotine-specific monoclonal antibody, nic9d9, and a nicotinic receptor antagonist on nicotine discrimination in rats*
Mark Lesage¹, Paul Pentel², Mylissa Staley¹, Amy Saykao¹, Bin Zhou³, Kim Janda³, Matthew Kalnik⁴, ¹Minneapolis Medical Research Foundation, Minneapolis, MN, ²Hennepin County Medical Center, Minneapolis, MN, ³Scripps Research Institute, La Jolla, CA, ⁴Antidote Therapeutics, Inc., Bethesda, MD
- 19 *Comparison by rat intravenous self-administration of the reinforcing effects of nicotine vs. three C-II drugs*
David Heal¹, Sharon Smith¹, ¹RenaSci Ltd, Nottingham, Nottinghamshire, United Kingdom

- 20 *Effects of nicotine exposure on behavioral inhibition and self-administration in differentially reared rats*
Dustin Stairs¹, Nicole Chacho¹, Rachel Busselman¹, Madison Wolfe¹, Scott Christenson¹, ¹Creighton University, Omaha, NE
- 21 *Flavor conditioned reinforcers promote nicotine self-administration in rats*
Amy Patterson¹, Amanda Smith¹, Curtis Bradley¹, Moss Sanders¹, Jessica Golson¹, Matthew Palmatier¹, ¹East Tennessee State University, Johnson City, TN
- 22 *Dorsal anterior cingulate glutamate is associated with engagement of the default mode network during exposure to smoking cues*
Amy Janes¹, Jennifer Betts¹, J. Eric Jensen¹, Scott Lukas¹, ¹McLean Hospital, Harvard Medical School, Belmont, MA
- 23 *Inhibiting the insula in smokers: Preliminary results using rTMS and fMRI*
Michael F. Regner¹, Benzi Kluger¹, Jason Tregellas¹, Brianne Mohl¹, Dorothy Yamamoto¹, Jody Tanabe¹, ¹University of Colorado, Boulder, CO
- 24 *Neural mechanisms of impaired learning from errors in dependent smokers*
Leonie Duehlmeier¹, Bianca Levis¹, Rob Hester¹, ¹University of Melbourne, Coburg, Victoria, Australia
- 25 *Influence of treatment-induced changes in smoking-cue reactivity on long-term smoking abstinence*
Paul Wannas¹, Peter Selby², Nancy Lobaugh², Laurie Zawertailo², ¹University of Toronto, Toronto, ON, ²Centre for Addiction and Mental Health, Toronto, ON, Canada
- 26 *Development of a measure for affect during cigarette smoking anticipation*
Philip Smith¹, Neelam Prashad¹, Lunden Sara¹, Christine Sheffer², Adam Leventhal³, Sherry McKee⁴, ¹CUNY School of Medicine, New York, NY, ²Roswell Park Cancer Institute, Buffalo, NY, ³University of Southern California, Los Angeles, CA, ⁴Yale School of Medicine, New Haven, CT
- 27 *Effects of positive and negative episodic future thinking on delay discounting and behavioral-economic demand for cigarettes*
Jeffrey Stein¹, Jamie Turner¹, Patsy Marshall¹, ¹Virginia Tech Carilion Research Institute, Roanoke, VA
- 28 *An analogue of relapse: Comparing monetary incentives, episodic future thinking, and implementation intentions*
Lara Moody¹, Lindsey Poe¹, Olivia Petrusky¹, Patsy Marshall¹, ¹Virginia Tech Carilion Research Institute, Roanoke, VA
- 29 *Priming 2.0: Reducing delay discounting*
Ria Malhotra¹, Alina Shevorykin², Jami Pittman¹, Neelam Prashad¹, Lunden Sara¹, Christine Sheffer³, ¹CUNY School of Medicine, New York, NY, ²Pace University, Westchester County, NY, ³Roswell Park Cancer Institute, Buffalo, NY
- 30 *Contingency management for abstinence vs. contingency management for shaping cessation among treatment-seeking smokers in a community setting*
Carla López Núñez¹, Roberto Secades Villa², Sara Weidberg³, Alba González Roz³, ¹Private Technical University, Loja, Ecuador, ²University of Oviedo, Oviedo, Spain, ³University of Oviedo, Oviedo, Spain
- 31 *Moderation of four behavioral interventions for smoking among juvenile detainees* L. Stein, University of Rhode Island, Kingston, RI

- 32 *Doxazosin improves inhibitory control and reduces withdrawal symptoms in smokers*
Walter Roberts¹, Sherry McKee¹, ¹Yale School of Medicine, New Haven, CT
- 33 *Real-world effectiveness of bupropion and varenicline for smoking cessation: An internet-based randomized controlled trial*
Helena Zhang¹, Bernard Le Foll², Peter Selby³, Laurie Zawertailo³, ¹University of Toronto, Toronto, ON, ²Centre for Addiction and Mental Health, Toronto, ON, ³Centre for Addiction and Mental Health, Toronto, ON, Canada
- 34 *Autonomy and perceived competence for predicting treatment adherence and abstinence among smokers taking varenicline*
Amir Abdolahi¹, Geoffrey Williams², ¹Philips, Sterling, VA, ²University of Rochester Medical Center, Rochester, NY
- 35 *Duration, intensity and frequency of physical activity as predictors of smoking cessation outcomes among treatment-seeking patients*
Michael Hoang¹, Peter Selby², Martin Zack³, Laurie Zawertailo², ¹University of Toronto, Toronto, ON, ²Centre for Addiction and Mental Health, Toronto, ON, Canada, ³Centre for Addiction and Mental Health, Toronto, ON
- 36 *Cerebral blood flow changes within abstinent vs. satiated smokers*
Bader Chaarani¹, Philip Spechler¹, Alexandra Ivanciu¹, Stephen Higgins¹, Hugh Garavan¹, ¹University of Vermont, Burlington, VT
- 37 *Harm reduction or tool for initiation: Testing two models of e-cigarette and cigarette use in a high-risk longitudinal cohort*
David Fink¹, Katherine Keyes¹, Renee Goodwin², Gregory Cohen³, Laura Sampson³, Marijo Tamburrino⁴, Israel Liberzon⁵, Joseph Calabrese⁶, Sandro Galea³, ¹Columbia University Mailman School of Public Health, Newark, NJ, ²CUNY School of Medicine, New York, NY, ³Boston University School of Public Health, Boston, MA, ⁴University of Toledo Health Science Center, Toledo, OH, ⁵University of Michigan-Psychology, Ann Arbor, MI, ⁶University Hospitals Case Medical Center, Case Western Reserve School of Medicine, Cleveland, OH

STIMULANTS: HUMAN STUDIES

- 38 *A randomized controlled trial of a simplified manual-only treatment for caffeine use disorder*
Mary Sweeney¹, Steven Meredith², Laura Juliano², Daniel Evatt², Roland Griffiths³, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³Johns Hopkins School of Medicine, Baltimore, MD
- 39 *Effects of N-acetylcysteine on drug seeking and frontocortical glutamate in cocaine abusers*
Mark Greenwald¹, Eric Woodcock¹, Leslie Lundahl¹, Dalal Khatib¹, Jeffrey Stanley¹, ¹Wayne State University, Detroit, MI
- 40 *Mindful attention to drug-cues reduces neural reactivity in reward-relevant brain regions*
Michael Gawrysiak¹, Kanchana Jagannathan², Stefanie Darnley², Elliott Sturgis-Berkowitz², Kathleen Marquez², Zach Monge², Kyle Kampman², Winnie Thuku¹, Norna Jules¹, Anna Rose Childress² ¹Delaware State University, Wilmington, DE, ²University of Pennsylvania, Philadelphia, PA

- 41 *Atomoxetine in abstinent cocaine users*
Elise DeVito¹, Aryeh Herman², Noah Konkus², Huiping Zhang², Mehmet Sofuoglu², ¹Yale School of Medicine, New Haven, CT, ²Yale University, New Haven, CT
- 42 *Reduction in cocaine use during a topiramate clinical trial among cocaine and alcohol-dependent participants predict better scores of SF-36 for quality of life after treatment*
Lysa Remy¹, George Woody², Kevin Lynch³, Kyle Kampman², ¹Postgraduate Program in Pharmaceutical Sciences, Federal University of Rio Grande do Sul, Porto Alegre, Brazil, ²University of Pennsylvania, Philadelphia, PA, ³University of Pennsylvania, Department of Psychiatry, Philadelphia, PA
- 43 *Impact of alcohol dependence diagnosis on self-reported alcohol and cocaine use in cocaine-dependent patients*
Michael Mancino¹, Jeff Thostenson¹, Joseph Guise¹, Janette McGaugh¹, Thomas Kosten², Alison Oliveto¹, ¹University of Arkansas for Medical Sciences, Little Rock, AR, ²Baylor College of Medicine, Houston, TX
- 44 *Higher prevalence of detectable troponin I among cocaine users without known cardiovascular disease*
Elise Riley¹, Priscilla Hsue¹, Eric Vittinghoff¹, Alan Wu¹, Phillip Coffin², Peter Moore¹, Kara Lynch¹, ¹UCSF, San Francisco, CA, ²San Francisco Department of Public Health, San Francisco, CA
- 45 *More severe executive abnormalities in crack vs. snorted cocaine dependent patients: A neuropsychological study*
Paulo Jannuzzi Cunha¹, Hercílio Pereira de Oliveira Junior², Priscila Dib Gonçalves², Mariella Ometto², Bernardo Santos², André Malbergier², Ricardo Amaral², Sergio Nicastrí², Arthur Andrade², ¹University of Sao Paulo Medical School, Sao Paulo SP, Brazil, ²University of Sao Paulo Medical School, Sao Paulo SP, Brazil
- 46 *Of sleet and snow: Are newly incident crack users at greater risk of developing cocaine dependence problems soon after onset of cocaine use?*
Madhur Chandra¹, James Anthony¹, ¹Michigan State University, Lansing, MI
- 47 *Combating craving with contingency management: Neuroplasticity and methamphetamine abuse in South Africa*
Lara van Nunen¹, Jonathan Ipser², Dan Stein², Samantha Brooks², Edythe London³, Steve Shoptaw³, ¹University of Cape Town, Western Cape, South Africa, ²University of Cape Town, Western Cape, South Africa, ³UCLA, Los Angeles, CA
- 48 *Contingency management and strengths-based case management interventions for methamphetamine users in Denver, CO*
Karen Corsi¹, Jonathan Davis¹, Janet Spradley¹, Robert Booth², ¹University of Colorado School of Medicine, Aurora, CO, ²University of Colorado School of Medicine, Denver, CO
- 49 *Baseline urinalysis as a mediator between education level and treatment outcomes in two contingency management stimulant use clinical trials*
Crystal Smith¹, Michael Orr², John Roll², Sterling McPherson³, ¹Washington State University, Program of Excellence in Addictions Research, Spokane, WA, ²Washington State University College of Nursing, Spokane, WA, ³Washington State University, College of Medicine, Spokane, WA

- 50 *Delay discounting, financial choices, and drug use in a therapeutic workplace*
Shrinidhi Subramaniam¹, Anthony DeFulio², Brantley Jarvis³, August Holtyn¹,
Kenneth Silverman⁴, ¹Johns Hopkins University School of Medicine, Baltimore,
MD, ²Western Michigan University, Kalamazoo, MI, ³Johns Hopkins University
School of Medicine, Parkville, MD, ⁴Johns Hopkins University, Baltimore, MD

IMPULSIVITY

- 51 *Implication of disrupted serotonin: Glutamate synergy upon impulsivity*
Brionna Davis-Reyes¹, Veronica Campbell¹, Noelle Anastasio¹, ¹University of Texas
Medical Branch, Galveston, TX
- 52 *A pilot feasibility and acceptability trial of inhibitory control training with cocaine
users*
Erika Pike¹, Christina Studts¹, William Stoops¹, Craig Rush¹, ¹University of Kentucky,
Lexington, KY
- 53 *Pre-intervention risky decision-making as a predictor of relapse in methamphetamine
users undergoing Contingency Management*
Marilyn Lake¹, Jonathan Ipser², Lara van Nunen¹, Edythe London³, Dan Stein²,
Samantha Brooks², Steve Shoptaw³, ¹University of Cape Town, Western Cape, South
Africa, South Africa, ²University of Cape Town, Western Cape, South
Africa, ³UCLA, Los Angeles, CA
- 54 *Nonmedical prescription stimulant users experience subjective but not objective
impairments in attention and impulsivity*
Alison Looby¹, Sarah Kittleson², ¹University of Wyoming, Laramie, WY, ²University
of North Dakota, Grand Forks, ND
- 55 *Motives, consequences, and personality factors associated with nonmedical fentanyl
use*
Tess Kilwein¹, Alison Looby¹, ¹University of Wyoming, Laramie, WY
- 56 *Translational neuroimaging to predict treatment outcome among patients in
residential treatment for prescription opiate use disorder*
S. Bunce¹, Andrew Huhn², Dean Stankoski³, E Deneke⁴, E. Bixler¹, Roger
Meyer⁵, ¹Penn State College of Medicine, Hershey, PA, ²Johns Hopkins University
School of Medicine, Baltimore, MD, ³Penn State University College of Medicine,
Hershey, PA, ⁴Caron Treatment Center, Wernersville, PA, ⁵Penn State College of
Medicine, Psychiatry, Washington, DC
- 57 *Thicker frontal lobe regions associated with impulsivity and craving in smokers*
Yasmin Mashhoon¹, Jennifer Betts¹, Stacey Farmer², Scott Lukas¹, ¹McLean Hospital,
Harvard Medical School, Belmont, MA, ²McLean Hospital, Brain Imaging Center,
Belmont, MA

GENES AND MOLECULAR MECHANISMS

- 58 *Comparative mammalian genetics of addiction disorders*
E. Vallender, University of Mississippi Medical Center, Jackson, MS
- 59 *Increased motivation to self-administer cocaine is linked to enhanced cocaine-induced
gene regulation in the frontal cortex and dorsal striatum*
Ellie-Anna Minogianis¹, Anne-Noël Samaha¹, ¹Université de Montréal, Department of
Pharmacology and Physiology, Outremont, QC, Canada

- 60 *Novel antiaddiction target and ligand: Illudalic acid derivatives inhibit recombinant PTPRD phosphatase and are tolerated in vivo*
George Uhl¹, Paul Paik², Maria MArtinez³, Agnes Sulima¹, Kenner Rice⁴, Jana Drgonova⁵, ¹NIDA, Bethesda, MD, ²NIDA Intramural Research Program, Baltimore, MD, ³BRINM, Albuquerque, NM, ⁴NIH, NIDA, Rockville, MD, ⁵Center for Scientific Review, Bethesda, MD
- 61 *Biomarker discovery for marijuana use utilizing modified aptamer and metabolomic panels*
Christian Hopfer¹, Laura Saba², Kristen Raymond², Jost Klawitter², Uwe Christians², ¹University of Colorado School of Medicine, Aurora, CO, ²University of Colorado, Denver, CO
- 62 *Polymorphisms and stressors associated with alcohol dependence*
Maria Lucia Souza-Formigoni¹, Isabel Cristina Cespedes², José Carlos Fernandes Galduroz², Tatiana Wscieklica², Patricia Varela², João Bosco Pesquero², ¹Universidade Federal de São Paulo, São Paulo, Brazil, ²Universidade Federal de São Paulo, São Paulo, Brazil
- 63 *Association of the DRD2/ANKK1 A1 allele with alcohol consumption in Mexican Native Amerindians and in a non-native population*
Octavio Campollo¹, Arturo Panduro², Omar Ramos Lopez², Eloy A. Zepeda Carrillo³, Karina Gonzalez Aldaco², Rafael Torres Valadez², Sonia Roman², ¹Universidad de Guadalajara, Guadalajara, Jalisco, Mexico, ²Universidad de Guadalajara, Guadalajara, Jalisco, ³Universidad de Colima, Colima, Mexico
- 64 *Neighborhood drug exposure modifies heritability of cigarette initiation in adolescents*
C. Bares, University of Michigan, Ann Arbor, MI

OPIOIDS I

- 65 *Medial frontal cortex glutathione levels and temperature are increased in GT-tg bigenic mice expressing HIV-Tat protein: A proton MRS study*
Jae Kim¹, Dionyssios Mintzopoulos², Timothy Gillis³, Gordana Vitaliano², Jay McLaughlin⁴, Marc Kaufman², ¹McLean Hospital, Harvard Medical School, Belmont, MA, ²McLean Hospital, Brain Imaging Center, Belmont, MA, ³ADARC - McLean Hospital, Belmont, MA, ⁴University of Florida, Gainesville, FL
- 66 *Identification of new psychoactive substances: Opioid receptor agonist in CHO cells expressing the cloned human mu opioid receptor*
M. Funada, NIMH, NCNP, Tokyo, Japan
- 67 *Oxycodone addiction: A multimodel magnetic resonance imaging study in response to acute and chronic oxycodone treatment in rats*
S. Iriah, Northeastern, Roxbury, MA
- 68 *Efficacy of heroin and oxycodone vaccines for reducing opioid distribution to brain over a range of drug doses in rats*
Michael Raleigh¹, Megan Laudenbach¹, Federico Baruffaldi¹, Samantha Peterson¹, Michaela Roslawski², Angela Birnbaum², F. Ivy Carroll³, Scott Runyon³, Scott Winston⁴, Paul Pentel⁵, Marco Pravetoni¹, ¹Minneapolis Medical Research Foundation, Minneapolis, MN, ²University of Minnesota College of Pharmacy, Minneapolis, MN, ³RTI International, Research Triangle Park, NC, ⁴Winston Biopharmaceutical Consulting, ⁵Hennepin County Medical Center, Minneapolis, MN

- 69 *Safety and efficacy of an oxycodone vaccine: Addressing some of the unique considerations posed by opioid abuse*
Marco Pravetoni¹, Michael Raleigh¹, Samantha Peterson¹, Megan Laudenbach¹, Federico Baruffaldi¹, F. Ivy Carroll², Scott Runyon², Scott Winston³, Paul Pentel⁴,
¹Minneapolis Medical Research Foundation, Minneapolis, MN, ²RTI International, Research Triangle Park, NC, ³Winston Biopharmaceutical Consulting, ⁴Hennepin County Medical Center, Minneapolis, MN
- 70 *Circadian disruption during opioid agonist maintenance: Associations with heroin and cocaine use*
Jeremiah Bertz¹, David Epstein¹, Mark Rea², Mariana Figueiro², Greg Ward², Kenzie Preston¹, ¹NIDA Intramural Research Program, Baltimore, MD, ²Lighting Research Center, Rensselaer Polytechnic Institute, Troy, NY
- 71 *Sleep disturbances in subjects with opioid use disorder on buprenorphine*
Alissa Coffey¹, V.B Krishnamurthy¹, S Yadav¹, J Singh¹, L Kong¹, E. F. Saunders¹, A.N Vgontzas¹, E. Bixler¹, Roger Meyer², ¹Penn State College of Medicine, Hershey, PA, ²Penn State College of Medicine, Psychiatry, Washington, DC
- 72 *Understanding use of buprenorphine without a prescription*
Howard Chilcoat¹, Theodore Cicero², Matthew Ellis², ¹Indivior Inc., Richmond, VA, ²Washington University in St. Louis, St. Louis, MO
- 73 *The frequency of tapering off buprenorphine maintenance in a primary care office-based opioid treatment program*
Zoe Weinstein¹, Jeffrey Samet¹, Colleen Labelle¹, Gabriela Gryczynski², Debbie Cheng¹, Emily Quinn¹, David Hui¹, Hyunjoong Kim¹, ¹Boston University School of Medicine, Boston, MA, ²Kaiser Permanente, Oakland, CA
- 74 *Acceptability of intravenous buprenorphine as a treatment for opioid dependence: Results from a community-based survey among people who inject drugs with high-risk behaviors in France*
Perrine Roux¹, Daniela Rojas-Castro², Khadim Ndiaye¹, Virginie Laporte², Marion Mora¹, Gwenaëlle Maradan¹, Stephane Morel², Bruno Spire¹, Patrizia Carrieri¹,
¹INSERM, Marseille, France, ²AIDES, France
- 75 *Relapse to opioid dependence after inpatient or outpatient treatment: Protective effect of injection naltrexone*
Edward Nunes¹, Michael Gordon², Peter Friedmann³, Mei-Chen Hu⁴, Joshua Lee⁵, Donna Chen⁶, Marc Fishman⁷, Tamara Boney⁸, Donna Wilson³, Charles O'Brien⁸,
¹Columbia University and NYSPI, New York, NY, ²Friends Research Institute, Baltimore, MD, ³Baystate Health, Springfield, MA, ⁴Columbia University Medical Center, Department of Psychiatry, New York, NY, ⁵New York University School of Medicine, New York, NY, ⁶University of Virginia, Charlottesville, VA, ⁷Mountain Manor Treatment Center, Emmitsburg, MD, ⁸University of Pennsylvania, Philadelphia, PA
- 76 *Injectable naltrexone, oral naltrexone, and buprenorphine/naloxone utilization and discontinuation among individuals treated for opioid use disorder in a U.S. commercially insured population*
Jake Morgan¹, Bruce Schackman², Jared Leff², Benjamin Linas¹, Alexander Walley¹, ¹Boston University School of Medicine, Boston, MA, ²Weill Cornell Medicine, New York, NY

- 77 *Baseline characteristics by randomization status in the extended-release naltrexone vs. buprenorphine for opioid treatment clinical trial*
Jeanine May¹, Dagmar Salazar¹, Patricia Novo², Dikla Blumberg¹, Abigail Matthews¹, John Rotrosen², ¹The Emmes Corporation, Rockville, MD, ²New York University School of Medicine, New York, NY
- 78 *Baseline characteristics of the opioid use disorder population enrolled in NIDA CTN-0051, “Extended-release naltrexone vs. buprenorphine for opioid treatment”*
Patricia Novo¹, Edward Nunes², Martina Pavlicova³, Jennifer Scodes², Joshua Lee¹, Jeanine May⁴, Dagmar Salazar⁴, Dikla Blumberg⁴, John Rotrosen¹, ¹New York University School of Medicine, New York, NY, ²Columbia University and NYSPI, New York, NY, ³Columbia University Mailman School of Public Health, Newark, NJ, ⁴The Emmes Corporation, Rockville, MD
- 79 *Comparison of long-term buprenorphine treatment retention in patients with opioid use disorder in the Veterans Health Administration and in privately insured adults*
Ajay Manhapra¹, Edeanya Agbese MPH², Douglas Leslie², Robert Rosenheck³, ¹Yale School of Medicine; Hampton VA Medical Center, Norfolk, VA, ²Penn State College of Medicine, Department of Public Health Sciences, Hershey, PA, ³Yale University-Psychiatry, New Haven, CT
- 80 *Treatment outcomes among a cohort of African-American buprenorphine patients: Follow-up at 12- and 18-months*
Laura Monico¹, Jan Gryczynski¹, Robert Schwartz¹, Jerome Jaffe¹, Kevin O’Grady², Shannon Mitchell¹, ¹Friends Research Institute, Baltimore, MD, ²University of Maryland-Psychology, College Park, MD
- 81 *The Recovery Line supports harm reduction in methadone maintenance*
Brent Moore¹, Frank Buono¹, Daniel Lloyd¹, Destiny Printz¹, Declan Barry¹, Richard Schottenfeld¹, David Fiellin¹, ¹Yale School of Medicine, New Haven, CT

HEALTH DISPARITIES

- 82 *Association of race and ethnicity on national prescribing patterns for childhood ADHD*
Leila Vaezazizi¹, Peter Bearman², Marissa King³, Edward Nunes¹, Helena Hansen⁴, ¹Columbia University and NYSPI, New York, NY, ²Columbia University Department of Sociology, New York, NY, ³Yale University, New Haven, CT, ⁴New York University Medical Center, New York, NY
- 83 *Associations between past-year marijuana use, arrests, and race/ethnicity among 18-49-year-olds in the United States, 2002-2014*
Alexander Perlmutter¹, Luis Segura², Julian Santaella-Tenorio², Christine Mauro², Pia Mauro², Silvia Martins³, ¹Columbia University, New York, NY, France, ²Columbia University, New York, NY, ³Columbia University Mailman School of Public Health, Newark, NJ
- 84 *National scope of adults in substance use treatment who attempt suicide*
Jane Pearson¹, Lisa Colpe¹, Michael Schoenbaum¹, ¹National Institute of Mental Health, Bethesda, MD
- 85 *Racial/ethnic trends of heroin and non-medical use of prescription opioids among entrants to opioid treatment programs, 2005-2016*
Andrew Rosenblum¹, Enrique Pouget², Chunki Fong², ¹Credit Services, Metuchen, NJ, ²National Development and Research Institute, Inc., New York, NY

- 86 *Extra-medical use of prescription pain relievers: US-born vs. non-US-born residents of 'First Nation' heritage*
Jose Parra-Cardona¹, Maria Parker², James Anthony¹, ¹Michigan State University, Lansing, MI, ²University of Vermont, Burlington, VT
- 87 *Gender and race/ethnic differences in the persistence of alcohol, drug, and poly-substance use disorders*
Elizabeth Evans¹, Christine Grella², Donna Washington³, Dawn Upchurch⁴, ¹US Department of Veterans Affairs, Woodland Hills, CA, ²UCLA-ISAP, Los Angeles, CA, ³VA Greater Los Angeles Healthcare System, Santa Fe Springs, CA, ⁴UCLA Fielding School of Public Health, Los Angeles, CA

PSYCHIATRIC COMORBIDITY

- 88 *How patients with PTSD+SUD change across CBT treatments: A secondary analysis of two randomized clinical trials*
Denise Hien¹, Kathryn Smith², Max Owens³, Teresa Lopez-Castro⁴, Lesia M. Ruglass⁵, ¹Adelphi University, Garden City, NY, ²Columbia University Medical Center, New York State Psychiatric Institute, New York, NY, ³University of South Florida, Tampa, FL, ⁴The City College of New York, New York City, NY, ⁵CUNY Graduate School of Public Health and Health Policy, New York, NY
- 89 *Coping-oriented cannabis use interacts with PTSD symptoms to predict veteran psychosocial functioning*
James Sottile¹, Kimberly Babson², Danielle Morabito², Mallory Loflin³, Marcel Bonn-Miller², ¹Palo Alto University, East Palo Alto, CA, ²VA Palo Alto Health Care System, San Francisco, CA, ³National Center for PTSD, Dissemination & Training Division, San Diego, CA
- 90 *Substance use is associated with increased risk-taking behavior in heavy drinking veterans with posttraumatic stress disorder*
David Pennington¹, Lamisha Muquit², Jennifer Bielenberg¹, Jennifer Dack¹, Melissa O'Donnell¹, Brooke Lasher¹, Alexander Kinzler¹, Ellen Herbst¹, Steven Batki¹, ¹San Francisco VA Medical Center, San Francisco, CA, ²Palo Alto University, Union City, CA
- 91 *Prediction of alcohol use disorder onset by latent internalizing psychopathology risk profiles in adolescence and young adulthood*
Silke Behrendt¹, Gerhard Bühringer¹, Michael Höfler², Roselind Lieb², Katja Beesdo-Baum³, ¹Technische Universität Dresden, Dresden, Germany, ²University Basel, Division of Clinical Psychology and Epidemiology, Basel, Switzerland, ³Behavioral Epidemiology, Technische Universität Dresden, Dresden, Germany
- 92 *A pilot test of a brief intervention for hazardous/harmful alcohol use and depression among chronic disease patients in the Western Cape, South Africa*
Bronwyn Myers¹, Katherine Sorsdahl², Petal Petersen¹, Claire van der Westhuizen², Tracey Naledi³, Crick Lund², Carl Lombard⁴, Chris Butler⁵, Naomi Levitt², John Joska², Peter Milligan³, Dan Stein², ¹South African Medical Research Council, Tygerberg, South Africa, Africa, ²University of Cape Town, Western Cape, South Africa, ³Western Cape Department of Health, Western Cape, South Africa, ⁴South African Medical Research Council, Tygerberg, South Africa, ⁵University of Oxford, Oxford, UK

- 93 *Seriously mentally ill adults who are stably housed are more likely to complete a contingency management intervention for alcohol dependence*
Emily Leickly¹, Jordan Skalisky², Oladunni Oluwoye¹, Sterling McPherson³, Debra Srebnik⁴, John Roll⁵, Richard Ries⁴, Michael McDonell¹, ¹Washington State University, Program of Excellence in Addictions Research, Spokane, WA, ²Washington State University, Pullman, WA, ³Washington State University, College of Medicine, Spokane, WA, ⁴University of Washington, Seattle, WA, ⁵Washington State University College of Nursing, Spokane, WA
- 94 *Depression among people living with HIV/AIDS receiving smoking cessation treatment*
David Ledgerwood¹, Leslie Lundahl¹, Mark Greenwald¹, Cynthia Arfken¹, Manuel Tancer¹, Jonathan Cohn¹, ¹Wayne State University, Detroit, MI
- 95 *Association between depressive symptoms and smoking status in individuals receiving behavioral activation treatment*
Alba González-Roz¹, Sara Weidberg², Víctor Martínez-Loredo¹, Aris Grande-Gonsende², Roberto Secades Villa², ¹University of Oviedo, Addictive Behaviors Group, Oviedo, Spain, ²University of Oviedo, Oviedo, Spain
- 96 *Effects of smoking abstinence on delay discounting in smokers with depression*
Sara Weidberg¹, Alba González-Roz², Ángel García-Pérez¹, Irene Pericot-Valverde³, Roberto Secades Villa⁴, ¹University of Oviedo, Oviedo, Spain, ²University of Oviedo, Addictive Behaviors Group, Oviedo, Spain, ³University of Vermont, Burlington, VT, ⁴University of Oviedo, Oviedo, Spain
- 97 *Synthetic cannabinoid use in relation to psychosis: Evaluation of the role of stress and immune systems*
Anahita Bassir Nia¹, Sharron Spriggs¹, Charles Perkel¹, Chloe Tessereau¹, Hadi Estakhri¹, Samantha Jankowski¹, Afshan Husain¹, Anna Oprescu¹, Igor Galynker¹, Yasmin Hurd¹, ¹Icahn School of Medicine at Mount Sinai, New York, NY
- 98 *Is nonmedical prescription opioid and/or marijuana use associated with higher major depression prevalence among U.S. young adults?*
Luis Segura¹, Julian Santaella-Tenorio¹, Christine Mauro¹, Silvia Martins¹, ¹Columbia University, New York, NY
- 99 *Gender differences in effects of interim buprenorphine treatment on psychiatric symptoms*
Joanna Streck¹, Taylor Ochalek², Gary Badger², Stacey Sigmon², ¹Vermont Center on Behavior and Health, Burlington, VT, ²University of Vermont, Burlington, VT

PROGRAM DESCRIPTIONS

- 100 *The National Institute on Drug Abuse drug supply program: Facilitating research through compound inventory and supply*
Richard Kline, Ph.D.¹, Kevin Gormley², Steven Gust³, Robert Walsh⁴, ¹CPB/DTMC/NIDA/NIH, Rockville, MD, ²RTI International, Research Triangle Park, NC, ³OD/NIDA/NIH, Bethesda, MD, ⁴NIDA NIH, Bethesda, MD
- 101 *NIDA addiction treatment discovery program: Evaluation of potential pharmacotherapies for substance use disorders*
David White¹, Jane Acri², ¹Medications Discovery and Toxicology Branch, Bethesda, MD, ²NIDA, Bethesda, MD

- 102 *Safety interactions of potential cocaine treatment medications: Example of a dopamine D3 antagonist*
Jane Acri¹, Nathan Appel², ¹NIDA, Bethesda, MD, ²NIDA, DTMC, Bethesda, MD
- 103 *Exploring various approaches to account for prescribed availability when estimating prescription opioid abuse rates using the ASI-MV®*
Ryan Black¹, Stephen Butler¹, Paul Coplan², ¹Inflexxion, Inc, Waltham, MA, ²Purdue Pharma L.P., Stamford, CT
- 104 *Improving care with standardized triage, assessment, placement and utilization review*
David Gastfriend¹, Desiree Crevecouer-MacPhail², Brian Hurley², Tina Kim³, Gary Tsai³, ¹Treatment Research Institute, Philadelphia, PA, ²UCLA, Los Angeles, CA, ³Los Angeles County, Dept of Public Health, Substance Abuse Prevention and Control, Los Angeles, CA
- 105 *INTAC® – a technology platform for extended release, immediate release and fixed-dose combination opioids with abuse deterrent characteristics*
Hans-Jürgen Stahlberg¹, Sebastian Schwier¹, Klaus Wening¹, Eric Galia¹, ¹The Grünenthal Group, Aachen, Germany
- 106 *The NIDA behavioral therapy development program*
Wil Aklin¹, Kevin Walton¹, ¹NIH, Bethesda, MD
- 107 *An investigation of an open access model for scaling up methadone maintenance treatment*
Lynn Madden¹, Kathryn Eggert¹, Scott Farnum¹, Robert Freeman¹, Declan Barry², ¹APT Foundation, Inc., New Haven, CT, ²Yale School of Medicine, New Haven, CT
- 108 *Developing a shared decision-making graphic novel curriculum on medication-assisted treatment*
Adam Brooks¹, Lawrence Schoen², Carolyn Carpenedo¹, Elizabeth Byrne¹, Douglas Boyd¹, ¹Treatment Research Institute, Philadelphia, PA, ²Wedge Medical Center, Philadelphia, PA
- 109 *Multisite study on comprehensive opioid overdose prevention strategies with special emphasis on community settings and the use of injectable or intranasal naloxone* Anja Busse¹, Gilberto Gerra², Vladimir Poznyak³, Rebecca McDonald⁴, Nicolas Clark³, Elizabeth Saenz⁵, Wataru Kashino⁵, Gabriele Aiello⁵, John Strang⁶, ¹United National Office on Drugs and Crime, Vienna, Austria, ²Global Challenges Section, Vienna, Austria, ³World Health Organization, Geneva, Switzerland, ⁴King's College, London, UK, ⁵United National Office on Drugs and Crime, Vienna, Austria, ⁶King's College, London, UK, United Kingdom
- 110 *A case study of the public response to the opioid overdose epidemic: The Philadelphia story*
Silvana Mazzella¹, Jerry Stahler², ¹Prevention Point Philadelphia, Temple University, Philadelphia, PA, ²Temple University, Philadelphia, PA
- 111 *Pain and affective symptoms in chronic pain patients in opioid addiction treatment recruited to test an online pain self-management program*
Myles Finlay¹, Marian Wilson¹, Michael Orr¹, Mary Lee A. Roberts¹, Celestina Barbosa-Leiker¹, John Roll¹, ¹Washington State University College of Nursing, Spokane, WA

Monday, June 19, 2017

- 112 *Achieving opioid safety with patient, clinician and pharmacist partnership*
Miltika Kanabar¹, Kimberly Kwok¹, Kevin Miller¹, Murtuza Ghadiali¹, David Pating¹, Julie Lim¹, ¹Kaiser Permanente, Oakland, CA
- 113 *The catalyst clinic: Implementing a primary care-based, multidisciplinary team approach for adolescents and young adult who use substances*
Brittany Carney¹, Scott Hadland¹, Sarah Bagley¹, ¹Boston University School of Medicine, Boston, MA
- 114 *Successful of non-scheduled urine drug tests among all students in a private high school in Las Vegas*
Miriam Adelson¹, Shirley Linzy², Mary Jeanne Kreek³, Paul Schiffman⁴, Einat Peles⁵, ¹Adelson Clinic, Tel Aviv Medical Center, Tel Aviv, Israel, ²Adelson Clinic, Las Vegas, NV, ³The Rockefeller University, New York, NY, ⁴Dr. Miriam and Sheldon G. Adelson Educational Campus, Las Vegas, NV, ⁵Tel Aviv University, Reut, Israel
- 115 *Acceptability of hair collection for drug testing among pregnant women*
Victoria Coleman-Cowger¹, Katrina Mark², ¹Battelle Memorial Institute, Baltimore, MD, ²University of Maryland, College Park, MD
- 116 *Characteristics of participants in a specialty court for commercially sexually exploited girls with substance use and mental health problems*
Eraka Bath¹, Lindsey Thompson², Elizabeth Barnert², Mekeila Cook¹, ¹UCLA, Los Angeles, CA, ²UCLA-Pediatrics, Los Angeles, CA
- 117 *Group prenatal care in a community based substance abuse treatment center*
Elizabeth Zadzielski¹, Yukiko Washio², Michelle Drew¹, Gina Scott¹, ¹Christiana Care Health System, Newark, DE, ²Christiana Care Health Services/University of Delaware, Media, PA
- 118 *Provision of care in a hub-and-spoke outpatient treatment model*
James Sorensen¹, Jasmin Llamas², Robin Stuart³, ¹UCSF at Zuckerberg San Francisco General Hospital, San Francisco, CA, ²Santa Clara University, Santa Clara, CA, ³CHI Recovery, Sebastopol, CA
- 119 *eClipse: An online portal to facilitate access to evidence-based eHealth treatments for substance use and mental health comorbidity*
Sally Hunt¹, Frances Kay-Lambkin², Katherine Mills¹, Louise Thornton¹, Maree Teesson¹, ¹University of New South Wales, Sydney, New South Wales, Australia ²University of Newcastle, New Castle, New South Wales, Australia
- 120 *Honoring our Native American warriors*
Anne Skinstad¹, Sean A Bear², ¹University of Iowa, Iowa City, IA, ²University of Iowa College of Public Health, National American Indian and Alaska Native ATTC, Iowa City, IA
- 121 *Development and validation of an Embodied Conversational Agent to detect problematic use of tobacco and alcohol: Study description*
Sarah Moriceau¹, Fuschia Serre¹, Melina Fatseas², Jean-Arthur Micoulaud-Franchi¹, Etienne de Sevin¹, Emilien Bonhomme¹, Pierre Philip¹, Marc Auriacombe¹, ¹Université de Bordeaux, Bordeaux, France, ²Centre Hospitalier Charles Perrens, Bordeaux, France

- 122 *The supera distance-learning course: A ten-year Brazilian experience on training professionals in screening and brief intervention to substance users*
Maria Lucia Souza-Formigoni¹, Ana Paula Leal Carneiro¹, Ana Regina Noto², José Carlos Fernandes Galduroz¹, ¹Universidade Federal de São Paulo, São Paulo, Brazil, ²Universidade Federal de São Paulo, Department of Psychobiology, São Paulo, Brazil
- 123 *Personal goal setting: Factors in substance use and academic achievement* Michaéla Schippers¹, Dominique Morisano², ¹Rotterdam School of Management, Erasmus University, Rotterdam, Netherlands, ²University of Toronto, Toronto, ON, Canada
- 124 *The effect of medical marijuana laws and regulations on prevalence of marijuana use and cannabis use disorder*
Arthur Robin Williams¹, Silvia Martins², Christine Mauro², Frances Levin³, Julian Santaella-Tenorio², ¹Columbia University Division on Substance Use Disorders, New York, NY, ²Columbia University, New York, NY, ³Columbia University and NYSPI, New York, NY

Oral Communications 6

Mont-Royal
10:00 - 12:00 PM

WHEN ONE ISN'T ENOUGH: POLYDRUG USE

Chairs: Johannes Thrul and Linda Cottler

- 10:00 *Marijuana, tobacco, and prescription sedatives: Differences in non-medical, medical, and no use*
Verlin Joseph¹, Linda Cottler¹, Catherine Woodstock Striley¹, ¹University of Florida, Gainesville, FL
- 10:15 *Polydrug use among opioid users: Results from the national and local studies*
Georgiy Bobashev¹, Lee Hoffer², Kira Tebbe³,
¹RTI International, Research Triangle Park, NC, ²Case Western Reserve University, Cleveland, OH, ³Yale University, New Haven, CT
- 10:30 *Nonmedical prescription tranquilizer use among individuals with opioid use disorder in a nationally representative sample*
Victoria Votaw¹, Olivera Bogunovic², R. Kathryn McHugh¹, ¹McLean Hospital, Belmont, MA, ²McLean Hospital, Harvard Medical School, Belmont, MA
- 10:45 *Illicit drug use is associated with increased cigarette smoking among buprenorphine-maintained adults*
Maria Parker¹, Taylor Ochalek¹, Stacey Sigmon¹, ¹University of Vermont, Burlington, VT
- 11:00 *Rapid-onset cannabis problems: Excess risk for polydrug users?*
Karl Alcover¹, James Anthony¹, ¹Michigan State University, Lansing, MI
- 11:15 *Typologies of female cocaine use rely on transitions from initiation, to first symptom, to heaviest use, by age and comorbid marijuana use*
Linda Cottler¹, Yiyang Liu¹, Catherine Woodstock Striley¹, Barry Setlow², Lori Knackstedt¹, ¹University of Florida, Gainesville, FL, ²University of Florida College of Medicine, Gainesville, FL

- 11:30 *Differences in co-use of cigarettes with alcohol vs. marijuana among young adults: A daily diary study*
Johannes Thrul¹, Noah Gubner¹, Louisa Holmes², Danielle Ramo¹, Pamela Ling¹,
¹UCSF, San Francisco, CA, ²State University of New York at Binghamton, Vestal, NY
- 11:45 *Electronic- and clinician-delivered screening, brief intervention, and referral to treatment for women in reproductive healthcare centers: A randomized clinical trial*
Steve Martino¹, Steven Ondersma², Ariadna Forray¹, Todd Olmstead³, Heather Howell¹,
Kathryn Gilstad-Hayden¹, Trace Kershaw⁴, Kimberly Yonkers¹, ¹Yale University-
Psychiatry, New Haven, CT, ²Wayne State University-Psychiatry and Behavioral
Neurosciences, Detroit, MI, ³University of Texas at Austin, Lyndon B. Johnson School of
Public Affairs, ⁴Yale School of Public Health, New Haven, CT

Oral Communications 7

Verdun
10:00 - 12:00 PM

ADDICTION-INFECTION CONNECTION

Chairs: Kristen McLaurin and Jennifer Havens

- 10:00 *Protracted sex differences in the core components of executive function in the HIV-1 transgenic rat*
Kristen McLaurin¹, Rosemarie Booze¹, Charles F Mactutus¹, ¹University of South
Carolina, Columbia, SC
- 10:15 *Cocaine use and HIV have independent effects on the neural processing of ambiguous decisions*
Andréa L. Hobkirk¹, Bennett W. Hartley¹, Sheri Towe¹, Christina Meade¹, ¹Duke
University School of Medicine, Durham, NC
- 10:30 *Respondent-driven sampling as a strategy to increase awareness of hepatitis C infection in stimulant users*
Christina Meade¹, Sheri Towe¹, Ehi Ihionkhan¹, ¹Duke University School of Medicine,
Durham, NC
- 10:45 *Transience, networks and hepatitis C and HIV risk among young persons who inject drugs*
Basmattee Boodram¹, Louis Shekhtman², Anna Hotton³, Alexander Gutfraind⁴, Mary-Ellen
Mackesy-Amiti³, Carl Latkin⁵, Harel Dahari⁴, ¹University of Illinois, Chicago,
IL, ²Bar-Ilan University, Department of Physics, Ramat Gan, Israel, ³University of Illinois,
Division of Epidemiology and Biostatistics, Chicago, IL, ⁴Loyola University Medical
Center, Division of Hepatology, Maywood, IL, ⁵Johns Hopkins Bloomberg School of
Public Health, Baltimore, MD
- 11:00 *The association between cigarette smoking and virologic suppression in HIV-infected substance users*
Theresa Winhusen¹, Daniel Feaster², Rui Duan³, Jennifer Brown¹, Lisa
Metsch⁴, ¹University of Cincinnati, Cincinnati, OH, ²University of Miami Miller School
of Medicine, Miami, FL, ³University of Miami, Miami, FL, ⁴Columbia University, New
York, NY

- 11:15 *Availability of HIV-related services in buprenorphine treatment: Data from a national survey*
Hannah Knudsen¹, Michelle Lofwall², Sharon Walsh¹, Jamie Studts¹, Jennifer Havens³, ¹University of Kentucky, Lexington, KY, ²University of Kentucky College of Medicine, Lexington, KY, ³University of Kentucky College of Medicine, Lexington, KY
- 11:30 *Assessment of the behavioral intervention “Steps towards Health” for HIV-positive persons who inject drugs in Ukraine*
Tetiana Kiriazova¹, Yuliia Sereda², Roman Yorick³, Inna Shvab³, Sergii Dvoriak¹, ¹Ukrainian Institute on Public Health Policy, Kiev, Ukraine, ²Ukrainian Institute on Public Health Policy, Kiev, Ukraine, ³USAID RESPOND Project, Pact Inc., Kyiv, Ukraine
- 11:45 *Naltrexone implant, compared to oral naltrexone, improves HIV treatment outcomes of opioid-addicted patients*
Evgeny Krupitsky¹, Edwin Zvartau², Elena Blokhina², Elena Vladimirovna Verbitskaya³, Dmitry Lioznov³, Tatyana Yaroslavtseva³, Vladimir Palatkin³, Maryia Vetrova³, Natalia Bushara³, Andrey Burakov³, Dmitry Masalov³, Olga Mamontova³, Sabrina Poole⁴, Robert Gross⁴, George Woody⁴, ¹St. Petersburg Bekhterev Research Psychoneurological Institute, St.-Peterburg, Russia, Russian Federation, ²First Pavlov State Medical University of St. Petersburg, St. Petersburg, Russia, Russian Federation, ³First Pavlov State Medical University of St. Petersburg, St. Petersburg, Russia, ⁴University of Pennsylvania, Philadelphia, PA

Symposium IV

Westmount
10:00 - 12:00 PM

BRAIN RECOVERY IN ADDICTION: FROM BIOMARKERS TO FUNCTIONAL OUTCOMES

Chairs: Rajita Sinha and Carlos Blanco

- 10:00 *Functional recovery in neural substrates underlying aversive interception and allostasis in substance use disorders*
M. Paulus, Laureate Institute for Brain Research; UCSD Psychiatry, Tulsa, OK
- 10:25 *Recovery of the neural substrates of iRISA (impairments in response inhibition and salience attribution) in cocaine addiction*
R. Goldstein, Icahn School of Medicine at Mount Sinai, New York, NY
- 10:50 *Structural and functional brain changes associated with improved cognitive control in abstinence from substance use disorders*
H. Garavan, University of Vermont, Burlington, VT
- 11:15 *Substance use recovery in neural stress and drug craving circuitry: Relations to clinical outcomes*
R. Sinha, Yale School of Medicine, New Haven, CT
- 11:40 *DISCUSSANT: Identifying brain recovery biomarkers to impact precision medicine in addiction*
N. Volkow, NIDA, Bethesda, MD

Monday, June 19, 2017

Symposium V

**Outremont
10:00 - 12:00 PM**

**INFORMING TOBACCO PRODUCT REGULATORY
POLICIES THROUGH ADDICTION-RELATED
RESEARCH**

Chairs: Jennifer Naylor and Lynn Hull

- 10:00 *Investigating the abuse liability of tobacco product constituents in nonhuman primates*
A. Goodwin, U.S. Food and Drug Administration - National Center for Toxicological Research, Jefferson, AR
- 10:25 *Translational behavioral neuroimaging model of nicotine dependence*
E. Stein, NIDA Intramural Research Program, Baltimore, MD
- 10:50 *Modulation of nicotine perception and use profiles by flavorants*
E. DeVito, Yale School of Medicine, New Haven, CT
- 11:15 *Behavioral economics to inform tobacco policy, from lab to marketplace*
M. Koffarnus, Virginia Tech Carilion Research Institute, Roanoke, VA
- 11:40 *DISCUSSANT: How can addiction-related research inform CTP's regulatory decisions?*
K. Jackson, U.S. Food and Drug Administration - Center for Tobacco Products, Silver Spring, MD

Policy Forum

**Westmount
12:15 - 1:45 PM**

Chairs: Martin Iguchi and William Dewey

- Update of activities and accomplishments of Friends of NIDA - Report from Capitol Hill*
W. Dewey, Virginia Commonwealth University, Richmond, VA
- Implications for NIDA's research portfolio*
E. Long, Van Scoyoc Associates, Washington, DC
- Treatment instead of incarceration: Police-assisted addiction recovery initiatives in Gloucester and 150 other communities: First-year experience*
D. Rosenblum, Boston University School of Medicine and Public Health, Department of Health Law, Policy & Management, Boston, MA
- Naloxone and good samaritan laws in two New England states: Impacts on law enforcement and opioid consumers*
T. Green, Boston University School of Medicine, Boston, MA
- Prescription drug monitoring programs: Of law enforcement or public health?*
L. Beletsky, Northeastern University School of Law & Bouve College of Health Sciences, Boston, MA

CHAUD, CHAUD, CHAUD: NOVEL TREATMENT STRATEGIES

Chairs: Eric Maltbie and Sandra Comer

- 2:00 *JPC-089, a 1,4-diphenethyl substituted piperidine, inhibits the neurotoxic, psychomotor stimulant and reinforcing effects of methamphetamine*
Justin Nickell¹, Arlington Wilson¹, Emily Denehy¹, John Culver¹, Venumadhav Janganati², Peter Crooks², Michael Bardo¹, Linda Dwoskin¹, ¹University of Kentucky, Lexington, KY, ²University of Arkansas for Medical Sciences, Little Rock, AR
- 2:15 *Suvorexant, a clinically available hypocretin/orexin receptor antagonist, attenuates positive affect and drug seeking associated with psychostimulant self-administration in rats*
Steven Simmons¹, Helene Philogene², Rose Martorana¹, Lili Mo¹, Fionya Tran¹, Taylor Gentile¹, Scott Rawls², John Muschamp¹, ¹Lewis Katz School of Medicine, Temple University Philadelphia, PA, ²Temple University, Philadelphia, PA
- 2:30 *Effects of BU08028, a mixed mu and nociceptin/orphanin FQ peptide receptor agonist, on alcohol drinking in rhesus monkeys*
Paul Czoty¹, Phillip Epperly¹, April Davenport¹, Mei-Chuan Ko², Stephen Husbands³, James Daunais¹, Shawn Flynn¹, ¹Wake Forest School of Medicine, Winston-Salem, NC, ²University of Michigan, Ann Arbor, MI, ³University of Bath, Bath, UK
- 2:45 *Investigating the effects of ketamine treatment on reinstatement of cocaine self-administration in rhesus monkeys*
Eric Maltbie¹, Leonard Howell¹, ¹Emory University, Atlanta, GA
- 3:00 *Reduction of smoking urges with intranasal insulin: A randomized, crossover, placebo-controlled clinical trial*
A. Hamidovic, University of Illinois, Chicago, IL
- 3:15 *Effects of pioglitazone, a PPAR γ agonist, on the subjective and reinforcing effects of tobacco cigarettes*
Suky Martinez¹, Jermaine Jones², Sandra Comer³, Adam Bisaga³, ¹Columbia University Medical Center, New York State Psychiatric Institute, New York, NY, ²Columbia University College of Physicians and Surgeons, New York, NY, ³Columbia University and NYSPI, New York, NY
- 3:30 *Effects of ibudilast on subjective, reinforcing and analgesic effects of oxycodone and drug craving in recently detoxified adults with opioid dependence*
Verena Metz¹, Jermaine Jones², Jeanne Manubay³, Maria Sullivan⁴, Shanthi Mogali¹, Andrew Segoshi⁵, Gabriela Madera³, Kirk Johnson⁶, Sandra Comer¹, ¹Columbia University and NYSPI, New York, NY, ²Columbia University College of Physicians and Surgeons, New York, NY, ³Columbia University, New York, NY, ⁴Alkermes, Inc., Waltham, MA, ⁵New York State Psychiatric Institute, New York, NY, ⁶Xoma Corporation, Berkeley, CA

Monday, June 19, 2017

- 3:45 *A Phase III outpatient randomized, double-blind, double-dummy controlled trial evaluating efficacy of CAM2038 (weekly and monthly buprenorphine FluidCrystal® injection depot) for opioid use disorder*
Michelle Lofwall¹, Edward Nunes², Genie Bailey³, Sharon Walsh⁴, Stacey Sigmon⁵, Fredrik Tiberg⁶, Margareta Linden⁷, Behshad Sheldon⁸, Sonnie Kim⁸, ¹University of Kentucky College of Medicine, Lexington, KY, ²Columbia University and NYSPI, New York, NY, ³Warren Alpert Medical School of Brown University, Providence, RI, ⁴University of Kentucky, Lexington, KY, ⁵University of Vermont, Burlington, VT, ⁶Camurus, Lund, Sweden, ⁷Camurus, Lund, Sweden, ⁸Braeburn Pharmaceuticals, Princeton, NJ

Oral Communications 9

Verdun
2:00 - 4:00 PM

TRAUMA, VIOLENCE AND ADDICTION

Chairs: Therese Killeen and Gregory Homish

- 2:00 *Trauma, substance use, and mental health problems among homeless veteran parents in Los Angeles: Lessons in stress and resilience*
Roya Ijadi-Maghsoodi¹, Sophie Feller², Gery Ryan³, Sheryl Kataoka², Donna Washington⁴, Lisa Altman⁴, Lillian Gelberg⁵, ¹UCLA, Los Angeles, CA, ²Semel Institute for Neuroscience and Human Behavior (UCLA), Los Angeles, CA, ³RAND Corporation, Arlington, VA, ⁴VA Greater Los Angeles Healthcare System, Santa Fe Springs, CA, ⁵UCLA Family Medicine, Los Angeles, CA
- 2:15 *Combat exposure, emotional and physical role limitations, and substance use among male reserve soldiers*
Rachel Hoopsick¹, D. Lynn Homish¹, Gregory Homish¹, ¹State University of New York at Buffalo, Buffalo, NY
- 2:30 *Association between PTSD symptom severity, mindfulness and emotional regulation*
Therese Killeen¹, Nathaniel Baker¹, Caroline Vrana¹, Victoria Brant¹, ¹Medical University of South Carolina, Charleston, SC
- 2:45 *Childhood traumatic experience and criminal justice involvement among women: Evaluating mediation by drug use and depression*
Joy Scheidell¹, Christopher Frueh², Maria Khan¹, ¹New York University School of Medicine, New York, NY, ²University of Hawaii at Hilo, Hilo, Hawaii
- 3:00 *Trauma exposure, sex and stress responding among cannabis smokers* Thomas Chao¹, Vanja Radoncic², Denise Hien², Gillinder Bedi³, Margaret Haney⁴, ¹New York State Psychiatric Institute, New York, NY, ²Adelphi University, Garden City, NY, ³Columbia University, New York, NY, ⁴Columbia University Medical Center, New York, NY
- 3:15 *The self and susceptibility: The role of the medial prefrontal cortex in addiction comorbidity*
Bradford Martins¹, Ricardo Caceda¹, Josh Cisler², G. Andrew James¹, Clinton Kilts¹, ¹University of Arkansas for Medical Sciences, Little Rock, AR, ²University of Wisconsin-Madison, Madison, WI

Monday, June 19, 2017

- 3:30 *Age trajectories of the association between violence exposure and past-30-day substance use*
Jason Goldstick¹, Justin Heinze¹, Sarah Stoddard¹, Rebecca Cunningham¹, Marc Zimmerman¹, ¹University of Michigan, Ann Arbor, MI
- 3:45 *The relationship between hazardous alcohol use and violence among street-involved youth*
Nadia Fairbarin¹, Evan Wood¹, Huiru Dong², Sabina Dobrer³, Thomas Kerr², Kora DeBeck⁴, ¹University of British Columbia, Vancouver, BC, Canada, ²University of British Columbia, Vancouver, BC, ³BC Centre for Excellence in HIV/AIDS, Vancouver, BC, ⁴British Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC

Oral Communications 10

Outremont
2:00 - 4:00 PM

THE CHANGING LANDSCAPE: HEALTH AND POLICY

Chairs: Samuel Friedman and Lilian Ghandour

- 2:00 *Assessing the impacts of minimum legal drinking age laws on police-reported criminal victimization in Canada from 2009-2013*
Claire Benny¹, Jodi Gatley¹, Marcos Sanches², Russell Callaghan³, ¹University of Northern British Columbia, Prince George, BC, ²Centre for Addiction and Mental Health, Toronto, ON, ³Northern Medical Program, Prince George, BC, Canada
- 2:15 *Social causation and neighborhood selection processes underlie associations among neighborhoods, social networks and illicit drug use among adults relocating from public housing*
Sabriya Linton¹, Danielle Haley², Josalin Hunter-Jones¹, Zev Ross³, Hannah Cooper¹, ¹Emory University, Atlanta, GA, ²University of North Carolina at Chapel Hill, Chapel Hill, NC, ³ZevRoss Spatial Analysis
- 2:30 *Research on determinants of service provision for people who use drugs*
S. Friedman, National Development and Research Institute, Inc., New York, NY
- 2:45 *Modelling youths' demand and ethanol intake responsiveness to alcohol taxes using Discrete Choice Experiment*
Lilian Ghandour¹, Ali Chalak², Nasser Yassin², Rima Nakkash², Sirine Anouti², Rima Afifi², ¹American University of Beirut, Beirut, Lebanon, ²American University of Beirut, Beirut, Lebanon
- 3:00 *Social determinants of recovery from substance abuse among justice-involved community members*
Linda Kahn¹, Bonnie Vest¹, Diane Berdine¹, Robert Granfield¹, Gregory Homish¹, ¹State University of New York at Buffalo, Buffalo, NY
- 3:15 *Medical marijuana laws and sedative/hypnotic overdose mortality in the United States*
Stephanie Peglow¹, Marilyn Stoler², William Becker², ¹Eastern Virginia Medical School and Yale University, Stamford, CT, ²Yale University, New Haven, CT

Monday, June 19, 2017

- 3:30 *Impact of mandatory minimum sentencing on crack and powder cocaine use*
Laurn Walker¹, Briana Mezuk¹, ¹Virginia Commonwealth University, Richmond, VA
- 3:45 *Behavioral health provider network structures and adequacy standards in private health plans*
Maureen Stewart¹, Constance Horgan², Sharon Reif², Deborah Garnick¹, Brooke Evans¹, Timothy Creedon¹, ¹Brandeis University, Waltham, MA, ²Brandeis University, Heller School for Social Policy and Management, Waltham, MA

Symposium VI

Westmount
2:00 - 4:00 PM

SEX AS A BIOLOGICAL VARIABLE: RESEARCH FINDINGS FROM NIH OFFICE OF RESEARCH ON WOMEN'S HEALTH AND NIDA CENTER GRANTS – AHEAD OF ITS TIME OR LONG OVERDUE?

Chairs: Cora Lee Wetherington and Sherry McKee

- 2:00 *Beyond mice and men: Innovations in translational sex and gender-sensitive tobacco treatment development*
S. McKee, Yale School of Medicine, New Haven, CT
- 2:25 *The stress – addictions relationship: A focus on sex/gender differences*
K. Brady, Medical University of South Carolina, Charleston, SC
- 2:50 *Treatments to reduce impulsivity decrease incubation of cocaine and nicotine craving and relapse in rats: Sex differences*
M. Carroll, University of Minnesota, Minneapolis, MN
- 3:15 *Sex as a biological variable in addiction research*
J. Becker, University of Michigan, Ann Arbor, MI
- 3:40 *DISCUSSANT: Sex as a biological variable we all knew about, but ignored*
R. Foltin, Columbia University Medical Center, New York, NY

Marian W. Fischman Memorial Award Lecture

Westmount/Outremont
4:15 - 5:15 PM

Presentation of the Marian W. Fishman Award to Sharon Walsh

Introduction by Michelle Lofwall

Lecture: *Opioid Euphoria and Dysphoria: A Tale of Two Cities*
Sharon L. Walsh

Student/Trainees Mixer

Salon Bonaventure
5:15 - 6:45 PM

2017 NIDA International Forum Abstracts

Fontaine A&B

7:00 to 9:00 PM

Information

100 National Institute on Drug Abuse International Program: Promoting diplomacy and addiction research

S. Gust¹, J. McCormally². ¹National Institute on Drug Abuse International Program, United States; ²National Institute on Drug Abuse International Program Contractor Staff, United States

101 The 4th Africa and Middle East Congress on Addiction: Research outreach and capacity-building activities

M. al'Absi¹, S. El Mhamdi². ¹University of Minnesota, United States; ²University of Monastir, Tunisia

102 Public availability of raw data in articles published in journals indexed in the Journal Citation Reports substance abuse category

R. Aleixandre-Benavent^{1,2}, F.J. Bueno-Canigral³, A. Vidal-Infer⁴. ¹Ingenio, Spain; ²Universitat de Valencia-Consejo Superior de Investigaciones Científicas, Spain; ³Plan Municipal de Drogodependencias, Ajuntament de Valencia, Regidoria de Sanitat, Salut i Esports, Spain; ⁴Departamento de Historia de la Ciencia y Documentacion, Universidad de Valencia, Spain

103 Addiction medicine for medical staff in the National Institute of Neurology and Neurosurgery in Mexico City: Pilot course

M. Azcarraga-Quiza^{1,2}, P. Leon-Ortiz¹. ¹National Institute of Neurology and Neurosurgery, Mexico; ²Virginia Commonwealth University, United States

104 Analysis of scientific subjects over consumption of addictive substances and road safety

F.J. Bueno-Canigral¹, D. Melero-Fuentes², R. Aleixandre-Benavent^{3,4}, J-C. Valderrama-Zurian⁵. ¹Plan Municipal de Drogodependencias, UPCCA, Ajuntament de Valencia, Regidoria de Sanitat, Salut i Esports, Spain; ²Institute of Documentation and Information Technologies, Catholic University of Valencia, Spain; ³Ingenio, Spain; ⁴Universitat de Valencia-CSIC, Spain; ⁵Departamento de Historia de la Ciencia y Documentacion, Universidad de Valencia, Spain

105 An alternative to prohibition and commercialization of cannabis: The experience of Uruguay

M.E. Cabrera^{1,2}, J.R. Koch³. ¹Hubert H. Humphrey Fellowship Program, Virginia Commonwealth University, United States; ²National Drug Board of Uruguay, Uruguay; ³Virginia Commonwealth University, United States

106 Management of substance use problems among children and adolescents in Iran

M. Chawarski¹, H.R. Fathi². ¹Yale University School of Medicine, United States; ²Addiction Studies Department, School of Advanced Medical Technologies, Tehran University of Medical Sciences, Iran

107 Increased smoking and reduced well-being following missile attacks in Israeli youth

P. Findley¹, I. Pruginin², R. Isralowitz². ¹Rutgers University, United States; ²Regional Alcohol and Drug Abuse Research Center, Ben Gurion University, Israel

108 Addiction education in Thai medical schools

W. Jiraporncharoen, S. Lkhitsathian, C. Angkurawaranon, A. Aramrattana. Chiang Mai University (CMU), Thailand; Substance Abuse and Mental Health Services Administration-University of California Los Angeles-CMU Southeast Asia HIV-Addiction Technology Transfer Center, Thailand

109 The Hubert H. Humphrey Fellowship Program at Virginia Commonwealth University

J.R. Koch, R.L. Balster, A. Breland, W.L. Kliever. Virginia Commonwealth University, United States

110 The International Society of Substance Use Professionals

J.T. Lee. The International Society of Substance Use Prevention and Treatment Professionals, United Kingdom

111 The Virginia Commonwealth University Hubert H. Humphrey Fellowship in Substance Abuse Prevention, Treatment and Policy: One year follow-up assessment

O. Leonchuk¹, J.R. Koch², R.L. Balster², A. Breland². ¹North Carolina State University, United States; ²Virginia Commonwealth University, United States

112 Emerging viral pathways among drug-using populations: Future directions of scientific studies

C. McCoy¹, A.J. McCoy Bengoa¹, B. Hayden², H.V. McCoy³, D. McBride⁴, S. Puri¹, P. Shapshak⁵. ¹University of Miami, United States; ²Banyan Health, United States; ³Florida International University, United States; ⁴Andrews University, United States; ⁵University of South Florida, United States

113 Face-to-face and virtual training programs to address late diagnosis of HIV among people who use drugs in Argentina

D. Rossi, P. Cymerman, P. Goltzman, M.P. Pawlowicz, G. Touze. Intercambios Civil Association, Argentina; University of Buenos Aires, Argentina

114 Indonesia policy review of people who inject drugs and HIV

R. Sarasvita^{1,2}, H. Susami^{2,3}, D. Utami^{1,3}, S. Rose⁴, D.S. Metzger⁵. ¹Indonesia National Narcotics Board, Indonesia; ²HPTN 074 Indonesia Site—Cipto Mangunkusumo Hospital, Indonesia; ³Abhipraya Foundation, Indonesia; ⁴FHI 360, HIV Prevention Trials Network, United States; ⁵Treatment Research Institute, University of Pennsylvania, United States

Basic Science

200 Acute and residual effects of cannabis on simulated driving performance of young adults

Bruna Brands^{1,2}, Robert Mann^{1,3}, Bernard Lefoll^{1,3}, Gina Stoduto³, Christine Wickens³, Marilyn Huestis⁴. ¹University of Toronto, Canada; ²Health Canada, Canada; ³Centre for Addiction and Mental Health, Canada; ⁴University of Maryland School of Medicine, United States

201 Recovery and withdrawal after suspending chronic toluene exposure in adolescent rats

S. Cruz¹, V. Nava-Rodriguez¹, M-T. Rivera-Garcia^{1,2}, C. Lopez-Rubalcava¹. ¹Department of Pharmacobiology, Cinvestav, Mexico; ²Department of Basic Science, Oregon Health & Science University, United States

202 Hepatotoxicity and nephrotoxicity induced by solvent inhalants

Alaaeldin Elkoussi. Assiut College of Medicine, Egypt

203 Discriminative stimulus effects of cocaine in rats: Training via the oral route of administration

C. Froger-Colleaux, S. Paillard, K. Davoust, V. Castagne. Porsolt, France

- 204 *Greater impact on brain volume change in chronic ketamine users with adolescent onset*
C-C. Hung^{1,2}, T. Szu-Hsien Lee³, C-C. Huang⁴, C-Po Lin^{4,5}, Y-S. Liu⁴, C-S.R. Li⁶, J-R. Duann⁷
¹Institute of Brain Science, National Yang Ming University, Taiwan; ²Bali Psychiatry Center, Ministry of Health and Welfare, Taiwan; ³Department of Health Promotion and Education, National Taiwan Normal University, Taiwan; ⁴Brain Connectivity Lab, National Yang Ming University, Taiwan; ⁵Institute of Neuroscience, National Yang Ming University, Taiwan; ⁶Departments of Psychiatry and Neuroscience, Yale University School of Medicine, United States; ⁷China Medical University, Biomedical Engineering Research and Development Center, Taiwan
- 205 *Using portable imaging to determine marijuana intoxication in humans*
H.O. Keles, J. Gilman, S. Sobolewski, M. Radoman, G. Pachas, A.E. Evins. Massachusetts General Hospital, United States
- 206 *Acute effects of cannabis on verbal memory in young adults: Relationship to tobacco use*
J. Matheson^{1,2}, R. Mann^{1,2}, B. Lefoll^{1,2}, G. Stoduto², C. Wickens², M. Huestis³, B. Brands^{1,2}.
¹University of Toronto, Canada; ²Centre for Addiction and Mental Health, Canada; ³University of Maryland School of Medicine, United States
- 207 *Influence of nicotinic receptor gene—CHRNA5—on crack cocaine dependence and severity*
J. Schuch^{1,2}, A. Aroche², D.L. Rovaris², A. Stolf³, T. Roman², B. Sanvicente-Vieira⁴, E. Vitola⁵, E. Grevet⁵, F. Pechansky¹, F. Kessler^{3,5}, L. von Diemen³, R. Grassi-Oliveira⁴, C. Bau². ¹Center for Drug and Alcohol Research, Federal University of Rio Grande do Sul (UFRGS), Brazil; ²Department of Genetics, UFRGS, Brazil; ³Center for Drug and Alcohol Research, Hospital de Clinicas de Porto Alegre, UFRGS, Brazil; ⁴Pontifical Catholic University of Rio Grande do Sul, Brazil; ⁵Department of Psychiatry and Legal Medicine, UFRGS, Brazil
- 208 *Gambling-induced stimulant craving in regular stimulant users: A cross-priming study*
S. Stewart¹, Z. Ghaferi¹, P. Collins¹, M. Cowie¹, M. Zack², B. Horiachka³, D. McGrath³.
¹Dalhousie University, Canada; ²Centre for Addiction and Mental Health, Canada; ³University of Calgary, Canada
- 209 *The regulatory role of trace amine-associated receptor 1 in acute and chronic effects of nicotine*
I. Sukhanov¹, A. Dolgorukova¹, A. Dorotenko¹, M. Dorofeikova¹, R. Gainetdinov², E. Zvartau¹. ¹First Pavlov State Medical University, Russia; ²Saint Petersburg State University, Russia
- 210 *Low insula glutamate/glutamine in chronic methamphetamine users: Association with depressive symptoms*
J. Tang^{1,2}, J. O'Neill², J.R. Alger², E.D. London². ¹Mental Health Institute, the Second Xiangya Hospital of Central South University, China; ²David Geffen School of Medicine, University of California Los Angeles, United States
- 211 *Assessment of oxidative DNA damage among adolescent inhalant users seeking treatment at a tertiary care centre*
A. Verma, R. Jain, A. Dhawan, R. Lakshmy, R. Raghav. All India Institute of Medical Sciences, India

Epidemiology

- 300 *Impact of legal highs on HIV vertical transmission in female injection drug users in Romania*
A. Abagiu^{1,2}, A. Koulosousas², L. Stoica¹, C. Blaga¹, F. Duna¹, C. Petre¹, R. Ungurianu¹, M. Mardarescu^{1,3}, A.M. Tudor^{1,4}, M. Mitran⁵, A. Streinu-Cercel^{1,4}. ¹National Institute for Infectious Diseases Prof. Dr. Matei Bals, Romania; ²Romanian Association Against AIDS, Romania; ³European Centre for Disease Prevention and Control, Sweden; ⁴Carol Davila University of Medicine and Pharmacy, Romania; ⁵Panait Sarbu Maternity Hospital, Romania
- 301 *Gender differences in tramadol use and abuse in university students, Egypt*
M. Abdelghan, G. Salah El-deen, M. Bassiouny. Zagazig University, Egypt
- 302 *Khat use and the occurrence of psychotic symptoms: Suggestive evidence for a mediating role of traumatic experiences*
K. Adorjan, M. Odenwald, M. Widmann, M. Tesfaye, F. Tessema, S. Toennes, S. Suleman, M. Soboka, Z. Mekonnen, E. Susser, T.G. Schulze. IPPG, Germany
- 303 *Characteristic trends in prevalence of synthetic designer drugs over the Territory of the Republic of Bashkortostan*
E. Akhmetova, A. Azat. Bashkir State Medical University, Russia
- 304 *Prevalence of simultaneous polydrug use and associated factors in first-year and last-year students from different areas of study at Universidad Politécnica de Nicaragua, Recinto Universitario Regional Esteli, Nicaragua, 2016*
T. Aleman, A. Herrera, I.M. Videá. Universidad Nacional Autónoma de Nicaragua-Leon, Nicaragua
- 305 *Risk of hepatitis C infection among heroin and methamphetamine users*
Z. Alexandercikova, L. Okruhlica. Center for Treatment of Drug Dependencies, Slovakia
- 306 *Prescription painkiller misuse and labor market: Misuse levels and differential effects*
P. Alexandre, V. Paz. Health Administration, College of Business, Florida Atlantic University, United States
- 307 *Substance abuse in Iraq: Psychiatrists' experience*
R. Aqrawi. Ministry of Health–Kurdistan Region, Iraq
- 308 *Substance use in Jamaican 12- to 65-year-olds*
U. Atkinson¹, N. Younger-Coleman², P. Clarke³, M. Hynes³. ¹National Council on Drug Abuse, Jamaica; ²University of the West Indies–Mona, Jamaica; ³Organization of American States, United States
- 309 *National survey on crack cocaine, Brazil, 2013*
F. Bastos¹, C. Coutinho¹, N. Bertoni². ¹Oswaldo Cruz Foundation, Brazil; ²Brazilian National Cancer Institute, Brazil
- 310 *Relationship between psychopathy and HIV risk behaviors among heroin and amphetamine users*
K. Bozgunov¹, E. Psederska¹, G. Vasilev¹, D. Nedelchev¹, J. Vassileva². ¹Bulgarian Addictions Institute, Bulgaria; ²Virginia Commonwealth University, United States
- 311 *Severity of dependence scale: Diagnostic cut-off for pharmaceutical opioid dependence*
R. Bruno^{1,2}, A. Peacock^{1,2}, B. Larance², N. Lintzeris³, R. Ali⁴, L. Degenhardt². ¹Department of Psychology, University of Tasmania School of Medicine, Australia; ²National Drug and Alcohol Research Centre, The University of New South Wales, Australia; ³Sydney University Medical School, Australia; ⁴The University of Adelaide, Australia

312 Patient concerns and help-seeking for problems with opioid medications for chronic noncancer pain

G. Campbell, B. Larance, S. Nielsen, T. Moore, C. O'Donnell, L. Degenhardt. National Drug and Alcohol Research Centre, The University of New South Wales, Australia

313 Association between Internet addiction and sleep quality among college students in Taiwan

Y-J. Chang. National Taiwan Normal University, Taiwan

314 Using Twitter for monitoring marijuana use and perceptions in Chile: An online approach to get real-time national data

V. Cortes¹, C. Ibanez², J. Velasquez¹. ¹Department of Industrial Engineering, University of Chile, Chile; ²Department of Psychiatry and Mental Health, University of Chile, Chile

315 Point prevalence and respective 95% confidence intervals for HIV and hepatitis C virus infection among crack cocaine and similar substances in Brazil (2012–2013)

C. Coutinho¹, L. Toledo¹, N. Bertoni², F. Bastos¹. ¹Oswaldo Cruz Foundation, Brazil; ²Brazilian National Cancer Institute, Brazil

316 Self-reported driving beliefs and practices of medical and recreational cannabis users in the United States

C. Cuttler¹, M. Sexton^{2,3}, L. Mischley⁴. ¹Washington State University, United States; ²University of California San Diego, United States; ³Center for the Study of Cannabis and Social Policy, United States; ⁴Bastyr University Research Institute, United States

317 The global burden of disease attributable to substance use and dependence: Findings from the 2015 global burden of disease study

L. Degenhardt¹, J. Leung^{2,3,4}, A. Ferrari², H. Erskine², F. Charlson², D. Santomauro², H. Whiteford², W. Hall⁵, T. Vos⁴. ¹National Drug and Alcohol Research Centre, The University of New South Wales, Australia; ²The University of Queensland School of Public Health, Australia; ³Policy and Epidemiology Group, Queensland Centre for Mental Health Research, Australia; ⁴Institute for Health Metrics and Evaluation, University of Washington, United States; ⁵Centre for Youth Substance Abuse Research, The University of Queensland, Australia

318 Prevalence of substance use and attachment dimensions among Czech adolescent girls in residential care

P. Dolezalova. National Institute of Mental Health, Czech Republic

319 The opioid epidemic in Canada: Trends in diversion of commonly abused prescription drugs in Ontario

O. Dziadkowiec¹, M-C. Lelait¹, Z. Margolin¹, T. Rosen¹, J. Green², R. Dart², S. Kurtz³. ¹Rocky Mountain Poison and Drug Center, United States; ²Canadian Consumer Product and Pharmaceutical Safety, Inc., Canada; ³Center for Applied Research on Substance Use and Health Disparities, Nova Southeastern University, United States

320 Association between prenatal exposure to cannabis and child behavior: A multi-informant approach

H. El Marroun¹, I. Franken², F. Verhulst¹, H. Tiemeier³. ¹Erasmus University Medical Center (Erasmus MC), Sophia Children's Hospital, The Netherlands; ²Erasmus University Rotterdam, The Netherlands; ³Erasmus MC, The Netherlands

- 321 *Assessment of exclusive and dual cigarette and hookah smoking among a sample of pregnant women in Egypt*
O. El Shahawy^{1,2}, K. Labib³, E. Mead⁴, A. Naghib³, S. Sherman^{1,2}, C. Oncken⁴. ¹New York University School of Medicine, United States; ²Public Health Research Center, New York University–Abu Dhabi, United Arab Emirates; ³Ain Shams University, Egypt; ⁴University of Connecticut, United States
- 322 *Prevalence of personality disorders in parents of patients with substance dependence disorder*
M. Elhamshary^{1,2}, D. Radwan^{2,3}, A. Haroun El Rasheed². ¹Psychological Medicine Hospital, Egypt; ²Ain Shams University, Egypt; ³National Research Center–Abu Dhabi, United Arab Emirates
- 323 *Global prevalence of illicit and prescription opioid misuse*
J. Ellerstrand¹, J. Leung^{1,2,3}, A. Ferrari^{1,2,3}, H. Whiteford¹, L. Degenhardt^{3,4}. ¹School of Public Health, The University of Queensland, Australia; ²Policy and Epidemiology Group, Queensland Centre for Mental Health Research, Australia; ³Institute for Health Metrics and Evaluation, University of Washington, United States; ⁴National Drug and Alcohol Research Centre, The University of New South Wales, Australia
- 324 *Khat use among mothers at Harar City and its effect on mental health, stress, anxiety, and commitment to parental role*
T. Feyissa. Ambo University, Ethiopia; Addis Ababa University, Ethiopia
- 325 *The Network for the Improvement of Addiction Treatment (NIATx): Ukraine's experience*
T. Fomenko¹, A. Mazhnaya^{1,2}, A. Meteliuk¹. ¹ICF Alliance for Public Health, Ukraine; ²Department of Health, Behavior and Society, Johns Hopkins Bloomberg School of Public Health, United States
- 326 *Patterns of cannabis use in patients admitted for addiction treatment in Spain*
F. Fonseca^{1,2}, M. Torrens^{1,2}, M. Farre^{1,2,3}, K. McBride⁴, I. Maremmani^{5,6}, M. Guareschi⁶, J. Green⁴, R. Dart^{4,7}. ¹Institut de Neuropsiquiatria i Addiccions, Hospital del Mar and Institut Hospital del Mar d'Investigacions Mèdiques, Spain; ²Universitat Autònoma de Barcelona, Spain; ³Germans Trias University I Pujol Hospital, Institute for Health Science Research Germans Trias i Pujol, Spain; ⁴Rocky Mountain Poison and Drug Center, United States; ⁵Department of Neurosciences, Santa Chiara University Hospital, University of Pisa, Italy; ⁶Association for the Application of Neuroscientific Knowledge to Social Aims, Italy; ⁷University of Colorado-Denver School of Medicine, United States
- 327 *The interplay between trajectories of drug injecting and housing instability over a 12-month period among people who inject drugs*
E. Fortier^{1,2}, M-P. Sylvestre², A.A. Artenie², D. Jutras-Aswad², E. Roy^{3,4}, J. Grebely⁵, J. Bruneau². ¹Department of Family and Emergency Medicine, Faculty of Medicine, Université de Montréal, Canada; ²Centre Hospitalier de l'Université de Montreal Research Center, Canada; ³Université de Sherbrooke, Canada; ⁴Institut National de Santé Publique du Québec, Canada; ⁵Kirby Institute, The University of New South Wales, Australia
- 328 *Factors associated with the history of drug use among female sex workers in India*
C.J.K. Francis. Nestle India Limited, India
- 329 *Smokeless tobacco use and low-birth-weight children among women in a rural setting of Chennai, India*
D.L. Francis. Tamil Nadu Dr. M.G.R. Medical University, India

330 Consults to an addiction unit in a tertiary hospital

D. Fuster^{1,2}, X. Garcia^{1,2}, Y. Zuluaga^{1,2}, J. Tor^{1,2}, A. Sanvisens^{1,2}. ¹Internal Medicine Department, Germans Trias University i Pujol Hospital, Spain; ²Universitat Autònoma de Barcelona, Spain

331 Traumatic events in childhood and drug abuse: A systematic review and meta-analysis of longitudinal studies

S. Halpern¹, F. Schuch¹, A. Sordi¹, J. Scherer², M. Pachado¹, L. Fara¹, C. Dalbosco¹, F. Pechansky², F. Kessler^{2,3}, L. von Diemen². ¹Center for Drug and Alcohol Research, Federal University of Rio Grande do Sul (UFRGS), Brazil; ²Center for Drug and Alcohol Research, Hospital de Clínicas de Porto Alegre, UFRGS, Brazil; ³Department of Psychiatry and Legal Medicine, UFRGS, Brazil

332 Iranian university students' knowledge, attitude, and behavior study on drug abuse, role of resilience, and emotional health

H. Hoseyni¹, S. Momtazi^{2,3}, M. Ayubi², F. Taremi⁴, S. Mazloomzadeh^{2,3}. ¹Iran University of Medical Sciences, Iran; ²Zanjan University of Medical Sciences, Iran; ³Social Determinants of Health Research Center, Iran; ⁴Addiction Research Center, University of Welfare Sciences, Iran

333 Drug use trends among Israeli school dropouts: Age, gender, and country-of-origin comparisons (2004–2014)

R. Isralowitz, A. Reznik. Ben Gurion University, Regional Alcohol and Drug Abuse Research Center, Israel

334 Drug use patterns, risk behavior, and psychosis in ketamine users

L. Jia-Jin¹, L. Chiang-shan², Z. Sheng², C-C. Hung³, T. Szu-Hsien Lee¹. ¹National Taiwan Normal University, Taiwan; ²Yale University School of Medicine, United States; ³Institute of Brain Science, National Yang Ming University, Taiwan

335 Psychosocial interventions for reducing marijuana smoking by pregnant women

B. Kariuki. Teenagers Plus Community-Based Organization, Kenya

336 Female crack users: High rates of social vulnerability in Brazil

F. Kessler^{1,2}, T. Vernaglia³, M. Siqueira⁴, T. Leite³, S. Faller⁵, F. Pechansky⁵, F. Sudbrack⁶, M. Cruz³. ¹Department of Psychiatry and Legal Medicine, Federal University of Rio Grande do Sul (UFRGS), Brazil; ²Center for Drug and Alcohol Research (CPAD), Hospital de Clínicas de Porto Alegre, UFRGS, Brazil; ³Federal University of State of Rio de Janeiro, Brazil; ⁴Federal University of Espírito Santo, Brazil; ⁵CPAD, UFRGS, Brazil; ⁶Brasília University, Brazil

337 Application of the randomized response technique to the nationwide general population survey on drugs in the Republic of Georgia

I. Kirtadze^{1,2}, D. Otiashvili¹, M. Tabatadze^{1,2}, I. Vardanashvili², L. Sturua³, T. Zabransky⁴, J. Anthony⁵. ¹Addiction Research Centre, Alternative Georgia, Georgia; ²Iliia State University, Georgia; ³National Center of Disease Control and Public Health, Georgia; ⁴ResAd Institute, Czech Republic; ⁵Michigan State University, United States

338 Prevalence of addictive behaviors: Thai national mental health survey 2013

P. Kittirattanapaiboon, A. Tanaree, N. Tantirangsee, W. Chutha. Department of Mental Health, Ministry of Public Health, Thailand

339 Prevalence of heavy alcohol use among people receiving methadone after a switch to Methadose

J. Klimas¹, M. Milloy², E. Nosova², E. Wood², T. Kerr², K. Hayashi². ¹University College Dublin, Ireland; ²University of British Columbia, Canada

- 340 *Sex differences in alcohol-related problems among individuals living with HIV in Lagos, Nigeria*
O.M. Koyejo¹, R.A. Lawal¹, W. Kliever², C.A. Gbiri³, D.S. Svikis². ¹Federal Neuropsychiatry Hospital, Nigeria; ²Department of Psychology, Virginia Commonwealth University, United States; ³Neurophysiotherapy Unit, Department of Physiotherapy, College of Medicine, University of Lagos, Nigeria
- 341 *Gender roles in Mexico, what is changing and what is not: Implications for youth substance use prevention*
S. Kulis¹, F. Marsiglia¹, S. Ayers¹, B. Nuno-Gutierrez², A. Gonzalvez¹. ¹Arizona State University, United States; ²Universidad de Guadalajara, Mexico
- 342 *Geographical inequalities in drug abuse risk in Taiwan due to sociodemographic, degree of industrialization, and health status differences*
Y-C. Lan¹, P-C. Kuo². ¹Department of Health Risk Management, China Medical University, China; ²Department of Public Health, China Medical University, China
- 343 *A comprehensive examination of the impacts of a potentially tamper-resistant oxycodone formulation in Australia*
B. Larance¹, A. Peacock¹, R. Ali², M. Farrell¹, R. Bruno³, N. Lintzeris⁴, T. Dobbins¹, L. Degenhardt¹. ¹National Drug and Alcohol Research Centre, The University of New South Wales, Australia; ²The University of Adelaide, Australia; ³Department of Psychology, University of Tasmania School of Medicine, Australia; ⁴Drug and Alcohol Services, South Eastern Sydney Local Health District, Australia
- 344 *Double whammy: Adverse childhood events and pain reflect symptomology and quality of life in women in substance abuse treatment*
M. Lawental^{1,2}, C. Zlotnick², D. Pud². ¹University of South Florida, United States; ²University of Haifa, Israel
- 345 *Prevalence rates and associated factors of frequent micturition and HIV infection in ketamine users in Taipei*
T. Szu-Hsien Lee¹, D.S. Metzger^{2,3}, C-C. Hung⁴, J-J. Lee¹. ¹Department of Health Promotion and Education, National Taiwan Normal University, Taiwan; ²University of Pennsylvania, United States; ³Treatment Research Institute, United States; ⁴Institute of Brain Science, National Yang Ming University, Taiwan
- 346 *Opioid use disorders 1990–2015: Results on sex and age differences from the global burden of disease*
J. Leung^{1,2,3}, A. Ferrari^{1,2,3}, F. Charlson^{1,2,3}, H. Whiteford^{1,2,3}, T. Vos³, L. Degenhardt⁴. ¹The University of Queensland School of Public Health, Australia; ²Policy and Epidemiology Group, Queensland Centre for Mental Health Research, Australia; ³Institute for Health Metrics and Evaluation, University of Washington, United States; ⁴National Drug and Alcohol Research Centre, The University of New South Wales, Australia
- 347 *HIV-1 and hepatitis C virus transmission bottleneck in Chinese people who inject drugs*
F. Li¹, Y. Feng¹, L. Ma¹, K.J. Bar², D.S. Metzger², Y. Shao¹. ¹Chinese Center for Disease Control and Prevention, China; ²University of Pennsylvania, United States
- 348 *The situational analysis of marijuana use in Thailand*
S. Likhitsathian, M. Srisurapanont, W. Jiraporncharoen, C. Angkurawaranon, A. Aramrattana. Chiang Mai University, Thailand
- 349 *Gambling in Iran*
M. Mardaneh, M. Maarefvand, Z. Zamani, Z. Morshedi. Substance Abuse and Dependence Research Center, University of Social Welfare and Rehabilitation Sciences, Iran

350 Co-occurring disorders: A challenge for community-based residential care facilities for substance use in Mexico

R. Marin-Navarrete¹, M.E. Medina-Mora¹, V. Horigian², I. Salloum², L. Villalobos-Gallegos¹. ¹National Institute of Psychiatry, Mexico; ²University of Miami Miller School of Medicine, United States

351 The impact of law enforcement on risk for injection drug use initiation assistance in North America

J. Melo¹, R. Garfein¹, K. Hayashi^{2,3}, M-J. Milloy², K. Debeck², S. Sun¹, S. Jain¹, S. Strathdee¹, D. Werb¹. ¹University of California San Diego, United States; ²British Columbia Centre for Excellence in HIV/AIDS, Canada; ³St. Paul's Hospital, Simon Fraser University, Canada

352 Risk perception and driving under the influence of marijuana: A study among Brazilian college students

J. Mendes^{1,2}, O. Jacobina³, C. Passos¹. ¹National Secretariat on Drugs Policy, Brazil; ²Institute of Higher Education of Brasília, Brazil; ³State Secretariat on Human Rights, Brazil; ⁴University of Brasilia, Brazil

353 Opium abuse and its relationship to depression among medical/surgical hospitalized patients

S. Momtazi¹, Y. Abolghasemi Fakhri², S. Faghihzadeh¹. ¹Zanjan University of Medical Sciences, Iran; ²Tabriz University of Medical Sciences, Iran

354 Hepatitis C virus infection and fibrosis of the liver in former injection drug users with alcohol use disorder

R. Muga¹, A. Sanvisens¹, F. Bolao², Y. Zuluaga¹, D. Fuster¹, I. Rivas³, J. Tor¹. ¹Internal Medicine Department, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, Spain; ²Hospital Universitari de Bellvitge, Spain; ³Centre Delta, Institute for Safe Medication Practices, Spain

355 Lifetime prevalence, correlates, and patterns of heroin use among youth in Ecuador

D. Ocana¹, W.L. Kliwer², E. Prom-Wormley³. ¹Humphrey Fellowship Program, Virginia Commonwealth University, United States; ²Department of Psychology, Virginia Commonwealth University, United States; ³Department of Family Medicine and Population Health, Virginia Commonwealth University, United States

356 Cannabis use disorders and associated factors among commercial drivers arrested for traffic offenses in Lagos

M. Ojo, A. Adegbohun, G. Morakinyo. Federal Neuropsychiatric Hospital Yaba, Nigeria

357 Psychological well-being and substance abuse among adolescents in a senior secondary school in Lagos, Nigeria

C. Okonkwo, A. Ajayi, J. Olusegun. Federal Neuropsychiatric Hospital Yaba, Nigeria

358 Emerging drugs of abuse: Current perspectives on substituted opiates, nicotine, cannabinoids, and cathinone among urban populations in Kenya

P. Okwarah^{1,2}, R. Gakunju^{1,3}, R. Kahuthia⁴, J. Thungu⁵. ¹Movement Against Substance Abuse in Africa, Kenya; ²Jomo Kenyatta University of Agriculture and Technology, Kenya; ³National Authority for the Campaign Against Alcohol and Drug Abuse, Kenya; ⁴Kenyatta University, Kenya; ⁵Thogoto Teachers College, Kenya

359 Psychological factors and risk perception as predictors of tobacco smoking behavior among undergraduates of University of Calabar, Nigeria

U. Onukogu. Federal Neuropsychiatric Hospital Calabar, Cross River State, Nigeria

360 High rates of incarceration due to drug trafficking in the last decade in Brazil

F. Ornell¹, J. Scherer¹, K. Ligabue², J. Narvaez¹, C. Dalbosco¹, R. Ornell¹, R. Dotta³, L. Telles¹, F. Pechansky², L. von Diemen¹, F. Kessler^{1,4}. ¹Center for Drug and Alcohol Research, Hospital de Clinicas de Porto Alegre, Federal University of Rio Grande do Sul (UFRGS), Brazil; ²Center for Drug and Alcohol Research, UFRGS, Brazil; ³Fundacao Escola Superior do Ministerio Publico, Brazil; ⁴Department of Psychiatry and Legal Medicine, UFRGS, Brazil

361 Exploring the new phenomena of homemade extraction and injection of ephedra plant product in Georgia

D. Otiashvili^{1,2}, I. Kirtadze¹, D. Bergen-Cico³. ¹Addiction Research Centre, Alternative Georgia, Georgia; ²Georgian Institute of Public Affairs, Georgia; ³Department of Public Health, Syracuse University, United States

262 Causal pathways between impulsiveness, crack cocaine use consequences, and attention deficit hyperactivity disorder

M. Pachado¹, A. Willhelm², L.S.P. Guimaraes³, F. Pechansky¹, F. Kessler^{4,5}, R.M. Martins De Almeida². ¹Center for Drug and Alcohol Research, Federal University of Rio Grande do Sul (UFRGS), Brazil; ²Department of Psychology, UFRGS, Brazil; ³Department of Epidemiology and Statistics, Hospital de Clinicas de Porto Alegre (HCPA), Brazil; ⁴Department of Psychiatry and Legal Medicine, UFRGS, Brazil; ⁵Center for Drug and Alcohol Research, HCPA, UFRGS, Brazil

363 Alcohol, substance use, and violence among secondary school students in Northeastern Thailand

S. Paileeklee¹, S. Dithisawatwet². ¹Faculty of Medicine, Khon Kaen University, Thailand; ²The Office of Disease Prevention and Control, Region 8, Thailand

364 Predictors of risk of illicit drug use during pregnancy among women attending midwife obstetric units in the Cape Metropole, South Africa

P. Petersen Williams^{1,2}, C. Mathews^{1,2}, E. Jordaan^{1,3}, C. Parry^{1,4}. ¹South African Medical Research Council, South Africa; ²University of Cape Town, South Africa; ³University of the Western Cape, South Africa; ⁴Stellenbosch University, South Africa

365 Driving under the effect of marijuana: Cross-sectional study using the 2014 Chilean National Drugs Survey

E. Pizarro¹, J. Marin¹, N. Rodriguez¹, C. Ibanez². ¹Research Department, National Service for Prevention and Rehabilitation of Drug and Alcohol Consumption, Chile; ²Department of Psychiatry and Mental Health, University of Chile, Chile

366 Characteristics of contemporary patients with heroin use disorder at the first treatment

I. Rivas¹, A. Sanvisens², E. Faure¹, M. Rubio¹, N. Espinach¹, T. Munoz¹, Y. Zuluaga², D. Fuster². ¹Municipal Center for Substance Abuse Treatment (IMSP Centre Delta), Spain; ²Internal Medicine Department, Hospital Universitari Germans Trias i Pujol, Universitat Autonoma de Barcelona, Spain

367 The Great Lakes effect: Discovering hot spots for rates of diversion of prescription opioids within Ontario, Canada

T. Rosen¹, Z. Margolin¹, M-C. Lelait¹, O. Dziadkowiec¹, J. Green², R. Dart², S. Kurtz³. ¹Rocky Mountain Poison and Drug Center, United States; ²Canadian Consumer Product and Pharmaceutical Safety, Inc., Ontario; ³Center for Applied Research on Substance Use and Health Disparities, Nova Southeastern University, United States

- 368 *Effects of telomere length on depression in a crack cocaine addiction background*
D.L. Rovaris¹, A. de Castro¹, B. Sanvicente-Vieira², C. Winkler¹, G. Xavier³, S.I.N. Belangero³, C. Bau¹, R. Grassi-Oliveira². ¹Department of Genetics, Universidade Federal do Rio Grande do Sul, Brazil; ²Pontifical Catholic University of Rio Grande do Sul, Brazil; ³Department of Morphology and Genetics, Universidade Federal de Sao Paulo, Brazil
- 369 *Could tobacco be responsible for the apparent increased frequency of orofacial clefts in Bolivia?*
I. Salvatierra. Arco Iris Hospital–La Paz, Bolivia; Hubert Humphrey Fellowship, Virginia Commonwealth University, United States
- 370 *Early substance use and child sexual abuse: Risk factors for adolescent entry to the sex trade in the U.S.–Mexico Border region*
A. Servin^{1,2}, K. Brouwer³, G. Rangel⁴, J. Silverman². ¹University Xochicalco School of Medicine, Mexico; ²Division of Global Public Health, University of California San Diego, United States; ³Department of Family Medicine and Public Health, University of California San Diego, United States; ⁴United States–Mexico Border Health Commission, United States
- 371 *Psychometric properties of the stigma scale among Pakistanis with substance use disorders*
S. Shahzad^{1,2}, N. Begum³, W. Kliever². ¹University of Karachi, Pakistan; ²Virginia Commonwealth University, United States; ³Area Study Center for Europe, University of Karachi, Pakistan
- 372 *Clinical characteristics of HPTN 074-screened people who inject drugs in Jakarta*
H. Susami¹, I. Octavianto¹, Z. Djoerban¹, S. Djauzi¹, R. Sarasvita², D. Imran¹, W.C. Miller³, I. Hoffman⁴, S. Rose⁵, D.S. Metzger⁶. ¹HPTN 074 Indonesia Site–Cipto Mangunkusumo Hospital, Indonesia; ²Indonesia National Narcotics Board, Indonesia; ³HIV Prevention Trials Network, Ohio State University, United States; ⁴HIV Prevention Trials Network, University of North Carolina, United States; ⁵FHI 360, HIV Prevention Trials Network, United States; ⁶Treatment Research Institute, University of Pennsylvania, United States
- 373 *Dual-diagnosis resource needs in Spain: A national survey of professionals*
N. Szerman. Hospital Universitario Gregorio Marañon, Spain; Spanish Society Dual Pathology, Spain
- 374 *Prevalence and correlates of misuse of benzodiazepines in Gjilan region, Kosovo*
Z. Tahiri, M. Qazimi. Main Family Medicine Center, Kosovo
- 375 *Substance use in Northern Thailand: Results from the 6th National Household Survey (2016)*
K. Thaikla, A. Aramrattana, A. Nimmannit. Chiang Mai University, Thailand
- 376 *Criminal involvement of crack cocaine users in the city of Rio de Janeiro and greater metropolitan area*
L. Toledo¹, I. Cano², L. Bastos¹, N. Bertoni³, C. Coutinho¹, F.I. Bastos¹. ¹Oswaldo Cruz Foundation, Brazil; ²State University of Rio de Janeiro, Brazil; ³Brazilian National Cancer Institute, Brazil
- 377 *Prevalence of tobacco use in Indonesia: A preliminary analysis of cultural and structural factors*
N. Widyaningrum, J. Yu. University at Albany, State University of New York, United States

378 Drug situation in the countries of Central Asia: Outputs of the Central Asia Drug Action Programme

T. Zabransky^{1,2,3}, V. Mravcik^{1,4}, A. Talu⁵, E. Jasaitis⁶. ¹ResAd Institute, Czech Republic; ²Palacky University, Czech Republic; ³Charles University in Prague, Czech Republic; ⁴National Monitoring Centre for Drugs and Addiction, Czech Republic; ⁵Department of Public Health, University of Tartu, Estonia; ⁶Drug Control Department Under the Government of the Republic of Lithuania, Réseau Européen d'Information sur les Drogues et les Toxicomanies (REITOX), National Focal Point, Lithuania

Prevention

400 Distribution risks involving psychological dependence among adults in primary health care systems in Kazakhstan

G. Altynbekova, G. Magauina, G. Sadvakasova. Republican Scientific and Practical Centre of Medical and Social Problems of Drug Abuse–Pavlodar, Kazakhstan

401 HIV/AIDS, hepatitis, and sexually transmitted infections prevention among Egyptian substance users

A. Bakhoun^{1,2}, A. Stock³, E. El Kharrat^{1,4}. ¹Freedom Drugs and HIV Program, Egypt; ²National Hepatology and Tropical Medicine Research Institute, Egypt; ³University of East Anglia, Norwich Medical School, United Kingdom; ⁴World Federation of Therapeutic Communities, Egypt

402 Intervening with young substance-using women who have left school early: Results of a pilot study in Cape Town

T. Carney^{1,2}, F. Browne³, B. Myers^{1,2}, T. Kline³, W. Wechsberg^{3,4,5,6}. ¹South African Medical Research Council, South Africa; ²University of Cape Town, South Africa; ³Research Triangle Institute International, United States; ⁴The University of North Carolina, United States; ⁵North Carolina State University, United States; ⁶Duke University, United States

403 High prevalence of HIV in noninjecting drug users in Brazil

L. Fara, J. Scherer, F. Ornell, V. Loss, J. Schuch, B.A. Ferlin, F. Kessler, F. Pechansky, L. von Diemen. Center for Drug and Alcohol Research, Hospital de Clinicas de Porto Alegre, Federal University of Rio Grande do Sul, Brazil

404 Assessment of a behavioral intervention for HIV-positive persons who inject drugs in Ukraine

T. Kiriazova. Ukrainian Institute on Public Health Policy, Ukraine

405 Typology of street substance users' communities in Tehran

M. Maarefvand, S. Shirazi, R. Peyravi, A. Farhoudian. Substance Abuse and Dependence Research Center, University of Social Welfare and Rehabilitation Sciences, Iran

406 High-risk behaviors among Iranian female drug users inspiring Health Belief Model

E. Merghati Khoei¹, M. Jamshidimanesh², F. Ilika². ¹Tehran University of Medical Sciences, Iranian National Center for Addiction Studies, Iran; ²Iran University of Medical Sciences, Iran

407 Predictors of HIV and hepatitis C virus seroconversion in people who inject drugs in Ukraine

A. Meteliuk¹, A. Mazhnaya², S. Filippovich¹, A. Zelenev³, F.L. Altice^{4,5}. ¹Alliance for Public Health, Ukraine; ²Department of Health, Behavior and Society, Johns Hopkins Bloomberg School of Public Health, United States; ³Center for Interdisciplinary Research on AIDS, Yale University, United States; ⁴AIDS Program, Section of Infectious Diseases, Yale University School of Medicine, United States; ⁵Division of Epidemiology of Microbial Diseases, Yale University School of Public Health, United States

408 HPTN074: Spatial accessibility to antiretroviral therapy care among people who inject drugs in Jakarta

M. Muslim^{1,2}, H. Susami^{1,3}, Z. Djoerban^{1,3}, S. Djauzi^{1,3}, R. Sarasvita^{1,3,4}, D. Imran¹, P. Richardson⁵, E. Piwowar-Manning⁵, W. Miller⁶, I. Hoffman⁷, S. Rose⁸, D. Metzger^{9,10}.

¹HPTN 074 Indonesia Site—Cipto Mangun Kusumo Hospital, Indonesia; ²Climate Change Research Center, Universitas Teknologi Sumbawa, Indonesia; ³Abhipraya Foundation, Indonesia; ⁴National Narcotics Board of Indonesia, Indonesia; ⁵Johns Hopkins University, United States; ⁶Ohio State University, United States; ⁷University of North Carolina, United States; ⁸FHI 360, HIV Prevention Trials Network, United States; ⁹University of Pennsylvania, United States; ¹⁰Treatment Research Institute, United States

409 HIV prevalence and linkage to care among trauma-exposed substance-using women in Cape Town, South Africa

B. Myers¹, T. Carney¹, F. Browne², W. Wechsberg². ¹South African Medical Research Council, South Africa; ²Research Triangle Institute International, United States

410 Antiretroviral therapy is the most essential intervention among people who inject drugs (PWID) to achieve reduction in HIV transmission through PWID to others in Burma (Myanmar)

R. Myint. Myanmar Anti-Narcotics Association, Burma (Myanmar)

411 The effectiveness of Choice-F on women freshman college students in reducing substance use and other risk behaviors

V. Ryabukha. Prevention Center, “Choice,” Ukraine

412 Opportunities for and awareness of pre-exposure prophylaxis among HIV-infected Russian women and men

J. Tsui^{1,2}, J. Wagman³, D. Cheng⁴, N. Gnatienco⁵, E. Blokhina⁶, L. Forman⁴, A. Bazzi⁴, D. Lioznov^{6,7}, J. Samet^{4,5}. ¹University of Washington, United States; ²Harborview Medical Center, United States; ³University of California San Diego, United States; ⁴Boston University, United States; ⁵Boston Medical Center, United States; ⁶First Pavlov State Medical University, Russia; ⁷Pasteur Research Institute of Epidemiology and Microbiology, Russia

413 Public injection and injection initiation assistance among people who inject drugs in two North American countries

D. Vashishtha¹, M.L. Mittal¹, R. Garfein¹, K. Hayashi², M-J. Milloy², J. Cuevas-Mota¹, S. Sun¹, S. Jain¹, S. Strathdee¹, D. Werb¹. ¹University of California San Diego, United States; ²British Columbia Centre for Excellence in HIV/AIDS, Canada

414 Systematic review of interventions to reduce harm associated with substance use in women

N. Yousaf¹, W.L. Kliever². ¹Hubert H. Humphrey Fellowship Program, Virginia Commonwealth University, United States; ²Department of Psychology, Virginia Commonwealth University, United States

Treatment

500 Paradoxical drugs policy and practice: The evil to worsen the lives of the people who use drugs and their families in Nepal

S. Acharya^{1,2}, S. Paudel^{2,3}. ¹Tribhuvan University, Nepal; ²National Association of People Living With HIV in Nepal, Nepal; ³University of Western Sydney, Australia

501 Pilot study on smokable cocaine users receiving treatment in Argentina, Brazil, Chile, Paraguay, and Uruguay

G. Ahumada¹, F. Cumsille², M. Hynes², A.C. Camarotti^{3,4}, L. De Oliveira Pinto⁵, N. Del Valle⁶, M. Oliva⁷, H. Suarez⁸. ¹Red Latinoamericana de Investigadores en Drogas, Argentina; ²The Inter-American Observatory on Drugs, Inter-American Drug Abuse Control Commission, Organization of American States, United States; ³Secretariat of Programming for the Prevention of Drug Addiction and Fight Against Drug Trafficking, Argentina; ⁴Instituto Gino Germani, Universidad de Buenos Aires, Argentina; ⁵Secretary of Health of the State of Bahia, Brazil; ⁶National Secretariat for Drug Policy (SENAD), Paraguay; ⁷SENAD, Chile; ⁸Junta Nacional de Drogas, Uruguay

502 Marijuana and amphetamine use among patients on methadone treatment in Malaysia

N. Ali¹, S. Aziz², S. Nordin³, N. Che Mi², N. Abdullah⁴, M. Mahmud⁵, V. Paranthaman⁶, M. Mazlan⁷. ¹Masjid Tanah Health Clinic, Melaka, Malaysia; ²Kuala Lumpur Hospital, Malaysia; ³Batu 9 Health Clinic, Malaysia; ⁴Tengku Ampuan Rahimah Hospital, Malaysia; ⁵Selangor Buluh Health Clinic, Malaysia; ⁶Jelapang Health Clinic, Malaysia; ⁷Muar Substance Abuse Research Centre, Malaysia

503 Depenalizing drug use: A pilot project to move arrested people who use drugs from police detention to treatment in Besut, Terengganu, Malaysia

M.F. Basir¹, G.D. Selventhiranathan², A. Khan², B. Vicknasingam¹. ¹Centre for Drug Research, Universiti Sains Malaysia, Malaysia; ²Performance, Management and Delivery Unit, Prime Minister's Department, Malaysia

504 United Nations Office on Drugs and Crime, World Health Organization multisite study on community management of opioid overdose including naloxone

A. Busse¹, G. Gerra¹, V. Poznyak², R. McDonald³, N. Clark², E. Saenz¹, W. Kashino¹, G. Aiello¹, J. Strang³. ¹United Nations Office on Drugs and Crime, Austria; ²World Health Organization, Switzerland; ³King's College London, United Kingdom

505 Diversion of patients attending emergency departments in Northern Ireland

A. Campbell, S. Millen. Drug and Alcohol Research Network, Queens University Belfast, Ireland

506 More severe executive abnormalities in crack versus snorted cocaine-dependent patients: A neuropsychological study

P. Cunha¹, H. Oliveira Jr.¹, P. Goncalves¹, M. Ometto¹, B. Santos², A. Malbergier¹, R. Amaral¹, S. Nicastri¹, A. Guerra De Andrade¹. ¹Institute of Psychiatry, University of São Paulo Medical School, Brazil; ²University of São Paulo School of Nursing, Brazil

507 Results from 10 years of a smoking cessation program in Florianopolis, Brazil

R. de Cerqueira Campos¹, F. De Conto¹, M. Pereira¹, P. Alexander². ¹City Health Department of Florianopolis–Santa Catarina, Brazil; ²Health Administration, College of Business, Florida Atlantic University, United States

508 Do males and females present similar needs and problems for drug abuse treatment? Comparative study between Brazil and the United States

F. De Conto^{1,2}, R. de Cerqueira Campos¹, S. Kelpin³, D. Svikis³. ¹City Health Department of Florianopolis–Santa Catarina, Brazil; ²Federal University of Santa Catarina, Brazil; ³Virginia Commonwealth University, United States

509 Providing PAWSitive support to methadone clients: A case study

C. Dell^{1,2}, D. Chalmers³. ¹University of Saskatchewan, Canada; ²Canadian Centre on Substance Abuse, Canada; ³University of Regina, Canada

510 Cost of an integrated treatment program for opiate addiction and HIV in Ho Chi Minh City, Vietnam

C. Denis^{1,2}, J. Becher¹, T. Doan³, H. Tran³, L. Nguyen³, T. Nguyen^{3,4}, L. Huang³, V. Trias³, M. Auriacombe², A. Voisin⁵, G. Raguin³, S. Hoai⁶, G. Le Truong⁶, J-P. Daulouede^{3,5}, C. O'Brien¹, D.S. Metzger⁷. ¹University of Pennsylvania Perelman School of Medicine, United States; ²CNRS USR 3413 SANPSY, University of Bordeaux, France; ³Expertise France, France; ⁴Ho Chi Minh City University of Medicine and Pharmacy, Vietnam; ⁵Bizia Addiction Clinic, France; ⁶Ho Chi Minh City Provincial AIDS Committee, Vietnam; ⁷Treatment Research Institute, University of Pennsylvania, United States

511 Correlates of retention in opioid agonist treatment of opioid dependence in Ukraine

K. Dumchev¹, S. Dvoriak¹, O. Chernova¹, O. Morozova², F. Altice³. ¹Ukrainian Institute on Public Health Policy, Ukraine; ²Yale University School of Public Health, United States; ³AIDS Program, Section of Infectious Diseases, Yale University School of Medicine, United States

512 Brief behavioral educational interventions to promote methadone expansion within prisons in Ukraine

S. Dvoriak^{1,2}, M. Polonsky³, F. Altice³. ¹Ukrainian Institute on Public Health Policy, Ukraine; ²Academy of Labour, Social Relations and Tourism, Department of Social Work, Ukraine; ³Yale University School of Medicine, United States

513 Challenges in detoxification of addicted traumatized patients in Nigeria

E. Ehikhamenor^{1,2}, P. Aliu^{2,3}. ¹University of Benin, Nigeria; ²Save Accident Victims Association of Nigeria, Nigeria; ³National Open University, Nigeria

514 Transcranial direct current stimulation modulates connectivity between dorsolateral prefrontal cortex and insula during drug cue exposure in methamphetamine users

H. Ekhtiari^{1,2}, M. Ebrahimpour³, A. Shahbabaie¹, M.A. Oghabian³. ¹Translational Neuroscience Program, Institute for Cognitive Science Studies, Iran; ²Iranian National Center for Addiction Studies, Iran; ³Neuroimaging and Analysis Group, Tehran University of Medical Sciences, Iran

515 Association between depressive symptoms and smoking in individuals receiving behavioral activation

A. Gonzalez-Roz, S. Weidberg, V. Martinez-Loredo, A. Grande-Gosende, R. Secades-Villa. University of Oviedo, Spain

516 Vulnerability and protective factors among female crack users who abandoned and concluded treatment

T. Guimaraes^{1,2}, S. Halpern¹, C. Dalbosco¹, L. Rosa^{2,3}, F. Pechansky¹, Joana Narvaez¹. ¹Center for Drug and Alcohol Research, Hospital de Clinicas de Porto Alegre, Federal University of Rio Grande do Sul, Brazil; ²Federal University of Piaui, Brazil; ³Regional Center of Reference About Drugs of Juiz de Fora, Brazil

517 Atypical versus typical antipsychotics for the treatment of addiction: A systematic review and meta-analytic study

S.C. Hanu. Hubert H. Humphrey Fellowship Program, Virginia Commonwealth University, United States; Mental Health Authority, Ghana

518 A mixed-methods evaluation of HIV risk among opioid-dependent women in Ukraine

E. Hoff¹, R. Marcus², F. Altice^{2,3,4}, J. Meyer². ¹Yale University School of Medicine, United States; ²AIDS Program, Section of Infectious Diseases, Yale University School of Medicine, United States; ³Department of Epidemiology of Microbial Diseases, Yale University School of Public Health, United States; ⁴University of Malaya-Kuala Lumpur, Malaysia

519 Opioid craving and HIV care cascade outcomes

B. Idrisov^{1,2}, K. Lunze¹, D. Cheng¹, E. Blokhina^{3,4}, N. Gnatienco^{1,4}, E. Quinn⁵, C. Bridden^{1,4}, A. Walley^{1,6}, K.J. Bryant⁷, D. Lioznov^{8,9}, E. Krupitsky^{10,11}, J. Samet^{1,5}. ¹Boston Medical Center, United States; ²Bashkir State Medical University, Russia; ³First Pavlov State Medical University, Russia; ⁴Uganda Russia Boston Alcohol Network for Alcohol Research Collaboration on HIV/AIDS, United States; ⁵Boston University, United States; ⁶Boston Public Health Commission, United States; ⁷National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, United States; ⁸Pasteur Research Institute of Epidemiology and Microbiology, Russia; ⁹Department of Infectious Diseases and Epidemiology, First St. Petersburg Pavlov State Medical University, Russia; ¹⁰St. Petersburg Bekhterev Research Psychoneurological Institute, Russia; ¹¹Laboratory of Clinical Pharmacology of Addictions, First St. Petersburg Pavlov State Medical University, Russia

520 Design of a multicenter randomized double-blind controlled trial of buprenorphine/naloxone versus placebo for treatment of opioid dependence in China

H. Jiang¹, J. Li², L. Sheng³, Y. Li⁴, W. Ling⁵, M. Zhao¹, W. Hao⁶. ¹Shanghai Jiao Tong University School of Medicine, Shanghai Mental Health Center, China; ²West Hospital of Sichuan University, China; ³Capital Medical University, Beijing An Ding Hospital, China; ⁴Wuhan Mental Health Center, China; ⁵Department of Psychiatry, Integrated Substance Abuse Program, University of California Los Angeles, United States; ⁶Mental Health Institute & Faculty of Psychiatry, Central South University, China

521 Guidelines for establishing an effective and cost-effective alcohol and drug abuse treatment program in Kenya

J.M. Kenga^{1,2}, M.N. Khaemba², F. Kamau³. ¹Hubert H. Humphrey Fellowship Program, Virginia Commonwealth University, United States; ²Kenya Correctional Services, Kenya; ³Drug Board–Nairobi County, Kenya

522 Naltrexone implant, compared to oral naltrexone, improves HIV treatment outcomes of opiate-addicted patients

E. Krupitsky¹, E. Zvartau², G. Woody³, E. Blokhina², R. Gross³. ¹St. Petersburg Bekhterev Research Psychoneurological Institute, Russia; ²First Pavlov State Medical University, Russia; ³University of Pennsylvania, United States

523 Salivary cortisol levels in Brazilian crack cocaine users and early inpatient discharge

K. Ligabue, J. Scherer, F. Ornell, V. Assuncao, M. Rocha, A. Valerio, F. Pechansky, Felix Kessler, L. von Diemen. Center for Drug and Alcohol Research, Hospital de Clinicas de Porto Alegre, Federal University of Rio Grande do Sul, Brazil

524 Ayahuasca as treatment for addictions

R. Lopez. Universidad Mayor de San Andres, Bolivia

525 Concurrent drug use during opioid agonist treatment among people who inject drugs in Ukraine

I. Makarenko^{1,2}, A. Mazhnaya¹, R. Marcus², S. Filippovich¹, S. Dvoriak³, F. Altice^{2,4}.

¹Alliance for Public Health, Ukraine; ²AIDS Program, Section of Infectious Diseases, Yale University School of Medicine, United States; ³Ukrainian Institute on Public Health Policy, Ukraine; ⁴Department of Epidemiology of Microbial Diseases, Yale University School of Public Health, United States

526 Substance use in children in Afghanistan: Gender differences at treatment entry and in response to treatment

A.S. Momand^{1,2}, H. Jones^{3,4}, E. Mattfeld⁵, B. Morales⁶, K. O'Grady⁷. ¹United Nations Office on Drugs and Crime (UNODC), Afghanistan; ²Hubert H. Humphrey Fellowship Program, Virginia Commonwealth University, United States; ³Horizons Program, Department of Obstetrics and Gynecology, University of North Carolina at Chapel Hill, United States; ⁴Department of Psychiatry, Johns Hopkins University, United States; ⁵UNODC, Austria; ⁶Bureau of International Narcotics and Law Enforcement Affairs, U.S. Department of State, United States; ⁷Department of Psychology, University of Maryland, College Park, United States

527 Providing methadone treatment in primary care reduces stigma among patients and providers in Ukraine

O. Morozova¹, S. Dvoriak², I. Pykalo², F. Altice³. ¹Yale University School of Public Health, United States; ²Ukrainian Institute on Public Health Policy, Ukraine; ³AIDS Program, Section of Infectious Diseases, Yale University School of Medicine, United States

528 Domestic violence and gender differences related to legal problems among crack users

J. Narvaez, V. Roglio, L. Dutra, F. Pechansky, F. Kessler. Center for Drug and Alcohol Research, Hospital de Clinicas de Porto Alegre, Federal University of Rio Grande do Sul, Brazil

529 Prevalence of substance use and challenges in accessing treatment among the transgender community in Pakistan

F. Naveed, K. Mushtaq. Drug Free Pakistan Foundation, Pakistan

530 Change over 12 months of an integrated treatment program for opiate addiction and HIV in Ho Chi Minh City, Vietnam: Highlighting the role of counseling

T. Nguyen¹, C. Denis^{2,3}, A. Voisin⁴, T. Doan⁵, H. Tran⁵, L. Nguyen⁵, V. Trias⁵, L. Huang⁵, M. Auriacombe³, G. Raguin⁵, S. Hoai⁶, G. Le Truong⁶, J-P. Daulouede^{4,5}, C. O'Brien², D.S. Metzger^{2,7}. ¹Ho Chi Minh City University of Medicine and Pharmacy, Vietnam; ²University of Pennsylvania Perelman School of Medicine, United States; ³CNRS USR 3413 SANPSY, University of Bordeaux, France; ⁴Bizia Addiction Clinic, France; ⁵Expertise France, France; ⁶Ho Chi Minh City Provincial AIDS Committee, Vietnam; ⁷Treatment Research Institute, United States

531 Initial establishment of pilot drug treatment courts in Vietnam

D. Nguyen¹, H. Vu². ¹National Committee for AIDS, Drugs, Prostitution Prevention and Control, Vietnam; ²Substance Abuse and Mental Health Services Administration, Vietnam

532 Longitudinal study of pharmaceutical opioid dependence in Australia: Patterns and correlates of substance use over 24 months

S. Nielsen^{1,2}, S. Cooper¹, B. Larance¹, R. Bruno^{1,3}, B. Murnion⁴, N. Lintzeris^{2,4}, S. Ling⁵, C. Sadler⁵, A. Dunlop⁵, M. Hardy⁶, P. Claire¹, J. Houseman⁶, N. Phung⁷, A. Brown⁵, P. Haber⁴, L. Degenhardt¹. ¹National Drug and Alcohol Research Centre, The University of New South Wales, Australia; ²Drug and Alcohol Services, South Eastern Sydney Local Health District, Australia; ³Department of Psychology, University of Tasmania School of Medicine, Australia; ⁴University of Sydney, Australia; ⁵Drug and Alcohol Services, Hunter New England Local Health District, Australia; ⁶Northern Sydney Local Health District, Australia; ⁷Drug Health, Western Sydney Local Health District, Australia

533 Contingency management for abstinence versus contingency management for shaping cessation among treatment-seeking smokers

C. Lopez Nunez^{1,2}, R. Secades-Villa², S. Weidberg², A. Gonzalez De La Roz². ¹Private Technical University of Loja, Ecuador; ²University of Oviedo, Spain

534 Influence of family support toward antiretroviral therapy adherence among HIV-infected people who inject drugs

I. Octavianto^{1,2}, A. Fahrudin^{3,4}, H. Susami^{1,5}, R. Sarasvita^{1,5}, D.S. Metzger^{6,7}. ¹HPTN 074 Indonesia Site—Cipto Mangunkusumo Hospital, Indonesia; ²Karisma Foundation, Indonesia; ³Universitas Muhammadiyah Jakarta, Indonesia; ⁴Asiana Foundation, Indonesia; ⁵Abhipraya Foundation, Indonesia; ⁶University of Pennsylvania, United States; ⁷Treatment Research Institute, United States

535 Marijuana disorder among outpatients receiving treatment in Uruguay: Examining consequences in cannabis policy changes

A. Pascale^{1,2}, C. Bares³, M. Valdez¹, C. Herrera¹, A. Usher¹, O. Binagi¹, C. Lopez¹, C. Mediza¹, L. Oliver¹. ¹Grupo de Cavia Outpatient Clinic, Uruguay; ²Red Latinoamericana de Investigadores en Drogas, Uruguay; ³University of Michigan, United States

536 Key challenges of an opioid substitution treatment program in Ukraine

T. Prokhorova, O. Burgay. ICF “Alliance for Public Health,” Ukraine

537 Patients’ attitudes toward opioid agonist therapy in primary health care settings in Ukraine

I. Pykalo¹, O. Morozova², S. Dvoriak¹. ¹Ukrainian Institute on Public Health Policy, Ukraine; ²Yale University, United States

538 Cognitive rehabilitation for individuals with opioid use disorder: A randomized controlled trial

T. Rezapour^{1,2}, H. Ekhtiari^{1,2}, J. Hatami^{1,3}, A. Farhoudian⁴, R. Daneshmand⁴, M. Sofuoglu^{5,6}, A. Noroozi^{2,7}, A. Samiei⁸. ¹Translational Neuroscience Program, Institute for Cognitive Science Studies, Iran; ²Neurocognitive Laboratory, Iranian National Center for Addiction Studies, Iran; ³Department of Psychology, Faculty of Psychology and Education, University of Tehran, Iran; ⁴Substance Abuse and Dependence Research Center, University of Social Welfare and Rehabilitation Sciences, Iran; ⁵Department of Psychiatry, Yale University School of Medicine, United States; ⁶VA Connecticut Healthcare System, United States; ⁷Iranian Institute for Reduction of High-Risk Behaviors, Tehran University of Medical Sciences, Iran; ⁸School of Medicine, Arak University of Medical Sciences, Iran

539 Evaluation of two screening devices for cocaine detection in oral fluid

J. Scherer¹, T. Fiorentin², T. Sousa¹, R. Limberger², F. Pechansky¹. ¹Center for Drug and Alcohol Research, Hospital de Clinicas de Porto Alegre, Federal University of Rio Grande do Sul, Brazil; ²Faculdade de Farmacia, Universidade Federal do Rio Grande do Sul, Brazil

540 Effects of khat (Catha edulis) on electrophysiologic properties of the heart and lung function indices

Y. Sewiye. Department of Physiology, Jimma University, Ethiopia

541 Feasibility, acceptability, and efficacy of a cognitive behavioral therapy for methamphetamine use disorders in South Africa

K. Sorsdahl¹, D.J. Stein¹, S. Pasche², Y. Jacobs³, R. Kader¹, S. Richter⁴, B. Myers³, J. Grant⁵.
¹University of Cape Town, South Africa; ²Stellenbosch University, South Africa; ³South African Medical Research Council, South Africa; ⁴Professional Data Analysts, Inc., United States; ⁵University of Chicago, United States

542 The efficacy of computerized interventions to reduce cannabis use: A systematic review and meta-analysis

J. Tirado Munoz¹, A. Olmos², M. Farre Albadalejo^{3,4}, M. Torrens Melich^{4,5}. ¹Addiction Research Group, Institut Hospital del Mar d' Investigacions Mediques (IMIM), Spain; ²Universitat Pompeu Fabra-Universitat Autònoma de Barcelona, Spain; ³Clinical Pharmacology Department, Hospital Universitari Germans Trias i Pujol-IGTP, Spain; ⁴Universitat Autònoma de Barcelona, Spain; ⁵Institut de Neuropsiquiatria i Addiccions, Hospital del Mar, Barcelona and IMIM, Spain

543 HIV infection in a methadone maintenance treatment program: Impact on retention

M. Torrens^{1,2}, F. Fonseca^{1,2}, C. Castillo¹, G. Vallecillo¹, C. Tamarit¹, A. Roquer³, M. Farre^{2,4}.
¹Institut de Neuropsiquiatria i Addiccions, Hospital el Mar and Institut Hospital del Mar d'Investigacions Mediques, Spain; ²Universitat Autònoma de Barcelona, Spain; ³Institut de Neuropsiquiatria i Addiccions-Parc de Salut Mar, Spain; ⁴Hospital Universitari Germans Trias i Pujol-IGTP, Spain

544 Quality of life after treatment in a private residential addiction treatment center

T. Tsarouk, G. Thompson. Sunshine Coast Health Centre, Canada

545 Drug rehabilitation model of amphetamine-type stimulants users

D. Utami^{1,2}, R. Sarasvita^{1,3}. ¹Indonesia National Narcotics Board, Indonesia; ²Abhipraya Foundation, Indonesia; ³HPTN 074 Indonesia Site-Cipto Mangunkusumo Hospital, Indonesia

546 The effect of agomelatine treatment on depression and methamphetamine withdrawal in methamphetamine-dependent patients with comorbid heroin dependence in a methadone maintenance treatment program: A randomized controlled trial

S. Wahab¹, N. Ali², H. Mohd Yusof³, N.A. Muhamad⁴, M. Mazlan⁵. ¹Universiti Kebangsaan Malaysia Medical Centre, Malaysia; ²Masjid Tanah Health Clinic, Melaka, Malaysia; ³Permai Hospital Johor Bharu, Malaysia; ⁴Ministry of Health, Malaysia; ⁵Muar Substance Abuse Center, Malaysia

547 Effects of smoking abstinence on delay discounting in smokers with depression

S. Weidberg^{1,2}, A. Gonzalez-Roz¹, A. Garcia-Perez¹, I. Pericot-Valverde³, R. Secades-Villa¹.
¹University of Oviedo, Spain; ²International University of la Rioja, Spain; ³University of Vermont, United States

548 Efficacy of prefrontal theta-burst stimulation in methamphetamine addiction: A randomized sham-controlled study

M. Zhao. Shanghai Jiao Tong University School of Medicine, Shanghai Mental Health Center, China

Monday, June 19, 2017

Workshop V

**Westmount
7:00 - 9:00 PM**

**NAVIGATING KEY STAGES OF A CAREER IN
ADDICTION SCIENCE**

Chairs: Denise Vidot and Qiana Brown

Navigating the pre-doctoral stage: Achieving the impossible!

Q. Brown, Columbia University Mailman School of Public Health, Newark, NJ

Navigating the post doctoral stage: I made it! Now what?

T. Franklin, University of Pennsylvania, Philadelphia, PA

Navigating the early career stage: How do I obtain NIH funding?

C. Bares, University of Michigan, Ann Arbor, MI

Workshop VI

**Outremont
7:00 - 9:00 PM**

**DEVELOPMENT OF ADAPTIVE TREATMENT
STRATEGIES IN THE MANAGEMENT OF DRUG
DEPENDENCE: LESSONS LEARNED FROM
CLINICAL TRIALS CURRENTLY IN THE FIELD**

Chairs: Joy Schmitz and Charles Green

*Rationale and design of a SMART for facilitating treatment entry and family planning in
substance-using NICU mothers*

A. Stotts, University of Texas Medical School at Houston, Houston, TX

Rationale and design of a SMART for adolescent marijuana use

C. Stanger, Dartmouth College, Hanover, NH

Rationale and design of a SMART for cocaine cessation and relapse prevention

J. Schmitz, University of Texas Health Science Center, Houston, TX

Rational and design of a SMART for smoking cessation

C. Green, University of Texas Health Science Center, McGovern Medical School,
Houston, TX

Discussant:

I. Nahum-Shani, University of Michigan, Ann Arbor, MI

Monday, June 19, 2017

Workshop VII

**Mont-Royal
7:00 - 9:00 PM**

PRESCRIPTION MONITORING PROGRAMS – ISSUES AND IMPACT

Chairs: Suzanne Nielsen and Beth Sproule

National implementation of prescription monitoring programs in Australia

S. Nielsen, University of South Wales, Sydney, Australia

*Using Florida's prescription drug monitoring program to monitor
pharmacoepidemiologic outcomes before and after the US Centers for Disease
Control and Prevention Opioid Prescribing Guidelines*

C. Delcher, University of Florida, Gainesville, FL

Evaluation of the effectiveness of prescription monitoring programs

B. Sproule, Centre for Addiction and Mental Health, Toronto, ON, Canada

*DISCUSSANT: Interventions in prescription opioid abuse – Do (or can) prescription
monitoring programs make a difference?*

R. Dart, Rocky Mountain Poison and Drug Center, Denver, CO

Workshop VIII

**Verdun
7:00 - 9:00 PM**

23ND ANNUAL CONTINGENCY MANAGEMENT WORKING GROUP

Chairs: Diann Gaalema and August Holtyn

Poster Session II

(Breakfast)

Fontaine

8:00 - 10:00 AM

Odd numbered posters manned first hour

Even-numbered, second hour

Set up time begins Monday, 1:00 PM

Must be removed by Tuesday, 12:00 noon

POLYDRUG

- 1 *Medical marijuana laws and youth alcohol and marijuana use in 45 states*
Julie Johnson¹, Renee Johnson², Sion Harris³, Ann-Marie Matteucci⁴, Dominic Hodgkin⁴, Abenaa Jones², ¹Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, ²Johns Hopkins Bloomberg School of Public Health, Department of Mental Health, Baltimore, MD, ³Harvard Medical School, Boston, MA, ⁴Brandeis University, Heller School for Social Policy and Management, Waltham, MA
- 2 *Marijuana use and cigar use initiation: Prospective studies of adolescents*
Grace Kong¹, Jessica Barrington-Trimis², Margaret Mayer¹, Adam Leventhal², Rob McConnell², Suchitra Krishnan-Sarin¹, ¹Yale School of Medicine, New Haven, CT, ²University of Southern California, Los Angeles, CA
- 3 *Prevalence of stimulant and opioid use among medical cannabis, non-medical cannabis, and non-cannabis using homeless and unstably housed women*
Meredith Meacham¹, Danielle Ramo¹, Alex Kral², Elise Riley¹, ¹UCSF, San Francisco, CA, ²RTI International, Research Triangle Park, NC
- 4 *Subjective effects of smoking among opioid-maintained individuals: Results from a pilot study examining reduced nicotine content cigarettes*
Stacey Sigmon¹, Joanna Streck², Sarah Heil¹, Maxine Stitzer³, Jennifer Tidey⁴, Diann Gaalema⁵, Stephen Higgins¹, ¹University of Vermont, Burlington, VT, ²Vermont Center on Behavior and Health, Burlington, VT, ³Johns Hopkins Bayview Medical Center, Baltimore, MD, ⁴Brown University School of Medicine, Providence, RI, ⁵University of Vermont UHC Campus, Burlington, VT
- 5 *The association between parental history and delay discounting among individuals in recovery from addiction*
Liqia Athamneh¹, Jeffrey Stein¹, Amanda Quisenberry², Derek Pope¹, Patsy Marshall¹, ¹Virginia Tech Carilion Research Institute, Roanoke, VA, ²Ohio State University, Columbus, OH
- 6 *Substance-using mothers experiencing suicidal thoughts: Impact of parenting behaviors on child behavior problems*
Brittany Brakenhoff¹, Natasha Slesnick¹, Quiong Wu¹, ¹Ohio State University, Columbus, OH

- 7 *Substance use escalation into early adulthood among the children in the MTA*
Andrea Howard¹, Brooke Molina², John Mitchell³, Traci Kennedy², Annamarie Stehli⁴, James Swanson⁴, ¹Carleton University, Department of Psychology, Ottawa, ON, Canada, ²University of Pittsburgh, Pittsburgh, PA, ³Duke University School of Medicine, Durham, NC, ⁴University of California Irvine, Irvine, CA
- 8 *Profiles of adverse childhood experiences and young adults' substance use*
Sunny Shin¹, Shelby McDonald¹, Michael Massey¹, ¹Virginia Commonwealth University, Richmond, VA
- 9 *Effects of trauma type on substance use in reserve soldiers and spouses*
Bonnie Vest¹, Rachel Hoopsick¹, D. Lynn Homish¹, Rachel Daws¹, Gregory Homish¹, ¹State University of New York at Buffalo, Buffalo, NY
- 10 *Associations between employment and addiction type and severity*
Camille Cibiel-Heintz¹, Fuschia Serre¹, Melina Fatseas², Marc Auriacombe¹, ¹Université de Bordeaux, Bordeaux, France, ²Centre Hospitalier Charles Perrens, Bordeaux, France
- 11 *Interoceptive awareness, emotion regulation and relapse among women in SUD treatment*
Cynthia Price¹, Sheila Crowell², Megan Puzia², Chieh Cheng¹, Elaine Thompson¹, ¹University of Washington, Seattle, WA, ²University of Utah, Salt Lake City, UT
- 12 *Life in recovery from addiction in Canada: A focus on barriers, relapse, and stigma*
Robyn McQuaid¹, Aqsa Malik², Amy Porath¹, ¹Canadian Centre on Substance Abuse, Ottawa, ON, Canada, ²Canadian Centre on Substance Abuse, Ottawa, ON
- 13 *The burden of disease attributable to alcohol and illicit drug use: Findings from the Global Burden of Disease Study 2015*
Louisa Degenhardt¹, Janni Leung², Alize Ferrari², Fiona Charlson³, Holly Erskine⁴, Damian Santomauro⁴, Whiteford Harvey³, Theo Vos⁵, ¹National Drug and Alcohol Research Centre, Sydney, Australia, Australia, ²Queensland Centre for Mental Health Research, Archerfield, Queensland, Australia, ³Queensland Centre for Mental Health Research, Archerfield, Queensland, ⁴University of Queensland, Brisbane, Australia, ⁵University of Washington, Institute for Health Metrics and Evaluation, Seattle, WA
- 14 *A randomized controlled analog trial for alcohol and tobacco smoking co-addiction using contingency management*
Michael Orr¹, Crystal Smith², Samantha Martin², Myles Finlay¹, Olivia Brooks², Oladunni Oluwoye², Emily Leickly², Michael McDonell², Matt Layton², John Roll¹, Sterling McPherson³, ¹Washington State University College of Nursing, Spokane, WA, ²Washington State University, Program of Excellence in Addictions Research, Spokane, WA, ³Washington State University, College of Medicine, Spokane, WA
- 15 *Overcoming barriers to adopting and implementing medication-assisted addiction treatment: The medication research partnership*
Croff Raina¹, Kim Hoffman¹, Kelly Alanis-Hirsch², James Ford, II³, Dennis McCarty¹, Laura Schmidt⁴, ¹Oregon Health and Science University, Hillsboro, OR, ²Services Effectiveness Research Program, Durham, NC, ³University of Wisconsin-Madison, Madison, WI, ⁴UCSF, San Francisco, CA

- 16 *Feasibility of an ED-based multi-session remote therapy intervention for drug use and violence*
Patrick Carter¹, Jessica Roche¹, Maureen Walton², Rebecca Cunningham¹, ¹University of Michigan, Ann Arbor, MI, ²University of Michigan-Addiction Research Center, Ann Arbor, MI
- 17 *Baseline attitudes toward addressing patient drug use: Differences across health professional training programs*
Aaron Johnson¹, Yunmi Chung¹, ¹Augusta University, Augusta, GA
- 18 *Training the future of health and social care providers: Outcomes from screening, brief intervention, and referral to treatment for substance use trainings*
Emily Sargent¹, Tess Kilwein², Joseph Miller¹, ¹University of North Dakota, Grand Forks, ND, ²University of Wyoming, Laramie, WY
- 19 *Private health plans' role in delivery and payment reform to support integrated care*
Constance Horgan¹, Sharon Reif¹, Maureen Stewart², Deborah Garnick², Amity Quinn², Timothy Creedon², Brooke Evans², ¹Brandeis University, Heller School for Social Policy and Management, Waltham, MA, ²Brandeis University, Waltham, MA
- 20 *A qualitative study of barriers and facilitators affecting implementation of electronic health record-integrated screening for substance use in primary care*
Jennifer McNeely¹, Pritika Kumar¹, Traci Rieckmann², Erica Sedlander¹, Sarah Farkas¹, Joseph Kannry³, Aida Vega³, Eva Waite³, Lauren Peccoralo³, Richard Rosenthal³, Dennis McCarty², John Rotrosen¹, ¹New York University School of Medicine, New York, NY, ²Oregon Health and Science University, Hillsboro, OR, ³Icahn School of Medicine at Mount Sinai, New York, NY
- 21 *Elevated risk of leaving hospital against medical advice for substance users admitted to a Canadian hospital*
Alexander Caudarella¹, Tim Guimond², Wiplove Lamba², Mary Yang², ¹University of Toronto, Toronto, ON, Canada, ²University of Toronto, Toronto, ON
- 22 *Substance misuse screening in primary care: TAPS Tool vs. ASSIST*
Robert Schwartz¹, Jennifer McNeely², Li-Tzy Wu³, Gaurav Sharma⁴, Aimee Wahle⁴, Carol Cushing⁵, courtney Nordeck¹, Anjalee Sharma¹, Kevin O'Grady⁶, Jan Gryczynski¹, Shannon Mitchell¹, Robert Ali⁷, John Marsden⁸, Geetha Subramaniam⁵, ¹Friends Research Institute, Baltimore, MD, ²New York University School of Medicine, New York, NY, ³Duke University School of Medicine, Durham, NC, ⁴The Emmes Corporation, Rockville, MD, ⁵NIDA, Bethesda, MD, ⁶University of Maryland-Psychology, College Park, MD, ⁷WHO Collaborating Centre for the Treatment of Drug and Alcohol Problems, Adelaide, South Australia, Australia, ⁸National Addiction Centre, Institute of Psychiatry, London, UK, United Kingdom
- 23 *Satisfaction, alliance and intervention experience: Comparing provider- vs. computer-delivered brief, motivational interventions for substance use among childbearing-aged women*
Amy Loree¹, Kimberly Yonkers², Steven Ondersma³, Kathryn Gilstad-Hayden², Steve Martino², ¹VA Connecticut/Yale University School of Medicine, New Haven, CT, ²Yale University-Psychiatry, New Haven, CT, ³Wayne State University-Psychiatry and Behavioral Neurosciences, Detroit, MI

OPIOIDS II

- 24 *An assessment of prevalence of substance abuse and associated factors among the medical and dental students in Chennai City, India*
D. Francis, The Tamil Nadu Dr. M.G.R. Medical University, Chennai, India
- 25 *Estimating heroin incidence in males and females using a back-calculation approach: Potential biases and re-calibration approaches*
Hsueh-Han Yeh¹, Samantha J. Bauer¹, Qing Lu², James Anthony¹, ¹Michigan State University, Lansing, MI, ²Michigan State University, Department of Epidemiology and Biostatistics/College of Human Medicine, East Lansing, MI
- 26 *Wet behind the ears? A Bayesian approach to estimating heroin incidence age by age*
Samantha J. Bauer¹, Chris Thompson¹, Olga Vselvolozhskaya², James Anthony¹, ¹Michigan State University, Lansing, MI, ²College of Public Health, Lexington, KY
Provider characteristics and opioid prescribing among primary care physicians treating Medicare patients in the US
Lewei (Allison) Lin¹, Amy Bohnert¹, Paul Christine¹, Donovan Maust¹, ¹University of Michigan, Ann Arbor, MI
- 28 *Assessing the risk of opioid abuse among individuals with high emergency department utilization*
Henry Young¹, Mirsada Serdarevic¹, Hannah Crooke¹, Joseph Tyndall¹, Linda Cottler¹, ¹University of Florida, Gainesville, FL
- 29 *Gun-carrying and suicidal behavior among substance-using women*
Krishna Vaddiparti¹, Linda Cottler¹, ¹University of Florida, Gainesville, FL
- 30 *Survey of treatment preferences for opioid use disorder*
Ravi Nahata¹, Michael Mancino², Jeff Thostenson², Alison Oliveto², ¹Central VA Healthcare System, North Central, VA, ²University of Arkansas for Medical Sciences, Little Rock, AR
- 31 *Prescription and over-the counter opioids: A three country comparative analysis of pharmacists' perspectives on codeine use and misuse*
Tara Carney¹, John Wells², Charles Parry³, Pdraig McGuinness⁴, Richard Harris⁵, Marie Claire van Hout², ¹South African Medical Research Council, Tygerberg, South Africa, South Africa, ²Waterford Institute of Technology, Waterford, Ireland, ³South African Medical Research Council, Tygerberg, South Africa, ⁴CARA Pharmacy, Dublin, Ireland, ⁵Weldricks Pharmacy, UK
- 32 *The global burden of opioid use disorders 1990-2015: Results on sex and age differences from the Global Burden of Disease Study 2015*
Janni Leung¹, Alize Ferrari¹, Fiona Charlson², Whiteford Harvey², Theo Vos³, Louisa Degenhardt⁴, ¹Queensland Centre for Mental Health Research, Archerfield, Queensland, Australia, ²Queensland Centre for Mental Health Research, Archerfield, Queensland, ³University of Washington, Institute for Health Metrics and Evaluation, Seattle, WA, ⁴National Drug and Alcohol Research Centre, Sydney, Australia
- 33 *A brief form of the SOAPP-R*
Stephen Butler¹, Stacey McCaffrey¹, Simon Budman¹, Ryan Black¹, ¹Inflexxion, Inc, Waltham, MA

- 34 *Strengths can decrease likelihood of drug use among high-risk rural women following brief intervention*
Katherine Marks¹, Justin Strickland¹, Carl Leukefeld¹, Carrie Oser¹, Michele Staton², ¹University of Kentucky, Lexington, KY, ²University of Kentucky College of Medicine, Lexington, KY
- 35 *Severity of dependence scale: Diagnostic cut-off for pharmaceutical opioid dependence*
Raimondo Bruno¹, Amy Peacock², Briony Larance³, Nichola Lintzeris⁴, Robert Ali⁵, Louisa Degenhardt⁶, ¹University of Tasmania, Sydney, New South Wales, Australia, ²National Drug and Alcohol Research Centre, Sydney, Australia, ³University of South Wales, Sydney, Australia, ⁴Drug and Alcohol Services, South Eastern Sydney Local Health District, Sydney, Australia, ⁵WHO Collaborating Centre for the Treatment of Drug and Alcohol Problems, Adelaide, South Australia, ⁶National Drug and Alcohol Research Centre, Sydney, Australia
- 36 *A prospective, observational study of hospitalized persons who inject drugs with severe infections: Substance use severity, risk behaviors, and motivation for treatment*
Laura Fanucchi¹, Michelle Lofwall², Paul Nuzzo¹, Sharon Walsh¹, ¹University of Kentucky, Lexington, KY, ²University of Kentucky College of Medicine, Lexington, KY
- 37 *Developing domains of negative consequences of regular heroin use*
Tabitha Moses¹, Eric Woodcock¹, Jamey Lister¹, Leslie Lundahl¹, Mark Greenwald¹, ¹Wayne State University, Detroit, MI

SEDATIVE, HYPNOTICS, INHALANTS

- 38 *Cues and stressors but not primes produce reinstatement of midazolam-maintained behavior in rats*
James Cook¹, Barak Gunter², Sally Huskinson¹, Kevin Freeman¹, James Rowlett¹, ¹University of Mississippi Medical Center, Jackson, MS, ²Vanderbilt University Medical Center, Nashville, TN
- 39 *An investigation of the reinforcing effects of diazepam and midazolam in rats trained to self-administer heroin*
Sharon Smith¹, Royston Gray², David Heal¹, ¹RenaSci Ltd, Nottingham, Nottinghamshire, United Kingdom, ²GW Pharmaceuticals PLC, Cambridge, UK, United Kingdom
- 40 *A comparison of the physical dependence syndromes produced in rats by morphine and diazepam*
David Heal¹, Simon Goddard², Sharon Smith¹, ¹RenaSci Ltd, Nottingham, Nottinghamshire, United Kingdom, ²RenaSci Ltd, Nottingham, Nottinghamshire
- 41 *Subjective abuse potential of brivaracetam compared to alprazolam, levetiracetam, and placebo in recreational CNS depressant users*
Edward Sellers¹, Armel Stockis², Kerri Schoedel³, ¹University of Toronto, Toronto, ON, Canada, ²UCB Pharma, Belgium, ³Altros Research Partners Inc., Toronto, ON, Canada
- 42 *Driving under the influence of benzodiazepines among high-risk rural women*
Matt Webster¹, Megan Dickson¹, Michele Staton², Carl Leukefeld¹, ¹University of Kentucky, Lexington, KY, ²University of Kentucky College of Medicine, Lexington, KY

- 43 *Toxic effects of solvent inhalants on liver and kidney functions in rats*
A. Elkoussi, Assiut College of Medicine, Assiut, Egypt, Egypt

PHARMACOKINETICS

- 44 *Incremental validity of estimated marijuana grams as a predictor of marijuana-related problems and urine cannabinoid level: Evidence from a clinical trial*
Rachel Tomko¹, Nathaniel Baker¹, Erin McClure¹, Kevin Gray¹, ¹Medical University of South Carolina, Charleston, SC
- 45 *PK/PD correlation in hydrocodone ER abuse potential studies*
Naama Levy-Cooperman¹, Michael Gillespie², Megan Shram¹, Laura Rabinovich-Guilatt², Kerri Schoedel¹, ¹Altreos Research Partners Inc., Toronto, ON, Canada, ²Teva Pharmaceuticals, Inc., Malvern, PA
- 46 *Assessment of the pharmacokinetic-pharmacodynamic relationship of the rate of drug onset and abuse liability with intranasally administered oxycodone and hydrocodone*
Sarah Boden¹, Megan Shram², Mark Leggas¹, Paul Nuzzo¹, Salvatore Colucci³, Steve Harris³, Sharon Walsh¹, ¹University of Kentucky, Lexington, KY, ²Altreos Research Partners Inc., Toronto, ON, Canada, ³Purdue Pharma L.P., Stamford, CT
- 47 *Characterization of recombinant humanized anti-cocaine monoclonal antibody from 3 clones: Selecting the master cell bank*
Rose Webster¹, Fatima Saeed², Hanna Wetzel¹, Cinder Cohen², William James Ball, Jr.¹, Andrew Norman², ¹University of Cincinnati, Cincinnati, OH, ²University of Cincinnati College of Medicine, Cincinnati, OH

CHEMISTRY

- 48 *Diarylurea-based allosteric modulators of the cannabinoid CB1 receptor*
Yanan Zhang¹, Thuy Nguyen¹, Ann Decker¹, Thomas Gamage¹, Jun-Xu Li², Brian Thomas¹, Jenny Wiley¹, Terrence Kenakin³, ¹RTI International, Research Triangle Park, NC, ²State University of New York at Buffalo, Buffalo, NY, ³University of North Carolina at Chapel Hill, Chapel Hill, NC
- 49 *4-Hydroxyphenylglycine derivatives as agonists for the orphan receptor GPR88, a potential target for drug abuse*
Chunyang Jin¹, Ann Decker¹, Tiffany Langston¹, ¹RTI International, Research Triangle Park, NC
- 50 *Benzylideneoxymorphone: A new lead for development of bifunctional mu/delta opioid receptor ligands*
Andrea Devereaux¹, Jason Healy², Nicholas Griggs³, John Traynor³, Rae Matsumoto⁴, Andrew Coop⁵, Christopher Cunningham⁶, ¹Concordia University Wisconsin School of Pharmacy, Neenah, WI, ²Thomas Jefferson University, Philadelphia, PA, ³University of Michigan, Ann Arbor, MI, ⁴Touro University California, Vallejo, CA, ⁵University of Maryland School of Pharmacy, Baltimore, MD, ⁶Concordia University Wisconsin, Mequon, WI
- 51 *Modular total synthesis approach towards salvinorin A-inspired designer opioids*
Alexander Sherwood¹, Samuel Williamson², Rachel Crowley¹, Thomas Prisinzano³, ¹University of Kansas, Lawrence, KS, ²University of Kansas, Department of Medicinal Chemistry, Lawrence, KS, ³University of Kansas School of Pharmacy, Lawrence, KS

- 52 *The Fab fragment of a humanized anti-cocaine monoclonal antibody: Development of a quality control method and its application to an ELISA*
Cinder Cohen¹, Hanna Wetzel², Fatima Saeed¹, Terence Kirley¹, Andrew Norman¹, Jordan Marckel¹, William Ball¹, Rose Webster¹, ¹University of Cincinnati College of Medicine, Cincinnati, OH, ²University of Cincinnati, Cincinnati, OH

STIMULANTS: PRECLINICAL

- 53 *Dramatically slower onset of DAT occupancy by dasotraline compared to methylphenidate*
Robert Lew¹, Cristian Constantinescu², Daniel Holden³, Evan Morris³, Richard Carson³, Vincent Carroll⁴, Olivier Barret², Gilles Tamagnan², Kenneth Koblan¹, Seth C. Hopkins¹, ¹Sunovion Pharmaceuticals Inc., Marlborough, MA, ²Molecular NeuroImaging LLC, New Haven, CT, ³Yale University, New Haven, CT, ⁴Institute for Neurodegenerative Disorders, New Haven, CT
- 54 *Potential abuse liability of orally self-administered methylphenidate in HIV-1 transgenic rats*
Steven Harrod¹, Hailong Li¹, Jessica Illenberger¹, Robert Roscoe¹, Srimal Samaranayake¹, Parastoo Hashemi¹, Charles Mactutus¹, Rosemarie Booze¹, ¹University of South Carolina, Columbia, SC
- 55 *Effects of GABAA receptor positive allosteric modulators on the behavioral and neurochemical effects of methamphetamine in rhesus monkeys*
Lais Berro¹, Monica Andersen², Cydney Eisenberg¹, Melis Odabas-Geldiay¹, Leonard Howell¹, ¹Emory University, Atlanta, GA, ²Universidade Federal de São Paulo, Department of Psychobiology, São Paulo, Brazil
- 56 *Reinforcing effects of l-methamphetamine in nonhuman primates*
Stephen Kohut¹, Bruce Blough², Jack Bergman³, ¹McLean Hospital / Harvard Medical School, Belmont, MA, ²RTI International, Research Triangle Park, NC, ³ADARC - McLean Hospital, Belmont, MA
- 57 *Continuous D-amphetamine treatment during intermittent cocaine intake reduces addiction-like behaviors*
Florence Allain¹, Anne-Noël Samaha¹, ¹Université de Montréal, Department of Pharmacology and Physiology, Outremont, QC, Canada
- 58 *Social rank change and dopamine in pigs*
Hui Cheng¹, Abiy Mohammed¹, Anthony Pease¹, Joshua Gehrke¹, George Bohart¹, Michael Nader², James Anthony¹, ¹Michigan State University, Lansing, MI, ²Wake Forest School of Medicine, Winston-Salem, NC
- 59 *The effects of social influence on cocaine self-administration in female rats*
Mark Smith¹, Andrea Robinson¹, Gaylen Fronk¹, Huailin Zhang¹, Scott Tonidandel¹, ¹Davidson College, Davidson, NC
- 60 *Contributions of central dopamine mechanisms to antipsychotic-induced dopamine supersensitivity*
Alice Servonnet¹, Pierre-Paul Rompré², Anne-Noël Samaha³, ¹Neuroscience Department; Université de Montréal, Montreal, QC, Canada, ²Neuroscience Department, Université de Montréal, Montreal, QC, Canada, ³Université de Montréal, Department of Pharmacology and Physiology, Outremont, QC, Canada

- 61 *Regulation of goal-directed action selection by cocaine, MDMA, and orbitofrontal BDNF-trkB*
Elizabeth Pitts¹, Shannon Gourley¹, ¹Emory University, Atlanta, GA
- 62 *Pathologic changes in the NAc post experimental TBI and susceptibility to the rewarding effects of a subthreshold dose of cocaine following brain injury*
Marquis Maynard¹, Lee Anne Cannella², Scott Rawls³, Servio Ramirez², ¹Temple University Lewis Katz School of Medicine, Philadelphia, PA, ²Lewis Katz School of Medicine at Temple University, Philadelphia, PA, ³Temple University, Philadelphia, PA
- 63 *Dexamethasone attenuates the enhanced rewarding effects of cocaine following experimental TBI*
Lee Anne Cannella¹, Steven F. Merkel¹, Allison Andrews², Evan M. Lutton¹, Roshanak Razmpour¹, Servio Ramirez¹, ¹Lewis Katz School of Medicine at Temple University, Philadelphia, PA, ²Temple University, Philadelphia, PA
- 64 *Evaluating the cellular effects of drugs of abuse using a next generation microfluidic model that recapitulates the human neurovascular unit*
Allison Andrews¹, Servio Ramirez², ¹Temple University, Philadelphia, PA, ²Lewis Katz School of Medicine at Temple University, Philadelphia, PA
- 65 *Cocaine-induced changes in perineuronal net and parvalbumin cell intensity in the rat medial prefrontal cortex*
Barbara Sorg¹, Megan Slaker², Kyrie-Anne Reyes³, ¹Washington State University, Pullman, WA, ²Medical College of Wisconsin, Milwaukee, WI, ³Oregon Health and Science University, Hillsboro, OR
- 66 *Dynorphin counteracts the effects of orexin in the paraventricular nucleus of the thalamus*
Remi Martin-Fardon¹, Marsida Kallupi¹, Friedbert Weiss¹, Olivier George¹, Paul Schweitzer¹, Alessandra Matzeu¹, ¹Scripps Research Institute, La Jolla, CA
- 67 *Activation of orexin neurons following orexin-A administration in the paraventricular nucleus of the thalamus in animals with a history of cocaine dependence*
Alessandra Matzeu¹, Friedbert Weiss¹, Remi Martin-Fardon¹, ¹Scripps Research Institute, La Jolla, CA
- 68 *Role of anterior dorsal lateral hypothalamic area perineuronal nets in the acquisition of cocaine-induced conditioned place preference and self-administration*
J. Blacktop, Washington State University, Pullman, WA
- 69 *A novel neuropeptide regulator of cocaine self-administration*
James Kasper¹, David McCue¹, Jonathan Hommel¹, ¹University of Texas Medical Branch, Galveston, TX
- 70 *Brain region and mechanism underlying 17beta-estradiol-potentiated reinstatement of cocaine-seeking behavior in female rats*
Elizabeth Doncheck¹, Margot DeBaker¹, Luke Urbanik¹, Laura Barron¹, Gage Liddiard¹, Jennifer Tuscher², Karyn Frick², Qing-song Liu³, Cecilia Hillard³, John Mantsch¹, ¹Marquette University, Milwaukee, WI, ²University of Wisconsin-Milwaukee, Milwaukee, WI, ³Medical College of Wisconsin, Milwaukee, WI
- 71 *Mechanisms of caffeine self-administration in rats*
Curtis Bradley¹, Moss Sanders¹, Amy Patterson¹, Samantha Malone¹, Amanda Smith¹, Matthew Palmatier¹, ¹East Tennessee State University, Johnson City, TN

- 72 *Effect of adolescent caffeine self-administration on adult nicotine self-administration in rats*
Jessica Golson¹, Amy Patterson¹, Moss Sanders¹, Samantha Malone¹, Curtis Bradley¹, Matthew Palmatier¹, ¹East Tennessee State University, Johnson City, TN

ALCOHOL

- 73 *Variable response to nucleus accumbens deep brain stimulation in a rat model of alcohol drinking*
Angela Henricks¹, Nicholas Deveau¹, Lucas Dwiell¹, Amanda Simon¹, Alan Green¹, Wilder Doucette¹, ¹Dartmouth College, Hanover, NH
- 74 *Considering sleep-related fatigue as a motivating factor in substance use*
Brett M Millar¹, Christian Grov¹, Jeffrey Parsons², ¹CUNY Graduate School of Public Health and Health Policy, New York, NY, ²Hunter College, CUNY, New York, NY
- 75 *Cognitive enhancer modafinil: A pharmacological intervention to decrease behavioral economic demand for alcohol*
Sarah Snider¹, Quan Phung², Stephen LaConte², Patsy Marshall², ¹Addiction Recovery Research Center, Roanoke, VA, ²Virginia Tech Carilion Research Institute, Roanoke, VA
- 76 *What predicts underage drinking? Investigating patterns of attachment, saying 'no', and alcohol expectancies*
Laura Anderson¹, Kiri Patton², Jeanie Sheffield², Andrew Wood³, Jason Connor², Matthew Gullo², ¹University of Queensland, Brisbane, Australia, ²University of Queensland, Brisbane, Australia, ³University of the Sunshine Coast, Queensland, Australia
- 77 *Goal commitment predicts outcome for adolescents with alcohol use disorder*
Yifrah Kaminer¹, Christine Ohannessian¹, James McKay², Rebecca Burke³, Kaitlin Flannery³, ¹University of Connecticut School of Medicine, Farmington, CT, ²University of Pennsylvania, Philadelphia, PA, ³University of Connecticut, Storrs, CT
- 78 *The structure of neuroticism and its relationship to problematic drinking in youth*
Nina Pocuca¹, Leanne Hides², Catherine Quinn³, Melanie White², Louise Mewton³, ¹University of Queensland, Brisbane, Australia, ²University of Queensland, Brisbane, Australia, ³Centre for Youth Substance Abuse Research, Herston, Queensland
- 79 *Effectiveness of a brief Internet-based alcohol intervention among risky college drinkers: Four-arm randomized controlled trial*
Andre Bedendo¹, Andre Luiz Monezi Andrade², Ana Regina Noto², ¹Universidade Federal de São Paulo, São Paulo, Brazil, ²Universidade Federal de São Paulo, Department of Psychobiology, São Paulo, Brazil
- 80 *Heavy drinking mediates the association between child maltreatment and violence victimization in adolescence, but not adulthood*
Kathryn Smith¹, Philip Smith², Lindsay Oberleitner³, Emily Grekin⁴, Sherry McKee⁵, ¹Columbia University Medical Center, New York State Psychiatric Institute, New York, NY, ²CUNY School of Medicine, New York, NY, ³Yale University, Milford, CT, ⁴Wayne State University, Detroit, MI, ⁵Yale School of Medicine, New Haven, CT

- 81 *Unpacking the association between alcohol use and intimate partner violence in sub-Saharan Africa*
M. Claire Greene¹, Jeremy Kane¹, Wietse Tol¹, ¹Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
- 82 *The contribution of COMT genotype and childhood trauma to alcohol approach and altruism in individuals with AUD*
Jennifer Mitchell¹, Dawn Weinstein¹, Josh Woolley¹, ¹UCSF, San Francisco, CA
- 83 *Approach bias modification training during detoxification: 3-Month outcomes of a pilot RCT*
Victoria Manning¹, Petra Staiger², Hall Kate³, Joshua Garfield⁴, Daniel Lubman⁴, Pinar Thorn⁴, Leung Daniel², Jarrad Lum², Antonio Verdejo-Garcia⁵, ¹Turning Point, Fitzroy, Victoria, Australia, ²Deakin University, Burwood, Australia, ³Deakin University, Burwood, Australia, ⁴Turning Point, Fitzroy, Victoria, ⁵Monash University, Victory, Australia
- 84 *Project engage program evaluation*
Anna Pecoraro¹, Terry Horton², Bailey Ingraham², Beverly Wilson², Claudine Jurkovitz², George Woody¹, ¹University of Pennsylvania, Philadelphia, PA, ²Christiana Care Health System, Newark, DE
- 85 *Integration of transcendental meditation into alcohol use disorder treatment*
Jan Gryczynski¹, Robert Schwartz¹, courtney Nordeck¹, Marc Fishman², Kevin O'Grady³, ¹Friends Research Institute, Baltimore, MD, ²Mountain Manor Treatment Center, Emmitsburg, MD, ³University of Maryland-Psychology, College Park, MD
- 86 *Evaluation of the factor structure of the Brazilian-Portuguese version of the Readiness to Change questionnaire applied to problem drinkers in the beginning of a web-based intervention*
Maria Lucia Souza-Formigoni¹, Andre Luiz Monezi Andrade², Henrique Gomide³, Laisa M A Sartes³, Leonardo Martins³, Telmo MotaEonzani³, Roseli Boerngen Lacerda⁴, ¹Universidade Federal de São Paulo, São Paulo, Brazil, ²Universidade Federal de São Paulo, Department of Psychobiology, São Paulo, Brazil, ³Universidade Federal de Juiz de Fora, Minas Gerais, Brazil, ⁴Universidade Federal do Paraná, Curitiba, Brazil

FOOD

- 87 *Body mass index and prevalence of obesity among individuals with substance dependence*
Abigail Matthews¹, Jacqueline King¹, Aimee Wahle¹, Lian Hu¹, Dikla Blumberg¹, ¹The Emmes Corporation, Rockville, MD
- 88 *Impact of quality of life and distress tolerance on successful behaviour change in separate cohorts of individuals with alcohol use disorder and obesity*
Daisy Thompson-Lake¹, Richard De La Garza, II², Peter Hajek³, ¹Queen Mary University of London, London, UK, ²Baylor College of Medicine, Houston, TX, ³Queen Mary University of London, London, UK
- 89 *Eating behaviors, weight loss practices and marijuana use among emerging adults*
Denise Vidot¹, Krystal Sardinas², Abenaa Jones³, Sarah Messiah¹, ¹University of Miami, Miami, FL, ²University of Miami Miller School of Medicine, Miami, FL, ³Johns Hopkins Bloomberg School of Public Health, Department of Mental Health, Baltimore, MD

HIV

- 90 *Short circuit: Disaggregation of adrenocorticotrophic hormone and cortisol levels in HIV-positive methamphetamine users*
Adam Carrico¹, Deborah Jones¹, Violeta Rodriguez¹, Mahendra Kumar¹, ¹University of Miami, Miami, FL
- 91 *Association between cumulative marijuana use and executive function and processing speed in HIV-positive and HIV-negative men*
Chukwuemeka Okafor¹, Michael Plankey², Xinguang Chen³, Pamela J Surkan⁴, Steve Shoptaw¹, Eileen Martin⁵, Ronald Cohen⁶, Ned Sacktor⁷, Robert L Cook³, ¹UCLA, Los Angeles, CA, ²Georgetown University Medical Center, Division of Infectious Diseases, Washington, DC, ³College of Medicine, University of Florida, Gainesville, FL, ⁴Johns Hopkins Bloomberg School of Public Health, Social and Behavioral Interventions Program, Baltimore, MD, ⁵Rush University Medical Center, Chicago, IL, ⁶University of Florida, Gainesville, FL, ⁷Johns Hopkins University, Department of Neurology, Baltimore, MD
- 92 *Comparison of motives for cannabis initiation and continued use in HIV+ and HIV-cannabis users*
Sheri Towe¹, Bianca Martin¹, Christina Meade¹, ¹Duke University School of Medicine, Durham, NC
- 93 *Understanding syringe distribution policy change in Baltimore, MD: Effects on syringe distribution and HIV incidence among people who inject drugs*
Sean Allen¹, Ju Park¹, Brian Weir¹, David Holtgrave¹, Susan Sherman¹, ¹Johns Hopkins University, Baltimore, MD
- 94 *HIV risk behaviors and providing recent injection initiation assistance among people who inject drugs in the San Diego – Tijuana border region*
Claudia Rafful¹, Richard S Garfein¹, Jazmine Cuevas¹, Shelly Sun¹, Sonia Jain¹, Steffanie Strathdee¹, Dan Werb¹, ¹UCSan Diego, La Jolla, CA
- 95 *Characteristics of attenders of safer injecting facilities among people who inject drugs in France: Baseline results from the COSINUS cohort study*
Charlotte Kervran¹, Marc Auriacombe², Marie Jauffret-Roustide³, Laurence Lalanne-Tongio⁴, Perrine Roux³, Laelia Briand-Madrid³, Antoine Vilotitch³, Patrizia Carrieri³, Cecile Denis⁵, ¹Université de Bordeaux, Bordeaux, France, ²Université de Bordeaux, Bordeaux, France, ³INSERM, Marseille, France, ⁴CHU Strasbourg, Paris, France, ⁵University of Pennsylvania, Philadelphia, PA
- 96 *Prescribing narcotics and recommending medicinal marijuana as incentives to retain patients in HIV care*
Kasey Claborn¹, Elizabeth Aston², Michael Saccoccio¹, Susan Ramsey¹, ¹Rhode Island Hospital, Providence, RI, ²Center for Alcohol and Addiction Studies, Brown University School of Public Health, Providence, RI
- 97 *Eligibility for heroin-assisted treatment among people who inject opioids and who live with HIV in a Canadian setting*
Jan Klimas¹, Evan Wood², Thomas Kerr³, huiru dong³, julio montaner³, MJ Milloy³, ¹UCD School of Medicine, Dublin, Ireland, ²University of British Columbia, Vancouver, BC, Canada, ³University of British Columbia, Vancouver, BC

- 98 *Opioid prescribing attitudes and risk mitigation practices in two HIV clinics*
Judith Tsui¹, Alexander Walley², Marlene C. Lira², Debbie Cheng², Christine Chaisson², Leah S. Forman², Jonathan Colasanti³, Jane Liebschutz², Christopher Shanahan², Carly Briden², Carlos del Rio³, Jeffrey Samet², ¹University of Washington Harborview, Seattle, WA, ²Boston University School of Medicine, Boston, MA, ³Emory University, Atlanta, GA
- 99 *Cost of an integrated treatment program for opiate addiction and HIV in Ho Chi Minh city, Vietnam*
Cecile Denis¹, Julie Becher¹, Thanh Doan², Huy Tran², Loan Nguyen², Trung Nguyen², Lisa Huang², Vincent Trias², Augustin Voisin³, Marc Auriacombe⁴, Gilles Raguin², Son Mai Thi Hoai⁵, Giang Le Truong⁵, Jean-Pierre Daulouede³, Charles O'Brien¹, David Metzger¹, ¹University of Pennsylvania, Philadelphia, PA, ²Expertise France, France, ³Bizia, ⁴Université de Bordeaux, Bordeaux, France, ⁵HCMC AIDS Committee, Ho Chi Minh City, Vietnam
- 100 *The importance of self-medication with substances in people with HIV infection and substance dependence*
Margo Godersky¹, Alexander Walley², Timothy Heeren¹, Michael Winter¹, Meg Sullivan², Seville Meli¹, Richard Saitz¹, ¹Boston University School of Public Health, Boston, MA, ²Boston University School of Medicine, Boston, MA
- 101 *Developing youth-informed media to increase HIV testing in emergency departments*
Robert Freeman¹, Ian Aronson², Tonya Taylor³, Lisa Marsch⁴, Theodore Bania⁵, ¹New York University School of Medicine, New York, NY, ²Digital Health Empowerment / NDRI, Brooklyn, NY, ³State University of New York Downstate Medical Center, Brooklyn, NY, ⁴Geisel School of Medicine at Dartmouth, Hanover, NH, ⁵Mount Sinai School of Medicine, New York, NY
- 102 *Improving identification of social harm among substance abusers in HIV trials*
K. Dugosh, Treatment Research Institute, Philadelphia, PA
- 103 *The prevalence and patterns of substance use across age cohorts in HIV+ adults within the state of Florida*
Zachary Mannes¹, Huiyin Lu¹, Nicole Ennis Whitehead¹, Robert Cook¹, ¹University of Florida, Gainesville, FL
- 104 *Opioid craving and HIV care cascade outcomes*
Bulat Idrisov¹, Karsten Lunze¹, Debbie Cheng¹, Elena Blokhina², Natalia Gnatienko¹, Emily Quinn¹, Alexander Walley¹, Carly Briden¹, Kendall Bryant³, Dmitry Lioznov⁴, Evgeny Krupitsky⁵, Jeffrey Samet¹, ¹Boston University School of Medicine, Boston, MA, ²First Pavlov State Medical University of St. Petersburg, St. Petersburg, Russia, Russian Federation, ³NIAAA, Bethesda, MD, ⁴First Pavlov State Medical University of St. Petersburg, St. Petersburg, Russia, ⁵St. Petersburg Bekhterev Research Psychoneurological Institute, St. Peterburg, Russia, Russian Federation

- 105 *Is substance use associated with HIV cascade outcomes in Latin America?*
Raquel De Boni¹, Meridith Blevins², Bryan E. Shepherd², Beatriz Grinsztejn³, Carina Cesar⁴, Claudia Cortes⁵, Denis Padgett⁶, Eduardo Gotuzzo⁷, Pablo F. Belaunzarán-Zamudio⁸, Peter F. Rebeiro², Stephany N. Duda², Catherine C. McGowan², ¹Oswaldo Cruz Foundation, Rio de Janeiro, Brazil, Brazil, ²Vanderbilt University Medical Center, Nashville, TN, ³INI Evandro Chagas, Fiocruz, Brazil, ⁴Fundacion Huesped, Buenos Aires, Argentina, ⁵University of Chile School of Medicine, Santiago, Chile, ⁶Caja Costarricense de Seguro Social, San José, Costa Rica, ⁷Universidad Peruana Cayetano Heredia, Lima, Peru, ⁸National Institute of Health Sciences and Nutrition “Salvador Zubirán, Tlalpan, Mexico
- 106 *Impact of multi-session SBIRT within primary care for people living with HIV/AIDS*
David Metzger¹, Sumedha Chhatre¹, Carolyn Carpenedo², Karen Dugosh², ¹University of Pennsylvania, Philadelphia, PA, ²Treatment Research Institute, Philadelphia, PA
- 107 *Associations between past month stimulant use and HIV-status in a representative sample of adults in the United States*
Emily Greene¹, Pia Mauro¹, Silvia Martins¹, ¹Columbia University, New York, NY

LITERATURE REVIEW

- 108 *Multi-setting community-based interventions to reduce population level harms arising from alcohol and other drug use*
Emily Stockings¹, Luke Wolfenden², Kate Bartlem³, Conor Gilligan³, Rebecca Hodder², Melanie Kingsland², John Wiggers², ¹University of South Wales, Sydney, Australia, Australia, ²Hunter New England Local Health District, Newcastle, New South Wales, ³University of Newcastle, Australia, Newcastle, New South Wales
- 109 *Diagnosis and treatment of Wernicke’s encephalopathy in patients with alcohol use disorder: Literature review and case series*
Anne-Sophie Wiet¹, Jacques Dubernet¹, Fuschia Serre¹, Melina Fatseas², Elizabeth Monthieux³, Sophie Auriacombe⁴, Marc Auriacombe¹, ¹Université de Bordeaux, Bordeaux, France, ²Centre Hospitalier Charles Perrens, Bordeaux, France, ³Centre Hospitalier Charles Perrens, Bordeaux, France, ⁴Université de Bordeaux, Bordeaux, France
- 110 *Health effects of electronic cigarettes: A systematic review of the literature*
Ginnie Ng¹, Robert Schwartz¹, Alexa Minichiello², Laurie Zawertailo³, ¹University of Toronto, Toronto, ON, ²Centre for Addiction and Mental Health, Toronto, ON, ³Centre for Addiction and Mental Health, Toronto, ON, Canada
- 111 *A mapping review of take-home naloxone for people released from correctional settings*
Meredith Horton¹, Rebecca McDonald², Traci Green³, Suzanne Nielsen⁴, John Strang⁵, Louisa Degenhardt⁶, Sarah Larney⁶, ¹New York University, New York, NY, ²King's College, London, UK, ³Boston University School of Medicine, Boston, MA, ⁴University of South Wales, Sydney, Australia, ⁵King's College, London, UK, United Kingdom, ⁶National Drug and Alcohol Research Centre, Sydney, Australia
- 112 *Extended-release injectable naltrexone for opioid use disorder: A systematic review*
Brantley Jarvis¹, August Holtyn¹, Shrinidhi Subramaniam², Kenneth Silverman², ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD
- 113 *Review of public-access data from human abuse potential studies of abuse-deterrent formulations*
K. Schoedel, Altreats Research Partners Inc., Toronto, ON, Canada

- 114 *Global prevalence of illicit and prescription opioid misuse*
Jerisha Ellerstrand¹, Janni Leung¹, Alize Ferrari¹, Whiteford Harvey², Louisa Degenhardt³, ¹Queensland Centre for Mental Health Research, Archerfield, Queensland, Australia, ²Queensland Centre for Mental Health Research, Archerfield, Queensland, ³National Drug and Alcohol Research Centre, Sydney, Australia
- 115 *Off-label pharmacotherapy in substance use disorders*
inmaculada Rivas Puy¹, Merce Rodriguez Barriba², Teresa Burguete³, Begoña Pascual Arce⁴, Victoria Olles³, Teresa Campillo⁵, Milagrosa Blanca Tamayo⁴, Ramon Ribera⁵, Gemma Hurtado Ruiz⁵, ¹IMSP Badalona, Barcelona, Spain, ²Catalan Health Service, ³IMSP Badalona, Barcelona, Spain, ⁴Badalona Serveis Assistencials, ⁵Parc de Salut Mar, Barcelona, Spain
- 116 *Contingency management and pharmacological treatment for stimulant users: A review*
Vitor Tardelli¹, Thiago Fidalgo², Dartiu Silveira², Adam Bisaga³, ¹Universidade Federal de Sao Paulo, São Paulo, Brazil, ²Universidade Federal de Sao Paulo, São Paulo, Brazil, ³Columbia University and NYSPI, New York, NY
- 117 *Pathway from adverse childhood experiences to problematic substance use - investigating emotional dysregulation*
A. Ralph, Centre for Youth Substance Abuse Research, Herston, Queensland, Australia
- 118 *Comparing integrated psychosocial treatment for co-occurring psychiatric and substance use disorders with addiction-focused treatment: A meta-analysis*
Elizabeth Saunders¹, Meagan Dechen², ¹The Dartmouth Institute, Lebanon, NH, ²Geisel School of Medicine at Dartmouth, Hanover, NH
- 119 *Sociocultural considerations of prescription drug misuse among racial/ethnic minorities: A systematic review*
Bridgette Peteet¹, Brittany Miller-Roenigk¹, Caravella McCuistian¹, Cami Mosley¹, ¹University of Cincinnati, Cincinnati, OH

Oral Communications 11**Outremont
11:15 - 12:15 PM****DRUG ENVIE? CRAVING**

Chairs: Julie McCarthy and Hedy Kober

- 11:15 *Craving predicts drug use: A quantitative meta-analysis*
Hedy Kober¹, Rebecca Boswell², ¹Yale School of Medicine, New Haven, CT, ²Yale University, New Haven, CT
- 11:30 *Reduced interhemispheric executive control network coupling and increased craving in cocaine users*
Julie McCarthy¹, Justin Shepherd¹, Scott Lukas¹, Amy Janes¹, ¹McLean Hospital, Harvard Medical School, Belmont, MA
- 11:45 *Intermittent intake of rapid cocaine injections promotes incubation of drug craving*
Aliou Badara Gueye¹, Florence Allain¹, Anne-Noël Samaha¹, ¹Université de Montréal, Department of Pharmacology and Physiology, Outremont, QC, Canada
- 12:00 *Augmenting endogenous glutamate within infralimbic cortex attenuates the incubation of cocaine-craving in rats*
Christina Shin¹, Taylor Templeton¹, Ellen Gable¹, Alvin Chiu¹, Jennifer Kim¹, Philip Vieira², Tod Kippin¹, Karen Szumlanski¹, ¹UCSF, San Francisco, CA, ²California State University, Los Angeles, CA

Oral Communications 12**Mont-Royal
10:00 - 12:00 PM****VIVE LA (SEX) DIFFERENCE!**

Chairs: Yasmin Zakiniaiez and Teresa Franklin

- 10:00 *Sex differences in subjective evaluations of reduced nicotine cigarettes*
Nicole Petersen¹, Paul Faulkner¹, Dara Ghahremani¹, Chelsea Cox², Edythe London¹, ¹UCLA, Los Angeles, CA, ²University of Illinois, Chicago, IL
- 10:15 *The impact of sex on brain responses to smoking cues: Replication in a new cohort*
Teresa Franklin¹, Nathan Hager¹, Kanchana Jagannathan¹, Kelly Dumais², Amy Janes², Michael Gawrysiak³, Heather Pater¹, Joyce Wong¹, H Rao¹, Anna Rose Childress¹, Reagan Wetherill¹, ¹University of Pennsylvania, Philadelphia, PA, ²McLean Hospital, Harvard Medical School, Belmont, MA, ³Delaware State University, Wilmington, DE
- 10:30 *Sex differences in dorsolateral prefrontal cortex dopamine release and the relationship to tobacco smoking treatment outcomes*
Yasmin Zakiniaiez¹, Ansel Hillmer¹, Laura Goetz¹, Evan Morris¹, David Matuskey¹, Nabeel Nabulsi¹, Yiyun Henry Huang¹, Sherry McKee², Kelly Cosgrove¹, ¹Yale University, New Haven, CT, ²Yale School of Medicine, New Haven, CT

- 10:45 *Ovarian hormones are associated with stress reactivity and smoking in human laboratory study*
Mackenzie Peltier¹, Terril Verplaetse², Sherry McKee², ¹Louisiana State University, Baton Rouge, LA, ²Yale School of Medicine, New Haven, CT
- 11:00 *The impact of sex, dose and inter-trial interval upon methamphetamine preference of rats*
Mari Purpura¹, Philip Vieira², Julia Adams¹, Christina Barkas¹, Sara Ghobadi¹, Mark Bocz¹, Serina Williams¹, Tod Kippin¹, ¹UCSF, San Francisco, CA, ²California State University, Los Angeles, CA
- 11:15 *Sex differences in early predictive biomarkers for cocaine seeking in adolescence and adulthood*
Chloe Jordan¹, Susan Andersen¹, ¹McLean Hospital, Harvard Medical School, Belmont, MA
- 11:30 *The effects of estradiol and progesterone on heroin self-administration in ovariectomized rats*
Andrea Robinson¹, Huailin Zhang¹, Alexander Casimir¹, Mark Smith¹, ¹Davidson College, Davidson, NC
- 11:45 *Stress- and sex-dependent changes in miRNA expression and their potential impact on opioid addiction*
Maria Mavrikaki¹, Lorena Pantano², David Norris¹, Maximilian A Rogers-Grazado³, Sami S Amr³, Elena Chartoff¹, ¹McLean Hospital, Harvard Medical School, Belmont, MA, ²Harvard School of Public Health, Boston, MA, ³Translational Genomics Core, Partners Healthcare Personalized Medicine, Cambridge, MA

Oral Communications 13

Verdun
10:00 - 12:00 PM

BRISER LES CHÂÎNES: CRIMINAL JUSTICE

Chairs: Diane Morse and David Festinger

- 10:00 *Juvenile offender's family and friends substance abuse*
Carl Leukefeld¹, Megan Dickson¹, Michel Tindall², Matt Webster², Carrie Oser², Hannah Knudsen¹, Katherine Marks¹, Jennifer Havens³, ¹University of Kentucky, Lexington, KY, ²Center on Drug and Alcohol Research University of Kentucky, Lexington, KY, ³University of Kentucky College of Medicine, Lexington, KY
- 10:15 *Drug use and mental health of caregivers of youth in the juvenile drug court: Implications for holistic family-based intervention*
Anna Harrison¹, Marina Tolou-Shams¹, ¹UCSF, San Francisco, CA

10:30 *FOCUS on women: Probation and Women's Initiative Supporting Health partnership targets legal and medical outcomes*

Diane Morse¹, Addie Bardin¹, Catherine Cerulli², ¹University of Rochester School of Medicine, Rochester, NY, ²University of Rochester School of Medicine and University of Rochester Susan B. Anthony Center, Rochester, NY

10:45 *Among women in drug court, marginally housed and marijuana only users at more risk for adversity*

Catherine Woodstock Striley¹, Jasmine Mack¹, Linda Cottler¹, ¹University of Florida, Gainesville, FL

11:00 *Patient perceptions of extended-release naltrexone, methadone, and re-entry following release from a large NYC jail*

Mara Flannery¹, Ryan McDonald², Melissa Velasquez², Joshua Lee², ¹NYU Langone Medical Center, New York, NY, ²New York University School of Medicine, New York, NY

11:15 *Delivering medication-assisted treatment in drug courts: A statewide evaluation*

David Festinger¹, Karen Dugosh², David Gastfriend², Brook Singletary², ¹University of Pennsylvania, Philadelphia, PA, ²Treatment Research Institute, Philadelphia, PA

11:30 *Results of a double blind placebo-controlled randomized trial of extended-release naltrexone among HIV+ inmates with opioid dependence*

Sandra Springer¹, Russell Barbour², Marwan Azar¹, Maua Herme¹, Tiara Winn³, Frederick Alice¹, Angela Di Paola³, ¹Yale School of Medicine, New Haven, CT, ²Yale School of Public Health, New Haven, CT, ³Yale School of Medicine-AIDS Program, New Haven, CT

11:45 *Access to opioid-agonist therapy among incarcerated people with opioid-use disorder in Vancouver, Canada*

Nikki Bozinoff¹, Kora DeBeck², M-J Milloy², Ekaterina Nosova², Thomas Kerr³, Evan Wood⁴, Kanna Hayashi², ¹Centre for Addiction and Mental Health, Toronto, ON, Canada, ²British Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC, ³University of British Columbia, Vancouver, BC, ⁴University of British Columbia, Vancouver, BC, Canada

Tuesday, June 20, 2017

Symposium VII

**Westmount
10:00 - 12:00 PM**

PAIN AND ADDICTION: OPIOIDS AND BEYOND

Chairs: Martin Cheatle and Peggy Compton

- 10:00 *Bidirectional relations between pain, nicotine withdrawal, and tobacco smoking*
J. Ditre, Syracuse University, Department of Psychology, Syracuse, NY
- 10:25 *The relationship between alcohol use and chronic pain among people living with HIV*
J. Merlin, University of Alabama, Birmingham, AL
- 10:50 *Phenotypic and genotypic characteristics of opioid use disorder in patients with chronic pain*
M. Cheatle, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
- 11:15 *Determining the efficacy of a psychosocial pain management intervention in men and women receiving substance use disorder treatment*
M. Ilgen, University of Michigan, Ann Arbor, MI
- 11:40 *DISCUSSANT: Pain and addiction: Future research directions*
P. Compton, Georgetown University, Washington, DC

Symposium VIII

**Outremont
10:00 - 11:00 PM**

**UNDERSTANDING ALCOHOL AND NICOTINE
CO-USE: RAT, NON-HUMAN PRIMATE, AND HUMAN
LABORATORY FINDINGS**

Chairs: Elise Weerts and David Drobos

- 10:00 *Co-use of alcohol and nicotine: Impact on responses to naltrexone and varenicline*
A. Le, CAMH, Toronto, ON, Canada
- 10:20 *Concurrent self-administration of alcohol and nicotine: Effects of abstinence and changing drug concentrations*
E. Weerts, Johns Hopkins University School of Medicine, Baltimore, MD
- 10:40 *Alcohol and nicotine interactions: Cue reactivity and pharmacological effects on drug-use motivation*
D. Drobos, Moffitt Cancer Center, Tampa, FL

Tuesday, June 20, 2017

**CPDD Outreach Event –
Moisson Montréal**

**Lobby
11:30 - 1:30 PM**

Meet in Lobby
(Advanced registration requested. Contact Colleen Hanlon or Jessica Weafer)

Media Forum

**Outremont
12:15 - 2:15 PM**

WHAT'S HOT? PIVOTAL RESEARCH IN CPDD 2017

Chairs: Margaret Chisolm and Bertha Madras

Introduction to working with the media
B. Madras, McLean Hospital, Belmont, MA
Using verbal and visual story-telling to effectively communicate your research to the public
M. Chisolm, Johns Hopkins School of Medicine, Baltimore, MD
Introduction to each speaker
M. Chisolm, Johns Hopkins School of Medicine, Baltimore, MD

Town Hall

**Westmount
12:15 - 2:15 PM**

**HOPES VS. REALITY: CHALLENGES IN DEVELOPMENT
OF A PRODUCT FOR THE TREATMENT OF SUBSTANCE
USE DISORDERS**

Chairs: Marco Pravetoni and Beatriz Rocha

Regulatory strategy for registration - Starting with the end in mind B. Rocha, Covance, Princeton, NJ
Operational hurdles in clinical trials: Medication nonadherence and professional subjects
D. McCann, NIH, NIDA, Bethesda, MD
Market access and reimbursement strategy
J. Haddox, Purdue Pharma L.P., Stamford, Connecticut
Development of vaccines for substance use disorders
S. Comer, Columbia University and NYSPI, New York, NY
Industry, government, and academia as a collaborative environment for development of a product for the treatment of substance use disorders A. Coop, University of Maryland School of Pharmacy, Baltimore, MD

Tuesday, June 20, 2017

Oral Communications 14**Mont-Royal
2:30 - 4:30 PM****GÉNÉTIQUE POTPOURRI**

Chairs: Andrew Smith and Mary Jeanne Kreek

- 2:30 *Effects of NAC Homer2 manipulation on methamphetamine reward in B6 mice*
Chelsea Brown¹, Elissa Fultz¹, Tod Kippin¹, Karen Szumlinski¹, ¹UCSF, San Francisco, CA
- 2:45 *Chronic (10-day) immobilization stress has no effect on quantitative AVP and AVPR1B mRNA levels in the male or female Sprague-Dawley rat hypothalamus*
Konrad Ben¹, Yan Zhou¹, Matthew Randesi¹, Sanoara Mazid², Shannon O'Dell², Bruce McEwen¹, Teresa Milner², Mary Jeanne Kreek¹, ¹The Rockefeller University, New York, NY, ²Weill Cornell Medicine, New York, NY
- 3:00 *Pharmacogenetic impact of the serotonin 2C receptor (5-HT_{2C}R) Cys23Ser single nucleotide polymorphism on receptor functional capacity*
Michelle Land¹, Ivana Gaziova¹, Kathryn Cunningham¹, F. Gerard Moeller², Lisa Elferink¹, Noelle Anastasio¹, ¹University of Texas Medical Branch, Galveston, TX, ²Virginia Commonwealth University, Richmond, VA
- 3:15 *Distinct subtypes of genetically defined serotonin neurons differentially modulate cocaine reward in mice*
Britahny Baskin¹, Susan Dymecki², Kathleen Katak¹, ¹Boston University School of Medicine, Boston, MA, ²Harvard Medical School, Boston, MA
- 3:30 *An androgen receptor polymorphism (cag repeats) and risk-taking in veterans*
Marc Rosen¹, Anne Black², Janitza Montalvo-Ortiz², Ifat Levy², Thomas McMahon², ¹VA Connecticut Healthcare System, West Haven, CT, ²Yale University, New Haven, CT
- 3:45 *Genome-wide association study of therapeutic opioid dosing identifies a novel locus upstream of OPRM1*
Andrew Smith¹, Kevin Jensen¹, Jin Li², Yaira Nunez¹, Lindsay Farrer³, Hakon Hakonarson², Scott Cook-Sather², Henry Kranzler², Joel Gelernter¹, ¹Yale University, New Haven, CT, ²University of Pennsylvania, Philadelphia, PA, ³Boston University School of Medicine, Boston, MA
- 4:00 *A comprehensive laboratory model of adolescent impulsivity and alcohol use*
Matthew Gullo¹, Natalie Loxton², Therese Price², Jo Voisey¹, Ross Young¹, Jason Connor¹, ¹University of Queensland, Brisbane, Australia, ²Griffith University, Brisbane, Australia
- 4:15 *Adverse neighborhoods and genetic risk*
Cristina Bares¹, Karen Chartier², Katherine Karriker-Jaffe³, Fazil Aliev², Brian Mustanski⁴, Danielle Dick², ¹University of Michigan, Ann Arbor, MI, ²Virginia Commonwealth University, Richmond, VA, ³Alcohol Research Group, Emeryville, CA, ⁴Northwestern University Feinberg School of Medicine, Chicago, IL

Oral Communications 15**Verdun
2:30 - 4:30 PM****DEUX HEURES OF PAIN**

Chairs: Luke Legakis and R. Kathryn McHugh

- 2:30 *Chemotherapy effects on motivated behaviors in male and female rats*
Luke Legakis¹, S. Stevens Negus¹, ¹Virginia Commonwealth University, Richmond, VA
- 2:45 *Modification of the antinociceptive effect of opiates by lorcaserin*
Kumiko Lippold¹, William Dewey², ¹Virginia Commonwealth University, Pharmacology and Toxicology, Richmond, VA, ²Virginia Commonwealth University, Richmond, VA
- 3:00 *The reinforcing and subjective effects of opioids in opioid users with and without chronic pain*
Gabriela Madera¹, Jermaine Jones², Jeanne Manubay¹, Shanthi Mogali³, Sandra Comer³, ¹Columbia University, New York, NY, ²Columbia University College of Physicians and Surgeons, New York, NY, ³Columbia University and NYSPI, New York, NY
- 3:15 *Discounting of delayed pain-related and monetary outcomes in chronic pain patients*
David Andrew Tompkins¹, Andrew Huhn¹, Michael Smith¹, Eric Strain¹, Matthew Johnson², ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins School of Medicine, Baltimore, MD
- 3:30 *Predictors of long-term opioid use in active duty military: Psychotropics, procedures, pain*
Jennifer Sharpe Potter¹, Mary Jo Pugh², Maj Joseph K. Maddry³, Col David H. Carnahan⁴, Vikhyat Bebar³, ¹University of Texas Health Science Center at San Antonio, San Antonio, TX, ²University of Texas Health Science Center at San Antonio, South Texas Veterans Health Care System, ³San Antonio Military Medical Center, University of Colorado, Fort Sam, Houston, ⁴Defense Health Agency, University of Colorado, Boulder, CO
- 3:45 *Study of gender differences in pain in relation to sleep deprivation*
Mary Stoermann¹, Douglas Glenn¹, Kelly Barth¹, Balliet Wendy¹, ¹Medical University of South Carolina, Charleston, SC
- 4:00 *Longitudinal associations of pain and craving with opioid use*
R. Kathryn McHugh¹, Linda Valeri¹, Margaret Griffin¹, Roger Weiss¹, ¹McLean Hospital, Belmont, MA
- 4:15 *Pain among individuals with HCV and substance use disorders: Impact of direct-acting antiviral treatment*
Joseph Goulet¹, Jeanette Tetrault², Amy Justice², William Becker², ¹Veterans Affairs, West Haven, CT, ²Yale University, New Haven, CT

Tuesday, June 20, 2017

Symposium IX

**Outremont
2:30 - 4:30 PM**

**LEGAL BUT NOT SO SAFE: PREVALENCE, EFFECTS,
STRATEGIES FOR PRENATAL ALCOHOL, MARIJUANA
AND TOBACCO USE**

Chairs: Yukiko Washio and Philip May

- 2:30 *Effects of tobacco use during pregnancy and treatment strategies*
C. Oncken, UConn Health, Farmington, CT
- 2:55 *Prenatal cannabis exposure and child neurodevelopment: A tolerated matter*
H. El Marroun, Erasmus MC - Sophia Children's Hospital, Rotterdam, Zuid-Holland, Netherlands
- 3:20 *The prevalence and characteristics of fetal alcohol spectrum disorders in the general populations of three different regions of the United States: Findings from the NIAAA-funded collaboration on FASD prevalence*
P. May, University of North Carolina, Nutrition Research Institute, Kannapolis, NC
- 3:45 *Maternal risk and protective factors for fetal alcohol spectrum disorders: US and worldwide*
C. Chambers, UCSan Diego, La Jolla, CA
- 4:10 *DISCUSSANT: Clinical implications and policy responses to substance use in pregnancy – what can we learn from each other (US and Australian comparisons)?*
A. Dunlop, Hunter New England Local Health District, Newcastle, New South Wales, Australia

Symposium X

**Westmount
2:30 - 4:30 PM**

**HOW FAST AND HOW OFTEN? THE TEMPORAL
PATTERN OF DRUG USE IS DECISIVE IN ADDICTION**

Chairs: Anne-Noël Samaha and Terry Robinson

- 2:30 *Patterns of heroin and cocaine taking in addicts*
A. Badiani, University of Sussex, Falmer, England, United Kingdom
- 2:55 *The temporal pattern of cocaine self-administration is critical for incentive-sensitization*
T. Robinson, University of Michigan, Ann Arbor, MI
- 3:20 *Intermittent and fast-rising cocaine spikes promote addiction*
A. Samaha, Université de Montréal, Department of Pharmacology and Physiology, Outremont, QC, Canada
- 3:45 *Temporal pattern of administration dictates dopaminergic alterations induced by cocaine*
E. Calipari, Icahn School of Medicine at Mount Sinai, New York, NY
- 4:10 *DISCUSSANT: Pharmacokinetics and addiction*
T. Robinson, University of Michigan, Ann Arbor, MI

Tuesday, June 20, 2017

Primm-Singleton Awardees Reception

**Salon Ville-Marie
5:00 - 6:30 PM**

Workshop IX

**Verdun
7:00 -9:00 PM**

**WRITING WORKSHOP FOR EMERGING
INVESTIGATORS: PROFITING FROM PEER REVIEW**

Chairs: James Sorensen and Eric Strain

Responding to criticism: Perspective of a junior investigator

D. Ramo, UCSF, San Francisco, CA

After manuscript feedback arrives: How to respond to journal reviews

E. Strain, Johns Hopkins University School of Medicine, Baltimore, MD

Tools for publishing – An interactive review

A. Freda, Elsevier Health and Medical Sciences (Publisher of DAD), Amsterdam, Netherlands

Using reviews to improve science: Issues for underrepresented scientists

C. Masson, UCSF, San Francisco, CA

Workshop X

**Westmount
7:00 - 9:00 PM**

**EPIDEMIOLOGY AND PUBLIC HEALTH RESEARCH
METHODS**

Chairs: James Anthony and Howard Chilcoat

*Introduction to multiphase optimization strategy for behavioral intervention research
(Introductory session: 7:15-8:00; Continuation session: 8:05-8:50)*

L. Collins, The Pennsylvania State University, University Park, PA

*What Hill functions can teach us in analysis of complex survey sample data. (2
introductory sessions: 7:15-8:00; Then repeated: 8:05-8:50)*

O. Vselvolozhskaya, College of Public Health, Lexington, KY

*Epidemiology's mutoscope and apc regressions: Introduction and beyond (2
introductory sessions: 7:15-8:00; Then repeated: 8:05-8:50)*

H. Cheng, Michigan State University, Lansing, MI

Workshop XI**Mont-Royal
7:00 - 9:00 PM****ADVANCES IN SUBSTANCE USE DISORDER
TREATMENTS FOR RACIAL/ETHNIC MINORITIES:
WHERE DO WE GO FROM HERE?**

Chairs: Kathy Burlew and LaTrice Montgomery

Racial and ethnic differences in treatment outcomes among adults with stimulant use disorders after a dosed exercise intervention

K. Sanchez, University of Texas, Arlington, TX

Racial and ethnic differences in history of sexual and physical abuse in relation to addiction severity

J. Korte, Medical University of South Carolina, Charleston, SC

Racial/ethnic subgroup differences in outcomes and acceptability of an Internet-delivered intervention for substance use disorders

L. Montgomery, University of Cincinnati College of Medicine, Cincinnati, OH

*Internet-based substance use disorder treatment for AI/AN: A systematic process of adaptation*Traci Rieckmann¹, Aimee Campbell², ¹Oregon Health and Science University, Hillsboro, OR, ²Columbia University and NYSPI, New York, NY**Workshop XII****Outremont
7:00 - 8:00 PM****NIDA MEDICATIONS DEVELOPMENT WORKSHOP:
ADDRESSING BAD BEHAVIOR IN CLINICAL TRIALS**

Chairs: David McCann and Tanya Ramey

Deception by research participants

E. Devine, Boston University School of Medicine, Boston, MA

Combating "professional subjects" with research subject registries

K. Weingard, Verified Clinical Trials, Garden City, NY

Aiview and other new medication adherence monitoring technologies

A. Hanina, AiCure, New York, NY

Tuesday, June 20, 2017

Workshop XIII

**Outremont
8:15 - 9:15 PM**

**NEW NIH GUIDELINES FOR REPRODUCIBILITY,
RIGOR AND TRANSPARENCY: ETHICAL AND
PRACTICAL CONUNDRUMS**

Chair: Michael Kuhar

Ethical guidelines in reproducibility in research

M. Kuhar, Emory University, Atlanta, GA

Why NIH strengthened its guidelines on rigor and reproducibility

S. Weiss, NIDA, Bethesda, MD

Please be advised that no photographing of presentations or data is permitted.
Badges must be worn at all times and are required for admission into all events and sessions.

Wednesday, June 21, 2017

Poster Session III

(Breakfast)

Fontaine

8:00 - 10:00 AM

Odd numbered posters manned first hour

Even-numbered, second hour

Set up time begins Tuesday, 1:00 PM

Must be removed by Wednesday, 12:00 noon

IMAGING

- 1 *Neural correlates of inhibitory control in abstinent vs. satiated smokers*
Philip Spechler¹, Bader Chaarani¹, Alexandra Ivanciu¹, Stephen Higgins¹, Hugh Garavan¹, ¹University of Vermont, Burlington, VT
- 2 *Neural activation during inhibition to smoking cues associated with smoking abstinence*
Jodi Gilman¹, Milena Radoman¹, Nour Azzouz¹, Nina Levar¹, Gladys Pachas¹, Maurizio Fava¹, Anne Eden Evins¹, ¹Massachusetts General Hospital-Psychiatry, Boston, MA
- 3 *A dynamic causal modeling study of the working memory system in marijuana users*
Liangsuo Ma¹, Joel Steinberg², James Bjork², Lori Keyser-Marcus², Jasmin Vassileva², Sergi Ferré³, F. Gerard Moeller¹, ¹Virginia Commonwealth University, Richmond, VA, ²Virginia Commonwealth University-Psychiatry, Richmond, VA, ³NIDA Intramural Research Program, Baltimore, MD
- 4 *An fMRI study to examine recognition memory for cocaine picture stimuli in cocaine smokers*
Suchismita Ray¹, Marsha Bates¹, Margaret Haney², Aradhana Srinagesh¹, Ashley Aya¹, ¹Rutgers University, New Brunswick, NJ, ²Columbia University Medical Center, New York, NY
- 5 **WITHDRAWN**
- 6 *Evaluating interrelationships between trajectories of choice behavior and ICA-derived brain network activation by game trials ordered according to self-benefit relative to other-harm in adolescents with substance use disorder and controls*
Susan Mikulich-Gilbertson¹, Manish Dalwani¹, Gary Grunwald², Gary Zerbe², Brandie Wagner², Joseph Sakai¹, ¹University of Colorado School of Medicine, Aurora, CO, ²University of Colorado School of Public Health, Aurora, CO

SEX/GENDER DIFFERENCES

- 7 *Sex differences and the role of estrous cyclicity in cocaine and remifentanyl demand in rats*
Ryan Lacy¹, Bridget Austin¹, Justin Strickland², ¹Franklin and Marshall College, Lancaster, PA, ²University of Kentucky, Lexington, KY
- 8 *Ovarian hormonal status influences 5-HT1B receptor agonist effects on cocaine self-administration in rats*
Samantha Scott¹, Raul Garcia¹, Alyssa Bralich¹, Jennifer Hesterman¹, Austin Stone¹, Janet Neisewander¹, ¹Arizona State University, Tempe, AZ

- 9 *Brain functional response to the presentation of cocaine-associated cues on rate of cerebral metabolism measured with FDG PET*
Taylor Stowe¹, Paul Czoty¹, Mack Miller¹, Joseph Noto¹, Sue Nader¹, Michael Nader¹,
- 10 *Sex differences in novelty- and cocaine-induced behaviors in Lewis and Fischer 344 rats*
Odochi Ohia-Nwoko¹, Colin Haile¹, Therese Kosten¹, ¹University of Houston, Houston, TX
- 11 *Sex and HIV serostatus effects on verbal memory for individuals with cocaine dependence in early vs. sustained remission*
Eileen Martin¹, Jasmin Vassileva², Leah Rubin³, Pauline Maki³, Michael Keutmann³, Raul Gonzalez⁴, ¹Rush University Medical Center, Chicago, IL, ²Virginia Commonwealth University-Psychiatry, Richmond, VA, ³University of Illinois, Chicago, IL, ⁴Florida International University, Miami, FL
- 12 *Gender differences in cannabis abstinence among adults in treatment for cannabis use disorder*
Dustin Lee¹, Nicolas Schlienz², Alan Budney³, Michael Smith², David Andrew Tompkins², Aidan Hampson⁴, Ryan Vandrey⁵, ¹Johns Hopkins Medicine, Lexington, KY, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Geisel School of Medicine at Dartmouth, Hanover, NH, ⁴NIDA, Bethesda, MD, ⁵Behavioral Pharmacology Research Unit, Baltimore, MD
- 13 *Sex-dependent effects of cannabis on physiological response and subjective drug effects in young adults*
Devika Govindarajah¹, Robert Mann¹, Bernard LeFoll², Gina Stoduto¹, Christine Wickens¹, Marilyn Huestis³, Bruna Brands⁴, ¹Centre for Addiction and Mental Health, Toronto, ON, ²University of Toronto, Toronto, ON, ³NIDA, Bethesda, MD, ⁴Health Canada, Toronto, ON
- 14 *Gender moderates chronic nicotine effects on cognition in young adults*
Megan Kangiser¹, Kyle Jennette¹, Alicia Thomas¹, Krista Lisdahl¹, ¹University of Wisconsin-Milwaukee, Milwaukee, WI
- 15 *Gender differences in tobacco use disorder phenotypes among smokers in the largest metropolitan area of South America*
Joao Mauricio Castaldelli-Maia¹, Silvia Martins², Erica Siu¹, Camila Silveira¹, Arthur Andrade¹, Laura Andrade¹, ¹University of Sao Paulo Medical School, Sao Paulo SP, Brazil, ²Columbia University, New York, NY
- 16 *Gender differences in smoking and use of nicotine and tobacco products among cardiac patients*
Irene Pericot-Valverde¹, Diann Gaalema², Rebecca Elliott¹, Philip Ades³, Stephen Higgins¹, ¹University of Vermont, Burlington, VT, ²University of Vermont UHC Campus, Burlington, VT, ³University of Vermont Medical Center, Burlington, VT
- 17 *Sex differences in heroin use: United States, 2002-2014*
David Barondess¹, Samantha J. Bauer¹, Hsueh-Han Yeh¹, James Anthony¹, ¹Michigan State University, Lansing, MI
- 18 *A national study: Gender, drug dependence and recent drug use*
Carol Boyd¹, James Cranford¹, Sean McCabe¹, ¹University of Michigan, Ann Arbor, MI

- 19 *Social influence on recent illicit drug use among army reserve couples*
Erin Anderson Goodell¹, D. Lynn Homish², Gregory Homish², ¹Johns Hopkins
Bloomberg School of Public Health, Baltimore, MD, ²State University of New York at
Buffalo, Buffalo, NY
- 20 **WITHDRAWN**
- 21 *Sex disparities in substance abuse research: Evaluating 23 years of structural
neuroimaging studies*
Dorothy Yamamoto¹, Kimberly E. Lind¹, Eric J. Gutierrez¹, Michael F. Regner¹, Sherry
McKee², Jody Tanabe¹, ¹University of Colorado, Boulder, CO, ²Yale School of

MARIJUANA/CANNABINOIDS I

- 22 *Effects of GPR55 activation on neural stem cell proliferation, differentiation, and
immune responses to chronic inflammation*
Jeremy Hill¹, Viviana Zuluaga-Ramirez¹, Malika Winfield¹, Sachin Gajghate¹, Yuri
Persidsky¹, ¹Lewis Katz School of Medicine at Temple University, Philadelphia, PA
- 23 *Pharmacological interrogation of hypothermia induced by vapor inhalation of THC in
rats*
Michael Taffe¹, Sophia A. Vandewater¹, Kevin Creehan¹, Jacques Nguyen¹, Mehrak
Javadi-Paydar¹, ¹Scripps Research Institute, La Jolla, CA
- 24 *A CB1 antagonist reverses analgesia induced by a combination of the cannabinoid
WIN55212-2 plus morphine in the mouse formalin test*
Xiaohong Chen¹, Martin Adler², A. Cowan¹, Ellen Geller³, J.J. Meissler¹, S. Inan¹,
Scott Rawls⁴, Ronald Tallarida⁴, M.N. Watson¹, Toby Eisenstein¹, ¹Center for
Substance Abuse Research, Lewis Katz School of Medicine of Temple University,
Philadelphia, PA, ²Lewis Katz School of Medicine at Temple University,
Philadelphia, PA, ³Temple University School of Medicine, Philadelphia, PA, ⁴Temple
University, Philadelphia, PA
- 25 *Effect of JWH-018 on prepulse inhibition of startle response*
B. Ginsburg, University of Texas Health Science Ctr at San Antonio, San Antonio, TX
- 26 *Tolerance and cross-tolerance to the discriminative-stimulus effects of CB1 agonists*
Jack Bergman¹, Nathaniel Gillis², Spyros Nikas³, Alexandros Makriyannis⁴, Carol
Paronis⁵, ¹ADARC - McLean Hospital, Belmont, MA, ²McLean Hospital, Belmont,
MA, ³CDD/Northeastern University, Boston, MA, ⁴Northeastern University, Boston,
MA, ⁵McLean Hospital, Harvard Medical School, Belmont, MA
- 27 *Cannabinoid-like effects of five synthetic compounds*
Michael Gatch¹, Michael Forster¹, ¹UNT Health Science Center, Fort Worth, TX
- 28 *Increases in locomotor activity in mice following cannabinoid antagonists and during
spontaneous cannabinoid withdrawal*
Carol Paronis¹, Lisa Wooldridge¹, Spyros Nikas², Kiran Vemuri², Alexandros
Makriyannis³, Jack Bergman⁴, ¹McLean Hospital, Harvard Medical School, Belmont,
MA, ²CDD/Northeastern University, Boston, MA, ³Northeastern University, Boston,
MA, ⁴ADARC - McLean Hospital, Belmont, MA
- 29 *Delta-9-tetrahydrocannabinol potentiates hyperlocomotion induced by nicotine in
rats*
Mehrak Javadi-Paydar¹, Jacques Nguyen¹, Sophia A. Vandewater¹, Maury Cole¹,
Michael Taffe¹, ¹Scripps Research Institute, La Jolla, CA

- 30 *A rodent model of nicotine and delta-9-tetrahydrocannabinol co-abuse*
Julie Marusich¹, Tim Lefever¹, Jenny Wiley¹, ¹RTI International, Research Triangle Park, NC
- 31 *Effects of cannabis dose and method of inhalation on subjective, cognitive, and physiological effects measures*
Nicolas Schlienz¹, Dustin Lee², Natalie Lembeck¹, Edward Cone¹, John Mitchell³, Ron Flegel⁴, George Bigelow¹, Ryan Vandrey⁵, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins Medicine, Lexington, KY, ³Duke University School of Medicine, Durham, NC, ⁴SAMHSA, Rockville, MD, ⁵Behavioral Pharmacology Research Unit, Baltimore, MD
- 32 *Impaired contrast sensitivity at low spatial frequency in cannabis users with early onset*
Laurence Lalanne¹, Vincent Laprevote², Anne Giersch³, ¹University Hospital of Strasbourg, Strasbourg, France, ²CHRU de Nancy, Paris, France, ³INSERM, Marseille, France
- 33 *Eye-tracking-based measures of inhibitory control and attentional bias in marijuana SUD and control subjects*
Jin Yoon¹, Ilana Haliwa¹, Jessica Vincent¹, Robert Suchting¹, Joy Schmitz¹, Scott Lane², ¹University of Texas Health Science Center, Houston, TX, ²University of Texas Medical Branch, Galveston, TX
- 34 *The effect of approach bias modification on cue-reactivity in individuals with cannabis use disorder*
Brian Sherman¹, Nathaniel Baker¹, Aimee McRae-Clark¹, ¹Medical University of South Carolina, Charleston, SC
- 35 *Neural and behavioral correlates of attentional bias and cue reactivity among adults with cannabis use disorders*
Lesia M. Ruglass¹, Alina Shevorykin², Naomi Dambreville¹, Ayman Baig³, Robert Melara³, ¹CUNY Graduate School of Public Health and Health Policy, New York, NY, ²Pace University, Westchester County, NY, ³The City College of New York, New York City, NY
- 36 *Evaluation of potentially abuse-related events in phase III clinical trials of cannabidiol (Epidiolex®) using the MADDERS® Prospective System*
Ryan Lanier¹, Imrana Kazam¹, Harrison Elder¹, Roi Treister¹, Maitreyee Mohanty¹, Reni Kunkel², Tilden Etges², Nathaniel Katz¹, ¹Analgesic Solutions, Natick, MA, ²GW Pharmaceuticals PLC, Cambridge, UK
- 37 *Evaluation of potentially abuse-related events in phase III clinical trials of a delta-9 tetrahydrocannabinol and cannabidiol (Sativex®) oromucosal spray*
Harrison Elder¹, Ryan Lanier¹, Imrana Kazam¹, Roi Treister¹, Maitreyee Mohanty¹, Matthew Hersch², Tilden Etges², Nathaniel Katz¹, ¹Analgesic Solutions, Natick, MA, ²GW Pharmaceuticals PLC, Cambridge, UK
- 38 *Acute and residual effects of cannabis on simulated driving performance of young adults*
Bruna Brands¹, Robert Mann², Bernard Le Foll², Gina Stoduto², Christine Wickens², Marilyn Huestis³, ¹Health Canada, Toronto, ON, ²Centre for Addiction and Mental Health, Toronto, ON, ³NIDA, Bethesda, MD

- 39 *Rejection sensitivity and anger during social exclusion in young adult marijuana users*
Naomi Dambreville¹, Lesia M. Ruglass¹, Grinband Jack², Michael Costa¹, Eric A. Fertuck¹, ¹CUNY Graduate School of Public Health and Health Policy, New York, NY, ²Columbia University Medical Center, New York, NY
- 40 *Patterns of cannabis use, related problems, and readiness to change among young adult college students*
Matthew Enkema¹, Mary Larimer¹, Kevin Hallgren¹, Kristen Lindgren¹, Sarah Bowen², ¹University of Washington, Seattle, WA, ²Pacific University, Forest Grove, OR
- 41 *Has college put students at higher risk for marijuana initiation in recent years?*
Richard Miech¹, Megan Patrick², Patrick O'Malley², Lloyd Johnston², ¹University of Michigan, Institute for Social Research, Ann Arbor, MI, ²University of Michigan, Ann Arbor, MI
- 42 *Urban, suburban and rural differences in patterns of alcohol, cigarette and marijuana initiation by age among US youth*
Shivani Khan¹, Bin Yu¹, Sadaf A Milani², Linda Cottler¹, Catherine Woodstock Striley¹, ¹University of Florida, Gainesville, FL, ²University of Florida, Department of Epidemiology, Gainesville, FL
- 43 *U.S. adult illicit cannabis use, cannabis use disorder, and medical marijuana laws: 1991-2012*
Deborah Hasin¹, Aaron Sarvet¹, Magdalena Cerda², Katherine Keyes³, Sandro Galea⁴, Melanie Wall⁵, ¹Columbia University, New York, NY, ²University of California, Davis, Davis, CA, ³Columbia University Mailman School of Public Health, Newark, NJ, ⁴Boston University School of Public Health, Boston, MA, ⁵Columbia University and NYSPI, New York, NY
- 44 *Marijuana and tobacco cigarettes: Estimating their behavioral economic relationship using purchasing tasks*
Erica Peters¹, Zachary Rosenberry¹, Gillian Schauer², Kevin O'Grady³, Patrick Johnson⁴, ¹Battelle Memorial Institute, Baltimore, MD, ²University of Washington, Seattle, WA, ³University of Maryland-Psychology, College Park, MD, ⁴California State University, Los Angeles, CA
- 45 *Cannabis use disorders among cigarette smokers in the United States, 2002-2014: Implications for the future of tobacco control*
Renee Goodwin¹, Lauren Pacek², Michael Zvolensky³, Melanie Wall⁴, Deborah Hasin⁵, ¹CUNY School of Medicine, New York, NY, ²Duke University School of Medicine, Durham, NC, ³University of Houston, Houston, TX, ⁴Columbia University and NYSPI, New York, NY, ⁵Columbia University, New York, NY
- 46 *Simultaneous vs. sequential approaches to target tobacco use during treatment of cannabis use disorder*
Alan Budney¹, Dustin Lee², Denise Walker³, Mary Brunette¹, John Hughes⁴, Samantha Auty¹, Jean-Francoise Etter⁵, Catherine Stanger⁶, ¹Geisel School of Medicine at Dartmouth, Hanover, NH, ²Johns Hopkins Medicine, Lexington, KY, ³University of Washington, Seattle, WA, ⁴University of Vermont, Burlington, VT, ⁵University of Geneva, Geneva, Switzerland, ⁶Dartmouth College, Hanover, NH

- 47 *Is cannabis use associated with risk of relapse to cigarette smoking? Potential implications of cannabis use on trends in cigarette smoking in the US*
Andrea Weinberger¹, Jonathan Platt², Jan Copeland³, Renee Goodwin⁴, ¹Yeshiva

- 48 *Marijuana use is associated with poorer smoking cessation treatment outcomes in young adults*
Danielle Ramo¹, Mark Rubinstein¹, ¹UCSF, San Francisco, CA

NICOTINE II

- 49 *Simulating demand for cigarettes among economically disadvantaged mothers of young children: A low-risk method for studying vulnerable populations*
Diana Keith¹, Derek Reed², Ryan Redner³, Allison Kurti¹, Stephen Higgins¹, ¹University of Vermont, Burlington, VT, ²University of Kansas, Lawrence, KS, ³Southern Illinois University, Carbondale, IL
- 50 *Evaluating reduced-nicotine standards on the addiction potential of cigarettes in vulnerable populations*
Stephen Higgins¹, Sarah Heil¹, Stacey Sigmon¹, Jennifer Tidey², Diann Gaalema³, John Hughes¹, Maxine Stitzer⁴, Hanna Durand¹, Janice Bunn¹, Jeff Priest¹, Christopher Arger¹, Mollie Patrick⁵, Cecilia Bergeria¹, Danielle Davis¹, Joanna Streck⁶, Derek Reed⁷, Joan Skelly¹, Lauren Tursi¹, ¹University of Vermont, Burlington, VT, ²Brown University School of Medicine, Providence, RI, ³University of Vermont UHC Campus, Burlington, VT, ⁴Johns Hopkins Bayview Medical Center, Baltimore, MD, ⁵Brown University, South Burlington, VT, ⁶Vermont Center on Behavior and Health, Burlington, VT, ⁷University of Kansas, Lawrence, KS
- 51 *Characteristics of homeless adults who successfully quit smoking*
Carla Rash¹, Darla Kendzor², Aaron Waters³, Michael Businelle², ¹UConn Health, Farmington, CT, ²Oregon Health and Science University, Hillsboro, OR, ³Louisiana State University, Shreveport, LA
- 52 *Heavy smoking among U.S. soldiers returning from combat*
Alexa Lopez¹, Robin Toblin², Lyndon Riviere², James Lee², Amy Adler², ¹University of Vermont, Burlington, VT, ²Walter Reed Army Institute of Research, Sandy Spring, MD
- 53 *High prevalence of menthol cigarette smoking among individuals in addiction treatment*
Denise Williams¹, Noah Gubner¹, Barbara Tajima², Joseph Guydish¹, ¹UCSF, San Francisco, CA, ²UCSF, San Francisco, CA
- 54 *Treating tobacco dependence in addiction settings: Substance use co-morbidity and other predictors of cessation*
Laurie Zawertailo¹, Carolyn Peters¹, Peter Selby¹, ¹Centre for Addiction and Mental Health, Toronto, ON, Canada
- 55 *Use topography and dependence in loose and portioned smokeless tobacco users*
Lynn Hull¹, Chad Reissig¹, Patricia Braschayko², Jennifer Potts², Meredith Thanner², Wallace Pickworth³, ¹FDA Center for Tobacco Products, Sandy Spring, MD, ²Battelle Public Health Center for Tobacco Research, Columbus, OH, ³Battelle Memorial Institute, Baltimore, MD

- 56 *Emotional responses to smokeless tobacco warning labels: Are graphics more powerful than text?*
Amanda Quisenberry¹, Abigail Shoben¹, Sarah Cooper¹, Amy Ferketich¹, Micah Berman¹, Ellen Peters¹, Mary Ellen Wewers¹, Elizabeth Klein¹, ¹Ohio State University, Columbus, OH
- 57 *Socioeconomic status and adolescent e-cigarette use: The mediating role of e-cigarette advertisement exposure*
Patricia Simon¹, Deepa Camenga¹, Krysten Bold¹, Grace Kong¹, Meghan Morean², Dana Cavallo¹, Suchitra Krishnan-Sarin¹, ¹Yale School of Medicine, New Haven, CT, ²Oberlin College, Oberlin, OH
- 58 *Examining menthol and nicotine effects in youth using e-cigarettes*
Suchitra Krishnan-Sarin¹, Grace Kong¹, Stephanie O'Malley¹, Barry Green², Eugenia Buta², ¹Yale School of Medicine, New Haven, CT, ²Yale University, New Haven, CT
- 59 *E-cigarettes use in a country with high prevalence of tobacco smoking: A population-based study*
Yi-Lung Chen¹, Shang-Chi Wu², Wen-Ing Tsay³, Yen-Tyng Chen¹, Po-Chang Hsiao¹, Ya-Hui Yu¹, Te-Tien Ting¹, Chuan-Yu Chen², Yu-Kang Tu¹, Jiun-Hau Huang¹, Hao-Jan Yang⁴, Chung-Yi Li⁵, Carol Strong⁵, Cheng-Fang Yen⁶, Chia-Feng Yen⁷, Jui Hsu³, Wei-J Chen¹, ¹National Taiwan University, Taipei City, Taiwan, ²National Taiwan University, Epidemiology and Preventive Medicine, Taipei City, Taiwan, ³Taiwan Food and Drug Administration, Taipei, Taiwan, ⁴Chung Shan Medical University, Taiwan, Taichung City, Taiwan, ⁵National Cheng Kung University, East District, Taiwan, ⁶Kaohsiung Medical University, Taiwan, Kaohsiung, Taiwan, ⁷Tzu Chi University, Taiwan, Hualien City, Taiwan
- 60 *Use of and attitudes towards e-cigarettes and conventional cigarettes in a tobacco-using cardiac population*
Diann Gaalema¹, Janice Bunn², Philip Ades³, Stephen Higgins², ¹University of Vermont UHC Campus, Burlington, VT, ²University of Vermont, Burlington, VT, ³University of Vermont Medical Center, Burlington, VT
- 61 *Perceived effects of electronic cigarette ingredients*
Arit Harvanko¹, Andrea McCubbin², Kristin Ashford², Thomas Kelly³, ¹University of Kentucky, Lexington, KY, ²University of Kentucky College of Nursing, Lexington, KY, ³University of Kentucky College of Medicine, Lexington, KY
- 62 *E-cigarette expectancy measure development*
Paul Harrell¹, Gwen Quinn², Laurel Brockenberry¹, Thomas Brandon², ¹Eastern Virginia Medical School, Norfolk, VA, ²Moffitt Cancer Center, Tampa, FL
- 63 *Daily vs. weekly electronic cigarette users in drug treatment: A comparison of tobacco use, device type, and flavor characteristics*
Noah Gubner¹, Anna Pagano², Barbara Tajima³, Joseph Guydish¹, ¹UCSF, San Francisco, CA, ²Prevention Research Center, Oakland, CA, ³UCSF, San Francisco, CA
- 64 *Does early onset of e-cigarette use predict cigarette smoking and other drug use among adolescents in the United States?*
Sean McCabe¹, Brady West¹, Vita McCabe², ¹University of Michigan, Ann Arbor, MI, ²St. Joseph Mercy Hospital, Ann Arbor, MI

ADOLESCENT

- 65 *Reward-related frontostriatal activity and smoking behavior among adolescents in treatment for smoking cessation*
Kathleen Garrison¹, Sarah Yip², Iris Balodis³, Kathleen Carroll¹, Marc Potenza¹, Suchitra Krishnan-Sarin¹, ¹Yale School of Medicine, New Haven, CT, ²Yale University, New Haven, CT, ³McMaster University, Hamilton, ON
- 66 *Brain pathways from parenting to adolescent substance use: Gender differences*
Tara Chaplin¹, Jennifer Poon², James Thompson², Rajita Sinha³, Emily Ansell⁴, ¹George Mason University, Vienna, VA, ²George Mason University, Fairfax, VA, ³Yale School of Medicine, New Haven, CT, ⁴Syracuse University, Syracuse, NY
- 67 *Parental substance use, adolescent physical activity, and cannabis use disorder in young adulthood*
Maureen Reynolds¹, Ralph Tarter¹, Levent Kirisci¹, Michael Vanyukov¹, ¹University of Pittsburgh, Pittsburgh, PA
- 68 *Material-specific sex differences in relationships between cannabis use and episodic memory among adolescents*
Jacqueline Duperrouzel¹, Ileana Pacheco-Colon¹, Catalina Quintero-Lopez¹, Samuel Hawes¹, Raul Gonzalez¹, ¹Florida International University, Miami, FL
- 69 *ADHD symptoms and marijuana exposure predict sustained attention accuracy*
Alexander Wallace¹, Natasha E Wright¹, Erika R. Gilbert¹, Krista Lisdahl¹, ¹University of Wisconsin-Milwaukee, Milwaukee, WI
- 70 *Mutoscope estimates for adolescent drug treatment in the United States, 2002-2014*
Chris Thompson¹, Hui Cheng¹, James Anthony¹, ¹Michigan State University, Lansing, MI
- 71 *Screening youth in the Ukraine for cigarette and marijuana use: Prevalence and correlates*
Tetiana Nickelsen¹, Oleksii Krugliachenko¹, Robert Zucker¹, Victor Burlaka², Maureen Walton³, ¹University of Michigan, Ann Arbor, MI, ²University of Mississippi, Mississippi, MS, ³University of Michigan-Addiction Research Center, Ann Arbor, MI
- 72 *Associations between adolescent energy drink use and bullying victimization and other problem behaviors*
Kathryn Polak¹, Dace Svikis¹, Pamela Dillon¹, David Pomm¹, Enkelejda Ngjelina¹, J. Randy Koch¹, Willis Miller¹, ¹Virginia Commonwealth University, Richmond, VA
- 73 *Teen substance use initiation: The role of self-efficacy and knowledge*
Genevieve Yang¹, Tassos Kyriakides², David Fiellin¹, Lynn Fiellin¹, ¹Yale School of Medicine, New Haven, CT, ²Yale School of Public Health, New Haven, CT
- 74 *Past 15-year trends in lifetime cocaine use among US high school students*
Kristin Schneider¹, Noa Krawczyk¹, Ziming Xuan², Renee Johnson¹, ¹Johns Hopkins Bloomberg School of Public Health, Department of Mental Health, Baltimore, MD, ²Boston University School of Public Health, Boston, MA
- 75 *Substance use and academic outcomes among high school seniors: Examining the influence of academic engagement*
Brittany Bugbee¹, Ken Beck², Craig Fryer², Amelia Arria¹, ¹University of Maryland School of Public Health, College Park, MD, ²University of Maryland, College Park, MD

- 76 *Risk estimates of cannabis use onset among US adolescents with conduct problems*
C. Lopez-Quintero, Florida International University, Miami, FL
- 77 *What brain regions are engaged by decisions with varying levels of other-harm vs. self-benefit typically developing adolescents and those with substance and conduct problems?*
Joseph Sakai¹, Manish Dalwani¹, Shannon McWilliams¹, Kristen Raymond², Susan Mikulich-Gilbertson¹, ¹University of Colorado School of Medicine, Aurora, CO, ²University of Colorado, Denver, CO
- 78 *Default mode network activity: Association with externalizing behavior problems with and without limited prosocial emotion*
Brian Walsh¹, Joseph Sakai², Manish Dalwani², ¹University of Colorado, Aurora,
- 79 *Diminished alternative reinforcement as a mechanism linking adolescent conduct problems and substance use*
Rubin Khoddam¹, Junhan Cho¹, Adam Leventhal¹, ¹University of Southern California, Los Angeles, CA
- 80 *Longitudinal associations between anxiety sensitivity and substance use in adolescents: Mediation by depressive affect*
Casey Guillot¹, Raina Pang², Steve Sussman², Adam Leventhal², ¹University of North Texas, Denton, TX, ²University of Southern California, Los Angeles, CA
- 81 *Developing decision rules for adolescent substance use treatment settings: Perspectives from four online stakeholder engagement panels*
Beth Ann Griffin¹, Sean Grant¹, Sarah Hunter¹, Pedersen Eric¹, ¹RAND Corporation, Arlington, VA
- 82 *Reliability and validity of the GAIN-SS to detect problem drinking and problem gambling with Spanish adolescents*
Sergio Fernandez-Artamendi¹, Víctor Martínez-Loredo², Irene Pericot-Valverde³, Jose Ramón Fernández-Hermida⁴, ¹Universidad Internacional de Andalucía-Psychology, Andalucía, Spain, ²University of Oviedo, Addictive Behaviors Group, Oviedo, Spain, ³University of Vermont, Burlington, VT, ⁴University of Oviedo, Oviedo, Spain
- 83 *A survey of potential internet gaming disorder extended to screen use in a community sample*
Jean-Marc Alexandre¹, Christophe Rassis², Fuschia Serre¹, Melina Fatseas³, Marc Auriacombe¹, ¹Université de Bordeaux, Bordeaux, France, ²Centre Hospitalier Charles Perrens, Bordeaux, France, ³Centre Hospitalier Charles Perrens, Bordeaux, France

OVERDOSE

- 84 *Comparison of overdose risk factors between intravenous and intranasal non-treatment-seeking heroin users*
Mudassir Mumtaz¹, Jermaine Jones², Sandra Comer³, ¹Sophie Davis School of Biomedical Education, Rockaway Beach, NY, ²Columbia University College of Physicians and Surgeons, New York, NY, ³Columbia University and NYSPI, New York, NY
- 85 *Violence and overdose among female users of harm reduction services*
Janna Ataiants¹, Stephen Lankenau², ¹Drexel University, Philadelphia, PA, ²Drexel University Dornsife School of Public Health, Philadelphia, PA

- 86 *What actually causes a stimulant overdose death? Comparison of clinical causes of death among opioid, cocaine, and methamphetamine overdose deaths*
Phillip Coffin¹, Dharsan Chandrakumar², Caitlin Turner¹, Glenn-Milo Santos¹, San Francisco Department of Public Health, San Francisco, CA, ²Brown University School of Medicine, Providence, RI, ³UCSF, San Francisco, CA
- 87 *Naloxone training for opioid users: Adherence to protocol and survival rates*
Jeanne Manubay¹, Benjamin Foote¹, Jermaine Jones², Aimee Campbell¹, Sandra Comer¹, ¹Columbia University and NYSPI, New York, NY, ²Columbia University College of Physicians and Surgeons, New York, NY
- 88 *UMass opioid overdose project: Review of clinical characteristics and healthcare services received in the year prior to death*
Gerardo Gonzalez¹, Christian Rose, BS², Abtin Shahanaghi, BS², Mauricio Romero-Gonzalez¹, Jorge Yarzebski², Michael Andre³, Gregory J. DiGirolamo¹, Alan Brown², ¹University of Massachusetts Medical School, Addiction Psychiatry, Worcester, MA, ²University of Massachusetts Medical School, Worcester, MA, ³College of the Holy Cross, Worcester, MA
- 89 *Mortality after nonfatal opioid overdose: Medication for opioid use disorder is associated with lower risk*
Marc Larochelle¹, Dana Bernson², Thomas Land², Thomas Stopka³, Alexander Walley¹, ¹Boston University School of Medicine, Boston, MA, ²Massachusetts Department of Public Health, Boston, MA, ³Tufts University School of Medicine, Boston, MA
- 90 *Characteristics of nonfatal opioid-related overdoses in Massachusetts among emerging adults*
Sarah Bagley¹, Dana Bernson², Marc Larochelle¹, Scott Hadland¹, Thomas Land², Alexander Walley¹, ¹Boston University School of Medicine, Boston, MA, ²Massachusetts Department of Public Health, Boston, MA
- 91 *Emergency department patients' knowledge gaps and perceived needs after non-fatal opioid overdose*
Kathryn Hawk¹, Grau Lauretta², Marek Chawarski³, David Fiellin⁴, Patrick O'Connor⁵, Gail D'Onofrio⁴, ¹Yale University, New Haven, CT, ²Yale School of Public Health, New Haven, CT, ³Yale University-Psychiatry, New Haven, CT, ⁴Yale School of Medicine, New Haven, CT, ⁵Yale University-Internal Medicine, New Haven, CT
- 92 *Understanding opioid overdoses in New Hampshire: A national drug early warning system rapid epidemiological study*
Andrea Meier¹, Sarah Moore², Elizabeth Saunders³, Bethany McLeman², Samantha Auty², Stephen Metcalf², Lisa Marsch², ¹Dartmouth College, Hanover, NH, ²Geisel School of Medicine at Dartmouth, Hanover, NH, ³The Dartmouth Institute, Lebanon, NH
- 93 *Heroin overdoses reach epidemic proportion in Thailand*
C. Areesantichai, Chulalongkorn University, Bangkok, Bangkok, Thailand

POLICY

- 94 *State-level alcohol policies and trajectories of heavy episodic drinking from 10th grade into young adulthood*
Brian Fairman¹, Bruce Simons-Morton¹, Denise Haynie¹, Liu Danping¹, Ralph Hingson², Stephen Gilman¹, ¹National Institute of Child Health and Human Development, Bethesda, MD, ²NIAAA, Bethesda, MD

- 95 *Assessing pathways between the legal environment, substance use and sexual risk among migrant and non-migrant workers in Kazakhstan*
Phillip Marotta¹, Nabila El-Bassel¹, Elwin Wu¹, Daniel Feaster², ¹Columbia University, New York, NY, ²University of Miami Miller School of Medicine, Miami, FL
- 96 *Staff and clients smoking together in drug abuse treatment: A target policy change*
Joseph Guydish¹, Deborah Yip¹, Barbara Tajima², Thao Le¹, Denise Williams¹, ¹UCSF, San Francisco, CA, ²UCSF, San Francisco, CA
- 97 *Impacts of minimum age of tobacco sales laws on youth smoking in Canada, 2000-2014*
Russell Callaghan¹, Jodi Gatley², Marcos Sanches³, Claire Benny², ¹Northern Medical Program, Prince George, BC, Canada, ²University of Northern British Columbia, Prince George, BC, ³Centre for Addiction and Mental Health, Toronto, ON
- 98 *Aversiveness enhances memory of cigarette warning messages*
An-Li Wang¹, Zhenhao Shi¹, Victoria Fairchild¹, Catherine Aronowitz¹, Daniel Langleben¹, ¹University of Pennsylvania, Philadelphia, PA
- 99 *Impact of medical marijuana laws on state-level marijuana use by age and gender, 2004-2013*
Christine Mauro¹, Paul Newswanger¹, Julian Santaella-Tenorio¹, Pia Mauro¹, Hannah Carliner², Silvia Martins¹, ¹Columbia University, New York, NY, ²Mailman School of Public Health, New York, NY
- 100 *Medical marijuana laws and state substance use disorder treatment by age, 2004-2013*
Pia Mauro¹, Julian Santaella-Tenorio¹, Christine Mauro¹, Niki Nourmohammadi¹, Arthur Robin Williams², Silvia Martins¹, ¹Columbia University, New York, NY, ²Columbia University Division on Substance Use Disorders, New York, NY
- 101 **WITHDRAWN**
- 102 *Self-medication of mood and anxiety disorders with marijuana: Higher in states with medical marijuana laws*
Aaron Sarvet¹, Melanie Wall², Katherine Keyes³, Mark Olfson², Magdalena Cerda⁴, Deborah Hasin¹, ¹Columbia University, New York, NY, ²Columbia University and NYSPI, New York, NY, ³Columbia University Mailman School of Public Health, Newark, NJ, ⁴University of California, Davis, Davis, CA
- 103 *Home cultivation and dispensary provisions of cannabis laws and use of cannabis edibles*
Jacob Borodovsky¹, Alan Budney¹, ¹Geisel School of Medicine at Dartmouth, Hanover, NH
- 104 *Appalachian women's use of substance abuse treatment: Examining the behavioral model for vulnerable populations*
Grant Victor¹, Athena Kheibari¹, Michele Staton², Carrie Oser¹, ¹University of Kentucky, Lexington, KY, ²University of Kentucky College of Medicine, Lexington, KY
- 105 *Changes in demographic characteristics and drug use among non-medical prescription opioid users, 2005-2014*
Kathi Harp¹, D. Keith Branham¹, ¹University of Kentucky, Lexington, KY

- 106 *The influence of prior authorization policies on opioid medication abuse and overdose among members of a large medicaid program*
Gerald Cochran¹, Adam Gordon², Walid Gellad¹, Chung-Chou H Chang¹, Jenny Lo-Ciganic³, Carroline Lobo¹, Evan Cole¹, Winfred Frazier¹, Ping Zheng¹, David Kelley⁴, Julie Donohue¹, ¹University of Pittsburgh, Pittsburgh, PA, ²Center for Health Equity Research and Promotion, Pittsburgh, PA, ³University of Arkansas for Medical Sciences, Little Rock, AR, ⁴Pennsylvania Department of Human Services, Harrisburg, PA
- 107 *Implementation of methadone therapy for opioid use disorder in Russia – a modeled cost-effectiveness analysis*
Sean Murphy¹, Donald Shepard², Tyler Morrill², Mayada Saadoun², Bulat Idrisov³, ¹Weill Cornell Medicine, New York, NY, ²Brandeis University, Waltham, MA, ³Boston University School of Medicine, Boston, MA
- 108 *High-value policy interventions in California’s publicly funded treatment of opioid use disorder: A cost-effectiveness analysis*
Emanuel Krebs¹, Benjamin Enns¹, Jeong Min¹, Richard Rawson², Yih-Ing Hser², Bohdan Nosyk¹, ¹BC Centre for Excellence in HIV/AIDS, Vancouver, BC, ²UCLA-ISAP, Los Angeles, CA
- 109 *Paying clinicians for program-level performance – early results from an RCT*
Sharon Reif¹, Maureen Stewart², Margot Davis², Torres Maria², AnMarie Nguyen², Dominic Hodgkin¹, Constance Horgan¹, ¹Brandeis University, Heller School for Social Policy and Management, Waltham, MA, ²Brandeis University, Waltham, MA

THEORETICAL COMMENTARY

- 110 *Drug abuse research and scientific integrity in the 21st century*
B. Kleykamp, Pinney Associates, Bethesda, MD
- 111 *A virtual self-administration laboratory*
Scott Shilling¹, Hanna Wetzel¹, Andrew Norman², ¹University of Cincinnati, Cincinnati, OH, ²University of Cincinnati College of Medicine, Cincinnati, OH
- 112 *A streamlined approach to the acquisition and analysis of data from drug self-administration sessions*
Hanna Wetzel¹, Andrew Norman², ¹University of Cincinnati, Cincinnati, OH, ²University of Cincinnati College of Medicine, Cincinnati, OH
- 113 *Standards for assessing the activity of anabolic steroids*
James Tolliver¹, E. Gregory Hawkins¹, Michael Klein², ¹U.S. Food and Drug
- 114 *Triaging which new psychoactive substances should be prioritized for further study*
E. Gregory Hawkins¹, Silvia Calderon¹, Michael Klein², ¹U.S. Food and Drug Administration, Silver Spring, MD, ²Food and Drug Administration, Chevy Chase, MD
- 115 *A comparison between a second generation AD product and an approved AD product*
L. Chen, U.S. Food and Drug Administration, Silver Spring, MD

- 116 *Pharmacovigilance in clinical trials of substance use disorder treatments with marketed drugs*
Radhika Kondapaka¹, Ashraf El Fiky¹, Dikla Blumberg¹, Robert Lindblad¹, ¹The Emmes Corporation, Rockville, MD
- 117 *Illness narratives of female substance users from an Indian urban slum: A clinical and social perspective on presentation and rehabilitation*
Shalini Singh¹, Sonali Jhanjee¹, Nimmy Chandran¹, Deepak Yadav¹, Rakesh Lal¹, ¹All India Institute of Medical Sciences, New Delhi, India
- 118 *Abuse liability assessment of new tobacco products: Application of human abuse potential study methodology and special considerations*
Megan Shram¹, Naama Levy-Cooperman¹, ¹Altreos Research Partners Inc., Toronto, ON, Canada
- 119 *Applicability of the socioecological model on e-cigarette trends*
Anastasiya Ferrell¹, Linda Haddad¹, ¹University of Florida College of Nursing, Gainesville, FL

Please be advised that no photographing of presentations or data is permitted.
Badges must be worn at all times and are required for admission into all events and sessions.

Wednesday, June 21, 2017

Oral Communications 16

**Outremont
10:00 - 12:00 PM**

STRESS IS STRESS (EVEN IN FRENCH)

Chairs: Shane Perrine and Eric Woodcock

- 10:00 *Effects of single prolonged stress on ethanol drinking and striatal function and neurochemistry in animals*
Shane Perrine¹, Alana Conti¹, ¹Wayne State University, Detroit, MI
- 10:15 *Predator-odor stress enhances alcohol self-administration in female rats*
Colin Haile¹, Steven Nieto¹, Therese Kosten¹, ¹University of Houston, Houston, TX
- 10:30 *Effects of early life stress on vulnerability to cocaine self-administration in male and female rhesus macaques*
Alison Wakeford¹, Sara Bramlett², Mar Sanchez¹, Leonard Howell², ¹Yerkes National Primate Research Center, Atlanta, GA, ²Emory University, Atlanta, GA
- 10:45 *Psychosocial stress-induced cocaine seeking in rats is associated with distinct coping strategies exhibited during prior social defeat stress*
Daniel Manvich¹, Saumya Karne¹, Taylor Stowe¹, David Weinshenker¹, ¹Emory University, Atlanta, GA
- 11:00 *Sources of stress and their correlates among adults who use drugs*
Kayla Tormohlen¹, Karin Tobin¹, Carl Latkin¹, ¹Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
- 11:15 *Effects of pharmacological stress-induction among non-treatment-seeking cigarette smokers*
Eric Woodcock¹, Jeffrey Stanley¹, Vaibhav Diwadkar¹, Dalal Khatib¹, Mark Greenwald¹, ¹Wayne State University, Detroit, MI
- 11:30 *Reregulation of cortisol levels in opioid-dependent patients during long-term residential treatment*
Dean Stankoski¹, Andrew Huhn², E. Bixler³, Roger Meyer⁴, E Deneke⁵, S. Bunce³, ¹Penn State University College of Medicine, Hershey, PA, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Penn State College of Medicine, Hershey, PA, ⁴Penn State College of Medicine, Psychiatry, Washington, DC, ⁵Caron Treatment Center, Wernersville, PA
- 11:45 *Intransal oxytocin increases stress reactivity in recreational cannabis-using women*
Stephanie Reed¹, Margaret Haney², Jeanne Manubay¹, Melissa Mahoney¹, Bianca Camagna¹, Suzette Evans³, ¹Columbia University, New York, NY, ²Columbia University Medical Center, New York, NY, ³Columbia University and NYSPI, New York, NY

Wednesday, June 21, 2017

Oral Communications 17

Mont-Royal
10:00 - 12:00 PM

#TECHNOLOGIE

Chairs: Dace Svikis and Frances Kay-Lambkin

- 10:00 *Contingency management technology for routine use in treatment and pilot risk prediction findings*
Eric Gastfriend¹, David Gastfriend², Paul Earley³, ¹DynamiCare Health, Boston, MA, ²Treatment Research Institute, Philadelphia, PA, ³Principal, Earley Consultancy, LLC
- 10:15 *A comparison of computer and therapist-delivered SBIRT for alcohol/drugs in an urban primary care setting*
Dace Svikis¹, Steven Ondersma², Pamela Dillon¹, Michael Weaver³, ¹Virginia Commonwealth University, Richmond, VA, ²Wayne State University-Psychiatry and Behavioral Neurosciences, Detroit, MI, ³University of Texas Health Science Center, Houston, TX
- 10:30 *Persuasive antismoking interventions via Facebook, email-listserv, and MTURK*
Sunny Jung Kim¹, Jesse Dallery², Mary Brunette¹, Lisa Marsch¹, Jeff T. Hancock³, John A. Naslund⁴, ¹Geisel School of Medicine at Dartmouth, Hanover, NH, ²University of Florida, Gainesville, FL, ³Stanford University, Stanford, CA, ⁴Dartmouth College, Hanover, NH
- 10:45 *Content analysis: Tobacco status project Facebook smoking cessation RCT*
Karma McKelvey¹, Danielle Ramo¹, ¹UCSF, San Francisco, CA
- 11:00 *Using artificial intelligence to predict substance use risk with social media data*
Benjamin Crosier¹, Timothy DeLise¹, Andrej Ficnar², Bruno Korbar¹, Cara Van Uden¹, Saeed Hassanpour¹, ¹Dartmouth College, Hanover, NH, ²University of Oxford, Oxford, UK
- 11:15 *A randomised controlled trial of online and social networking interventions in youth with alcohol use disorders and comorbid depression (the iTreAD Study)*
Frances Kay-Lambkin¹, Sally Hunt², Amanda Baker¹, Maree Teesson², Kathleen Brady³, Mark Deady², Jenny Geddes¹, ¹University of Newcastle, New Castle, New South Wales, ²University of New South Wales, Sydney, New South Wales, ³Medical University of South Carolina, Charleston, SC
- 11:30 *The development of game-based incentives to increase utilization of an automated, computer-based treatment for methadone-maintained patients*
Frank Buono¹, Daniel Lloyd¹, Ryan Sullivan², Destiny Printz¹, Natalia Zenoni², Brent Moore¹, ¹Yale School of Medicine, New Haven, CT, ²APT Foundation, Inc, New Haven, CT
- 11:45 *Mobile Intervention Kit for PWID outreach*
Ian Aronson¹, Alexander Bennett², Lisa Marsch³, Theodore Bania⁴, ¹Digital Health Empowerment / NDRI, Brooklyn, NY, ²National Development and Research Institute, Inc., New York, NY, ³Geisel School of Medicine at Dartmouth, Hanover, NH, ⁴Mount Sinai School of Medicine, New York, NY

Oral Communications 18

Verdun
10:00 - 12:00 PM

MICE, RATS AND MONKEYS, OH MU

Chairs: Francesco Leri and Matthew Banks

- 10:00 *ELK1 is a key regulator of synaptic plasticity and heroin addiction*
Noël Warren¹, Stephanie Sullivan¹, Yasmin Hurd², ¹Icahn School of Medicine at Mount Sinai, New York, NY, ²Mount Sinai School of Medicine, New York, NY
- 10:15 *Inhibition of gap junctions impair the development of opioid tolerance*
Maciej Gonek¹, William Dewey¹, ¹Virginia Commonwealth University, Richmond, VA
- 10:30 *Effects of steady-state methadone exposure on hedonic reactivity and related gene expression in laboratory rats*
Francesco Leri¹, Stephen Daniels¹, Mick Pratt¹, ¹University of Guelph, Guelph, ON
- 10:45 *Antinociceptive interactions between mu-opioid receptor agonists and NMDA antagonists in rhesus monkeys*
Jeremy Cornelissen¹, Floyd Steele¹, Katherine Nicholson¹, Kenner Rice², Matthew Banks³, ¹Medical College of Virginia, Richmond, Virginia, ²NIH, NIDA, Rockville, MD, ³Virginia Commonwealth University, Richmond, VA
- 11:00 *Regulation of dopaminergic and serotonergic neurons in response to co-administration of nalbuphine in morphine-dependent rats*
Rahul Raghav¹, Raka Jain¹, T S ROY¹, Anju Dhawan¹, Punit Kumar¹, ¹All India Institute of Medical Sciences, New Delhi, India
- 11:15 *Role of mu opioid receptors in mediating the effects of amphetamine on cocaine-vs.-food choice in rhesus monkeys*
Megan Moerke¹, Matthew Banks¹, S. Stevens Negus¹, ¹Virginia Commonwealth University, Richmond, VA
- 11:30 *Heroin vaccine abrogates nociceptive and locomotive effects of heroin in rodents and induces cross-reactive antibodies to other abused prescription opioids*
Gary Matyas¹, Rashmi Jalah², Joshua F G Antoline³, Oscar Torres², Arthur Jacobson⁴, Zoltan Beck², Carl R Alving¹, Kenner Rice⁵, ¹Walter Reed Army Institute of Research, Sandy Spring, MD, ²Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, ³NIDA, Bethesda, MD, ⁴NIH, Bethesda, MD, ⁵NIH, NIDA, Rockville, MD
- 11:45 *Effects of a heroin vaccine in assays of schedule-controlled responding and drug discrimination in rhesus monkeys*
Kathryn Schwienteck¹, Matthew Banks², Kim Janda³, Paul Bremer³, ¹Virginia Commonwealth University, Pharmacology and Toxicology, Richmond, VA, ²Virginia Commonwealth University, Richmond, VA, ³Scripps Research Institute, La Jolla, CA

Symposium XI

Westmount
10:00 - 12:00 PM

CLOUDY, WITH A CHANCE OF INTOXICATION: E-VAPE MODELS OF DRUG EXPOSURE IN LABORATORY ANIMALS

Chairs: Michael Taffe and Julie Marusich

- 10:00 *Pharmacological effects of synthetic cannabinoid vapor*
 T. Lefever, RTI International, Research Triangle Park, NC
- 10:25 *Towards a translationally relevant model of developmental cannabis exposure:
 Implications for stress coping and executive function*
 R. McLaughlin, Washington State University, Pullman, WA
- 10:50 *A novel e-vape system produces compulsive-like opioid intake in rats*
 L. Vendruscolo, NIDA, Bethesda, MD
- 11:15 *Reinforcing effects of vapor inhalation of psychostimulants in rats*
 J. Nguyen, Scripps Research Institute, La Jolla, CA
- 11:40 *DISCUSSANT: Leveraging alternative methods of cannabis
 administration research to inform science, practice, and policy*
 M. Taffe, Scripps Research Institute, La Jolla, CA

Animals in Research Forum

Westmount
12:15 - 2:15 PM

ADVANCING OUR KNOWLEDGE OF ADDICTION AND RELATED PSYCHIATRIC DISORDERS WITH NONHUMAN PRIMATE RESEARCH

Chairs: Marilyn Carroll and Leonard Howell

*Introduction: How nonhuman primate research is essential for advancing knowledge on
addiction and related psychiatric disorders*

L. Howell, Emory University, Atlanta, GA

*The value of primate research to gain knowledge complex cognitive behavior and
addiction in humans*

J. Rowlett, University of Mississippi Medical Center, Jackson, MS

Comparative nonhuman primate genomics: Implications for animal models

E. Vallender, University of Mississippi Medical Center, Jackson, MS

*Studying early life stress in primates: Parallels for human models of addiction and
psychiatric illness*

M. Sanchez, Yerkes National Primate Research Center, Atlanta, GA

Oral Communications 19

Outremont
2:30 - 4:30 PM

SPEED BUMPS: PUTTING THE BRAKES ON AMPHETAMINES

Chairs: T. Celeste Napier and Steven M. Graves

- 2:30 *Effects of amphetamine maintenance on abuse-related behavioral effects of MDPV and methamphetamine in rats*
Amy Johnson¹, Matthew Banks¹, S. Stevens Negus¹, ¹Virginia Commonwealth University, Richmond, VA
- 2:45 *In utero exposure to moderate doses of methamphetamine alters sensitivity to the same drug in adults*
Daniela Rüedi-Bettschen¹, Maggie Neal¹, Donna Platt², ¹University of Mississippi Medical Center, Jackson, MS, ²Division of Neurobiology and Behavior Research, Jackson, MS
- 3:00 *Investigating the role of protein kinase C-beta inhibitors as potential therapeutics for amphetamine abuse*
Rachel Altshuler¹, Colleen Carpenter¹, Margaret Gnegy¹, Emily Jutkiewicz¹, ¹University of Michigan, Ann Arbor, MI
- 3:15 *A novel interference peptide disrupts reconsolidation of methamphetamine-associated memory*
Xiaojie Zhang¹, Cuizhu Dong², Mengqi Liu¹, Lidong Liu³, Yu Tian Wang³, Wei Hao¹, ¹Central South University, Changsha, China, ²Central South University, Psychiatry, Changsha, China, ³University of British Columbia, Brain Research Centre, Vancouver, BC
- 3:30 *Methamphetamine increases mitochondrial oxidant stress in substantia nigra pars compacta dopamine neurons: Implications for Parkinson's disease*
Steven M. Graves¹, Zhong Xie¹, Enrico Zampese¹, Kristen Stout¹, Rex Tai¹, Sarah Schwarzschild¹, Lena Burbulla¹, Dimitri Krainc¹, Paul Schumacker¹, D. James Surmeier¹, ¹Northwestern University Feinberg School of Medicine, Chicago, IL
- 3:45 *Brain and behavior parkinsonism-like pathology in rats with a history of self-administered methamphetamine: Exacerbation by rotenone*
Isadora D. Calma¹, Amanda Persons¹, Matt Kase¹, T. Celeste Napier¹, ¹Rush University Medical Center, Chicago, IL
- 4:00 *Abuse-deterrent pseudoephedrine to hinder one-pot conversion to methamphetamine*
Carmen Stomberg¹, Klaus Wening¹, Sebastian Schwier¹, Brandon Presley², ¹The Grünenthal Group, Aachen, Germany, ²NMS Labs, Willow Grove, PA
- 4:15 *Brain activation during methamphetamine-paired cues in humans*
Kathryne Van Hedger¹, Sarah Keedy¹, Leah Mayo², Markus Heilig², Harriet de Wit¹, ¹University of Chicago, Chicago, IL, ²Linköping University, Linköping, Sweden

WHAT'S HAUTE NOW: EMERGING DRUG USE TRENDS

Chairs: Steven Kurtz and Joseph Palamar

- 2:30 *"Not for human consumption": An investigation into motives, consequences, and personality factors associated with bath salt use*
Danielle Beyer¹, Tess Kilwein², Alison Looby², ¹University of North Dakota, Grand Forks, ND, ²University of Wyoming, Laramie, WY
- 2:45 *Systematic surveillance of illicitly manufactured fentanyl cases initiated by law enforcement*
Steven Kurtz¹, Mance Buttram¹, ¹Nova Southeastern University, Miami, FL
- 3:00 *Undetected illicit fentanyl use among patients receiving opioid agonist treatment*
Taylor Ochalek¹, Stacey Sigmon¹, Maria Parker¹, Stephen Higgins¹, ¹University of Vermont, Burlington, VT
- 3:15 *Exploring the new phenomena of home-made extraction and injection of ephedra plant product in Georgia*
David Otiashvili¹, Irma Kirtadze¹, Dessa Bergen-Cico², ¹Addiction Research Center, Tbilisi, GA, ²Syracuse University, Department of Public Health, Syracuse, NY
- 3:30 *User characteristics and effect profiles of butane hash oil: An extremely high-potency cannabis concentrate*
Gary Chan¹, Wayne Hall², Tom Freeman³, Jason Ferris², Adrian Kelly¹, Adam Winstock⁴, Jan Copeland⁵, ¹Centre for Youth Substance Abuse Research, Herston, Queensland, ²University of Queensland, Brisbane, Australia, ³University College London, London, UK, ⁴Global Drug Survey Ltd., London, England, ⁵University of South Wales, Sydney, Australia
- 3:45 *Nonmedical benzodiazepine use among young adult opioid users: A prescription for overdose?*
Pedro Mateu-Gelabert¹, Honoria Guarino¹, Lauren Jessell², Elizabeth Goodbody¹, Dongah Kim³, K. Gile⁴, ¹National Development and Research Institute, Inc., New York, NY, ²New York University, New York, NY, ³University of Massachusetts, Amherst, MA, ⁴UMassAmherst, Amherst, MA
- 4:00 *Trends in ecstasy use among nightclub attendees in the United States and United Kingdom, 2013-2015*
Joseph Palamar¹, Larissa Maier², Monica Barratt³, Jason Ferris⁴, Katherine Keyes⁵, Adam Winstock⁶, ¹New York University School of Medicine, New York, NY, ²University of Zurich, Zurich, Switzerland, ³National Drug and Alcohol Research Centre, Sydney, Australia, ⁴University of Queensland, Brisbane, Australia, ⁵Columbia University Mailman School of Public Health, Newark, NJ, ⁶Global Drug Survey Ltd., London, England
- 4:15 *PET imaging detects dopamine transporter occupancy of new psychoactive substances: Alpha-PVP, pyrovalerone and analogs*
Bertha Madras¹, Peter Meltzer², Elijah Livni³, Ali Bonab⁴, Alan Fischman⁴, ¹McLean Hospital, Belmont, MA, ²Organix, Inc., Woburn, MA, ³Massachusetts General Hospital, Boston, MA, ⁴deceased MGH

WIN, LOSE OR DRAW: REWARD AND EXTINCTION LEARNING

Chairs: Justin Strickland and Marc Kaufman

- 2:30 *Putamen MRS changes induced by stimulus discrimination and reversal learning in nonhuman primates*
Brian Kangas¹, Dionyssios Mintzopoulos², Timothy Gillis¹, Jack Bergman¹, Marc Kaufman², ¹ADARC - McLean Hospital, Belmont, MA, ²McLean Hospital, Brain Imaging Center, Belmont, MA
- 2:45 *Sign-tracking is difficult to extinguish and resistant to multiple cognitive enhancers*
Christopher Fitzpatrick¹, Justin Creeden¹, Jonathan Morrow¹, ¹University of Michigan, Ann Arbor, MI
- 3:00 *Relationship between loss aversion and delay discounting in an online drug-using sample*
William Stoops¹, Justin Strickland¹, ¹University of Kentucky, Lexington, KY
- 3:15 *Loss aversion in cocaine users: Role of risk and commodity type*
Justin Strickland¹, Joshua Beckmann¹, Craig Rush¹, William Stoops¹, ¹University of Kentucky, Lexington, KY
- 3:30 *Negative income shock narratives reduce valuation of extended, prosocial reinforcers in smokers*
Alexandra Mellis¹, Warren Bickel¹, ¹Virginia Tech Carilion Research Institute, Roanoke, VA
- 3:45 *Reward/punishment learning and the subjective effects of oxycodone in recreational opioid users*
Nehal Vadhan¹, Jermaine Jones², Mogali Shanthi², Catherine Myers³, Sandra Comer⁴, ¹Feinstein Institute for Medical Research, Great Neck, NY, ²Columbia University College of Physicians and Surgeons, New York, NY, ³New Jersey Health Care System, Newark, NJ, ⁴Columbia University and NYSPI, New York, NY
- 4:00 *Failure of extinction in limbic regions predicts more drug use*
Paul Regier¹, Kanchana Jagannathan¹, Jesse Suh¹, Teresa Franklin¹, Daniel Langleben¹, Stefanie Darnley¹, Elliott Sturgis-Berkowitz¹, Kyle Kampman¹, Charles O'Brien², Anna Rose Childress¹, ¹University of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania, VA Medical Center, Philadelphia, PA
- 4:15 *Passion "de novo"? In cocaine patients, neutral videos that signal cocaine videos can themselves rapidly come to evoke mesolimbic activation – and this new learning is strongly linked to future relapse*
Anna Rose Childress¹, Kanchana Jagannathan¹, Paul Regier¹, Jesse Suh¹, Zach Monge¹, Teresa Franklin¹, Reagan Wetherill¹, Kimberly Young¹, Stefanie Darnley¹, Elliott Sturgis-Berkowitz¹, Michael Gawrysiak², Regina Szucs-Reed¹, Daniel Langleben¹, Kyle Kampman¹, Charles O'Brien³, ¹University of Pennsylvania, Philadelphia, PA, ²Delaware State University, Wilmington, DE, ³University of Pennsylvania, VA Medical Center, Philadelphia, PA

Symposium XII

Westmount
2:30 - 4:30 PM

OPIOID AND CANNABINOID INTERACTIONS: PRECLINICAL AND CLINICAL MEASURES OF PAIN, ABUSE LIABILITY AND DEPENDENCE

Chairs: Margaret Haney and Aron Lichtman

- 2:30 *Targeting the endogenous cannabinoid system to reduce opioid use and dependence in preclinical studies*
A. Lichtman, Virginia Commonwealth University, Richmond, VA
- 2:55 *Antinociceptive effects and abuse liability of opioid/cannabinoid mixtures*
C. France, University of Texas Health Science Center, San Antonio, TX
- 3:20 *Assessing the analgesic and reinforcing effects of opioid-cannabinoid combinations in the human laboratory*
Z. Cooper, Columbia University and NYSPI, New York, NY
- 3:45 *Evaluation of dronabinol for the treatment of opioid withdrawal*
S. Walsh, University of Kentucky, Lexington, KY
- 4:10 *DISCUSSANT: Opioid antagonism and cannabis reinforcement in the human laboratory*
M. Haney, Columbia University Medical Center, New York, NY

Late-Breaking Research News

Verdun
4:45 - 5:45 PM

Chair: William Stoops

- 4:45 *mGluR5 availability in emerging adults at risk for addictions: A high-resolution PET [11C]ABP688 Study*
Sylvia Cox¹, Natalia Jaworska², Maria Tippler¹, Natalie Castellanos Ryan³, France Durand¹, Dominique Allard¹, Chawki Benkelfat¹, Alain Dagher¹, Frank Vitaro³, Mara Brendgen⁴, Michel Boivin⁵, Robert Pihl¹, Richard Tremblay⁶, Jean Séguin⁴, Marco Leyton¹, ¹McGill University, Montreal, QC, ²The Royal's Institute of Mental Health Research, Ottawa, Ontario, Canada, ³Université de Montréal, Outremont, QC, ⁴Université de Montréal, Montreal, QC, ⁵Université Laval, Québec, Canada, ⁶CHU Sainte-Justine, Montreal, QC
- 4:50 *Cannabidiol: Non-clinical assessment of abuse potential*
Royston Gray¹, David Heal², Colin Stott¹, Stephen Wright¹, ¹GW Pharmaceuticals PLC, Cambridge, UK, United Kingdom, ²RenaSci Ltd, Nottingham, Nottinghamshire, United Kingdom
- 4:55 *Altered functional connectivity in ventral attention network in young adult cannabis users*
Alicia Thomas¹, Krista Lisdahl¹, ¹University of Wisconsin-Milwaukee, Milwaukee, WI
- 5:00 *Preventing the use of synthetic marijuana and new psychoactive substances: Two-year outcomes from a cluster randomised controlled trial*
Katrina Champion¹, Nicola Newton¹, Lexine Stapinski¹, Maree Teesson¹, ¹University of New South Wales, Sydney, New South Wales

Wednesday, June 21, 2017

- 5:05 *Striatal parkin regulates methamphetamine seeking in long-access self-administration in rats.*
Akhil Sharma¹, Arman Harutyunyan², Shane Perrine¹, Anna Moszczynska², ¹Wayne State University, Detroit, MI, ²Eugene Applebaum College of Pharmacy and Health Science, Detroit, MI
- 5:10 *Methamphetamine exposure and withdrawal impacts gut microbiota in rats*
Odochi Ohia-Nwoko¹, Therese Kosten¹, ¹University of Houston, Houston, TX
- 5:15 *CXCR4 and CCR5 antagonism reduce the rewarding effects of the 'bath salt', 3,4-methylenedioxy-N-methylcathinone (MDPV)*
Chicora Oliver¹, Jae Kim², Sunil Nayak¹, ¹Temple University, Philadelphia, PA, ²McLean Hospital, Harvard Medical School, Belmont, MA
- 5:20 *Paternal nicotine exposure transgenerationally alters fear learning and cholinergic function*
Munir Kutlu¹, Rob Cole², Jess Tumolo², Vinay Parikh², Thomas Gould³, ¹Penn State University, University Park, PA, ²Temple University, Philadelphia, PA, ³The Pennsylvania State University, University Park, PA
- 5:25 *RBP-6000 Buprenorphine monthly depot demonstrates efficacy, safety, and exposure/response relationship in opioid use disorder*
Susan Learned¹, Barbara Haight¹, Celine Laffont¹, Dayong Li¹, Paul Fudala¹, Christian Heidbreder¹, ¹Indivior Inc., Richmond, VA
- 5:30 *Outpatient transition to extended-release naltrexone in opioid use disorder*
Adam Bisaga¹, Paolo Mannelli², Miao Yu³, Narinder Nangia³, Christine Graham³, David Andrew Tompkins⁴, Thomas Kosten⁵, Sarah Ackerman³, Bernard Silverman³, Maria Sullivan³, ¹Columbia University and NYSPI, New York, NY, ²Duke University School of Medicine, Durham, NC, ³Alkermes, Inc., Waltham, MA, ⁴Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Baylor College of Medicine, Houston, TX
- 5:35 *Results of a double blind placebo controlled randomized trial of extended-release naltrexone among HIV+ inmates with alcohol use disorders*
Sandra Springer¹, Russell Barbour², Marwan Azar¹, Frederick Alice¹, Angela Di Paola³, ¹Yale School of Medicine, New Haven, CT, ²Yale School of Public Health, New Haven, CT, ³Yale School of Medicine-AIDS Program, New Haven, CT
- 5:40 *New general population data from the USA on maternal risk factors for fetal alcohol spectrum disorders (FASD) and the prevalence of children with FASD in the USA*
P. May, University of North Carolina, Nutrition Research Institute, Kannapolis, NC

Business Meeting
(Members Only)

Salon Bonaventure
6:00 - 7:00 PM

Dinner/Dancing

Montreal Ballroom
7:30 - 10:30 PM

Poster Session IV

(Breakfast)

Fontaine

7:00 - 9:00 AM

Odd numbered posters manned first hour

Even-numbered, second hour

Set up time begins Wednesday, 1:00 PM

Must be removed by Thursday, 9:30 AM

SEROTONIN

- 1 *Effect of 5HT polymorphisms on response to vilazodone for cannabis cessation*
Lynneice Bowen¹, Aimee McRae-Clark¹, Nathaniel Baker¹, ¹Medical University of South Carolina, Charleston, SC
- 2 *Buspirone attenuates naloxone-precipitated withdrawal behaviors in morphine-dependent rats*
Catherine Davis-Takacs¹, Kelly Dunn², Yuqing Cao³, Elise Weerts², ¹Johns Hopkins University, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Sandy Spring Friends High School, Sandy Spring, MD
- 3 *Beta-Arrestin2 involvement in the serotonin 5-HT_{2C} receptor signalosome*
Claudia Soto¹, Kathryn Cunningham¹, Noelle Anastasio¹, Scott Gilbertson², Robert Fox¹, Huang-Chi Du², ¹University of Texas Medical Branch, Galveston, TX, ²University of Houston, Houston, TX
- 4 *The 5-HT_{2A} receptor in the medial prefrontal cortex controls incubation of cocaine cue reactivity*
Erica Holliday¹, Joanna Miszkiel¹, Dennis Sholler¹, Sonja Stutz¹, Robert Fox¹, Noelle Anastasio¹, Kathryn Cunningham¹, ¹University of Texas Medical Branch, Galveston, TX
- 5 *LSD discrimination in male and female Sprague-Dawley rats*
Keli Herr¹, Lisa Baker¹, ¹Western Michigan University, Kalamazoo, MI

CLUB DRUGS/NEW PSYCHOACTIVE SUBSTANCES

- 6 *Serotonergic street drugs, inactive "fillers" or potential recreational compounds?*
Michael Gatch¹, Sean Dolan², Michael Forster¹, ¹UNT Health Science Center, Fort Worth, TX, ²University of North Texas, Denton, TX
- 7 *Potent rewarding and reinforcing properties of the amphetamine-type stimulant 3-fluoromethamphetamine in rodents*
Seong Shoon Yoon¹, Mee Jung Choi², ¹Korea Institute of Toxicology, Korea, Korea, Republic of, ²Korea Institute of Toxicology, Republic of Korea
- 8 *Stereoselectivity in abuse-related neurochemical and behavioral effects of novel synthetic amphetamine isomers*
Farhana Sakloth¹, Umberto Battisti¹, Alan Harris¹, Ramsey Sitta¹, Jose Eltit¹, Richard Glennon¹, S. Stevens Negus¹, ¹Virginia Commonwealth University, Richmond, VA

- 9 *Synthetic cannabinoid augments methamphetamine-induced conditioned place preference in C57BL/6J mice*
Jaesuk Yun¹, Sunmi Gu¹, Hyungsoo Kim¹, Younghoon Kim¹, Kyoung Moon Han¹, Hey Jin Cha¹, Hye-kyung Park¹, Ji Soon Shin¹, ¹National Institute of Food and Drug Safety Evaluation, Cheongju-si, China
- 10 *Effects of low dose mixtures of MDPV and cocaine on locomotor activity and brain monoamine content in Sprague-Dawley rats*
Robert Kohler¹, Shane Perrine², Lisa Baker¹, ¹Western Michigan University, Kalamazoo, MI, ²Wayne State University, Detroit, MI
- 11 *“Ecstasy” to addiction: Discriminative stimulus and reinforcing effects of synthetic cathinone analogs of MDMA*
Sean Dolan¹, Michael Gatch², ¹University of North Texas, Denton, TX, ²UNT Health Science Center, Fort Worth, TX
- 12 *Broad range of drugs detected in pooled urine at an electronic dance music event*
Gantt Galloway¹, Reshmi Pal¹, Roy Gerona², ¹Friends Research Institute, Baltimore, MD, ²San Francisco VA Medical Center, San Francisco, CA
- 13 *Community ketamine users in Taiwan*
Sheng-Chang Wang¹, Yu-Cheng Zhao¹, Chieh-Liang Huang², Hsiao-Hui Tsou¹, ¹National Health Research Institutes, Zhunan, Taiwan, ²China Medical University, Taichung, China
- 14 *Developing psilocybin as a potential pharmacotherapy: Identifying optimal dosing parameters*
Albert Garcia-Romeu¹, Frederick Barrett², Matthew Johnson², Roland Griffiths², ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins School of Medicine, Baltimore, MD
- 15 *Comparative psychopharmacology of psilocybin and dextromethorphan*
Theresa Carbonaro¹, Frederick Barrett², Matthew Johnson², Roland Griffiths², ¹University of North Texas Health Science Center, Watauga, TX, ²Johns Hopkins School of Medicine, Baltimore, MD
- 16 *Psilocybin mushroom occasioned experiences: Impact on attitudes about death and dying*
Darrick May¹, Mary Sweeney², Roland Griffiths³, Matthew Johnson³, Ethan Hurwitz², ¹Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Johns Hopkins School of Medicine, Baltimore, MD

STRESS

- 17 *Expression of FKBP5 is elevated following chronic cocaine administration*
Krista Connelly¹, Ellen Unterwald², ¹Lewis Katz School of Medicine at Temple University, Philadelphia, PA, ²Temple University School of Medicine, Philadelphia, PA
- 18 *Glucocorticoid-endocannabinoid interactions in the prelimbic cortex mediate stress-potentiated reinstatement of cocaine seeking*
Jayme McReynolds¹, Elizabeth Doncheck¹, Todd Stollenwerk², Xiaojie Liu², Paul Gottshall¹, Qing-song Liu², Cecilia Hillard², John Mantsch¹, ¹Marquette University, Milwaukee, WI, ²Medical College of Wisconsin, Milwaukee, WI

- 19 *Exacerbated craving in the presence of stress and drug cues in drug-dependent patients*
Kenzie Preston¹, William Kowalczyk², Karran Phillips³, Vahabzadeh Massoud¹, Jia-Ling Lin¹, Mustapha Mezghanni¹, David Epstein¹, ¹NIDA Intramural Research Program, Baltimore, MD, ²NIH, Bethesda, MD, ³NIDA, Bethesda, MD
- 20 *Salivary cortisol levels and early inpatient discharge in Brazilian crack-cocaine users*
Karina Ligabue¹, Felix Kessler¹, Juliana Scherer¹, Flavio Pechansky¹, Felipe Ornell¹, Vanessa Assuncao¹, Andrei Valerio¹, Marcelo Rocha¹, Milena Stivelmam¹, Lisia von Diemen¹, ¹Center for Drug and Alcohol Research, Federal University of Rio Grande do Sul, Porto Alegre, Brazil
- 21 *Markers for hypnotic abuse liability: Cortisol in insomnia?*
Timothy Roehrs¹, Thomas Roth¹, ¹Henry Ford Health System, Detroit, MI
- 22 *Perceived stress among methadone maintenance treatment patients - a cross-sectional study*
Einat Peles¹, Elad Malik², Shaul Schreiber², Anat Sason², Miriam Adelson², ¹Tel Aviv University, Reut, Israel, Israel, ²Adelson Clinic, Tel Aviv Medical Center, Tel Aviv, Israel
- 23 *Methamphetamine users exhibit fronto-insular inflexibility during a cue reactivity paradigm involving an interoceptive stressor*
Jennifer Stewart¹, April May², Susan Tapert³, Martin Paulus⁴, ¹CUNY Graduate School of Public Health and Health Policy, New York, NY, ²UCSan Diego-Psychiatry, San Diego, CA, ³VA San Diego Healthcare System, San Diego, CA, ⁴Laureate Institute for Brain Research; UCSD Psychiatry, Tulsa, OK
- 24 *Sex differences in daily life stress and craving in drug-dependent patients*
Landhing Moran¹, David Epstein¹, William Kowalczyk², Karran Phillips³, Vahabzadeh Massoud¹, Mustapha Mezghanni¹, Kenzie Preston¹, ¹NIDA Intramural Research Program, Baltimore, MD, ²NIH, Bethesda, MD, ³NIDA, Bethesda, MD
- 25 *Perceived stress and depression in substance use disorder treatment*
Shelly Greenfield¹, R. Kathryn McHugh¹, Dawn Sugarman¹, Meghan Reilly¹, Garrett Fitzmaurice¹, ¹McLean Hospital, Belmont, MA

TECHNOLOGY

- 26 *Correlates of trust in online health information among patients in opioid treatment*
Carmen Masson¹, Ida Chen¹, James Sorensen², Isabel Allen¹, Evan Kletter³, Mandana Khalili¹, ¹UCSF, San Francisco, CA, ²UCSF at Zuckerberg San Francisco General Hospital, San Francisco, CA, ³Baymark, San Francisco, CA
- 27 *Development of a mHealth tool to enhance linkage and retention to office-based opioid treatment and HIV-HCV care among inpatient detoxification program patients*
Babak Tofighi¹, Joshua Lee¹, Mara Flannery², Edward Nunes³, Scott Sherman⁴, Amalia Pinguello⁵, ¹New York University School of Medicine, New York, NY, ²NYU Langone Medical Center, New York, NY, ³Columbia University and NYSPI, New York, NY, ⁴New York University Medical Center, New York, NY, ⁵Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul

- 28 *Text messaging reduces methamphetamine use and HIV risk behaviors among MSM*
Cathy Reback¹, Jesse Fletcher², ¹Friends Research Institute, Los Angeles, CA, ²Friends Research Institute, Baltimore, MD
- 29 *Mobile phone and Internet use among people who inject drugs in Fresno, California*
Catherine Paquette¹, Jennifer Syvertsen², Robin Pollini³, ¹Pacific Institute for Research and Evaluation, Washington, DC, ²Ohio State University, Columbus, OH, ³West Virginia University-Injury Control Research Center, Morgantown, WV
- 30 *Public perceptions of fentanyl on Twitter*
Lamisha Muquit¹, Nancy Haug², Steven Linder³, ¹Palo Alto University, Union City, CA, ²Palo Alto University, Los Altos, CA, ³VA Palo Alto Health Care System, San Francisco, CA
- 31 *Using Twitter to monitor negative effects of cannabis and synthetic cannabinoid products*
Francois Lamy¹, Raminta Daniulaityte¹, Amit Sheth¹, Ramzi W. Nahhas¹, Alan G. Smith¹, Silvia Martins², Robert Carlson¹, ¹Wright State University, Fairborn, OH, ²Columbia University Mailman School of Public Health, Newark, NJ
- 32 *A Web-based self-help intervention with and without chat counseling to reduce cannabis use in problematic cannabis users: Three-arm randomized controlled trial*
M. Schaub, Research Institute for Public Health and Addiction, Zurich, Switzerland
- 33 *Clinician attitudes, perceived social norms, and intentions to implement Web-delivered interventions*
Traci Rieckmann¹, Aimee Campbell², ¹Oregon Health and Science University, Hillsboro, OR, ²Columbia University and NYSPI, New York, NY
- 34 *Clinician attitudes, social norms, and intention to use internet-delivered addiction treatment*
Aimee Campbell¹, Traci Rieckmann², Sheila Markwardt², Edward Nunes¹, ¹Columbia University and NYSPI, New York, NY, ²Oregon Health and Science University, Hillsboro, OR
- 35 *Feasibility of the veterans' recovery line as ancillary care for substance abuse treatment*
Destiny Printz¹, David Pilkey¹, Marc Rosen¹, Alicia Heapy¹, Frank Buono², Brent A. Moore¹, ¹VA Connecticut Healthcare System, West Haven, CT, ²Yale School of Medicine, New Haven, CT
- 36 *Substance use following brief motivational interviewing intervention among women in a reproductive healthcare clinic*
Ariadna Forray¹, Steve Martino¹, Kathryn Gilstad-Hayden¹, Steven Ondersma², Todd Olmstead³, Trace Kershaw⁴, Kimberly Yonkers¹, ¹Yale University-Psychiatry, New Haven, CT, ²Wayne State University-Psychiatry and Behavioral Neurosciences, Detroit, MI, ³University of Texas at Austin, Lyndon B. Johnson School of Public Affairs, ⁴Yale School of Public Health, New Haven, CT
- 37 *Acceptability of the therapeutic education system in dually diagnosed inpatients*
Alexis Hammond¹, Denis Antoine¹, Maxine Stitzer², Eric Strain¹, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins Bayview Medical Center, Baltimore, MD

- 38 *Cognitive functioning and treatment outcomes in a trial of internet-delivered drug and alcohol treatment*
Matis Shulman¹, Aimee Campbell¹, Edward Nunes¹, Mei-Chen Hu², Martina Pavlicova³, ¹Columbia University and NYSPI, New York, NY, ²Columbia University Medical Center, Department of Psychiatry, New York, NY, ³Columbia University Mailman School of Public Health, Newark, NJ

DETECTION

- 39 *Evaluation of two screening devices for cocaine detection in oral fluid*
Juliana Scherer¹, Tais Fiorentin², Tanara Sousa¹, Renata Limberger², Flavio Pechansky¹, ¹Center for Drug and Alcohol Research, Federal University of Rio Grande do Sul, Porto Alegre, Brazil, ²Postgraduate Program in Pharmaceutical Sciences, Federal University of Rio Grande do Sul, Porto Alegre, Brazil
- 40 *Drug use among Brazilian drivers with oral fluid screening devices as part of traffic checkpoints*
Tanara Sousa¹, Juliana Scherer¹, Roberta B. Silvestrin¹, Vinicius S. Roglio¹, Giovana Brolese¹, Graciela G. Pasa¹, Jaqueline B. Schuch¹, Tais Fiorentin², Renata Limberger², Flavio Pechansky¹, ¹Center for Drug and Alcohol Research, Federal University of Rio Grande do Sul, Porto Alegre, Brazil, ²Postgraduate Program in Pharmaceutical Sciences, Federal University of Rio Grande do Sul, Porto Alegre, Brazil
- 41 *Detection of ethylglucuronide and ethylsulfate in urine after acute administration of different doses of alcohol*
Francina Fonseca¹, Julián Andrés Mateus², Clara Pérez Mañá¹, Esther Papasseit³, Adriana Farré¹, Esther Menoyo², Marta Pérez², Soraya Martín², Mitona Pujadas², Rafael de la Torre⁴, Marta Torrens¹, Magí Farré³, ¹Institut de Neuropsiquiatria i Addiccions, Barcelona, Spain, ²Autonomous University of Barcelona, Catalonia, Spain, ³Hospital Universitari Germans Trias i Pujol, School of Medicine, Barcelona, Spain, ⁴d'Investigacio Medica, Barcelona, Spain, Spain
- 42 *Sex differences in concordance of cannabis self-report and bioassays*
Emmalee Bandstra¹, Veronica Accornero¹, Alexandra Fernandez¹, Denise Vidot², Elana Mansoor¹, Lihua Xue¹, James Anthony³, ¹University of Miami Miller School of Medicine, Miami, FL, ²University of Miami, Miami, FL, ³Michigan State University, Lansing, MI

SEXUAL RISK AND DRUG USE

- 43 *Talking about drugs and sexual risk in HIV primary care: A qualitative exploration of provider practices and patient perceptions*
Laurel Weaver¹, Aimee Campbell², Susan Tross³, Don Des Jarlais¹, Margaret Wolff¹, ¹Icahn School of Medicine at Mount Sinai, New York, NY, ²Columbia University and NYSPI, New York, NY, ³Columbia University, New York, NY
- 44 *Developmental patterns of adolescent marijuana and alcohol use and their joint association with sexual risk behavior and outcomes in young adulthood*
Kerry Green¹, Rashelle Musci², Pamela Matson³, Renee Johnson², Beth Reboussin⁴, Nicholas Ialongo⁵, ¹University of Maryland, College Park, MD, ²Johns Hopkins Bloomberg School of Public Health, Department of Mental Health, Baltimore, MD, ³Johns Hopkins University, Baltimore, MD, ⁴Wake Forest School of Medicine, Winston-Salem, NC, ⁵Johns Hopkins Bloomberg School of Public Health, Baltimore, MD

- 45 *Development of a mobile game app to reduce high-risk sexual behavior in adolescents under the influence of drugs and/or alcohol*
Aileen Garipey¹, Kimberly Hieftje¹, Tyra Pendergass¹, Erica Miller¹, Lynn Fiellin¹, ¹Yale University, New Haven, CT
- 46 *Using a “Positive Deviance” framework to discover adaptive risk reduction behaviors among substance-using HIV negative Black men who have sex with men*
Allison Ober¹, Derek Dangerfield II², Steve Shoptaw³, Gery Ryan¹, Brian Stucky¹, Samuel Friedman⁴, ¹RAND Corporation, Arlington, VA, ²University of Southern California, Los Angeles, CA, ³UCLA, Los Angeles, CA, ⁴National Development and Research Institute, Inc., New York, NY
- 47 *Partner-level substance use associated with increased sexual risk behaviors among men who have sex with men in San Francisco, CA*
Robert Brown¹, Caitlin Turner², Jaclyn Hern², Glenn-Milo Santos³, ¹University of California Berkeley, Berkeley, CA, ²San Francisco Department of Public Health, San Francisco, CA, ³UCSF, San Francisco, CA
- 48 *Substance use facilitates sexual interactions and increases HIV risk in Black South African MSM*
Justin Knox¹, Kate Collier¹, Amanda Mtshengu², Matthew Lee¹, Tim Lane³, Vasu Reddy⁴, Deborah Hasin¹, Theo Sandfort¹, ¹Columbia University, New York, NY, ²Human Sciences Research Council, Pretoria, South Africa, ³UCSF, San Francisco, CA, ⁴University of Pretoria, Gauteng, South Africa
- 49 *Substance use and sexual expectancies among gay and bisexual men*
Thomas Whitfield¹, Brett M Millar², Christian Grov², Jeffrey Parsons³, ¹Center for HIV Educational Studies and Training, New York, NY, ²CUNY Graduate School of Public Health and Health Policy, New York, NY, ³Hunter College, CUNY, New York, NY
- 50 *The prevalence and impact of sexual violence among Latino men in federally qualified health centers with a history of risky drug use*
Amelia Goodfellow¹, Curtis Bone², Mani Vahidi¹, Melvin Rico³, Lillian Gelberg³, ¹UCLA, Los Angeles, CA, ²Yale School of Medicine, New Haven, CT, ³UCLA Family Medicine, Los Angeles, CA

CRIMINAL JUSTICE

- 51 *Social support and motivation to change among drug-involved juvenile offenders*
Megan Dickson¹, Carl Leukefeld¹, Hannah Knudsen¹, Matt Webster², Katherine Marks¹, Carrie Oser¹, Michele Staton³, Jennifer Havens³, ¹University of Kentucky, Lexington, KY, ²Center on Drug and Alcohol Research University of Kentucky, Lexington, KY, ³University of Kentucky College of Medicine, Lexington, KY
- 52 *Childhood parental incarceration and adulthood drug use, sexually transmitted infection, and arrest risk among Blacks and Hispanics in the US: Assessment of moderation by mentorship*
Maria Khan¹, Joy Scheidell¹, Danielle Ompad², Kelly Quinn¹, ¹New York University School of Medicine, New York, NY, ²New York University, New York, NY
- 53 *Correlates of hepatitis c seropositivity among high-risk rural women: Opportunities for treatment and services in the criminal justice system*
Michele Staton¹, Justin Strickland², Jennifer Havens¹, Matt Webster², ¹University of Kentucky College of Medicine, Lexington, KY, ²University of Kentucky, Lexington, KY

- 54 *Women in drug court: Differences between sex traders and non-sex traders and longitudinal substance use outcomes*
Abenaa Jones¹, Denise Vidot², Catherine Woodstock Striley³, Linda Cottler³, ¹Johns Hopkins Bloomberg School of Public Health, Department of Mental Health, Baltimore, MD, ²University of Miami, Miami, FL, ³University of Florida, Gainesville, FL
- 55 *Accumulated criminal justice system involvement and mental health outcomes among women who use illicit drugs: Latent class analysis*
Jennifer Lorvick¹, Barrot Lambdin¹, Megan Comfort¹, Alex Kral¹, ¹RTI International, Research Triangle Park, NC
- 56 *High rates of incarceration due to drug trafficking in the last decade in Brazil*
Felipe Ornell¹, Juliana Scherer¹, Karina Ligabue¹, Joana Correa de Magalhães Narvaez¹, Carla Dalbosco¹, Rafaela Ornell¹, Renata Maria Dotta², Lisieux Borba Telles¹, Flavio Pechansky¹, Lisia von Diemen¹, Felix Kessler¹, ¹Center for Drug and Alcohol Research, Federal University of Rio Grande do Sul, Porto Alegre, Brazil, ²Fundação Escola Superior do Ministério Público, Porto Alegre, Brazil
- 57 *Risks for nonmedical use of prescription opiates among incarcerated African-American men*
Carlos Mahaffey¹, Danelle Stevens-Watkins¹, Paris Wheeler¹, ¹University of Kentucky, Lexington, KY
- 58 *Standardized mortality ratio and rate ratio of hospitalization among illicit drug offenders identified from integrated national databases from 2009 to 2013 in Taiwan*
Shang-Chi Wu¹, Chia-Mei Kuo¹, Kevin Chien-Chang Wu¹, Tzu-Pin Lu¹, Wei-J Chen², ¹National Taiwan University, Epidemiology and Preventive Medicine, Taipei City, Taiwan, ²National Taiwan University, Taipei City, Taiwan
- 59 *Costs of crime associated with stimulant use disorders*
Benjamin Enns¹, Emanuel Krebs¹, Kora DeBeck¹, Lindsey Richardson¹, Kanna Hayashi¹, Bohdan Nosyk¹, ¹BC Centre for Excellence in HIV/AIDS, Vancouver, BC

MARIJUANA/CANNABINOIDS II

- 60 *Daily patterns of substance use and violence among a high-risk urban sample*
Aaron Dora-Laskey¹, Patrick Carter¹, James Cranford¹, Anne Buu¹, Maureen Walton², Marc Zimmerman¹, Rebecca Cunningham¹, ¹University of Michigan, Ann Arbor, MI, ²University of Michigan-Addiction Research Center, Ann Arbor, MI
- 61 *Association between cannabis use and lifetime coronary disease*
Hannah Crooke¹, Linda Cottler¹, Catherine Woodstock Striley¹, ¹University of Florida, Gainesville, FL
- 62 *Associations of marijuana quantity and frequency with marijuana motives among emerging adults*
Brooke Arterberry¹, Alan Davis², Maureen Walton³, Rebecca Cunningham¹, Frederic Blow³, Erin Bonar¹, ¹University of Michigan, Ann Arbor, MI, ²Bowling Green State University, Ann Arbor, MI, ³University of Michigan-Addiction Research Center, Ann Arbor, MI

- 63 *The impact of the urban neighborhood environment on longitudinal transitions in marijuana use during emerging adulthood*
Beth Reboussin¹, Nicholas Ialongo², Kerry Green³, Debra Furr-Holden⁴, Renee Johnson⁵, Adam Milam⁶, ¹Wake Forest School of Medicine, Winston-Salem, NC, ²Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, ³University of Maryland, College Park, MD, ⁴Michigan State University, Lansing, MI, ⁵Johns Hopkins Bloomberg School of Public Health, Department of Mental Health, Baltimore, MD, ⁶Johns Hopkins University, Baltimore, MD
- 64 *Abstinence and reductions in cannabis use are associated with improvements in quality of life among treatment-seeking individuals with cannabis use disorder*
Christina Brezing¹, C. Jean Choi¹, Martina Pavlicova², Daniel Brooks³, Amy Mahony³, John Mariani³, Frances Levin¹, ¹Columbia University and NYSPI, New York, NY, ²Columbia University Mailman School of Public Health, Newark, NJ, ³NYSPI, New York, NY
- 65 *Repetitive transcranial magnetic stimulation can be safely and feasibly applied to the dorsolateral prefrontal cortex of non-treatment-seeking heavy cannabis users*
G. Sahlem, Medical University of South Carolina, Charleston, SC
- 66 *Trends and factors related to coping-related motives for cannabis use among a large sample of adult cannabis users*
Ashley Knapp¹, Catherine Stanger², Jacob Borodovsky¹, Alan Budney¹, ¹Geisel School of Medicine at Dartmouth, Hanover, NH, ²Dartmouth College, Hanover, NH
- 67 *Alcohol control policies and youth past 30-day marijuana and heavy marijuana use in 45 states, 1991- 2011*
Sherri-Chanelle Brighthaupt¹, Renee Johnson², Julie Johnson³, ¹Johns Hopkins University, Baltimore, MD, ²Johns Hopkins Bloomberg School of Public Health, Department of Mental Health, Baltimore, MD, ³Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
- 68 *Documentation of marijuana use in the electronic health records of community health center patients*
Steffani Bailey¹, John Muench¹, Allison O'Neill², Lynn Kunkel¹, Stuart Cowburn², Kim Hoffman¹, Javier Ponce Terashima³, Dennis McCarty¹, ¹Oregon Health and Science University, Hillsboro, OR, ²OCHIN, Inc., Portland, OR, ³International Center for Advanced Research and Applied Science, Lima, Peru
- 69 *Hospitalizations due to cannabis-related disorders in Canada*
Sarah Wallingford¹, Amy Porath², Matthew Young¹, ¹Canadian Centre on Substance Abuse, Ottawa, ON, ²Canadian Centre on Substance Abuse, Ottawa, ON, Canada
- 70 *Mortality from cardiovascular disease and diabetes among cannabis users*
Omayma Alshaarawy¹, James Anthony¹, ¹Michigan State University, Lansing, MI
- 71 *Examining the relationship between exposure to marijuana advertising and recent marijuana use*
Sean LeNoue¹, Joseph Sakai¹, Christian Thurstone², Susan Young², Shannon McWilliams¹, Tamara Wall³, Christian Hopfer¹, ¹University of Colorado School of Medicine, Aurora, CO, ²University of Colorado School of Medicine, Department of Psychiatry, Aurora, CO, ³UCSan Diego, La Jolla, CA

- 72 *Survey of Australians' knowledge, perception and use of cannabis for medicinal purposes*
Jan Copeland¹, Peter Gates¹, Stephanie Todd¹, ¹University of South Wales, Sydney, Australia
- 73 *Medicinal versus recreational cannabis use among returning veterans*
Jane Metrik¹, Shayna Bassett², Elizabeth Aston³, Kristina Jackson³, Brian Borsari⁴, ¹Warren Alpert Medical School, Providence, RI, ²University of Rhode Island, Department of Psychology, Kingston, RI, ³Center for Alcohol and Addiction Studies, Brown University School of Public Health, Providence, RI, ⁴San Francisco VA Medical Center, San Francisco, CA
- 74 *Cross-validation of the CUDIT-R among a sample of veteran medicinal cannabis users: Evidence of poor model fit*
Mallory Loflin¹, Kimberly Babson¹, Kendall Browne², Marcel Bonn-Miller¹, ¹VA Palo Alto Health Care System, San Francisco, CA, ²VA Puget Sound Healthcare System, Seattle, WA
- 75 *Latent factor structure of a behavioral economic marijuana demand curve*
Elizabeth Aston¹, Samantha Farris², James MacKillop³, Jane Metrik², ¹Center for Alcohol and Addiction Studies, Brown University School of Public Health, Providence, RI, ²Warren Alpert Medical School, Providence, RI, ³McMaster University, Peter Boris Centre for Addictions Research, Hamilton, ON
- 76 *Budtender perspectives on shared decision-making in medical cannabis dispensaries*
Nicholas Peiper¹, Angelica Meinhofer¹, Scott Novak¹, ¹RTI International, Research Triangle Park, NC
- 77 *Exploring the relationship between medical marijuana laws and educational attainment.*
Andrew Plunk¹, Paul Harrell¹, ¹Eastern Virginia Medical School, Norfolk, VA

DRUGS AND MEMORY

- 78 *The association of learning strategy and delayed recall in adolescents and young adult marijuana users and controls*
Kyle Jennette¹, Erika R. Gilbert¹, Krista Lisdahl¹, ¹University of Wisconsin-Milwaukee, Milwaukee, WI
- 79 *Does physical activity influence the association between cannabis use and memory?*
Ileana Pacheco-Colon¹, Samuel Hawes¹, Jacqueline Duperrouzel¹, Raul Gonzalez¹, ¹Florida International University, Miami, FL
- 80 *Acute effects of cannabis on verbal memory in young adults: Relationship to tobacco use*
Justin Matheson¹, Robert Mann¹, Bernard Le Foll¹, Gina Stoduto¹, Christine Wickens¹, Marilyn Huestis², Bruna Brands³, ¹Centre for Addiction and Mental Health, Toronto, ON, ²NIDA, Bethesda, MD, ³Health Canada, Toronto, ON
- 81 *Testing a novel prospective memory training program in substance users*
Meredith Berry¹, Mary Sweeney¹, Matthew Johnson², ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins School of Medicine, Baltimore, MD

- 82 *Cognitive rehabilitation for individuals with opioid use disorder: A randomized controlled trial*
Mehmet Sofuoglu¹, Alireza Noroozi², Reza Daneshmand³, Ahmadreza Samiei⁴, Tara Rezapour⁵, Javad Hatami⁵, Ali Farhoudian³, Hamed Ekhtiari⁶, ¹Yale University, New Haven, CT, ²Tehran University of Medical Sciences, Tehran, Iran, ³University of Social Welfare and Rehabilitation Sciences, Tehran, Iran, ⁴Arak University of Medical Sciences, Arak, Iran, ⁵Institute for Cognitive Science Studies, Tehran, Iran, ⁶Institute for Cognitive Science Studies, Tehran, Tehran

PRESCRIPTION MISUSE

- 83 *Non-medical prescription opioid use and age at first use: Examination of gender differences in youth*
Vicki Osborne¹, Catherine Woodstock Striley¹, Linda Cottler¹, ¹University of Florida, Gainesville, FL
- 84 *Trajectories of nonmedical prescription drug use: Assessing the impact of early exposure to prescription drugs*
Philip Veliz¹, John Schulenberg¹, Sean McCabe¹, ¹University of Michigan, Ann Arbor, MI
- 85 *Prevalence of non-medical use of prescription drugs in the United States in 2016*
Kevin Patrick May¹, Colleen Haynes¹, Karilynn Rockhill¹, Zachary Margolin¹, Richard Dart¹, Jody Green¹, ¹Rocky Mountain Poison and Drug Center, Denver, CO
- 86 *Prevalence of illicit drug use: Survey of non-medical use of prescription drugs program compared to NSDUH*
Karilynn Rockhill¹, Colleen Haynes¹, Kevin Patrick May¹, Zachary Margolin¹, Richard Dart¹, Jody Green¹, ¹Rocky Mountain Poison and Drug Center, Denver, CO
- 87 *Motivations for prescription opioid use by diversion pattern*
Amy Elliott¹, Jasmine Mack¹, Kelly Gurka¹, Catherine Woodstock Striley¹, Linda Cottler¹, ¹University of Florida, Gainesville, FL
- 88 *Increased incoming diversion among users of both non-medical prescription opioids and sedatives compared to individual users*
Sadaf A Milani¹, Mirsada Serdarevic², Vicki Osborne², Linda Cottler², Catherine Woodstock Striley², ¹University of Florida, Department of Epidemiology, Gainesville, FL, ²University of Florida, Gainesville, FL
- 89 *Illicit gabapentin (GBP) use among nonmedical prescription opioid users: Findings from the national opioid misuse, abuse, and diversion study (NOMAD)*
Scott Novak¹, Erica Peters², Nick Peiper¹, Mark Edlund¹, ¹RTI International, Research Triangle Park, NC, ²Battelle Memorial Institute, Baltimore, MD
- 90 *Mandatory use of a prescription drug monitoring program and impact on opioid dispensing*
Erin Winstanley¹, Yifan Zhang¹, Rebecca Mashni², Sydney Schnee², Jonathan Penm², Jill Boone², Cameron McNamee³, Neil MacKinnon², ¹West Virginia University, Morgantown, WV, ²University of Cincinnati, Cincinnati, OH, ³State of Ohio Board of Pharmacy, Columbus, OH

- 91 *The impact of a potentially tamper-resistant controlled-release formulation of oxycodone: Key findings from the national opioid medications abuse deterrence (NOMAD) study*
Briony Larance¹, Robert Ali², Michael Farrell³, Amy Peacock³, Raimondo Bruno⁴, Nichola Lintzeris⁵, Timothy Dobbins³, Louisa Degenhardt⁶, ¹University of South Wales, Sydney, Australia, ²WHO Collaborating Centre for the Treatment of Drug and Alcohol Problems, Adelaide, South Australia, Australia, ³National Drug and Alcohol Research Centre, Sydney, Australia, ⁴University of Tasmania, Sydney, New South Wales, Australia, ⁵Drug and Alcohol Services, South Eastern Sydney Local Health District, Sydney, Australia, ⁶National Drug and Alcohol Research Centre, Sydney, Australia
- 92 *Impact of Florida PDMP introduction, pill mill legislation and oxycontin reformulation on tablets dispensed in Florida and California*
Paul Coplan¹, Angela DeVaugh-Geiss¹, V. anna Gyarmathy¹, Venkatesh Harikrishnan¹, ¹Purdue Pharma L.P., Stamford, CT
- 93 *HCV in social networks of young adults who misuse prescription opioids and heroin*
Alia Al-Tayyib¹, Stephen Muth², Eric Rice³, Paula Riggs⁴, ¹Denver Public Health, Denver, CO, ²Quintus-ential Solutions, Colorado Springs, CO, ³University of Southern California, Los Angeles, CA, ⁴University of Colorado School of Medicine, Aurora, CO
- 94 *Medical consequences of the use of prescription opiates and other medications in intentional self-harm*
Kenneth Conner¹, Timothy Wiegand¹, Rachel Gorodetsky¹, Rachel Schult¹, Kimberly Kaukeinen¹, Peter Crane¹, ¹University of Rochester Medical Center, Rochester, NY
- 95 *“That fentanyl dope is way worse”: Characterizing fentanyl outbreaks in the Dayton, Ohio, area*
Raminta Daniulaityte¹, Francois Lamy¹, Matthew Juhascik², Ioana Sizemore¹, Mussa Zatreh¹, Kraig Strayer¹, Robert Carlson¹, ¹Wright State University, Fairborn, OH, ²Montgomery Co. Coroner's Office, Montgomery, PA
- 96 *The association between neighborhood deprivation and past month prescription opioid use*
Hui Hu¹, Catherine Woodstock Striley¹, Linda Cottler¹, ¹University of Florida, Gainesville, FL
- 97 *Risk of amphetamine use disorder and mortality among incident users of prescribed stimulant medications in the Veterans Administration*
Arthur Westover¹, Bryon Adinoff¹, Ethan Halm¹, Paul Nakonezny¹, ¹University of Texas Southwestern Medical Center, Dallas, TX
- 98 *The association between different patterns of non-medical use of stimulants and motivations for use*
Yiyang Liu¹, Catherine Woodstock Striley¹, Linda Cottler¹, ¹University of Florida, Gainesville, FL
- 99 *Prescription medication misuse and hazardous drinking among national guard soldiers*
Lynn Massey¹, Maureen Walton², Richard McCormick³, Marcia Valenstein¹, Kristen Barry¹, Heather Walters¹, Amy Bohnert¹, Mark Ilgen¹, James Cranford¹, Frederic Blow², ¹University of Michigan, Ann Arbor, MI, ²University of Michigan-Addiction Research Center, Ann Arbor, MI, ³Case Western Reserve University, Cleveland, OH

- 100 *Attitudes toward pharmacotherapies among current prescription opioid users*
Andrew Huhn¹, David Andrew Tompkins¹, Kelly Dunn¹, ¹Johns Hopkins University
School of Medicine, Baltimore, MD
- 101 *Association between mutual-help groups and abstinence among prescription opioid
dependent patients, with and without agonist treatment, during 42-month post-
treatment follow-up*
Roger Weiss¹, Margaret Griffin¹, R. Kathryn McHugh¹, Sterling Karakula¹, ¹McLean
Hospital, Belmont, MA
- 102 *The psychiatric medication discontinuation/reduction (PMDR) study: Initial findings*
Lauren Jessell¹, Laysha Ostrow², David Cohen³, Manton Hurd, ¹New York University,
New York, NY, ²Live and Learn, Morro Bay, CA, ³UCLA, Los Angeles, CA

PAIN

- 103 *Peripheral pro-inflammatory cytokines participate in chronic morphine-induced
hyperalgesia in mice*
Shiroh Kishioka¹, Fumihiro Saika¹, Norikazu Kiguchi¹, Shinsuke Matsuzaki¹,
¹Wakayama Medical University, Wakayama, Japan
- 104 *Tolerance and cross-tolerance to the antinociceptive effects of oxycodone and
the imidazoline I2 receptor agonist phenylzoline in adult male rats*
Jun-Xu Li¹, David Thorn¹, Yanan Zhang², ¹State University of New York at
Buffalo, Buffalo, NY, ²RTI International, Research Triangle Park, NC
- 105 *Chronic pain, trauma, and psychosocial functioning among patients entering
methadone maintenance treatment*
Declan Barry¹, Mark Beitel², Lynn Madden³, Reed Bobroff⁴, Scott Farnum³,
Kathryn Eggert³, Robert Freeman³, Ehab Hussein³, ¹Yale School of Medicine,
New Haven, CT, ²Yale University-APT Foundation, New Haven, CT, ³APT
Foundation, Inc., New Haven, CT, ⁴Yale University, New Haven, CT
- 106 *Opioid use for chronic pain among patients with HIV*
Jonathan Colasanti¹, Marlene C. Lira², Debbie Cheng², Leah S. Forman², Meg
Sullivan², Christin Root¹, Catherine Abrams¹, Melissa Podolsky², Wendy S.
Armstrong¹, Jeffrey Samet², Carlos del Rio¹, ¹Emory University, Atlanta, GA,
²Boston University School of Medicine, Boston, MA
- 107 *Patient concerns and help-seeking for problems with opioid medications for
chronic non- cancer pain*
Gabrielle Campbell¹, Briony Larance¹, Suzanne Nielsen¹, Teleri Moore¹, Courtney
O'Donnell¹, Louisa Degenhardt², ¹University of South Wales, Sydney, Australia,
²National Drug and Alcohol Research Centre, Sydney, Australia
- 108 *The between and within-person moderation of associations between negative affect
and cravings by experiences of pain among patients with opiate use disorder*
H.H. Cleveland¹, M Cleveland², Dean Stankoski³, E Deneke⁴, E. Bixler⁵, Roger
Meyer⁶, S. Bunce⁵, ¹Penn State University, University Park, PA, ²Washington State
University, Pullman, WA, ³Penn State University College of Medicine, Hershey,
PA, ⁴Caron Treatment Center, Wernersville, PA, ⁵Penn State College of Medicine,
Hershey, PA, ⁶Penn State College of Medicine, Psychiatry, Washington, DC

- 109 *Evaluating LTP-like rTMS as a tool to reduce pain and craving in individuals with non- medical prescription opiate use*
Logan Dowdle¹, Sarah Hamilton¹, Jeffrey Borckardt¹, Sudie Back¹, Colleen Hanlon¹,
¹Medical University of South Carolina, Charleston, SC
- 110 *Prophylactic sleep improvement reduces post-surgery pain and opiate use*
Timothy Roehrs¹, Thomas Roth¹, ¹Henry Ford Health System, Detroit, MI
- 111 *Do cannabinoids have the potential to be opioid-sparing in chronic pain treatment? A systematic review and meta-analyses*
Suzanne Nielsen¹, Pamela Sabioni², Jose Trigo², Mark Ware³, Brigid Betz-Stablein¹,
Bridin Murnion⁴, Kok Eng Khor⁵, Nichola Lintzeris⁶, Michael Farrell⁷, Smith
Andrew², Bernard Le Foll², ¹University of South Wales, Sydney, Australia, ²Centre
for Addiction and Mental Health, Toronto, ON, ³McGill University, Montreal,
Quebec, Canada, ⁴University of Sydney, Sydney, Australia, ⁵Prince of Wales
Hospital, New Territories, Hong Kong, ⁶Drug and Alcohol Services, South Eastern
Sydney Local Health District, Sydney,
Australia, ⁷National Drug and Alcohol Research Centre, Sydney, Australia
- 112 *Tobacco use and debilitating pain: Understanding sex and gender differences in a primary care cohort with a history of risky drug use*
Curtis Bone¹, Lori Bastian², Amelia Goodfellow³, William Becker², Lillian
Gelberg⁴, ¹Yale School of Medicine, New Haven, CT, ²Yale University, New
Haven, CT, ³UCLA, Los Angeles, CA, ⁴UCLA Family Medicine, Los Angeles, CA

Please be advised that no photographing of presentations or data is permitted.
Badges must be worn at all times and are required for admission into all events and sessions.

Thursday, June 22, 2017

Oral Communications 22

**Westmount
9:00 - 10:00 AM**

DEFENSE DE FUMER: NICOTINE

Chairs: Lance McMahon and Sean Luo

- 9:00 *Examining the capacity of nAChR antagonists to block the effects of nicotine in nicotine-tolerant C57BL/6J mice*
Fernando de Moura¹, Lance McMahon², ¹McLean Hospital, Harvard Medical School, Belmont, MA, ²University of Texas Health Science Center, San Antonio, TX
- 9:15 *Positron emission tomography imaging of nicotine-induced dopamine release in squirrel monkeys using [18F]Fallypride*
Jennifer Naylor¹, Amy Goodwin², Katelin Matazel¹, Takato Hiranita¹, Merle Paule¹, ¹U.S. Food and Drug Administration, Silver Spring, MD, ²U.S. Food and Drug Administration - National Center for Toxicological Research, Jefferson, AR
- 9:30 *A course of methylphenidate may improve smoking cessation outcome in patients with more severe ADHD: Results from follow-up data from a multi-site randomized controlled trial*
Sean Luo¹, Edward Nunes², Lirio Covey¹, Mei-Chen Hu¹, Theresa Winhusen³, ¹Columbia University, New York, NY, ²Columbia University and NYSPI, New York, NY, ³University of Cincinnati, Cincinnati, OH
- 9:45 *The effectiveness of a peer-led tobacco cessation intervention among poor and underserved using community-based participatory research*
Payam Sheikhattari¹, Jummai Apata¹, Jane Buccheri², Mary Gunning³, Fernando Wagner¹, Kevon-Mark Jackman¹, ¹Morgan State University, Baltimore, MD, ²CEASE Community Action Board, ³Catholic Charities Head Start of Baltimore City, Baltimore, MD

Oral Communications 23

**Outremont
9:00 - 10:00 AM**

LA CHIMIE: DRUG DEVELOPMENT STRATEGIES

Chair: Andrew Coop

- 9:00 *UMB 426: A pyranomorphinan with a profile of mu agonism/delta antagonism*
Andrew Coop¹, Mohammad Ansari¹, Jason Healy², Rae Matsumoto³, ¹University of Maryland School of Pharmacy, Baltimore, MD, ²West Virginia University, Morgantown, WV, ³Touro University California, Vallejo, CA
- 9:15 *In vitro and in vivo characterization of N-butyl-N-phenylethyl-N-3-hydroxyphenylethyl- amine as an “extremely” G-protein signaling biased kappa opioid receptor agonist*
Amelia Dunn¹, Alexandra Dunn¹, Brian Reed¹, Eduardo Butelman¹, Mary Jeanne Kreek¹, ¹The Rockefeller University, New York, NY

Thursday, June 22, 2017

- 9:30 *Chemical studies towards understanding functional selectivity at peripheral kappa receptors*
Stephanie Johnson¹, Joshua Zamora², Rachel Crowley¹, Teresa Chavera², William Clarke², Kelly Berg², Thomas Prisinzano³, ¹University of Kansas, Lawrence, KS, ²University of Texas Health Science Center, Houston, TX, ³University of Kansas School of Pharmacy, Lawrence, KS
- 9:45 *Predicting opioid binding affinity using molecular docking*
Christopher Ellis¹, Marlene Kim¹, Naomi Kruhlak¹, E. Gregory Hawkins¹, Lidiya Stavitskaya¹, ¹U.S. Food and Drug Administration, Silver Spring, MD

Oral Communications 24

Mont-Royal
9:00 - 10:00 AM

BETTER THAN BLOBS: NEURAL CONNECTIVITY

Chairs: Kelly Dumais and Colleen Hanlon

- 9:00 *Sex differences in behavioral and neural responses to reduced-nicotine cigarettes*
Paul Faulkner¹, Dara Ghahremani¹, Nicole Petersen¹, Edythe London¹, ¹UCLA, Los Angeles, CA
- 9:15 *Sex differences in default mode network suppression during exposure to smoking cues in nicotine-dependent individuals*
Kelly Dumais¹, Reagan Wetherill², Teresa Franklin², Amy Janes¹, ¹McLean Hospital, Harvard Medical School, Belmont, MA, ²University of Pennsylvania, Philadelphia, PA
- 9:30 *TMS targeting ventromedial prefrontal cortex modulates craving and salience circuitry in cocaine users*
Tonisha Kearney-Ramos¹, Logan Dowdle¹, Mark George¹, Colleen Hanlon¹, ¹Medical University of South Carolina, Charleston, SC
- 9:45 *Cortico-limbic-striatal functional connectivity and behavior are impacted by dietary environment and exposure to social stressors in female rhesus macaques*
Jodi Godfrey¹, Melanie Pincus¹, Eric Feczko², Eric Earl², Damien Fair², Vasiliki Michopoulos¹, Mark Wilson¹, Mar Sanchez¹, ¹Yerkes National Primate Research Center, Atlanta, GA, ²Oregon Health and Science University, Hillsboro, OR

Oral Communications 25

Verdun
9:00 - 10:00 AM

TREATMENT POUTINE-STYLE: COMBINATION TREATMENTS

Chair: Gregory Collins

- 9:00 *Effects of the nicotinic agonist varenicline, the novel nicotinic antagonist r-bPiDI, and the dopamine transporter inhibitor r-modafinil on co-use of alcohol and nicotine in female P rats*
Sarah Maggio¹, Meredith Saunders², Thomas Baxter², Kimberly Nixon³, Mark Prendergast², Gaungrong Zheng⁴, Peter Crooks⁴, Rachel Slack⁵, Amy Newman⁵, Jon Thorson⁶, Linda Dwoskin¹, Michael Bardo¹, ¹University of Kentucky, Lexington, KY, ²University of Kentucky, Department of Psychology, Lexington, KY, ³University of Kentucky, Department of Pharmaceutical Sciences, Lexington, KY, ⁴University of Arkansas for Medical Sciences, Little Rock, AR, ⁵NIDA Intramural Research Program, Baltimore, MD, ⁶Department of Pharmaceutical Sciences, University of Kentucky, Lexington, KY
- 9:15 *Effects of lorcaserin and bupirone, administered alone and in combination, on cocaine self-administration in rhesus monkeys*
Gregory Collins¹, Charles France¹, ¹University of Texas Health Science Center, San Antonio, TX
- 9:30 *Effect of varenicline alone and in combination with nabilone on cannabis withdrawal and relapse in tobacco-smoking cannabis users*
Evan Herrmann¹, Ziva Cooper², Gillinder Bedi³, Divya Ramesh⁴, Rebecca Balter¹, Stephanie Reed³, Sandra Comer², Richard Foltin¹, Margaret Haney¹, ¹Columbia University Medical Center, New York, NY, ²Columbia University and NYSPI, New York, NY, ³Columbia University, New York, NY, ⁴University of Connecticut, Storrs, CT
- 9:45 *Bupropion-naltrexone combinations as a pharmacotherapy for cocaine-use disorder*
Craig Rush¹, B. Levi Bolin¹, Abner Rayapati¹, Hays Lon¹, Joshua Lile¹, William Stoops¹, ¹University of Kentucky, Lexington, KY

WHO'S USING WHAT NOW: OPIOID EPIDEMIOLOGY

Chairs: Alexander Walley and Silvia Martins

- 10:15 *Changes in lifetime heroin use and heroin use disorder: United States 2001-2002 to 2012-2013*
Silvia Martins¹, Aaron Sarvet¹, Julian Santaella-Tenorio¹, Tulshi Saha², Bridget Grant², Deborah Hasin¹, ¹Columbia University, New York, NY, ²NIAAA Intramural Research Program, Bethesda, MD
- 10:30 *The impact of opioid poisonings on hospital use in Canada*
Vera Grywacheski¹, Sarah Wallingford², Aqsa Malik², Sheril Perry¹, Krista Louie¹, Matthew Young², ¹Canadian Institute for Health Information, Montreal, Quebec, ²Canadian Centre on Substance Abuse, Ottawa, ON
- 10:45 *Excess mortality in children born to opioid-involved parents: A national register study in Taiwan*
Chuan-Yu Chen¹, Shao-You Fang², Nicole Huang³, Su-Hui Chang², ¹National Taiwan University, Taipei, Taiwan, ²Children and Family Research Center, National Taiwan University, Taipei, Taiwan, ³National Taiwan University, Epidemiology and Preventive Medicine, Taipei City, Taiwan
- 11:00 *Emergency department visits, along with medical doctor visits, greatly increase odds of prescription opioid use*
Mirsada Serdarevic¹, Sadaf A Milani², Henry Young¹, Catherine Woodstock Striley¹, Linda Cottler¹, ¹University of Florida, Gainesville, FL, ²University of Florida, Department of Epidemiology, Gainesville, FL
- 11:15 *Long-term opioid prescribing after inpatient surgery*
Karsten Bartels¹, Shannon McWilliams², Angela Moss³, Ingrid Binswanger⁴, Christian Hopfer², Susan Mikulich-Gilbertson², ¹University of Colorado, Boulder, CO, ²University of Colorado School of Medicine, Aurora, CO, ³University of Colorado, Denver, CO, ⁴Kaiser Permanente, Oakland, CA
- 11:30 *Overdoses on prescribed opioids in Massachusetts, 2013-14*
Alexander Walley¹, Dana Bernson², Marc Laroche¹, Traci Green¹, Leonard Young², Thomas Land², ¹Boston University School of Medicine, Boston, MA, ²Massachusetts Department of Public Health, Boston, MA
- 11:45 *"Hooked on" prescription opioids prior to heroin use among people who inject drugs in Fresno, California*
Robin Pollini¹, Catherine Paquette², Jennifer Syvertsen³, ¹West Virginia University-Injury Control Research Center, Morgantown, WV, ²Pacific Institute for Research and Evaluation, Washington, DC, ³Ohio State University, Columbus, OH
- 12:00 *Fentanyl in methadone-maintained treatment clients*
Cynthia Arfken¹, Jessica Suchanek¹, Gary Rhodes¹, Joseph Urbiel¹, Mark Greenwald¹, ¹Wayne State University, Detroit, MI

Oral Communications 27**Mont-Royal
10:15 AM - 12:15 PM****MOVERS AND SHAKERS: PHARMACOKINETIC
OUTCOMES**

Chairs: Philip Vieira and Sharon Walsh

- 10:15 *Individual differences in drug pharmacokinetics using a novel biosensor technology in awake behaving animals*
Philip Vieira¹, Christina Shin², Tod Kippin², Netz Arroyo-Curras³, Kevin Plaxco³, ¹California State University, Los Angeles, CA, ²UCSF, San Francisco, CA, ³UCSB, Santa Barbara, CA
- 10:30 *Therapeutic potential of highly efficient long-acting cocaine hydrolases*
Fang Zheng¹, Chang-Guo Zhan¹, ¹University of Kentucky, Lexington, KY
- 10:45 *Influence of pregnancy on the nicotine metabolite ratio: Changes during antepartum and postpartum*
Christopher Arger¹, Taraneh Taghavi², Sarah Heil¹, Joan Skelly¹, Rachel Tyndale², Stephen Higgins¹, ¹University of Vermont, Burlington, VT, ²University of Toronto, Toronto, ON
- 11:00 *Does electronic cigarette propylene glycol and vegetable glycerin ratio influence nicotine delivery, subjective effects, and puff topography?*
Thomas Eissenberg¹, Tory Spindle¹, Hannah Mayberry², Nareg Karaoghlanian³, Alan Shihadeh³, Marzena Hiler¹, ¹Virginia Commonwealth University, Richmond, VA, ²Center for the Study of Tobacco Products, Virginia Commonwealth University, Richmond, VA, ³American University of Beirut, Beirut, Lebanon
- 11:15 *Buprenorphine weekly depot provides rapid and sustained hydromorphone blockade in individuals with opioid use disorder: A phase II study*
Sharon Walsh¹, Sandra Comer², Brad Vince³, Naama Levy-Cooperman⁴, Michelle Lofwall⁵, Jermaine Jones⁶, Debra Kelsh, Paul Nuzzo¹, Marion Coe¹, Behshad Sheldon⁷, Fredrik Tiberg⁸, Sonnie Kim⁷, ¹University of Kentucky, Lexington, KY, ²Columbia University and NYSPI, New York, NY, ³Vince and Associates, Malvern, PA, ⁴Altreos Research Partners Inc., Toronto, ON, Canada, ⁵University of Kentucky College of Medicine, Lexington, KY, ⁶Columbia University College of Physicians and Surgeons, New York, NY, ⁷Braeburn Pharmaceuticals, Princeton, NJ, ⁸Camurus, Lund, Sweden
- 11:30 *CAM2038 (q1w): Pharmacokinetics and pharmacokinetic/pharmacodynamic evaluation of opioid blockade in humans*
Marion Coe¹, Paul Nuzzo¹, Naama Levy-Cooperman², Sandra Comer³, Fredrik Tiberg⁴, Sonnie Kim⁵, Sharon Walsh¹, ¹University of Kentucky, Lexington, KY, ²Altreos Research Partners Inc., Toronto, ON, Canada, ³Columbia University and NYSPI, New York, NY, ⁴Camurus, Lund, Sweden, ⁵Braeburn Pharmaceuticals, Princeton, NJ

- 11:45 *Concentrated naloxone nasal spray for opioid overdose reversal: A pharmacokinetic study in healthy volunteers*
Rebecca McDonald¹, Ulrike Lorch², Jo Woodward³, Björn Bosse³, Helen Johnson³, Gill Mundin³, Kevin Smith³, John Strang⁴, ¹King's College, London, UK, ²Richmond Pharmacology Ltd, London, UK, ³Mundipharma Research Ltd., Cambridge, UK, ⁴King's College, London, UK, United Kingdom
- 12:00 *Scenarios that affect alcohol pharmacokinetics: Exercise and last call*
Elizabeth Ryan¹, Scott Lukas¹, Jane McNeil², Justin Shepherd¹, ¹McLean Hospital, Harvard Medical School, Belmont, MA, ²McLean Hospital, Belmont, MA

Oral Communications 28

Verdun

10:15 AM - 12:15 PM

CAN'T WAIT FOR A SESSION ON IMPULSIVITY!!!

Chairs: Dennis Sholler and Eduardo Butelman

- 10:15 *Reducing impulsivity for food and cocaine with progesterone and atomoxetine in male and female rats*
John Smethells¹, Natashia Swalve¹, Rebecca Younk¹, Marilyn Carroll¹, ¹University of Minnesota, Minneapolis, MN
- 10:30 *A new model of cortical 5-HT_{2A} receptor dysfunction in rats*
Dennis Sholler¹, Noelle Anastasio¹, Robert Fox¹, Erica Holliday¹, Amanda Price¹, Kathryn Cunningham¹, ¹University of Texas Medical Branch, Galveston, TX
- 10:45 *Varieties of impulsivity in opiate and stimulant users*
Jasmin Vassileva¹, Kiril Bozgunov², Elena Psederska², Dimitar Nedelchev², Victoria Dobrojalieva², Georgi Vasilev², ¹Virginia Commonwealth University-Psychiatry, Richmond, VA, ²Bulgarian Addictions Institute
- 11:00 *Relationship between trait impulsivity and maximum lifetime exposure to specific drugs: A dimensional analysis*
Eduardo Butelman¹, Rebecca Fry¹, Rachel Kimani¹, Joel Correa da Rosa¹, Mary Jeanne Kreek¹, ¹The Rockefeller University, New York, NY
- 11:15 *Regional cerebral blood flow in buprenorphine-maintained opioid addicts: Associations with cognition, impulsivity, and substance use*
Dieter Meyerhoff¹, Donna Murray¹, Thomas Schmidt¹, Troy Murray², Timothy C Durazzo³, Joseph Gyudish⁴, ¹San Francisco VA Medical Center, San Francisco, CA, ²The Center for Imaging of Neurodegenerative Diseases, San Francisco, CA, ³Stanford University, Stanford, CA, ⁴UCSF, San Francisco, CA
- 11:30 *Causal pathways between impulsiveness, crack cocaine use consequences and attention-deficit/hyperactivity disorder*
Mayra Pachado¹, Alice Willhelm¹, Luciano S. P. Guimarães¹, Flavio Pechansky², Felix Kessler², Rosa M. M. de Almeida², ¹Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, ²Center for Drug and Alcohol Research of, Federal University of Rio Grande do Sul, Porto Alegre, Brazil

- 11:45 *Marijuana expectancies and impulsivity: Acquired preparedness in marijuana users*
Rachel Luba¹, Melissa Slavin¹, Stacey Farmer¹, Mitch Earleywine¹, ¹State University of
New York at Albany, Albany, NY
- 12:00 *Cognitive-behavioral mediators and moderators of the relationship between impulsivity
traits and adolescent alcohol use: Identifying unique targets for prevention*
Kiri Patton¹, Matthew Gullo¹, Jason Connor¹, Gary Chan², Adrian Kelly², John
Toumbourou³, Richard F Catalano⁴, ¹University of Queensland, Brisbane, Austria,
²Centre for Youth Substance Abuse Research, Herston, Queensland, ³Deakin
University, School of Psychology, Burwood, Australia, ⁴Social Development Research
Group, University of Washington, Seattle, WA

Symposium XIII

Westmount

10:15 AM - 12:15 PM

IS TWO BETTER THAN ONE? ENDOCANNABINOID INVOLVEMENT IN STRESS, REWARD AND MOTIVATION: IMPLICATIONS FOR UNDERSTANDING AND TREATING SUBSTANCE USE DISORDER

Chairs: John Mantsch and Cecilia Hillard

- 10:15 *Endocannabinoid signaling and stress*
C. Hillard, Medical College of Wisconsin, Milwaukee, WI
- 10:40 *Causal control of negative reinforcement by dopamine release and its modulation
by endogenous cannabinoids*
J. Cheer, University of Maryland School of Medicine, Baltimore, MD
- 11:05 *Setting the stage for relapse: CB1 cannabinoid receptors mediate stress and
sex hormone regulation of drug seeking*
J. Mantsch, Marquette University, Milwaukee, WI
- 11:30 *Brain CB2 receptor: A potential new target for treatment of cocaine
addiction* Z. Xi, NIDA, Bethesda, MD
- 11:55 *DISCUSSANT: Endocannabinoids and substance use disorder: Clinical
implications, treatment opportunities and future research directions*
S. Patel, Vanderbilt University Medical Center, Nashville, TN

BRUNCH WITH CHAMPIONS (Pre-Registrants Only)

Salon Ville-Marie

12:15 - 1:15 PM

**INTOXICATING CONNAISSANCE:
ALCOHOL RESEARCH**

Chairs: Jessica Weafer and Elise Weerts

- 1:15 *Maternal alcohol consumption during 1st trimester and child internalizing and externalizing problems: A sibling control study*
Ingunn Olea Lund¹, Espen Moen Eilertsen¹, Line C. Gjerde¹, Eivind Ystrøm¹, ¹The Norwegian Institute of Public Health, Oslo, Norge
- 1:30 *Alcohol expectancy in early adolescence with problematic drinking in young adulthood*
Wan-Ting Chen¹, Kuan-Chia Lin¹, Fang-Yi Tseng¹, Wei-J Chen², Chuan-Yu Chen³, ¹National Yang-Ming University, Taipei, Taiwan, ²National Taiwan University, Taipei City, Taiwan, ³National Taiwan University, Taipei, Taiwan
- 1:45 *Restrictive media parenting predicts alcohol-related attitudes and drinking onset in youth*
Joy Gabrielli¹, Mike Stoolmiller², Zoe Brennan³, James Sargent³, ¹Geisel School of Medicine/Norris Cotton Cancer Center, Enfield, NH, ²Michigan State University, Lansing, MI, ³Department of Biomedical Data Science at Dartmouth, Hanover, NH
- 2:00 *Alcohol abuse, polydrug use, impulsivity and sensation among adolescents: Two year's follow-up*
V́ctor Mart́nez-Loredo¹, Sergio Fernandez-Artamendi², Aris Grande-Gonsende³, Ángel García-Pérez³, Irene Pericot-Valverde⁴, Jose Ramón Fernández-Hermida³, ¹University of Oviedo, Addictive Behaviors Group, Oviedo, Spain, ²Universidad Internacional de Andalucía-Psychology, Andalucía, Spain, ³University of Oviedo, Oviedo, Spain, ⁴University of Vermont, Burlington, VT
- 2:15 *Risk and protective factors for sexual risk behaviors in college students: Marijuana use, binge drinking, HIV risk knowledge and coping style*
Angela Heads¹, Joseph Dickson², Joy Schmitz¹, Aisha Asby³, ¹University of Texas Health Science Center, Houston, TX, ²Prairie View A and M University, Prairie View, TX, ³Asby Consulting, Sacramento, CA
- 2:30 *Sex differences in brain activation during response inhibition in heavy drinkers*
Jessica Weafer¹, Harriet de Wit¹, ¹University of Chicago, Chicago, IL
- 2:45 *Effect of nicotine use on prospective memory performance and associated intrinsic functional brain connectivity in binge drinkers*
Jonathan Ipser¹, Dan Stein¹, Hetta Gouse¹, Carla Freeman¹, John Joska¹, ¹University of Cape Town, Western Cape, South Africa
- 3:00 *Changing alcohol related beliefs: Implications for successful treatment of alcohol use disorder*
Jason Coates¹, Matthew Gullo², Gerald Feeney³, Ross Young², Jason Connor², ¹Centre for Youth Substance Abuse Research, Herston, Queensland, Australia, ²University of Queensland, Brisbane, Australia, ³Princess Alexandra Hospital, Queensland, Australia

**LES LIAISONS DANGEREUSES: PSYCHIATRIC
COMORBIDITY**

Chairs: Jibran Khokhar and Suzette Glasner-Edwards

- 1:15 *Impaired brain reward circuitry may underlie alcohol drinking in a rat model of schizophrenia and co-occurring alcohol use disorder*
Jibran Khokhar¹, Alan Green¹, Hanbing Lu², Elliot Stein², ¹Dartmouth College, Hanover, NH, ²NIDA Intramural Research Program, Baltimore, MD
- 1:30 *Anxiety- and depression- like behaviors in rats selectively bred for intravenous cocaine self-administration*
Ken Grasing¹, Michael Grasing¹, Jessica Idowu¹, Haiyang Xu², ¹Kansas City VA Medical Center, Kansas City, MO, ²Florida State University, Tallahassee, FL
- 1:45 *Cigarette smoking and cognitive function in Chinese male inpatients with schizophrenia: A comparison of heavy and light smokers*
Huiqiong Deng¹, Jair Soares¹, Xiang Yang Zhang¹, ¹University of Texas Health Science Center, McGovern Medical School, Houston, TX
- 2:00 *The efficacy of valproate in cocaine-bipolar comorbidity: Results from a randomized placebo-controlled preliminary study*
Ihsan Salloum¹, Olga Maria Villar-Loubet¹, Feng Miao², Jack Cornelius³, ¹University of Miami, Miami, FL, ²University of Miami Miller School of Medicine, Miami, FL, ³University of Pittsburgh Medical Center, Pittsburgh, PA
- 2:15 *Improving comorbid substance use and posttraumatic stress disorder treatments through methodological innovation: Combined symptom trajectories following treatment*
Teresa Lopez-Castro¹, Nicholas Allan², Santiago Papini³, Sudie Back⁴, Therese Killeen⁴, Daniel Gros⁴, Emma Barrett⁴, Lesia M. Ruglass⁵, Denise Hien⁶, ¹The City College of New York, NY, ²Oregon Health and Science University, Hillsboro, OR, ³University of Texas at Austin, Austin, TX, ⁴Medical University of South Carolina, Charleston, SC, ⁵CUNY Graduate School of Public Health and Health Policy, New York, NY, ⁶Adelphi University, Garden City, NY
- 2:30 *Preliminary outcomes of a computerized CBT/MET intervention targeting depression and cannabis use in a psychiatric care setting*
Suzette Glasner-Edwards¹, Frances Kay-Lambkin², Alan Budney³, Helene Chokron Garneau⁴, Alexandra Venegas¹, Anne Lee¹, ¹Integrated Substance Abuse Programs (UCLA), Los Angeles, CA, ²University of Newcastle, New Castle, New South Wales, ³Geisel School of Medicine at Dartmouth, Hanover, NH, ⁴UCLA, Los Angeles, CA
- 2:45 *Suicide attempts and substance use disorders among veterans seeking specialty pain services*
Lisham Ashrafioun¹, Cathleen Kane¹, Todd Bishop¹, Peter Britton¹, Wilfred Pigeon¹, ¹VA VISN 2 Center of Excellence for Suicide Prevention, Canandaigua, NY

- 3:00 *Mental disorders and persistent alcohol/tobacco use among adolescents in São Paulo, Brazil: A follow-up study*
Mariel Mendez¹, Silvia Martins², Thiago Fidalgo³, Marcos Ribeiro³, Sheila C. Caetano³, Zila M. Sanchez³, ¹Columbia University Mailman School of Public Health, Newark, NJ, ²Columbia University, New York, NY, ³Universidade Federal de São Paulo, São Paulo, Brazil

Symposium XIV

Fontaine F
1:15 - 3:15 PM

EVALUATING THE THERAPEUTIC POTENTIAL OF MEDICAL CANNABIS AND PHYTOCANNABINOIDS FROM PRECLINICAL ANIMAL MODELS TO THE PHARMACOEPIDEMIOLOGY OF MEDICAL CANNABIS USE

Chairs: Ziva Cooper and Igor Grant

- 1:15 *Investigating variables that alter the analgesic effects and abuse liability of cannabis and cannabinoids under controlled conditions in the human laboratory*
Z. Cooper, Columbia University and NYSPI, New York, NY
- 1:40 *Evaluation of lesser known phytocannabinoids in preclinical animal models of drug abuse and pain*
A. Lichtman, Virginia Commonwealth University, Richmond, VA
- 2:05 *Going green: Exploring the impact of medical marijuana*
S. Gruber, McLean Hospital, Harvard Medical School, Belmont, MA
- 2:30 *Long-term studies of medical cannabis use: Real world evidence*
M. Ware, McGill University, Montreal, Quebec, Canada
- 2:55 *DISCUSSANT: The scientific basis for the therapeutic effects of medical cannabis: What we know and future considerations for research?*
I. Grant, UC San Diego, La Jolla, CA

Symposium XV

Fontaine G
1:15 - 3:15 PM

APPLICATIONS OF CHOICE PROCEDURES TO DRUG ABUSE RESEARCH

Chairs: S. Stevens Negus and Richard Lamb

- 1:15 *Modeling treatment by conceptualizing addiction as a behavioral allocation disorder*
R. Lamb, University of Texas Health Science Center, San Antonio, TX
- 1:40 *The influence of social rank, sex and drug history on cocaine-food choice in monkeys*
M. Nader, Wake Forest School of Medicine, Winston-Salem, NC
- 2:05 *Sex differences in the choice between cocaine and food reinforcers*
A. Perry, University of Texas at El Paso, El Paso, TX
- 2:30 *The influence of alternative reinforcers and d-amphetamine maintenance on intravenous cocaine choice in parallel studies in humans and rhesus monkeys*
J. Lile, University of Kentucky, Lexington, KY
- 2:55 *DISCUSSANT: Common themes and future directions in research with drug choice procedures*
S. Negus, Virginia Commonwealth University, Richmond, VA

Oral Communications 31

Fontaine G
3:30 - 5:30 PM

IS IT A BEAUTIFUL DAY IN THE QUARTIER? ENVIRONMENTAL INFLUENCES ON DRUG USE

Chairs: Natacha De Genna and Adam Milam

- 3:30 *All you need is love: Rearing environment predicts opioid self-administration and oxytocin expression*
Rebecca Hofford¹, Dolores Vazquez-Sanroman¹, Michael Bardo¹, ¹University of Kentucky, Lexington, KY
- 3:45 *Environmental enrichment restores oxidative balance in animals exposed to toluene: Comparison with melatonin*
Nayeli Paez-Martinez¹, Yepci Yee-Rios¹, Sergio Montes¹, ¹Instituto Politécnico Nacional, Mexico City, Mexico
- 4:00 *The effects of environmental enrichment during abstinence from cocaine on RNA expression within the nucleus accumbens*
Gregory Powell¹, Madeleine St. Peter¹, Trisha Chaudhury¹, Daniela Alcazar¹, Thomas Benson¹, Ryan Bastle¹, Nora Perrone-Bizzozero², Janet Neisewander¹, ¹Arizona State University, Tempe, AZ, ²University of New Mexico, Albuquerque, New Mexico

- 4:15 *Impact of environmental enrichment on context dependency of cocaine-cue extinction learning for relapse prevention*
Jamie Gauthier¹, Kyle Mabry¹, Kathleen Kantak¹, ¹Boston University School of Medicine, Boston, MA
- 4:30 *Childhood's pro-alcohol environment and sensation seeking in relation to drinking problems in early adolescence and young adulthood*
Nadia Wang¹, Po-Hsiu Kuo¹, Wei-J Chen², Chuan-Yu Chen¹, ¹National Taiwan University, Epidemiology and Preventive Medicine, Taipei City, Taiwan, ²National Taiwan University, Taipei City, Taiwan
- 4:45 *Brain dopamine response and modulatory effect of environmental context to morphine in healthy men*
Primavera Spagnolo¹, Alane Kimes², Melanie Scwhandt³, Karran Phillips⁴, Nancy Diazgranados³, Ehsan Shokri Kojori³, Kenzie Preston⁵, Dardo Tomasi³, Peter Herscovitch⁶, Markus Heilig⁷, Vijay Ramchandani³, ¹NIH, NIAAA, Bethesda, MD, ²NIH, NIDA, Bethesda, MD, ³NIAAA, Bethesda, MD, ⁴NIDA, Bethesda, MD, ⁵NIDA Intramural Research Program, Baltimore, MD, ⁶NIH, PET, CC, Bethesda, MD, ⁷Linköping University, Linköping, Sweden
- 5:00 *The impact of environmental disorder on stress, craving, and mood*
William Kowalczyk¹, Matthew Matthew², Karran Phillips³, Debra Furr-Holden⁴, Adam Milam⁵, Vahabzadeh Massoud², Mustapha Mezghanni², Jia-Ling Lin², David Epstein², Kenzie Preston², ¹NIH, Bethesda, MD, ²NIDA Intramural Research Program, Baltimore, MD, ³NIDA, Bethesda, MD, ⁴Michigan State University, Lansing, MI, ⁵Johns Hopkins University, Baltimore, MD
- 5:15 *Neighborhood factors in co-use of cigarettes and cannabis among young adults*
Natacha De Genna¹, Dara Mendez², Lidush Goldschmidt³, Nancy Day¹, Marie Cornelius¹, ¹University of Pittsburgh, Pittsburgh, PA, ²University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, ³University of Pittsburgh Medical Center, Pittsburgh, PA

Oral Communications 32

Fontaine H
3:30 - 5:30 PM

THE YOUNG AND THE RESTLESS: ADOLESCENTS

Chairs: Kristin Maple and Kenzie Preston

- 3:30 *Associations between cannabis use, gender, and frontolimbic white matter integrity in adolescents and emerging adults*
Kristin Maple¹, Alicia Thomas¹, Krista Lisdahl¹, ¹University of Wisconsin-Milwaukee, Milwaukee, WI
- 3:45 *Trends in cannabis treatment admissions in adolescents/young adults: Analysis of Teds-D 1992-2012*
Lindsay Standeven¹, Mishka Terplan², Margaret Chisolm³, ¹Johns Hopkins Hospital, Baltimore, MD, ²Virginia Commonwealth University, Richmond, VA, ³Johns Hopkins School of Medicine, Baltimore, MD

- 4:00 *Sex and age differences in risk factors of marijuana involvement during adolescence*
Lian-Yu Chen¹, Silvia Martins², Eric Strain³, Ramin Mojtabai⁴, Carla Storr⁵, ¹Taipei City Hospital, Taipei, Taiwan, ²Columbia University Mailman School of Public Health, Newark, NJ, ³Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Johns Hopkins Bloomberg School of Public Health, Department of Mental Health, Baltimore, MD, ⁵University of Maryland School of Nursing, Baltimore, MD
- 4:15 *Using timeline methodology to visualize qualitative treatment trajectories of youth enrolled in an RCT of extended-release naltrexone*
Shannon Mitchell¹, Laura Monico¹, Elizabeth Lertch¹, Robert Schwartz¹, Jan Gryczynski¹, Kevin O'Grady², Marc Fishman³, ¹Friends Research Institute, Baltimore, MD, ²University of Maryland-Psychology, College Park, MD, ³Mountain Manor Treatment Center, Emmitsburg, MD
- 4:30 *Time trend analysis of gender differences in the prevalence of deviant behavior, risk preference and marijuana use among adolescents from 2002 to 2014*
Shadiya Moss¹, Silvia Martins¹, Katherine Keyes², ¹Columbia University, New York, NY, ²Columbia University Mailman School of Public Health, Newark, NJ
- 4:45 *A pilot randomized controlled trial of a technology-based substance use intervention for youth exiting foster care*
Jordan Braciszewski¹, Golfo Tzilos², Roland Moore³, Robert Stout³, ¹Henry Ford Health System, Detroit, MI, ²University of Michigan, Ann Arbor, MI, ³Pacific Institute for Research and Evaluation, Washington, DC
- 5:00 *Short-term effects of a smartphone application plus BMI in reducing substance use and sexual risk among homeless young adults: Results from a randomized controlled trial*
Ronald Thompson¹, Deborah Hasin¹, ¹Columbia University, New York, NY
- 5:15 *Physician screening and advice on adolescent substance use according to sexual orientation*
Jeremy Luk¹, Stephen Gilman¹, Denise Haynie¹, Bruce Simons-Morton¹, ¹National Institute of Child Health and Human Development, Bethesda, MD

Oral Communications 33

Fontaine E
3:30 - 5:30 PM

DESIGNED FOR SUCCESS: IMPROVING CLINICAL TRIALS

Chairs: Margaret Wolff and Karen Hartwell

- 3:30 *Smart capsules are a promising tool to improve medication adherence in clinical trials*
K. Hartwell, Medical University of South Carolina, Charleston, SC
- 3:45 *Reconsidering the removal of the legal problems criterion from DSM-V: Legal problems and substance use disorder severity in a nationally representative sample*
Kelly Moore¹, Sherry McKee¹, ¹Yale School of Medicine, New Haven, CT
- 4:00 *Application of randomized response technique to the nationwide general population survey on drugs in the Republic of Georgia*
Irma Kirtadze¹, David Otiashvili¹, Mzia Tabatadze¹, Irina Vardanashvili², Lela Sturua³, Tomas Zabransky⁴, James Anthony⁵, ¹Addiction Research Center, Tbilisi, GA, ²Ilia State University, Tbilisi, GA, ³National Center of Disease Control and Public Health, Tbilisi, GA, ⁴Real Escuela Superior de Arte Dramático, Madrid, Spain, ⁵Michigan State University, Lansing, MI
- 4:15 *Substance use disorder symptoms and HIV medication adherence*
Margaret Wolff¹, Aimee Campbell², Susan Tross³, Laurel Weaver¹, Don Des Jarlais¹, ¹Icahn School of Medicine at Mount Sinai, New York, NY, ²Columbia University and NYSPI, New York, NY, ³Columbia University, New York, NY
- 4:30 *Adherence across FDA-approved medications for alcohol use disorders in a VA population*
James Walker¹, Jeffrey Korte¹, Aimee McRae-Clark¹, Karen Hartwell¹, ¹Medical University of South Carolina, Charleston, SC
- 4:45 *Study characteristics account for the majority of variance in clinical trials of medications for alcohol use disorders: A meta-analysis*
Elias Klemperer¹, John Hughes², ¹Vermont Center on Behavior and Health, Burlington, VT, ²University of Vermont, Burlington, VT
- 5:00 *Development, feasibility, and implementation of the misuse, abuse, and diversion drug event reporting system (MADDERS®) for classifying misuse and abuse-related events in clinical trials*
Roi Treister¹, Ryan Lanier¹, Imrana Kazam¹, Nathalie Erpelding¹, Harrison Elder¹, Maitreyee Mohanty¹, Dolapo Lawal¹, Judith Jones², Nathaniel Katz¹, ¹Analgesic Solutions, Natick, MA, ²The Degge Group, Ltd.
- 5:15 *Retention and drug use among treatment-resistant patients transferred to a 'Second Chance' methadone maintenance treatment program*
Emytis Tavakoli¹, Emily Deal², Gary Rhodes³, Edward Mischel³, Carl Christensen³, Alireza Amirsadri³, Mark Greenwald³, ¹Wayne State University, Alborz University of Medical Sciences, Montreal, Quebec, Canada, ²Kalamazoo College, Kalamazoo, MI, ³Wayne State University, Detroit, MI

Thursday, June 22, 2017

Symposium XVI

**Fontaine F
3:30 - 5:30 PM**

**SYNTHETIC CANNABINOIDS: THINKING OUTSIDE
OF THE POT**

Chairs: Jenny Wiley and Brian Thomas

- 3:30 *The epidemiology of synthetic cannabinoids: It's frustrating and confusing*
J. Maxwell, University of Texas at Austin, Salisbury, NC
- 3:55 *Synthetic cannabinoids and spice – A real-life chemical exposure potpourri*
B. Thomas, RTI International, Research Triangle Park, NC
- 4:20 *Role of biotransformation in the pharmacological and toxicological effects of
synthetic cannabinoids*
B. Fantegrossi, University of Arkansas for Medical Sciences, Little Rock, AR
- 4:45 *Journey to the dark side and back: From super agonists to antagonists*
J. Wiley, RTI International, Research Triangle Park, NC
- 5:10 *DISCUSSANT: Translational implications: A “street-level” view*
J. Trecki, Drug Enforcement Administration (DEA), Springfield, VA

SWEEPSTAKES DRAWING

**Fontaine F
5:35 - 6:00 PM**

**YOU MUST BE SEATED IN ONE OF THE
SESSIONS STARTING AT 1:15 PM IN ORDER TO
HAVE YOUR BADGE COLLECTED**

**HAVE A SAFE TRIP HOME!
SEE YOU IN SAN DIEGO, CALIFORNIA
JUNE 9 – 14, 2018**

AUTHOR INDEX

- Abatemarco, D 12
 Abbinanti, K 11
 Abdolahi, A 15
 Abrams, C 111
 Accornero, V H 104
 Ackerman, S C 99
 Acri, J B 21 , 22
 Adams, J 68
 Adelson , M 23, 102
 Ades, P 79, 84
 Adinoff, B H 110
 Adler, A 83
 Adler, M W 80
 Afifi, R 30
 Agbese, E 19
 Aiello, G 22
 Akbarali, H 3
 Aklin, W 22
 Al-Tayyib, A 110
 Alanis-Hirsch, K 54
 Alcazar, D 123
 Alcover, K 24
 Alexandre, J 86
 Ali , R 55 , 57 , 110
 Alice, F 69 , 99
 Aliev, F 72
 Allain, F 59, 67
 Allan, N 121
 Allard, D 98
 Allen, I 102
 Allen, S 63
 Alshaarawy, O 107
 Altman , L 29
 Altshuler, R 95
 Alving, C 93
 Amaral, R 15
 Amaro, H 3
 Amirsadri, A 126
 Amr, S 68
 Anastasio, N C 6, 16, 72 , 100 , 118
 Andersen, M 59
 Andersen, S 68
 Anderson, L 61
 Anderson Goodell, E 80
 Andrade, A 15, 79
 Andrade, L 79
 Andre, M 87
 Andrew, S 112
 Andrews, A M 60
 Anouti, S 30
 Ansari, M 113
 Ansell, E 85
 Anthony, E 3
 Anthony, J C 15, 20, 24, 56, 59, 79, 85 104 , 107, 126
 Antoine, D 6, 103
 Antoline, J 93
 Apata, J 113
 Appel, N 22
 Areesantichai, C 87
 Arfken, C L 21, 116
 Arger, C A 83, 117
 Armstrong, W 111
 Aronowitz, C 88
 Aronson, I 64 , 92
 Arria, A 85
 Arroyo-Curras, N 117
 Arterberry, B 106
 Asby, A 120
 Ashford, K 84
 Ashrafioun, L 121
 Assuncao, V 102
 Aston, E 63, 108
 Ataiants, J 86
 Athamneh, L 53
 Auriacombe, M 23, 54 , 63, 64, 65, 86
 Auriacombe, S 65
 Austin, B 78
 Auty, S 82 , 87
 Aya, A 78
 Azar, M 69, 99
 Azzouz, N 78
 Babalonis, S 4 , 6
 Babson, K 20 , 108
 Back, S E 112, 121 ,
 Badger, G 21
 Badiani, A 74
 Bagley, S 23, 87
 Baig, A 81
 Bailey, G 29
 Bailey, S 107
 Baker, A 92
 Baker, L 100, 101
 Baker, N 29, 58, 81, 100
 Ball, W 59
 Ball, Jr., W 58
 Balodis, I 85
 Balter , R 115
 Bandstra, E 104
 Bania, T 64, 92
 Banks, M L 93, 95
 Barbosa-Leiker, C 22
 Barbour, R 69, 99,
 Bardin, A 69
 Bardo, M T 28 , 115, 123
 Bares, C B 17, 51, 72
 Barkas, C 68
 Barnert, E 23
 Barondess, D A 79
 Barratt, M 96
 Barret, O 59
 Barrett, E 121
 Barrett, F S 101
 Barrington-Trimis, J 53
 Barron, L 60
 Barry, D T 22 , 19, 111
 Barry, K 110
 Bart, G 8
 Bartels, K 116
 Barth, K 73
 Bartlem, K 65
 Baruffaldi, F 17, 18
 Baskin, B 72
 Bassett, S 108
 Bassir Nia, A 21
 Bastian, L 112
 Bastle, R 123
 Bates, M 78
 Bath, E 23
 Batki, S L 20
 Battisti, U 100

Bauer, S 56, 79
 Baxter, T 115
 Bear, S 23
 Bearman, P 19
 Bebarta, V 73
 Becher, J 64
 Beck, K 85
 Beck, Z 93
 Becker, J B 31
 Becker, W 30, 73, 112
 Beckmann, J 97
 Bedendo, A 61
 Bedi, G 29, 115
 Beesdo-Baum, K 20
 Behrendt, S 20
 Beitel, M 111
 Belaunzarán-Zamudio, P 65
 Beletsky, L 27
 Ben, K 72
 Benkelfat, C 98
 Bennett, A 92
 Benny, C 30, 88
 Benson, T 123
 Berdine, D 30
 Berg, K 114
 Bergen-Cico, D 96
 Bergeria, C 4, 12, 83
 Bergman, J 59, 80, 97
 Berman, M 84
 Bernson, D 87, 116
 Berro, L 59
 Berry, M 108
 Bertz, J 18
 Betts, J 14, 16
 Betz-Stablein, B 112
 Beyer, D 96
 Bielenberg, J 20
 Bigelow, G E 81
 Binswanger, I 116
 Birnbaum, A 17
 Bisaga, A 28, 66, 99
 Bishop, T 121
 Bixler, E 16, 18, 91, 111
 Bjork, J 78
 Black, A 72
 Black, R 7, 22, 56
 Blacktop, J 60
 Blanca Tamayo, M 66
 Blevins, M 65
 Blokhina, E 26, 64
 Blough, B 59
 Blow, F C 106, 110
 Blumberg, D 19, 62, 19, 90
 Blycker, G 3
 Bobashev, G 24
 Bobroff, R 111
 Bocz, M 68
 Boden, S A 58
 Boerngen Lacerda, R 62
 Bogunovic, O 24
 Bohart, G 59
 Bohnert, A 56, 110
 Boivin, M 98
 Bold, K 84
 Bolin, B 115
 Bonab, A 96
 Bonar, E 106
 Bond, K 2
 Bone, C 105, 112
 Boney, T 18
 Bonhomme, E 23
 Bonn-Miller, M O 20, 108
 Bonson, K 10
 Boodram, B 25
 Boone, J 109
 Booth, R E 15
 Booze, R M 25, 59
 Borba Telles, L 106
 Borckardt, J 112
 Borodovsky, J 88, 107
 Borsari, B 108
 Bosse, B 118
 Boswell, R 67
 Bowen, L 100
 Bowen, S 82
 Boyd, C J 79
 Boyd, D 22
 Bozgunov, K 118
 Bozinoff, N 69
 Braciszewski, J 125
 Bradley, C 14, 60, 61
 Brady, K T 92, 31
 Brakenhoff, B 53
 Bralich, A 78
 Bramlett, S 91
 Brandon, T 84
 Brands, B 79, 81, 108
 Branham, D 88
 Brant, V 29
 Braschayko, P 83
 Bremer, P 93
 Brendgen, M 98
 Brennan, Z 120
 Brents, L K 5
 Brezing, C 107
 Briand-Madrid, L 63
 Bridden, C 64
 Brighthaupt, S 107
 Britch, S 3
 Britton, P 121
 Brockenberry, L 84
 Brolese, G 104
 Brooks, A 22
 Brooks, D 107
 Brooks, O 54
 Brooks, S 16, 15
 Brown, A 87
 Brown, C 72
 Brown, J 25
 Brown, Q L 3, 51
 Brown, R 105
 Browne, K 108
 Brunette, M 82, 92
 Bruno, R 57, 110
 Bryant, K 64
 Buccheri, J 113
 Budman, S 56
 Budney, A J 79, 82, 88, 107, 121
 Bugbee, B 85
 Bühringer, G 20
 Bunce, S 16, 91, 111
 Bunn, J 4, 13, 83, 84
 Buono, F 19, 92, 103
 Burakov, A 26
 Burbulla, L 95
 Burguete, T 66
 Burke, R 61
 Burlaka, V 85
 Bushara, N 26
 Businelle, M 83
 Busse, A 22
 Busselman, R 14
 Buta, E 84
 Butelman, E R 113, 118
 Butler, C 20
 Butler, S F 7, 22, 56
 Buttram, M E 96

Buu, A 106	Chaarani, B 15 , 78	Christine, P 56
Byrne, E 22	Chacho, N 14	Chung, Y 55
Byrnes, E 5	Chaisson, C 64	Cibiel-Heintz, C 54
Caceda, R 29	Chalak, A 30	Cicero, T J 18
Caetano, S 122	Challagolla, D 11	Cisler, J 29
Calabrese, J 15	Chambers, C 74	Claborn, K 63
Calderon, S N 10, 88	Champion, K E 98	Clark, H 8
Calipari, E S 74	Chan, G 119 , 96	Clark, N 22
Callaghan, R 30, 88	Chandra, M 15	Clarke, W 114
Calma, I 95	Chandran, N 90	Cleveland , H 111
Camagna, B 91	Chang, C 88	Cleveland, M 111
Camenga, D 84	Chang, S 116	Coates, J 120
Campbell, A N 2, 76, 87, 103 , 104, 126	Chao, T 29	Cochran , G 88
Campbell, G 111	Chaplin, T 85	Coe, M 117
Campbell, V 16	Charlson, F 54 , 56	Coffey, A 18
Campillo, T 66	Chartier, K 72	Coffin, P 15 , 87
Campollo, O 17	Chartoff, E 68	Cohen, C 58 , 59
Cannella, L 60	Chaudhury, T 123	Cohen, D 111
Cao, Y 100	Chavera, T 114	Cohen, G 15
Carbonaro, T 101	Chawarski, M 87	Cohen, R 63
Carliner, H 88	Cheatle, M D 70	Cohn, J 21
Carlson, C 11	Cheer, J 119	Coker, J 5 , 11
Carlson, R G 103, 110	Chen, 124 , 84	Colasanti, J 64 , 111
Carnahan, C 73	Chen, C 116 , 120	Cole, E 88
Carney, B 23	Chen, D 18	Cole , M 80
Carney, T 56	Chen, I 102	Cole, R G 99
Carpenedo, C 22 , 65	Chen, L 125	Coleman-Cowger, V H 23
Carpenter, C 95	Chen, L 88	Collier, K 105
Carrico, A 9, 63	Chen, W 120	Collins, G T 3, 115
Carrieri, P 18, 63	Chen, W 84, 120 , 124 , 106	Collins, L M 75
Carroll, F 17, 18	Chen, X 80	Colpe, L 19
Carroll, K M 85	Chen, X 63	Colucci, S 58
Carroll, M E 31, 118	Chen, Y 84	Comer, S D 6 , 28, 71, 73, 86, 87, 97, 115, 117
Carroll, V 59	Chen, Y 84	Comfort, M 106
Carson, R 59	Cheng, C 54	Compton, P 70
Carter, P 55 , 106	Cheng, D 18 , 64, 111	Cone, E 81
Casimir, A 68	Cheng, H 85 , 59 , 75	Connelly, K 101
Castaldelli-Maia, J M 79	Chhatre, S 65	Conner, K R 110
Castellanos Ryan, N 98	Chilcoat, H D 18	Connor, J 61, 72, 119, 120
Catalano, R 119	Childress, A R 15 , 67, 97	Conroy, D A 4
Caudarella, A 55	Chisolm, M S 71, 124	Constantinescu, C 59
Cavallo, D 84	Chiu, A 67	Contet, C 6
Cepeda-Benita, A 13	Cho, J 86	Conti, A 91
Cerda, M 82, 88	Choi, C 107	Cook, J E 57
Cerulli, C 69	Choi, M 100	Cook, M 23
Cesar, C 65	Chokron Garneau, H 121	Cook, R 64
Cespedes, I 17	Christensen, C 126	Cook, R 63
Cha, H 101	Christenson, S 14	Cook-Sather, S 72
	Christians, U 17	

Coop, A 58 , 71, 113
 Cooper, H 30
 Cooper, S 84
 Cooper, Z 98 , 115 , 122
 Copeland, J 83, 96, 108
 Coplan, P 22, 110
 Cornelissen, J 93
 Cornelius, J R 121
 Cornelius, M D 124
 Correa da Rosa, J 118
 Correa de Magalhães Narvaez, J 106
 Corsi, K F 15
 Cortes, C 65
 Cosgrove, K P 67
 Costa, M 82
 Cottler, L B 24 , 56, 69, 82, 106 ,109, 110, 116
 Covey, L 113
 Cowan, A 80
 Cowburn, S 107
 Cox, C 67
 Cox, S M 98
 Craft, R M 3
 Crane, P 110
 Cranford, J 79, 106, 110
 Creeden, J 97
 Creedon, T 31, 55
 Creehan, K 80
 Crevecouer-MacPhail, D 22
 Crooke, H 56 , 106
 Crooks, P 28 , 115
 Crosier, B 92
 Crowell, S 54
 Crowley, R 5, 58, 114
 Cuevas, J 63
 Culver, J 28
 Cunningham, C W 58
 Cunningham, K A 6, 72, 100 , 118
 Cunningham, R 30
 Cunningham, R 55, 106
 Cushing, C 55
 Czoty, P 79 , 28
 D'Onofrio, G 87
 Dack, J 20
 Dagher, A 98
 Dahari, H 25
 Dalbosco, C 106
 Dallery, J 92
 Dalwani, M 78, 86
 Dambreville, N 82 , 81
 Daneshmand , R 109
 Dangerfield II, D 105
 Daniel, L 62
 Daniels, S 93
 Daniulaityte, R 103 , 110
 Danping, L 87
 Darnley, S 15 , 97
 Dart, R C 52 , 109
 Daulouede, J 64
 Daunais, J 28
 Davenport, A 28
 Davis, A K 106
 Davis, D R 4 , 83
 Davis, J 15 , 10
 Davis, M 88
 Davis-Reyes, B 16
 Davis-Takacs, C M 100
 Daws, R 54
 Day, N 124
 de Almeida, R 118
 De Boni, R 65
 De Genna, N M 124
 De La Garza, II, R 62
 de la Torre, R 104
 de Moura, F 113
 de Sevin, E 23
 de Wit, H 95 , 120
 Deady, M 92
 Deal, E 126
 DeBaker, M 60
 DeBeck, K 69
 DeBeck, K 106
 DeBeck, K 30
 Dechen, M 66
 Decker, A 58 , 58
 DeFulio, A 16
 Degenhardt, L 54 , 56, 57, 65, 66 , 110, 111
 del Rio, C 111 , 64
 Delcher, C 52
 DeLise, T 92
 Denehy, E 28
 Deneke, E 16, 91, 111
 Deng, H 121
 Denis, C 63 , 64
 Des Jarlais, D C 9, 104, 126
 Deveau, N 61
 DeVaugh-Geiss, A 110
 Devereaux, A 58
 Devine, E 76
 DeVito, E 15 , 27
 Dewey, W L 3, 27, 73, 93
 Dezman, Z 7
 Dhawan, A 93
 Di Paola, A 69, 99
 Diazgranados, N 124
 Dib Gonçalves, P 15
 Dick, D 72
 Dickson, J 120
 Dickson, M 57, 68, 105
 DiGirolamo, G 87
 Dillon, P M 85 , 92
 Ditre, J 70
 Diwadkar, V 91
 Doan, T 64
 Dobbins, T 110
 Dobrer, S 30
 Dobrojalieva , V 118
 Dolan, S 100 , 101
 Doncheck, E 60 , 101
 Dong, C 95
 Dong, H 63 , 30
 Donohue, J 88
 Doogan, N 13
 Dora-Laskey, A 106
 Dotta, R 106
 Doucette, W 61
 Dowdle, L T 112, 114
 Drew, M 23
 Drgonova, J 17
 Drobes, D 70
 Du, H 100
 Duan, R 25
 Dubernet, J 65
 Duda, S 65
 Duehlmeier, L 14
 Dugosh, K 64 , 65 , 69
 Dukes, K 3
 Dumais, K 67 , 114
 Dunlop, A 74
 Dunn, A 113
 Dunn, A 113
 Dunn, K E 100 , 111
 Duperrouzel, J C 85 , 108
 Durand, F 98
 Durand, H 83
 Durazzo, T 118

Dvoriak, S 26	Fantegrossi, B 127	Flynn, S 28
Dwiel, L 61	Fanucchi, L 4 , 57	Foltin, R W 31 , 115
Dwoskin, L P 28 , 115	Farhoudian , A 109	Fong, C 19
Dymecki, S 72	Farkas, S 55	Fonseca, F 104
Earl, E 114	Farmer, S 119	Foote, B 87
Earley, P 92	Farmer, S 16	Ford,II, J H 54
Earleywine, M 119	Farnum, S 22, 111	Forman, L 64 , 111
Edlund, M 109	Farré, A 104	Forray, A 25, 103
Edwards, S 6	Farré, M 104	Forster, M 80, 100
Eggert, K 22, 111	Farrell, M 110, 112	Foster, D 3
Eisenberg, C 59	Farrer, L 72	Fox, H 8
Eisenstein, T K 80	Farris, S 108	Fox, R 100 , 118
Eissenberg, T E 117	Fatseas, M 23, 54 , 65, 86	France, C P 115 , 98
Ekhtiari, H 109	Faulkner, P 67 , 114	Francis, D 56
El Fiky, A 90	Fava, M 78	Franklin, T 51, 67, 97, 114
El Marroun, H 74	Feaster, D 10, 25, 88	Fraser, H 6
El-Bassel, N 88	Feczko, E 114	Frazier, W 88
Elder, H 81, 126	Feder, K 3	Freda, A 75
Elferink, L 72	Feeney, G 120	Freeman, C 120
Elkoussi, A 58	Feller , S 29	Freeman, K B 4, 6, 57
Ellerstrand, J 66	Ferketich, A 84	Freeman, R 22 , 111
Elliott, A 109	Fernandes Galduroz, J 24 , 17	Freeman, R 64
Elliott, R 79	Fernandez, A 104	Freeman, T 96
Ellis, C 114	Fernandez-Artamendi, S 86 , 120	Frick, K 60
Ellis, M S 18	Fernández-Hermida, J 86, 120	Friedman, A 3
Eltit, J 100	Ferrari, A 54 , 56, 66	Friedman, S 30, 105
Enkema, M 82	Ferré, S 78	Friedmann, P 18
Ennis Whitehead, N 64	Ferrell, A 90	Fronk, G 59
Enns, B 88, 106	Ferris, J 96	Frueh, C 29
Epperly, P 28	Fertuck, E 82	Fry, R 118
Epstein, D H 18 , 102, 124	Festinger, D S 69	Fryer, C 85
Eric, P 86	Ficnar, A 92	Fudala, P J 99
Erpelding, N 126	Fidalgo, T 66 , 122	Fultz, E 72
Erskine, H 54	Fiellin, D A 19 , 85, 87	Funada, M 17
Escalona-Vargas, D 11	Fiellin, L 105	Furr-Holden, D 75, 107, 124
Estakhri, H 21	Fiellin, L 85	Gaalema, D 4, 13, 53, 79, 83, 84
Eswaran, H 11	Figueiro, M 18	Gable, E 67
Etges, T 81	Finan, P 4	Gabrielli, J 120
Etter, J 82	Fink, D S 15	Gajghate, S 80
Evans, B 31, 55	Finlay , M 22 , 54	Galea, S 82 , 15
Evans, E 20	Fiorentin, T 104 , 104	Galia, E 22
Evans, S M 91	Fischman, A 96	Galindo, K 3
Evatt, D 15	Fishman, M 18 , 62 , 125	Galloway, G P 101
Evins, A 78	Fitzmaurice , G 102	Galynker, I 21
Fair, D 114	Fitzpatrick, C 97	Game, T 58
Fairbarin, N 30	Flannery, K 61	Gannon, B 3
Fairchild , V 88	Flannery, M 69, 102	Garavan, H 15, 26, 78
Fairman, B J 87	Flegel, R 81	Garcia, R 78
Fang, S 116	Fletcher, J 103	García-Pérez, Á 21 , 120

Garcia-Romeu, A 101	Godersky, M 64	Greenfield, S F 102
Garey, L 7	Godfrey, J 114	Greenwald, M K 11 , 15, 21, 57, 91, 116, 126
Garfein, R 63	Goetz, L 67	Grekin, E 61
Garfield, J 62	Goldschmidt, L 124	Grella, C 20
Garipey, A 105	Goldstein, N 11	Griffin, B 86
Garnick, D 31, 55	Goldstein, R Z 26	Griffin, M 73 , 111
Garrison, K 85	Goldstick, J 30	Griffiths, R R 15, 101
Gastfriend, D R 22, 60, 92	Golson, J 14 , 61	Griggs, N 58
Gastfriend, E 92	Gomide, H 62	Grinsztejn, B 65
Gatch, M B 80, 100, 101	Gonek, M 93	Gros, D 121
Gates, P 108	Gonzalez, G 87	Gross, R 26
Gatley, J 30, 88	Gonzalez, R 85 , 79 , 108	Grov, C 105 , 61
Gauthier, J 124	Gonzalez Aldaco, K 17	Gruber, S 122
Gawrysiak, M J 15 , 67 , 97	González Roz, A 14, 21	Grunwald, G 78
Gaziova, I 72	Goodbody, E 96	Gryczynski, G 18
Geddes, J 92	Goodfellow, A 105 , 112	Gryczynski, J 19 ,55, 62, 125
Gehrke, J 59	Goodwin, A K 113 , 27	Grywacheski, V 116
Gelberg, L 29 , 105 , 112	Goodwin, R D 15 , 82 , 83	Gu, S 101
Gelernter, J 72	Gordon, A J 88	Guarino, H 96
Gellad, W 88	Gordon, M 18	Gubner, N R 3, 25 , 83, 84
Geller, E B 80	Gorelick, D A 7	Gueye, A 67
Gentile, T 28	Gormley, K 21	Guillot, C 86
George, M 114	Gorodetsky, R 110	Guimarães, L 118
George, O 60	Gottshall, P 101	Guimond, T 55
Gerona, R 101	Gotuzzo, E 65	Guise, J 15
Gerra, G 22	Gould, T J 99	Gullo, M 61, 72 , 119, 120
Ghadiali, M 23	Goulet, J 73	Gunn, A 2
Ghahremani, D 67 , 114	Gourley, S 60	Gunning, M 113
Ghandour, L 30	Gouse, H 120	Gunter, B 57
Ghobadi, S 68	Govindarajah , D 79	Gurka, K 109
Giersch, A 81	Graham, C 99	Gust, S 21
Gilbart, E 85, 108	Grande-Gonsende, A 21, 120	Gutfraind, A 25
Gilbertson, S 100	Granfield, R 30	Gutierrez, E 80
Gile, K 96	Grant, B 116	Guydish, J 3, 83, 84, 88 , 118
Gillespie, M 58	Grant, I 122	Gyarmathy, V 110
Gilligan, C 65	Grant, S 86	Haddad, L 90
Gillis, N 80	Grasing, K 121	Haddox, J D 71
Gillis, T 17, 97	Grasing, M 121	Hadland, S E 87 , 23
Gilman, J 78	Graves, S M 95	Hager, N 67
Gilman, S 87, 125	Gray, K 58	Haight, B 99
Gilstad-Hayden, K 25, 55, 103	Gray, R 98 , 57	Haile, C 79, 91
Ginsburg, B C 80	Green, A 121 , 61	Hajek, P 62
Gjerde, L 120	Green, B 84	Hakonarson, H 72
Glasner-Edwards, S 121	Green, C E 51	Haley, D 30
Glenn, D 73	Green, J 109	Haliwa, I 81
Glennon, R 100	Green, K 104, 107	Hall, W 96
Gnatienko, N 64	Green, T 27, 65, 116	Hallgren, K 82
Gnegy, M E 95	Greene, E 65	Halm, E 110
Goddard, S 57	Greene, M 62	

Hamidovic, A 28	Heil, S H 4 , 11, 12, 53, 83, 117	Hopkins, S 59
Hamilton, S 112	Heilig, M 95 , 124	Horgan, C M 88 , 55 , 31
Hammond, A 103	Heinze, J 30	Horton, M 65
Hampson, A 79	Henderson, G 3	Horton, T 62
Han, K 101	Henningfield, J E 10	Hotton, A 25
Hancock, J 92	Henricks, A M 61	Howard, A 54
Hand, D J 12	Henthorn, T 10	Howell, H 25
Haney, M 29, 78, 91, 98, 115	Herbst, E 20	Howell, L L 6, 28, 59, 91, 94
Hanina, A 76	Herman, A 15	Hser, Y 88
Hanlon, C A 112, 114	Herme, M 69	Hsiao, P 84
Hansen, H 19	Hern, J 105	Hsu, J 84
Hao, W 95	Herr, K 100	Hsue, P 15
Hardee, J E 8	Herrmann, E 115	Hu, H 110
Harikrishnan, V 110	Hersch, M 81	Hu, L 62
Harp, K L 88	Herscovitch, P 124	Hu, M 104 , 18
Harrell, P 84, 108	Hester, R 14	Hu, M 113
Harris, A 100	Hesterman, J 78	Huang, C 101
Harris, R 56	Hewitt, J 4	Huang, J 84
Harris, S 53	Hides, L 61	Huang, L 64
Harris, S 58	Hieftje, K 105	Huang, N 116
Harrison, A 68	Hien, D 2 , 20, 29, 76 , 121	Huang, Y 67
Harrod, S 59	Higgins, S 4 , 11, 12, 13, 15, 53, 78,	Huestis, M 79, 81, 108
Hartley, B 25	79, 83, 84, 96, 117	Hughes, J 82 , 83 , 126
Hartwell, K J 126	Hiler, M 117	Huhn, A S 16 , 73, 91, 111
Harutyunyan, A 99	Hill, J 80	Hui, D 18
Harvanko, A 84	Hillard, C 60, 101, 119	Hulen, J 11
Harvey, W 54, 56 , 66	Hillmer, A 67	Hull, L 83
Hashemi, P 59	Hinckley, J 4	Hunt, S 23, 92
Hasin, D 3, 82 , 88 , 105, 116 , 125	Hingson, R 87	Hunter, S 86
Hasler, B 4	Hiranita, T 113	Hunter-Jones, J 30
Hassanpour, S 92	Hoang, M 15	Hurd , M 111
Hatami, J 109	Hobkirk, A 25	Hurd, Y 21
Haug, N 103	Hodder, R 65	Hurd, Y 93
Havens, J 26, 68, 105	Hodgkin, D 88 , 53	Hurley, B 22
Hawes, S 85, 108	Hoffer, L 24	Hurtado Ruiz, G 66
Hawk, K 87	Hoffman, K 107 , 54	Hurwitz, E 101
Hawkins, E 88 , 114	Hoffman, M 11	Husain, A 21
Hayashi, K 106	Hofford, R S 123	Husbands, S 28
Hayashi, K 69	Höfler, M 20	Huskinson, S L 4, 57
Haynes, C 109	Holden, D 59	Hussein, E 111
Haynie, D 125	Holliday, E 100 , 118	Ialongo, N 104 , 107
Haynie, D 87	Holmes, L 25	Idowu, J 121
Heads, A M 120	Holtgrave, D 63	Idrisov, B 64 , 88
Heal, D J 13 , 57 , 98	Holtyn, A 65 , 16	Iguchi, M Y 9
Healy, J 113	Homish, D 29, 54, 80	Ihionkhan, E 25
Healy, J 58	Homish, G G 29, 30, 54, 80	Ijadi-Maghsoodi , R 29
Heapy, A 103	Hommel, J 60	Ilgen, M 70, 110
Heeren, T 64	Hoopsick, R 54 , 29	Illenberger, J 59
Heidbreder, C 99	Hopfer, C J 4 , 17, 107, 116	Inan, S 80

Ingraham, B 62	Jordan, A 2	Kessler, F 102 , 106 , 118
Ipsen, J 15, 16 , 120	Jordan, C J 68	Keutmann, M 79
Iriah, S 17	Joseph, V 24	Keyes, K 15 , 96 , 125
Ivanciu, A 15, 78	Joska, J 20 , 120	Keyes, K 82
Jack, G 82	Juhascik, M 110	Keyes, K 88
Jackman, K P 113	Jules, N 15	Keyser-Marcus, L 78
Jackson, K 27	Juliano, L 15	Khalili, M 102
Jackson, K 108	Jurkovitz, C 62	Khan, M 29, 105
Jacobson, A E 93	Justice, A 73	Khan, S R 82
Jaffe, J H 19	Jutkiewicz, E 3 , 95	Khatib, D 15, 91
Jagannathan, K 15 , 67 , 97	Kahn, L 30	Kheibari, A 88
Jain, R 93	Kallupi, M 60	Khoddam, R 86
Jain, S 63	Kalnik, M 13	Khokhar, J 121
Jalah, R 93	Kaminer, Y 61	Khor, K 112
James, G 29	Kampman, K M 15, 97	Kiguchi, N 111
Janda, K 13, 93	Kanabar, M 23	Killeen, T 29, 121
Janes, A C 14 , 67, 114	Kane, C 121	Kilts, C 29
Janganati, V 28	Kane, J 62	Kilwein, T 16, 55, 96
Jankowski, S 21	Kangas, B 97	Kim, D 96
Jannuzzi Cunha, P J 15	Kangiser, M 79	Kim, H 101
Jardin, C 7	Kannry, J 55	Kim, H 18
Jarvis, B 16, 65	Kantak, K M 72 , 124	Kim, J 17, 99
Jauffret-Roustide, M 63	Karakula, S 111	Kim, J 67
Javadi-Paydar, M 80	Karaoghlanian, N 117	Kim, M 114
Jaworska, N 98	Karne, S 91	Kim, S 29 , 117
Jennette, K 79, 108	Karriker-Jaffe, K 72	Kim, S 92
Jensen, J 14	Kase, M 95	Kim, T 22
Jensen, K 72	Kashino, W 22	Kim, Y 101
Jessell, L 111, 96	Kasper, J M 60	Kimani, R 118
Jhanjee, S 90	Kataoka , S 29	kimes, A 124
Jin, C 58	Kate, H 62	King, J 7, 62
Johnson, A 55	Katz, N 10 , 81 , 126	King, M 19
Johnson, A 95	Kaufman, M J 97 , 17	Kingsland, M 65
Johnson, H 118	Kaukeinen, K 110	Kinzler, A 20
Johnson, J 53, 107	Kay-Lambkin, F 23, 92, 121	Kippin, T 67, 68, 72 , 117
Johnson, K 28	Kazam, I 81, 126	Kiriazova, T 26
Johnson, L 3	Kearney-Ramos, T 114	Kirisci, L 85
Johnson, M W 73, 101 , 108	Keedy, S 95	Kirley, T 59
Johnson, P 82	Keith, D 13, 83	Kirtadze, I 96 , 126
Johnson, R 53, 85, 104, 107	Kelley, D 88	Kishioka, S 111
Johnson, S 114	Kelly, A 96, 119	Kittleson, S 16
Johnston , L D 82	Kelly, T H 84	Kivell, B M 5
Jones, A 53, 62, 106	Kelsh, D 117 , 6	Klawitter, J 17
Jones, D 63	Kenakin, T 58	Klein, E 84
Jones, J 6, 28, 73, 86, 87, 97, 117	Kendzor, D 83	Klein, M 88, 88
Jones, J 11 , 13	Kennedy, T 54	Klemperer, E 126
Jones, J 126	Kerr, T 63 , 30 , 69	Kletter, E 102
Jones, M 11	Kershaw, T 103 , 25	Kleykamp, B A 88
Jordaan, E 13	Kervran, C 63	Klimas, J 63

Kline, Ph.D., R 21	Kyriakides, T 85	Leggas, M 58
Kluger, B 14	Labelle, C 18	Leickly, E 21 , 54
Knackstedt, L 24	LaConte, S 61	Lembeck, N 81
Knapp, A 107	Lacy, R T 78	LeNoue, S R 107
Knox, C 3	Laffont, C 99	Leri, F 93
Knox, J 105	Lake, M 16	Lertch, E 125
Knudsen, H K 26, 68 , 105	Lal, R 90	Lesage, M G 13
Ko, M 28	Lalanne, L 81	Leslie, D 19
Kober, H 67	Lalanne-Tongio, L 63	Leukefeld, C G 57 , 57 , 68, 105
Koblan, K 59	Lamb, R J 123	Leung, J 54 , 56 , 66
Koch, J 85	Lamba, W 55	Levar, N 78
Koffarnus, M N 27	Lambdin, B 106	Leventhal, A M 7, 14, 53, 86
Kohler, R 101	Lamy, F 103 , 110	Levin, F R 24 , 107
Kohut, S J 59	Land, M 72	Levis, B 14
Kondapaka, R 90	Land, T 87 , 116	Levitt, N 20
Kong, G 53 , 84	Lane, S D 81	Levy, I 72
Kong, L 18	Lane, T 105	Levy-Cooperman, N 58, 90, 117
Konkus, N 15	Langleben , D 88, 97	Lew, R 59
Korbar, B 92	Langston, T 58	Leyton, M 98
Korte, J 76 , 126	Lanier, R K 81, 126	Li, C 84
Kosten, T A 79 , 91 , 99	Lankenau, S 86	Li, D 99
Kosten, T R 15, 99	Laporte, V 18	Li, H 59
Kouyate, A 87	Laprevote, V 81	Li, J 72
Kowalczyk, W J 8, 102 , 124	Larance, B 57 , 110 , 111	Li, J 58, 111
Krainc, D 95	Larimer, M 82	Liberzon, I 15
Kral, A 106 , 53	Larney, S 65	Lichtman, A H 98, 122
Kranzler, H R 72	Larochelle, M 87 , 116	Liddiard, G 60
Krawczyk, N 3 , 85	Lasher, B 20	Lieb, R 20
Krebs, E 106 , 88	Latkin, C 25 , 91	Liebschutz, J 64
Kreek, M 23 , 72, 113, 118	Laudenbach, M 17 , 18	Ligabue, K 102, 106
Kreisler, A 6	Lauretta, G 87	Lile, J 115, 123
Krishnamurthy, V 18	Lawal, D 126	Lim, J 23
Krishnan-Sarin, S 53, 84, 85	Layton, M 54	Limberger, R 104
Krist, A 11	Le, A 70	Lin, J 102, 124
Krugliachenko, O 85	Le, T 3 , 88	Lin, K 120
Kruhlak, N 114	Le Foll, B 15, 81, 108, 112	Lin, L 56
Krupitsky, E 26, 64	Le Truong, G 64	Linan, B 18
Kuhar, M J 77	Leal Carneiro, A 24	Lind, K 80
Kumar, M 63	Learned, S M 99	Lindblad, R 90
Kumar, P 55	Ledgerwood, D M 11 , 21	Linden, M 29
Kumar, P 93	Lee, A 121	Linder, S 103
Kunkel, L 107	Lee, D C 4, 79, 81, 82	Lindgren, K 82
Kunkel, R 81	Lee, J 83	Ling, P 25
Kuo, C 106	Lee, J D 102 , 18, 19 , 69, 102	Linton, S 30
Kuo, P 124	Lee, M 105	Lintzeris, N 112 , 57 , 110
Kurti, A 12, 13, 83	Lefever, T 87 , 94	Linzy, S 23
Kurtz, S 96	Leff, J 18	Lioznov, D 26
Kutlu, M G 99	LeFoll, B 79	Lioznov, D 64
Kwok, K 23	Legakis, L 73	Lippold, K 73

Lira, M 64 , 111
 Lisdahl, K M 79, 85, 98, 108 , 124
 Lister, J 57
 Liu, L 95
 Liu, M 95
 Liu, Q 60, 101
 Liu, X 101
 Liu, Y 24, 110
 Livni, E 96
 Llamas, J 23
 Lloyd, D 19 , 92
 Lo-Ciganic , J 88
 Lobaugh, N 14
 Lobo, C 88
 Locke, R 11
 Loflin, M 20
 Loflin, M 108
 Lofwall, M R 4, 6 , 26, 29 , 57 , 117
 Lombard, C 20
 Lon, H 115
 London, E D 15, 16 , 67, 114
 Long, E 27
 Looby, A 16 , 96
 Lopez, A 13, 83
 López Núñez, C 14
 Lopez-Castro, T 20, 121
 Lopez-Quintero, C 86
 Lorch, U 118
 Loree, A 55
 Lorvick, J 106
 Louie, K 116
 Lowery, C 11
 Loxton, N 72
 Lu, H 121
 Lu, H 64
 Lu, Q 56
 Lu, T 106
 Luba, R 119
 Lubman, D 62
 Luk, J 125
 Lukas, S 14 , 16, 67, 118
 Lum, J 62
 Lund, C 20
 Lund, I 120
 Lundahl, L H 11 , 15 , 21 , 57
 Lunze , K 64
 Luo, S X 113
 Lutton, E 60
 Lynch, K 15
 Lynch, K 15
 M A Sartes, L 62
 Ma, L 78
 Mabry, K 124
 Macafee, L 11
 Mack, J 69 , 109
 Mackesy-Amiti, M 25
 MacKillop, J 108
 MacKinnon, N 109
 Mackley, A 11
 Mactutus, C 59
 Mactutus, C 25
 Madden, L 22, 111
 Maddry , M 73
 Madera, G 28 , 73
 Madras, B K 71 , 96
 Maggio, S 115
 Mahaffey, C 106
 Mahoney, M 91
 Mahony, A 107
 Mai Thi Hoai, S 64
 Maier, L 96
 Maki, P 79
 Makriyannis, A 80
 Malbergier, A 15
 Malhotra, R 14
 Malik, A 54 , 116
 Malik, E 102
 Malone, S 60 , 61
 Maltbie, E A 28
 Mamontova, O 26
 Mancino, M J 56 , 15
 Manhapra, A 19
 Mann, R 79, 81, 108
 Mannelli, P 99
 Mannes, Z 64
 Manning, K 7
 Manning, V 62
 Mansoor, E 104
 Mantsch, J R 60, 101 , 119
 Manubay, J 28 , 91
 Manubay, J 87
 Manubay, J 73
 Manvich, D 91
 Maple, K 124
 Maradan, G 18
 Marckel, J 59
 Marcus, R 6
 Margolin, Z 109 , 109
 Maria, T 88
 Mariani, J J 107
 Mark, K 23
 Marks, K 57, 68 , 105
 Markwardt, S 103
 Marotta, P 88
 Marquez, K 15
 Marsch, L 64 , 87 , 92
 Marsden, J 55
 Marshall, P K 14, 53 , 61, 97
 Martin, B 63
 Martin, E 79 , 63
 Martin, S 54
 Martín, S 104
 Martin-Fardon, R 60
 MArtinez, M 17
 Martinez, S 6 , 28
 Martínez-Loredo, V 21, 86, 120
 Martino, S 25, 55, 103
 Martins, B 29
 Martins, L 62
 Martins, S S 65 , 116
 Martins, S 103, 125
 Martins, S S 21 , 88 , 122
 Martins, S 19
 Martins, S S 24, 79, 88, 125
 Martorana, R 28
 Marusich, J A 87
 Masalov, D 26
 Mashhoon, Y 16
 Mashni, R 109
 Massey, L 110
 Massey, M 54
 Masson, C L 75, 102
 Massoud, V 102, 124
 Matazel, K 113
 Mateu-Gelabert, P 96
 Mateus, J 104
 Matheson, J 108
 Mathews, C 13
 Matson, P 104
 Matsumoto, R 58, 113
 Matsuzaki, S 111
 Matteucci, A 53
 Matthew, M 124
 Matthews, A 19, 62
 Matusiewicz, A 11, 12
 Matuskey, D 67
 Matyas, G 93

Matzeu, A 60	McLeman, B 87	Milani, S 82, 109, 116
Mauro, C 19, 21, 24 , 88	McLendon, H 6	Millar, B 61, 105
Mauro, P 65	McMahon, L R 113	Miller, E 105
Mauro, P 88	McMahon, T J 72	Miller, J 55
Mauro, P 19, 88	McNamee, C 109	Miller, K 23
Maust, D 56	McNeely, J 7 , 55	Miller, M 79
Mavrikaki, M 68	McNeil, J 118	Miller, W G 85
Maxwell, J C 127	McNulty, E 6	Miller-Roenigk, B 66
May, A 102	McPherson, S 15 , 21 , 54	Milligan, P 20
May, D 101	McQuaid, R 54	Milloy, M 69
May, J 19	McRae-Clark, A L 81 , 126 , 100	Milloy, M 63
May, K 109	McReynolds, J 101	Mills, K 23
May, P A 74 , 99	McWilliams, S 86, 107, 116	Milner, T 72
Mayberry, H 117	Meacham, M 53	Min, J 88
Mayer, M 53	Meade, C 9, 25, 63	Minichiello, A 65
Mayes, L 11	Meier, A 87	Minogianis, E 16
Maynard, M 60	Meinhofer, A 108	Mintzopoulos, D 17, 97
Mayo, L 95	Meissler, J 80	Mischel, E 126
Mazid, S 72	Melara, R 81	Miszkiel, J 100
Mazzella, S 22	Melbostad, H 11 , 12	Mitchell, J 62
McCabe, S E 79 , 84 , 109	Meli, S 64	Mitchell, J 54, 81
McCabe, V 84	Mellis, A 97	Mitchell, S G 19, 55, 125
McCaffrey, S 7, 56	Meltzer, P C 96	Mo, L 28
McCann, D J 71	Mendez, D 124	Moeller, F 72 , 78
McCarthy, J 67	Mendez, M 122	Moen Eilertsen, E 120
McCarty, D 54, 55, 107	Menoyo, E 104	Moerke, M 93
McClure, E 58	Meredith, S 15	Mogali, S 73 , 28
McConnell, R 53	Merkel, S 60	Mohammed, A M 59
McCormick, R 110	Merlin, J 70	Mohanty, M 126 , 81 , 81
McCubbin, A 84	Mesmin, M 3	Mohl, B 14
McCue, D 60	Messiah, S 62	Mojtabai, R 125
McCuistian, C 66	Metcalf, S 87	Molina, B 54
McCurdy, C 6	Metrik, J 108	Monezi Andrade, A 61, 62
McDonald, R 22, 65 , 118	Metsch, L 25	Monge, Z 15 , 97
McDonald, R 69	Metz, V E 28	Monico, L B 19, 125
McDonald, S 54	Metzger, D 64	Montalvo-Ortiz, J 72
McDonell, M 21, 54	Metzger, D 65	montaner, j 63
McEwen, B 72	Mewton, L 61	Montes, S 123
McGaugh, J 15	Meyer, R E 16, 18, 91, 111	Montgomery, L 76
McGowan, C 65	Meyerhoff, D 118	Monthieux, E 65
McGuinness, P 56	Mezghanni, M 102 , 124	Moody, L 14
McHugh, R 24, 73, 102, 111	Mezuk, B 31	Moore, B A 19, 92
McKay, J R 61	Miao, F 121	Moore, B 103
McKee, S 14, 15, 31, 61, 67, 68, 80, 126	Michopoulos , V 114	Moore, K 126
McKelvey, K 92	Micoulaud-Franchi, J 23	Moore, P 15
McLaughlin, J P 17	Miech, R 82	Moore, R 125
McLaughlin, R J 94	Mikulich-Gilbertson, S K 10, 78 , 86, 116	Moore, S 87
McLaurin, K 25	Milam, A J 107, 124	Moore, T 111
		Mora, M 18

Morabito, D 20	Neal, M 95	Oberleitner, L 61
Moran, L 102	Nedelchev, D 118	Ochalek, T 12, 21, 24, 96
Morean, M 84	Negus, S 6, 73, 93, 95, 100, 123	Odabas-Geldiay, M 59
Morel, S 18	Neighbors, C 7	Ohannessian, C 61
Morgan, J 18	Neisewander, J L 78, 123	Ohia-Nwoko, O 79, 99
Morgan, P 4	Newman, A 115	Okafor, C 63
Moriceau, S 23	Newswanger, P 88	Olfson, M 88
Morie, K 11	Newton, N C 98	Oliver, C F 99
Morisano, D 24	Ng, G 65	Oliveto, A 15, 56
Morrill, T 88	Ngjelina, E 85	Olles, V 66
Morris, E 59, 67	Nguyen, A 88	Olmstead, T 25, 103
Morrow, J 97	Nguyen, J D 80, 94	Oluwoye, O 21, 54
Morse, D 69	Nguyen, L 64	Ometto, M 15
Moses, T 57	Nguyen, T 58	Ompad, D C 105
Mosley, C 66	Nguyen, T 64	Oncken, C 74
Moss, A 116	Nicastri, S 15	Ondersma, S 25, 55, 92, 103
Moss, S 125	Nicholson, K 93	Opreescu, A 21
Moszczynska, A 99	Nickell, J 28	Ornell, F 102
MotaEonzani, T 62	Nickelsen, T 85	Ornell, R 106
Mtshengu, A 105	Nielsen, D A 5	Orr, M 15, 22, 54
Muench, J 107	Nielsen, S 52, 65, 112, 111	Osborne, V 109
Mumtaz, M 86	Nieto, S 91	Oser, C 68
Mundin, G 118	Nikas, S 80, 80	Oser, C 88
Muquit, L 20, 103	Nixon, K 115	Oser, C B 57, 105
Murnion, B 112	Nordeck, c 62, 55	Ostojic, D 11
Murphy, S M 10, 88	Norman, A B 58, 59, 88	Ostrow, L 111
Murray, D 118	Noroozi, A 109	Otiashvili, D 96, 126
Murray, T 118	Norris, D 68	Owens, M 20
Muschamp, J 28	Nosova, E 69	O'Grady, K 19, 55, 62, 82, 125
Musci, R 104	Nosyk, B 88, 106	Pacek, L R 82
Mustanski, B 72	Noto, A 24, 61	Pachado, M 118
Muth, S 110	Noto, J 79	Pachas, G 78
Myers, B 20	Nourmohammadi, N 88	Pacheco-Colon, I 85, 108
Myers, C 97	Novak, S 108, 109	Padgett, D 65
Nabulsi, N 67	Novo, P 19	Paez-Martinez, N 123
Nader, M 59, 79, 123	Nunes, E V 18, 19, 29, 102, 103, 104, 113	Pagano, A 3, 84
Nader, S 79	Nunez, Y 72	Paik, P 17
Nahata, R 56	Nuzzo, P 117, 117, 58, 4, 57	Pal, R 101
Nahhas, R 103	O'Brien, C P 97	Palamar, J J 96
Nahum-Shani, I 51	O'Brien, C 18, 64	Palatkin, V 26
Nakkash, R 30	O'Connor, P 87	Palmatier, M 14, 61, 60
Nakonezny, P 110	O'Dell, S 72	Panduro, A 17
Naledi, T 20	O'Donnell, C 111	Pang, R 86, 7
Nangia, N 99	O'Donnell, M 20	Pantano, L 68
Napier, T 95	O'Malley, P 82	Papasseit, E 104
Naslund, J 92	O'Malley, S 3, 8	Papini, S 121
Nayak, S U 99	O'Neill, A 107	Paquette, C 103, 116
Naylor, J 6, 113	Ober, A J 105	Parikh, V 99
Ndiaye, K 18		Park, H 101

Park, J 63	Persons, A 95	Prendergast, M 115
Parker, M 20, 24, 96	Pesquero, J 17	Presley, B 95
Paronis, C 80	Peteet, B 66	Preston, K L 18, 102, 124
Parra-Cardona, J R 20	Peters, C 83	Price, A 6, 118
Parry, C 13, 56	Peters, E 84	Price, C 54
Parsons, J T 61, 105	Peters, E N 82, 109	Price, T 72
Pasa, G 104	Petersen, N 67, 114	Priest, J 83
Pascual Arce, B 66	Petersen, P 13, 20	Printz, D 19, 92, 103
Patel, S 119	Peterson, S 17, 18	Prisinzano, T E 5, 58, 114
Pater, H 67	Petrusky, O 14	Psederska, E 118
Pating, D 23	Philip, P 23	Pugh, M 73
Paton, K 5	Phillips, J 13	Pujadas, M 104
Patrick, M 82	Phillips, K A 102, 124	Purpura, M 68
Patrick, M 83	Philogene, H 28	Puzia, M 54
Patterson, A 14, 61, 60	Phung, Q 61	Quinn, A 55
Patton, K 61, 119	Pickworth, W B 83	Quinn, C 61
Paul, D 11	Pigeon, W 121	Quinn, E 18, 64
Paule, M 113	Pihl, R O 98	Quinn, G 84
Paulus, M 26, 102	Pike, E 16	Quinn, K 105
Pavlicova, M 104	Pilkey, D 103	Quintero-Lopez, C 85
Pavlicova, M 19, 107	Pincus, M 114	Quisenberry, A 53, 84
Peacock, A 57, 110	Pinguello, A 102	Qureshi, H 6
Pearson, J 19	Pittman, J 14	Rabinovich-Guilatt, L 58
Pease, A 59	Pitts, E 60	Radoman, M 78
Peccoralo, L 55	Plankey, M 63	Radoncicic, V 29
Pechansky, F 102, 104, 106, 118	Platt, D M 95	Rafful, C 63
Pecoraro, A 62	Platt, J 83	Raghav, R 93
Pecsok, J 11	Plaxco, K 117	Raguin, G 64
Peglow, S 30	Plunk, A 108	Raina, C 54
Peiper, N 108	Pocuca, N 61	Raines, A 7
Peiper, N 109	Podolsky, M 111	Raleigh, M 17, 18
Peles, E 23, 102	Poe, L 14	Ralph, A 66
Peltier, M R 68	Polak, K 85	Ramchandani, V 124
Pendergass, T 105	Pollini, R A 103, 116	Ramesh, D 115
Penm, J 109	Pomm, D 85	Ramirez, S 60
Pennington, D 20	Ponce Terashima, J P 107	Ramo, D E 25, 53, 75, 83, 92
Pentel, P R 13, 17, 18	Poole, S 26	Ramos Lopez, O 17
Pereira de Oliveira Junior, H 15	Poon, J 85	Ramsey, S 63
Pérez, M 104	Pope, D 53	Randesi, M 72
Perez Diaz, M 6	Porath, A 107, 54	Rao, H 67
Pérez Mañà, C 104	Porrino, L J 79	Rash, C 83
Pericot, I 21, 79, 86, 120	Potenza, M 11, 85	Rassis, C 86
Perkel, C 21	Potts, J 83	Rawls, S M 28, 60, 80
Perlmutter, A 19	Pouget, E 19	Rawson, R A 88
Perrine, S 91, 99, 101	Powell, G L 123	Ray, S 78
Perrone-Bizzozero, N 123	Poznyak, V 22	Ray-Griffith, S 11
Perry, A N 123	Prashad, N 14	Rayapati, A 115
Perry, S 116	Pratt, M 93	Raymond, K 17, 86
Persidsky, Y 80	Pravetoni, M 18, 17	Razmpour, R 60

Rea, M 18
 Reback, C J 103
 Rebeiro, P 65
 Reboussin, B 104 , 107
 Reddy , V 105
 Redner, R 13, 83
 Reed, B 113
 Reed, D 83
 Reed, S 91 , 115
 Regier, P 97
 Regner, M 14 , 80
 Reid, L 12
 Reif, S 31, 55, 88
 Reilly, M 102
 Reissig, C 83
 Remy, L 15
 Reyes, K 60
 Reynolds, M D 85
 Rezapour, T 109
 Rhodes, G L 116 , 126
 Ribeiro, M 122
 Ribera, R 66
 Rice, E 110
 Rice, K C 3 , 17 , 93
 Richardson, L 106
 Rico, M 105
 Rieckmann, T 55 , 76 , 103
 Ries, R 21
 Riggs, P 110
 Riley, E 15 , 53
 Rivas Puy, I 66
 Riviere, L 83
 Roberts , M 22
 Roberts, M 13
 Roberts, W 15
 Robinson, A 59 , 68
 Robinson, T E 74
 Rocha, B A 71
 Rocha, M 102
 Roche, J 55
 Rockhill, K 109
 Rodriguez, V 63
 Rodriguez Barriba, M 66
 Roehrs, T A 102 , 112
 Rogers-Grazado , M 68
 Roglio, V 104
 Rojas-Castro, D 18
 Roll, J 15 , 21, 22, 54
 Roman, S 17
 Romero-Gonzalez, M 87
 Rompré, P 59
 Root, C 111
 Roscoe, R 59
 Rose, BS, C 87
 Rosen, M I 72, 102
 Rosenberry, Z 82
 Rosenblum, A 19
 Rosenblum, D 27
 Rosenheck, R 19
 Rosenthal, R 55
 Roslawski, M 17
 Ross, Z 30
 Roth, T 102 , 112
 Rotrosen, J 19, 55
 Roux, P 63 , 18
 Rowlett, J K 4 , 57 , 94
 ROY, T 93
 Rubin, L 79
 Rubinstein, M 83
 Rüedi-Bettschen, D 95
 Ruglass, L 20, 81, 82, 121
 Runyon, S 17, 18
 Rush, C 115
 Rush, C R 97
 Rush, C 16
 Ryan, E 118
 Ryan , G 29 , 105
 Saadoun, M 88
 Saba, L 17
 Sabioni, P 112
 Sabo, R 11
 Saccoccio, M 63
 Sacktor, N 63
 Saeed, F 58 , 59
 Saenz, E 22
 Saha, T 116
 Sahlem, G 107
 Saika, F 111
 Saitz, R 64
 Sakai, J 78, 86, 107
 Sakloth, F 100
 Salazar, D 19
 Salloum, I 121
 Saloner, B 3
 Samaha, A 16, 59 , 67, 74
 Samaranayake, S 59
 Samet, J H 18 , 64, 111
 Samiei , A 109
 Sampson, L 15
 Sanches, M 30, 88
 Sanchez, K 76
 Sanchez, M 91 , 94, 114
 Sanchez, Z 122
 Sanders, M 14 , 60 , 61
 Sandfort, T 105
 Santaella-Tenorio, J 19, 21, 24 , 88 , 116
 Santomauro, D 54
 Santos, B 15
 Santos, G 87 , 105
 Sara, L 14
 Saraiya, T 2
 Sardinas, K 62
 Sargent, E 55
 Sargent, J 120
 Sartor, C 3
 Sarvet, A 3, 82, 88, 116
 Sason, A 102
 Sato-Bigbee, C 5
 Saunders, E 18
 Saunders, E 66 , 87
 Saunders, M 115
 Saykao, A 13
 Schackman, B R 18
 Schaub, M 103
 Schauer, G 82
 Scheidell, J 29 , 105
 Scherer, J 102 , 104 , 106
 Schiffman, P 23
 Schippers, M 24
 Schlienz, N 79, 81
 Schmidt, L 54
 Schmidt, N 7
 Schmidt, T 118
 Schmitz, J M 51 , 81 , 120
 Schnee, S 109
 Schneider, K 85
 Schoedel, K A 57 , 58, 65
 Schoen, L 22
 Schoenbaum, M 19
 Schottenfeld, R S 19
 Schreiber, S 102
 Schuch, J 104
 Schulenberg, J 109
 Schult, R 110
 Schumacker, P 95
 Schwartz, R P 7, 19, 55, 125

Schwartz, R 65
 Schwartz, R P 62
 Schwarzschild, S 95
 Schweitzer, P 60
 Schwienteck, K 93
 Schwier, S 22, 95
 Scodes, J 19
 Scott, G 23
 Scott, S 78
 Scwhandt, M 124
 Secades Villa, R 14 , 21
 Sedlander, E 55
 Segoshi, A 28
 Séguin, J 98
 Segura, L 19, 21
 Selby, P 15 , 83 , 14 , 15
 Sellers, E M 57
 Serdarevic, M 56 , 109, 116
 Sereda, Y 26
 Serre, F 23, 54, 65, 86
 Servonnet, A 59
 Setlow, B 24
 Shahanaghi, BS, A 87
 Shanahan, C 64
 Shane, K 3
 Shanthi, M 97
 Sharma, A 99
 Sharma, A 55
 Sharma, G 7 , 55
 Sharpe Potter, J 73
 Sheffer, C 14 , 14
 Sheffield, J 61
 Sheikhattari, P 113
 Shekhtman, L 25
 Sheldon, B 29 , 117
 Shepard, D 88
 Shepherd, B 65
 Shepherd, J 67, 118
 Sherman, B 81
 Sherman, S 102
 Sherman, S 63
 Sherwood, A 58
 Sheth, A 103
 Shevorykin, A 14, 81
 Shi , Z 88
 Shihadeh, A 117
 Shilling, S 88
 Shin, C 117 , 67
 Shin, J 101
 Shin, S 54
 Shoben, A 84
 Shokri Kojori, E 124
 Sholler, D 100 , 118
 Shoptaw, S 15, 16, 63, 105
 Shram, M 58 , 90
 Shulman, M 104
 Shvab, I 26
 Sigmon, S C 4, 11, 21, 24, 29, 53, 83, 96
 Sullivan, S 93
 Silveira, C 79
 Silveira, D 66
 Silverman, B 99
 Silverman, K 16, 65
 Silvestrin, R 104
 Simmons, S 28
 Simon, A 61
 Simon, P 84
 Simons-Morton, B 87, 125
 Singh, J 18
 Singh, S 90
 Singletary, B 69
 Sinha, R 11, 26, 85
 Sitta, R 100
 Siu, E 79
 Sizemore, I 110
 Skalisky, J 21
 Skelly, J 12
 Skelly , J 117 , 83
 Skinstad, A H 23
 Slack, R 115
 Slaker, M 60
 Slavin, M 119
 Slesnick, N 53
 Sloan, P 4
 Smethells, J 118
 Smith, A 103
 Smith, A 14 , 60
 Smith, A 72
 Smith, C 15, 54
 Smith, K 20 , 61
 Smith, K 118
 Smith, M A 59 , 68
 Smith, M 79 , 73
 Smith, P 14 , 61
 Smith, S 10
 Smith, S 13, 57
 Snider, S 61
 Soares, J 121
 Soderstrom, C 7
 Sofuoglu, M 109 , 15
 Sorensen, J L 23 , 102
 Sorg, B 60
 Sorsdahl, K 20
 Soto, C 100
 Sottile, J 20
 Sousa, T 104
 Souza-Formigoni, M 17, 24, 62
 Spagnolo, P 124
 Spechler, P 15, 78
 Spindle, T 117
 Spire, B 18
 Spradley, J 15
 Spriggs, S 21
 Springer, S 69, 99
 Sproule, B 52
 Srebnik, D 21
 Srinagesh, A 78
 St. Peter, M 123
 Stahlberg, H 22
 Stahler, J J 22
 Staiger, P 62
 Stairs, D J 14
 Staley, M 13
 Stallings, M 4
 Standeven, L 124
 Stanger, C 51 , 82 , 107
 Stankoski, D 16, 91, 111
 Stanley, J 15, 91
 Stanton, C 13
 Stapinski, L 98
 Staton, M 57, 88 , 105
 Stavitskaya, L 114
 Steele, F 93
 Stehli, A 54
 Stein, D 15 , 16 , 20 , 120
 Stein, E 27, 121
 Stein, J 53 , 14
 Stein, L A 14
 Steinberg, J 78
 Sterling , S A 8
 Stevens-Watkins, D 106
 Stewart, J L 102
 Stewart, M 31, 55, 88
 Stitzer, M L 83 , 53 , 4 , 103
 Stivelmam, M 102
 Stockings, E 65

Stockis, A 57	Svikis, D S 11, 85, 9	Tidey, J W 4, 53, 83
Stoddard, S 30	Swalve, N 118	Tindall, M 68
Stoduto, G 79, 81, 108	Swanson, J 54	Ting, T 84
Stoermann, M 73	Sweeney, M M 15, 101, 108	Tippler, M 98
Stoler, M 30	Syvertsen, J 103, 116	Tobin, K 91
Stollenwerk, T 101	Szucs-Reed, R 97	Toblin, R 83
Stomberg, C 95	Szumliniski, K K 67	Todd, S 108
Stone, A 78	Szumliniski, K 72	Tofighi, B 102
Stone, M 7	Tabatadze, M 126	Tol, W 62
Stoolmiller, M 120	Taffe, M A 80 , 94	Tolliver, J 88
Stoops, W W 16, 97, 115	Taghavi, T 117	Tolou-Shams, M 68
Stopka, T 87	Tai, R 95	Tomasi, D 124
Storr, C L 125	Tajima, B 3, 83, 84, 88	Tomko, R 58
Stott, C 98	Tallarida, R J 80	Tompkins, D 73, 79, 99, 111
Stotts, A 51	Tamagnan, G 59	Tong, S 11
Stout, K 95	Tamburrino, M 15	Tonidandel, S 59
Stout, R 125	Tanabe, J 14, 80	Tormohlen, K 91
Stowe, T 79	Tancer, M 21	Torrens, M 104
Stowe, T 91	Tapert, S F 102	Torres, O 93
Stowe, Z 11	Tardelli, V 66	Torres Valadez, R 17
Strain, E C 6, 73, 75, 103, 125	Tarter, R E 85	Toumbourou, J 119
Strang, J 22, 65, 118	Tavakoli, E 126	Towe, S 25, 63
Strathdee, S 63	Taylor, T 64	Townsend, D 6
Strayer, K 110	Tebbe, K 24	Tran, F 28
Streck, J 4, 21, 53, 83	Teesson, M R 23, 92, 98	Tran, H 64
Strickland, J C 57, 78 , 97, 108	Templeton, T 67	Traynor, J 58
Strong, C 84	Terplan, M 13, 124	Trecki, J 127
Stuart, R 23	Tessereau, C 21	Tregellas, J 14
Stucky, B 105	Tetrault, J 73	Treister, R 81, 126
Studts, C 16	Thanner, M 83	Tremblay, R E 98
Studts, J 26	Thomas, A 79	Trias, V 64
Sturgis-Berkowitz, E 15, 97	Thomas, A M 98	Trigo, J 112
Sturua, L 126	Thomas, A 124	Tross, S 104 , 126
Stutz, S 6 , 100	Thomas, B F 127 , 58	Tsai, G 22
Subramaniam, G 7, 55	Thompson, C 56 , 85	Tsay, W 84
Subramaniam, S 16, 65	Thompson, E 54	Tseng, F 120
Suchanek, J 116	Thompson, J 85	Tsou, H 101
Suchting, R 81	Thompson, L 23	Tsui, J 64
Sufka, K 6	Thompson, R 125	Tu, Y 84
Sugarman, D 102	Thompson-Lake, D 62	Tumolo, J M 99
Suh, J 97	Thorn, D 111	Turner, C 87 , 105
Sulima, A 17	Thorn, P 62	Turner, J 14
Sullivan, M 28, 99	Thornton, L 23	Tursi, L 83
Sullivan, M 64 , 111	Thorson, J 115	Tuscher, J 60
Sullivan, R 92	Thostenson, J 56 , 15	Tyndale , R 117
Sun, S 63	Thrul, J 25	Tyndall, J 56
Surkan, P 63	Thuku, W 15	Tzilos, G 125
Surmeier, D 95	Thurstone, C 107	Uhl, G R 17
Sussman, S 86	Tiberg, F 29, 117	Unger, J 3

Unterwald, E M 101
 Upchurch, D 20
 Urbanik, L 60
 Urbiel, J 116
 Vaddiparti, K 56
 Vadhan, N P 97
 Vaezazizi, L M 19
 Vahidi, M 105
 Valenstein, M 110
 Valeri, L 73
 Valerio, A 102
 Vallender, E J 94 , 16
 van der Westhuizen, C 20
 Van Hedger, K 95
 van Hout, M 56
 van Nunen, L 15 , 16
 Van Uden, C 92
 Vandewater , S 80
 Vandrey, R G 79 , 81
 VanVeldhuisen, P 7
 Vanyukov, M 85
 Vardanashvili, I 126
 Varela, P 17
 Vasilev, G 118
 Vassileva, J 78, 79 , 118
 Vazquez-Sanroman, D B 123
 Vega, A 55
 Velasquez, M 69
 Veliz, P 109
 Vemuri, K 80
 Vendruscolo, L 94
 Venegas, A 121
 Verbitskaya , E 26
 Verdejo-Garcia, A 62
 Verplaetse, T 68
 Vest, B 54 , 30
 Vetrova, M 26
 Vgontzas, A 18
 Victor, G 88
 Vidot, D C 62, 104, 106
 Vieira, P 67
 Vieira, P 68
 Vieira, P 117
 Villamil Grest, C 3
 Villar-Loubet, O 121
 Vilotitch, A 63
 Vince, B 6, 117
 Vincent, J 81
 Vitaliano, G 17
 Vitaro, F 98
 Vittinghoff, E 15
 Voisey, J 72
 Voisin, A 64
 Volkow, N 26
 von Diemen, L 102, 106
 Vos, T 54 , 56
 Votaw, V 24
 Vrana, C 29
 Vselvolozhskaya, O 56, 75
 Wagner, B 78
 Wagner, F A 113
 Wahle, A 7, 55, 62
 Waite, E 55
 Wakeford, A 91
 Walker, D 82
 Walker, J 126
 Walker, L 31
 Wall, M 82 , 82 , 88
 Wall, T L 107
 Wallace, A 85
 Walley, A Y 18, 64 , 87 , 116
 Wallingford, S 107, 116
 Walsh, B 86
 Walsh, R 21
 Walsh, S L 4, 6, 26, 29, 57, 58, 98, 117
 Walter, D 6
 Walters, H 110
 Walton , K 22
 Walton, M 55, 85, 106 , 110
 Wang, A 88
 Wang, N 124
 Wang, S 101
 Wang, Y 95
 Wannas, P 14
 Ward, G 18
 Ware, M 112, 122
 Warren, N 93
 Washington , D 20, 29
 Washio, Y 11 , 13 , 23
 Waters, A 83
 Watson, M 80
 Weafer, J 120
 Weaver, L 104 , 126
 Weaver, M 92
 Webster, M 68
 Webster, M 105
 Webster, M 105
 Webster, M 57
 Webster, R 59
 Webster, R 58
 Wechsberg, W M 9
 Weerts, E M 100 , 70
 Weidberg, S 14, 21
 Weinberger, A 83
 Weingard, K K 76
 Weinshenker, D 91
 Weinstein, D 62
 Weinstein, Z 18
 Weir, B 63
 Weiss, F 60
 Weiss, R D 73, 111
 Weiss, S 77
 Wells, J 56
 Wendy, B 73
 Wening, K 22, 95
 Werb, D 63
 West, B 84
 Westover, A 110
 Wetherill, R R 67, 97, 114
 Wetzels, H 58 , 59 , 88
 Wewers, M 84
 Wheeler, P 106
 White, D A 21
 White, M 61
 Whitfield, T 105
 Wickens, C 79, 81, 108
 Wiegand, T 110
 Wiet, A 65
 Wiggers, J 65
 Wiley, J L 3, 58, 87, 127
 Willhelm, A 118
 Williams, A 24, 88
 Williams, D 83, 88
 Williams, G 15
 Williams, P 2
 Williams , S 68
 Williamson, S 5 , 58
 Wilson, A G 28
 Wilson, B 62
 Wilson, D 18
 Wilson , M 22
 Wilson, M 114 , 6
 Winfield, M 80
 Winhusen, T 25, 113
 Winn, T 69
 Winstanley, E L 109

Winstock, A 96
 Winston, S 17, 18
 Winter, M 64
 Wolf, E 11
 Wolfe, M 14
 Wolfenden, L 65
 Wolff, M 104 , 126
 Wong, J 67
 Wood, A 61
 Wood, E 30 , 69 , 63
 Woodcock, E 91 , 15 , 57
 Woodstock Striley, C 24 , 110 , 116 ,
 106 , 109 , 106 , 82 , 109 , 109 , 110 ,
 24 , 69
 Woodward, J 118
 Woody, G 62
 Woody, G E 15
 Woody, G 26
 Wooldridge, L 80
 Woolley, J 62
 Wright, N 85
 Wright, S 98
 Wscieklica, T 17
 Wu, A 15
 Wu, E 88
 Wu, K 106
 Wu, L 55 , 7
 Wu, Q 53
 Wu, S 84 , 106
 Xi, Z 119
 Xie, Z 95
 Xu, H 121
 Xu, J 11
 Xuan, Z 85
 Xue, L 104
 Yadav, D 90
 Yadav, S 18
 Yamamoto, D 80 , 14
 Yang, G 85
 Yang, H 84
 Yang, M 55
 Yaroslavtseva, T 26
 Yarzebski, J 87
 Yassin , N 30
 Yee-Rios, Y 123
 Yeh, H 79 , 56
 Yen, C 84
 Yip, D 88
 Yip, S W 8, 11, 85
 Yonkers, K 25, 55, 103
 Yoon, J 81
 Yoon, S 100
 Yorick, R 26
 Young, H 56 , 116
 Young, K 97
 Young, L 116
 Young, M 107 , 116
 Young, R 120 , 72
 Young, S 4 , 107
 Younk, R 118
 Ystrøm, E 120
 Yu, B 82
 Yu, M 99
 Yu, Y 84
 Yun, J 101
 Zabransky, T 126
 Zack, M 15
 Zadzielski, E 23
 Zakiniaez, Y 67
 Zamora, J 114
 Zampese, E 95
 Zatreh, M 110
 Zawertailo, L 83 , 14 , 65 , 15
 Zenoni, N 92
 Zepeda Carrillo, E 17
 Zerbe, G 78
 Zhai, Z 11
 Zhan, C 117
 Zhang, H 15
 Zhang, H 59 , 68
 Zhang, H 15
 Zhang, X 121
 Zhang, X 95
 Zhang, Y 111 , 58
 Zhang, Y 109
 Zhao, Y 101
 Zheng, F 117
 Zheng, G 115
 Zheng, P 88
 Zhou, B 13
 Zhou, Y 72
 Zimmerman, M 30 , 106
 Zorrilla, E 6
 Zucker, R A 85
 Zuluaga-Ramirez, V 80
 Zvartau, E E 26
 Zvolensky, M 7, 82
 Zvorsky, I 12

SYMPOSIA

Sunday, June 18

I. What is the Role of Sleep in Substance Use? Evidence from Studies of Cannabis, Alcohol, and Opioid Use

Chairs: Patrick Finan and Brant Hasler

Sleep disturbance is pervasive in society. Between 10% and 30% of the population experience a range of symptoms of insomnia, defined as difficulty initiating or maintaining sleep with accompanying daytime impairments. Recently, there has been a surge in research investigating sleep among individuals with substance use disorders (SUDs), revealing that sleep disturbance is more prevalent and severe among those with SUDs compared to the general public. This symposium addresses the current state of the science on sleep in SUDs by evaluating sleep and circadian disturbance through multiple assessment modalities [self-report, salivary melatonin, and electroencephalography (EEG)] and in the context of varying degrees of substance use. Topics covered will include the theoretical view that sleep disturbance increases risk for SUDs by altering affective tone via alterations to mesolimbic reward system neurocircuitry; the role of circadian rhythms in altering reward system function in adolescents and young adults with regular alcohol use; ambulatory sleep EEG data from treatment-seeking cannabis users; and sleep and circadian differences, gathered across multiple assessment modalities, in cannabis and alcohol users. Novel, unpublished data will be presented throughout the symposium.

II. Translational Approaches to Uncovering the Mechanisms Underlying Neonatal Abstinence Syndrome

Chairs: Lisa Brents and Jessica Coker

Neonatal abstinence syndrome (NAS) is a constellation of withdrawal symptoms that most often occurs in newborns chronically exposed to opioids during the prenatal period. Opioid-induced NAS is characterized by inconsolable high-pitched crying, tremor, feeding problems (vomiting, diarrhea, poor sucking and breathing coordination), heightened pain sensitivity, and sleep disturbances. In step with the ongoing opioid abuse epidemic, the incidence of NAS has risen almost 5-fold since 2000, from 120 to 580 per 100,000 children born in U.S. hospitals. As such, important clinical research focusing on NAS epidemiology, NAS assessment and symptom scoring, and clinical care for the mother-child dyad has increased; however, basic research that delves into the mechanisms of NAS risk and development has not been as greatly stimulated. Such research, which can be conducted in both humans and rodent models, is needed for the development of new pharmacological and non-pharmacological preventions and treatments for NAS. Research to be presented in this symposium focuses on NAS mechanisms; specific topics will include opioid pharmacokinetics and pharmacogenetics in human mother-child dyads and rodent models of prenatal opioid exposure and neonatal opioid withdrawal. The overall goal of the symposium is to synergize the development of new NAS preventions and therapies by focusing the attention of a diverse audience of addiction researchers on the untapped potential of applying basic science research to NAS.

SYMPOSIA

Sunday, June 18

III. *Dark Minds: Neural and Biobehavioral Substrates of Negative Affect Regulation in Addiction*

Chairs: Sarah Yip and Lora Cope

Emotion regulation, the ability to dynamically influence the experience and expression of one's emotions, is a central adaptive process that is altered in addiction and plays a key role in the acquisition, maintenance, and outcome of substance use disorders. However, the neurobiological substrates of emotion regulation among individuals with addictions remain poorly characterized. This symposium will showcase novel human neuroimaging and laboratory work in order to explore negative affective and control-related aspects of emotion regulation as: (i) a vulnerability factor for addiction; (ii) a predictor of future substance use; and (iii) a target for treatment development. Speakers will present neuroimaging evidence for altered processing of negative affect among adolescents with illicit substance use and among young adults with a non-drug addiction (Internet gaming disorder), as well as on the prognostic significance of brain activations to negative affective stimuli in relation to later cannabis- and alcohol-use in youth. In addition, data from laboratory studies will be presented to demonstrate that cognitive regulation of emotion is impaired during early withdrawal from cocaine, and is an effective predictor of relapse outside the laboratory that may be improved by adrenergic agents.

Monday, June 19

IV. *Brain Recovery in Addiction: From Biomarkers to Functional Outcomes*

Chairs: Rajita Sinha and Carlos Blanco

Chronic drug abuse results in structural and functional brain changes that map onto cognitive, social and emotional adaptive processes that significantly impact development, course and severity of addictive disorders. At the same time, with effective treatments and abstinence, addicted patients recover, and yet, little is known about brain recovery and its impact on clinical and functional outcomes. Speakers in this symposium will present new neuroimaging findings combined with clinical relapse and recovery outcomes to begin to shed light on brain processes that prevent relapse and are significant in regaining cognitive, emotional and adaptive functioning during addiction recovery. Talks will demonstrate that 1) neural substrates that process aversive states undergo significant changes as a function of recovery from acute substance use disorder, consistent with the notion that prolonged substance use is associated with an allostatic state; 2) brain structural, fMRI and event-related potential results in cocaine-addicted individuals showing recovery of the neural correlates underlying advantageous decision making and other executive functions, drug-seeking and cue-induced craving; 3) former cigarette and cocaine users have structural and functional brain changes associated with improved cognitive control in abstinence; 4) brain structural and fMRI of stress, trauma and drug cue responses can prospectively predict relapse and recovery from substance use disorders. The discussion will include potential biomarkers of addiction relapse and recovery that can inform novel treatment development efforts in addiction from a precision medicine perspective.

SYMPOSIA

Monday, June 19

V. Informing Tobacco Product Regulatory Policies through Addiction-Related Research Chairs: Jennifer Naylor and Lynn Hall

The Tobacco Control Act granted the Food and Drug Administration's (FDA) Center for Tobacco Products (CTP) the authority to regulate the manufacture, marketing, and distribution of tobacco products to reduce the harm from tobacco use and protect the public health. CTP relies on tobacco regulatory science research to inform its regulatory activities in several priority areas, including reducing the addictiveness of tobacco products. The overall goal of this symposium is to bring the addiction community up to date about how current addiction research is being used to inform FDA's regulatory authority. Speakers will present an overview and data related to multiple research areas currently informing tobacco regulatory science, including rodent, nonhuman primate, and human subjects. Specifically, the proposed research areas include investigations of the reinforcing effects of tobacco product constituents, preclinical models aimed at describing and validating biological markers of nicotine dependence, the role of flavor additives in the potential abuse liability of tobacco products, and the usefulness of behavioral economics and behavioral marketplace models to describe and predict tobacco use behavior. The discussant will highlight parameters that characterize tobacco regulatory science, and stimulate discussion of how future addiction-related studies may inform the FDA's regulation of tobacco products.

VI. Sex as a Biological Variable: Research Findings from NIH Office of Research on Women's Health and NIDA Center Grants – Ahead of Its Time or Long Overdue? Chairs: Cora Lee Wetherington and Sherry McKee

The first three speakers in this symposium are recipients of P50 center grants co-funded by the NIH Office of Research on Women's Health (ORWH) and NIDA under ORWH's Specialized Centers of Research (SCOR) on Sex Differences program which supports established scientists conducting research at 11 centers across the country that each integrate basic, clinical, and translational research approaches with a primary sex/gender focus. The ORWH/NIDA SCORs, now in at least their fifth year, each take a sex/gender-based translational perspective with a view toward therapeutic approaches, both pharmacologic and behavioral. Research findings will be presented from animal and human projects focusing on probing the noradrenergic system and its interactions with cholinergic and dopamine systems in stress-induced smoking relapse; the impact of oxytocin and noradrenergic system manipulations in cocaine and nicotine dependence; and medications to reduce cocaine, nicotine and marijuana use and relapse via reducing impulsivity. A fourth speaker will elaborate on the recent NIH Sex as a Biological Variable (SABV) policy with recent research findings that inform implementation of that policy in drug addiction research. Finally, the discussant will tie together and synthesize the presentations from an historical, translational and moving-forward perspective, leaving time for panel and audience dialogue. The underlying goal of the symposium is to emphasize the scientific and translational benefit, indeed necessity, of incorporating SABV across the full continuum of drug abuse research in order to achieve the goals of the Precision Medicine Initiative for both men and women.

SYMPOSIA

Tuesday, June 20

VII. Pain and Addiction: Opioids and Beyond

Chairs: Martin D. Cheatile and Peggy Compton

The prevalence of chronic pain continues to rise in the United States causing individual suffering and contributing to morbidity, mortality and disability and burgeoning economic and societal costs. Approximately 30% of adult Americans suffer from chronic pain and the estimated annual cost of chronic pain in the United States is between \$560 to over \$600 billion including the cost of healthcare and lost productivity. Individuals suffering from chronic pain tend to present with multiple medical and psychiatric co-morbidities including opioid misuse/abuse. The national attention on the “opioid epidemic” has stimulated a great deal of scholarly activity on identifying risk factors and mitigation strategies to curtail the soaring rate of prescription opioid misuse, abuse and opioid-related fatalities. While prescription opioid misuse and abuse has become a public health crisis, other substances of abuse are also common in patients with pain and can be equally as devastating to an individual’s quality of life. The specific aim of this symposium is to provide an overview of the current state of the field of pain and addiction including the highly-debated issues surrounding prescription opioids but going beyond opioids to address other substances of abuse. This multidisciplinary panel will provide data from original research on a spectrum of substances of abuse in the pain population including: nicotine; alcohol, opioids and cannabis and a novel pain treatment program for individuals completing substance abuse treatment.

VIII. Understanding Alcohol and Nicotine Co-Use: Rat, Nonhuman Primate, and Human Laboratory Findings

Chairs: Elise Weerts and David Drobes

Alcohol and nicotine are often co-abused, and individuals with concurrent alcohol and tobacco use disorder have the poorest treatment outcomes. Basic research can increase our understanding of the environmental and biobehavioral mechanisms underlying alcohol and nicotine use and co-addiction, and facilitate the development of better treatments. This symposium will provide a translational view of alcohol and nicotine interactions on drug-taking behaviors and cue reactivity in rodents, non-human primates and humans. The first speaker will present his preclinical rodent model of co-administration of alcohol and nicotine. As both drugs have been shown to affect endogenous opioid as well as nicotinic acetylcholinergic activity, his studies examined data on how co-administration impacts the effects of naltrexone and varenicline on alcohol and nicotine self-administration. A second talk will present a preclinical non-human primate model of concurrent alcohol and nicotine self-administration, with research that addresses current questions on how to treat alcoholic smokers; Another talk will describe a series of human laboratory studies examining the effects of salient alcohol and nicotine cues, as well as drug priming effects, on motivation to use both substances and discuss a common theme that involves the role of individual differences in drug intake and/or dependence as moderators of cue and drug effects.

SYMPOSIA

Tuesday, June 20

- IX. *Legal but Not So Safe: Prevalence, Effects, Strategies for Prenatal Alcohol, Marijuana, and Tobacco Use*
Chairs: Yukiko Washio and Philip May

Drinking alcohol and smoking cigarettes during pregnancy are the leading modifiable risk factors for pregnancy-related morbidity, mortality, and adverse outcomes in children. Fetal alcohol spectrum disorders (FASD) as a result of prenatal alcohol exposure are currently known as the leading cause of mental retardation in the U.S. and far more prevalent among children than was previously thought. Cigarette smoking is associated with a number of adverse maternal and child health problems and more information is needed regarding the impact of alternative tobacco products on health outcomes. Recent evidence has shown that prenatal exposure to cannabis and THC can cause many serious, adverse effects on birth outcomes. Although most women are able to abstain from drug use in the prenatal period, these three substances remain the most commonly co-used substances during pregnancy, with alcohol being used by women of all social strata especially during the first two trimesters. While marijuana is becoming more available legally, potentially impacting public perception of the harm of using marijuana, public health education on the neonatal consequences of drinking alcohol and smoking has contributed to an increase in maternal under-reporting of these substances. The specific aims of the proposed session are to (1) present the most recent evidence on the prevalence and effects of maternal alcohol, tobacco, and marijuana use on birth and child outcomes with the most recent evidence with regard to FASD; and (2) present clinical and public health strategies that can potentially reduce maternal drinking, tobacco, and marijuana use.

- X. *How Fast and How Often? The Temporal Pattern of Drug Use Is Decisive in Addiction*
Chairs: Anne-Noël Samaha and Terry Robinson

Core features of cocaine use in addicts are intermittency, between and within bouts of use, and the use of routes that lead to rapid drug onset. However, how often and how fast drug levels rise are generally ignored in animal models of addiction. This symposium will show that these temporal factors are critical in addiction and ignoring them can lead to false conclusions. There is increasing data on the patterns of voluntary drug taking in laboratory rodents, but virtually none in humans. The work presented includes studies on the frequency and dosage of heroin and cocaine taking in outpatients of an addiction clinic. The findings will be linked to results from animal studies and drug reward theories. Intermittency of use is not captured by traditional self-administration procedures in animals. An Intermittent-Access self-administration procedure promotes addiction-like behaviors, including escalation of intake, high motivation for cocaine and robust reinstatement of drug seeking. Intermittent and rapid spikes in brain cocaine levels each promote addiction. Intermittent-Access self-administration leads to less cocaine intake than continuous access, but promotes greater motivation for the drug. Furthermore, within Intermittent-Access sessions, rapid cocaine injections evoke more motivation for the drug than slower injections. It will be shown that the temporal pattern of cocaine use is critical in determining neurochemical adaptations. These studies highlight the importance of using animal models of addiction that consider the temporal kinetics of drug use.

SYMPOSIA

Wednesday, June 21

- XI. *Cloudy, with a Chance of Intoxication: E-vape Models of Drug Exposure in Laboratory Animal Models*
Chairs: Michael Taffe and Julie Marusich

Humans ingest a wide variety of psychotropic drugs via inhalation and this route of administration has been associated with increased liability for uncontrolled use and addiction. Inhalation techniques include combustion of dried plant matter (tobacco, cannabis), vaporization of crystalized drug (cocaine, methamphetamine) and, increasingly, via vapor produced with e-cigarette devices. Despite this fact, laboratory animal models of drug inhalation have been rare compared with other routes of administration. Recent adaptation of vapor inhalation techniques based on e-cigarette type technology has facilitated study of drug inhalation in rodent models. Participants in this symposium will overview 1) the behavioral effects of inhalation of synthetic cannabinoids in mice; 2) the self-administration, and behavioral effects, of vaporized sufentanil; 3) the affective and cognitive effects of inhalation of crude cannabis extracts in rats; 4) the self-administration of vaporized methamphetamine and substituted-cathinone stimulants in rats. The symposium will therefore address a range of behavioral and physiological endpoints relevant to many aspects of substance use and demonstrate the efficacy of inhalation approaches for multiple drugs. The Discussant will summarize the data presented within the context of this emerging field of drug abuse research, describe related progress from the field at large and lead an audience discussion of the advantages, disadvantages and future application of these approaches.

- XII. *Opioid and Cannabinoid Interactions: Preclinical and Clinical Measures of Pain, Abuse Liability and Dependence*
Chairs: Margaret Haney and Aron Lichtman

The current opioid abuse and overdose crisis coincides with increased societal acceptance of cannabis for medical use. Given the bidirectional, modulatory relationship between the opioid and cannabinoid systems, a symposium highlighting recent preclinical and clinical evidence of the interaction between these two drug classes on endpoints related to pain, abuse liability and dependence is timely and significant. Talks will cover cannabinoid receptor agonists and endocannabinoid catabolic enzyme inhibitors, both which increase the antinociceptive potency of opioids in mouse models of acute and chronic pain, and ameliorate symptoms of opioid withdrawal; combining opioid receptor agonists and cannabinoid receptor agonists to achieve antinociceptive effects at doses that are much smaller than the effective doses of each administered alone in non-human primates; human laboratory data showing that smoked cannabis enhances the analgesic effects of sub-therapeutic effects of opioids; evaluating the efficacy of dronabinol (synthetic THC), to suppress opioid withdrawal signs in adults with physical dependence on opioids; and the effects of an opioid receptor antagonist on the reinforcing effects of smoked cannabis. Overall, this translational symposium is expected to be of significant interest to both the CPDD and ICRS memberships and to generate an engaged scientific discussion.

SYMPOSIA

Thursday, June 22

XIII. Is Two Better Than One? Endocannabinoid Involvement in Stress, Reward and Motivation: Implications for Understanding and Treating Substance Use Disorder

Chairs: John Mantsch and Cecilia Hillard

Endocannabinoids are endogenous lipid signaling molecules that are functionally related to delta-9-tetrahydrocannabinol (the primary active constituent in cannabis) and exert their effects via G-protein coupled CB1 and CB2 receptors. Brain endocannabinoid signaling modulates synaptic activity in regions implicated in reward, affect and motivation and is stress-responsive. The anatomy, regulation and functional consequences of endocannabinoid signaling suggest that it contributes to illicit drug use and addiction. Accordingly, preclinical animal studies have implicated endocannabinoids and their actions at both CB1 and CB2 receptors in drug-taking and drug-seeking behavior, as well as other addiction-related phenotypes, while genetic polymorphisms in the endocannabinoid system have been associated with substance use disorder in clinical populations. This symposium will first describe findings supporting critical roles for endocannabinoid signaling in stress-related responses and in the regulation of positive and negative reinforcement through modulation of the dopamine system. Evidence implicating endocannabinoid signaling via both CB1 and CB2 receptors in the regulation of drug-seeking and drug-taking behavior in experimental animal models will be presented. Discussion topics will include opportunities and challenges for developing medications targeting the endocannabinoid signaling, potential implications for cannabis users, and gaps in our understanding of the endocannabinoid system as it relates to findings presented in the symposium.

XIV. Evaluating the Therapeutic Potential of Medical Cannabis and Phytocannabinoids from Preclinical Animal Models to the Pharmacoepidemiology of Medical Cannabis Use

Chairs: Ziva Cooper and Igor Grant

While half of the U.S. has enacted laws to legalize the use of medical cannabis, controlled studies investigating its potential therapeutic effects remain sparse. The overarching aim of this symposium is to present findings from preclinical laboratory animal studies to large population-based studies that speak directly to the potential therapeutic effects of specific phytocannabinoids and cannabis, while also addressing adverse effects including abuse liability and cognitive performance. The panel will include 1) preclinical studies investigating the effects of phytocannabinoids hypothesized to have therapeutic effects including cannabidiol alone and in combination with delta-9-tetrahydrocannabinol in animal models of neuropathic pain, learning and memory, and physical dependence, 2) controlled human laboratory studies investigating variables that contribute to the analgesic effects of cannabis and cannabinoids including route of administration and sex-dependent effects, 3) data from the MIND (Marijuana Investigations for Neuroscientific Discovery) Program that assesses clinical endpoints, cognitive performance, as well as multimodal neuroimaging findings in patients using medical cannabis and 4) the pharmacoepidemiology of medical cannabis use, including data from a Canadian-based national multicenter study looking at the safety of medical cannabis use among patients suffering from chronic pain (COMPASS) and the Quebec Cannabis Registry to highlight the impact that cannabis use may have on clinical outcomes.

SYMPOSIA

Thursday, June 22

XV. Applications of Choice Procedures to Drug Abuse Research
Chairs: Steve Negus and Richard Lamb

Drugs of abuse are stimuli that can reinforce behavior. Determinants of drug reinforcement are often studied preclinically with self-administration procedures in which no other behavior is programmed for reinforcement; however, natural environments contain many non-drug stimuli that can function as reinforcers, and individuals allocate their behavior (or “choose”) between activities maintained by drug and non-drug stimuli. Moreover, addiction is defined in part by maladaptive allocation of behavior to drug choice, and treatment seeks both to reduce drug choice and to promote behavioral re-allocation to more adaptive choice of non-drug alternatives. The determinants of drug choice can be studied with laboratory choice procedures, in which drug and non-drug alternatives are available under concurrent schedules of reinforcement, and principal dependent variables include measures of both response allocation and response rate. This symposium will feature talks that illustrate use of drug choice procedures to investigate behavioral, environmental, biological and pharmacological determinants of drug choice in rats, monkeys, and humans. Talks will describe an ethanol-vs.-food choice procedure in rats to model recovery from, and relapse to, ethanol self-administration; social rank as an environmental determinant of cocaine-vs.-food choice in group-housed cynomolgus monkeys; the role of sex as a biological determinant of cocaine-vs.-food choice in rats; and development of parallel cocaine choice procedures in rhesus monkeys and humans for translational research on mechanisms of cocaine reinforcement. The discussant will highlight shared themes and future research opportunities.

XVI. Synthetic Cannabinoids: Thinking Outside of the Pot
Chairs: Jenny Wiley and Brian Thomas

Originally developed as research tools, synthetic cannabinoids contributed to significant scientific advances in the cannabinoid field before they were diverted for recreational use beginning in the early 2000s. Since then, the number of compounds with diverse chemical structures that have appeared on the streets has proliferated and the consequences in damaged and lost lives have multiplied. This symposium will focus on recent research on synthetic cannabinoids. The symposium will be introduced with a presentation of the latest epidemiological findings on synthetic cannabinoid use, including an overview of demographics of use and specific compounds being used. These compounds do not reach or travel through the body unchanged; rather, they undergo potential degradative and thermolytic processes prior to entry and metabolic processes after smoking. These processes may change the actual chemicals to which individuals are exposed and may alter their subsequent effects on behavior. Findings on the thermolytic and metabolic fate of synthetic cannabinoids will be followed by a presentation on the in vivo pharmacological consequences of synthetic cannabinoids and their metabolites. In addition, novel structural templates for synthetic cannabinoids will be presented, along with data on their diverse functional activities, ranging from super agonists to antagonists. The discussant will provide a street-level view of how use of these compounds is affecting individual lives and communities. Findings presented in the symposium and their translational implications are expected to serve as the basis for a lively audience discussion with the speaker panel.

WORKSHOPS

Sunday, June 18

I. Big data: Ethical considerations in human subjects research

Chairs: Jonathan Stoltman and H. Westley Clark

This workshop is aimed at benefiting both junior and senior investigators in the audience through exposure to and discussion of potential ethical challenges when operating in this burgeoning area of research. The talks will be bookended by an introduction and robust discussion period moderated by an expert senior discussant. To appeal to a wide array of audience members, the panel includes human researchers ranging from junior to senior status with diverse interests within the substance abuse field. The workshop design includes brief description of Big Data in an addiction research context (e.g. CTNs and hospitals), the opportunities mining these repositories (i.e. electronic medical records, discussion boards, and mobile data) can offer, and the ethical considerations when using these sources. The workshop is designed to cover ethical considerations when using Big Data in a comprehensive manner, covering historical context, current controversies, the Common Rule, and human subject's protection. Additionally, our expert discussant is prepared to comment on the legal perspective of ethics in Big Data projects as well as facilitate discussion on these important topics.

II. Using behavioral and implementation sciences to achieve an AIDS-free generation among people who use drugs

Chairs: Wendee Wechsberg and Don Des Jarlais

Since the beginning of the HIV/AIDS epidemic, people who use psychoactive drugs have been at increased risk for HIV infection and transmission from risky injection drug practices and risky sexual behaviors. As the epidemic has evolved, people who use opiates, stimulants, and marijuana have faced increasing disparities related to the continuum of care. Moreover, drug addiction can interfere with HIV treatment outcomes, directly through biological processes and indirectly through difficulties with HIV disease management. With the goal of an AIDS-free generation, funding priorities now emphasize biomedical approaches and implementation of evidence-based interventions. Biobehavioral research remains critical to ensure that all individuals—including the most difficult to reach—can derive the maximum benefit from new biomedical treatments to reduce HIV transmission, improve HIV-related clinical outcomes, and effectively manage HIV-associated comorbidities such as cognitive disorders and co-infections. Emphasis on implementation research pushes this evidence-based science to adoption and sustainability in real world settings. This workshop will highlight recent interdisciplinary research advances, examine the associations of prevalent use of psychoactive drugs among persons living with HIV on neurobehavioral processes and gene expression, and the implementation of biobehavioral prevention approaches for groups at high risk for HIV/AIDS in usual care. Our discussant will highlight the importance of integrating biobehavioral data and advancing science through implementation research.

WORKSHOPS

Sunday, June 18

III. Assessment of abuse potential in clinical trials in the context of the finalized FDA guidance

Chairs: Jack Henningfield and Michael Klein

Although misuse and abuse of centrally (CNS) active prescription drugs is a major public health issue, there is currently no well accepted standardized way to measure, characterize, and quantify misuse, abuse, and diversion related events for drugs in Phase II or Phase III clinical trials (CTs). Laboratory assessments of abuse liability typically involve drug-experienced subjects, and may not be generalizable to patients receiving CNS-active drugs during Phase II-III CTs or as part of routine clinical care. Sponsors may collect adverse events (AEs) of interest during CTs to identify abuse-related events, however no systematic method has previously been validated and accepted for characterizing and reporting such events. Opioid analgesics receive great scrutiny in regard to the potential for abuse, misuse, and diversion; however, other psychoactive drugs, such as stimulants and sedatives would also benefit from a standardized classification system to assess abuse potential during clinical development. The lack of suitable methods led the FDA-ACTION public-private partnership to develop consensus terms and definitions for abuse-related events, and to review and provide guidance on standards for evaluation of abuse-related events in clinical trials. This workshop will address the need for reliable, validated tools to identify abuse-related events in clinical trials and classify them using standardized terminology, allowing the quantification of these events for regulatory submissions, providing participants information on recently developed approaches. The regulatory implications, including impacts on approval, labeling, and scheduling recommendations, of prospectively assessing abuse-related events in efficacy and safety CTs will also be addressed.

IV. Annual CPDD design and analysis workshop

Chairs: Sterling McPherson and Susan Mikulich-Gilbertson

In this third Annual CPDD Design and Analysis Workshop, the primary goal is to expose attendees to a variety of design and analysis issues and state-of-the art methods relevant to substance use research. Our specific aims are to present overviews with real-world examples on the following topics: 1) how to use count models to evaluate the impact of population level events (e.g., marijuana legalization, prescription opioid reformulation) in quasi-natural experiments 2) a primer on health utilities and quality-adjusted life years (QALYs) as relates to substance use research; 3) an overview of pharmacokinetics and pharmacodynamics and how to estimate drug exposure and understand drug and metabolite values; 4) how to use existing data to estimate population level pharmacokinetics and pharmacodynamics; followed by a discussion of 5) how to use these novel methodologies to ask and answer questions in substance use research. Each of these topics is timely and important for multiple domains of substance use research. Each will be presented in a non-technical, accessible fashion in an effort to generate discussion among presenters and audience members around how such considerations are applicable to various situations. Our intent is to empower other researchers by disseminating state-of-the-art methods as applied to real-world examples. The overall goal is to raise awareness and the level of quality in the methods that prevail throughout substance use research.

WORKSHOPS

Monday, June 19

V. Navigating key stages of a career in addiction science

Chairs: Denise Vidot and Qiana Brown

If you are a budding addictions investigator with new ideas and eager to find your niche in the world of research, but could use some guidance, then this workshop is for you. The workshop will focus on navigating three key early career stages: 1) Pre-Doctoral, 2) Post-Doctoral, and 3) Early Career/Faculty. Three of your colleagues, who have ‘been there and done that’ want to share their experiences with you. Each presentation will outline steps that can be taken to maximize your career stage-specific experience and make you a competitive job applicant for the next stage of your career. Examples of topics that will be covered include how to choose your mentors; striking a balance between executing your mentor’s vision and growing as an independent scientist; how to narrow down an innovative and significant research question; publishing amidst other responsibilities; obtaining grant-writing experience; establishing your niche and conveying its importance to potential employers; collaborating and networking; deciding whether to teach; life-work balance; finding the NIH funding mechanisms that are most appropriate for you and how to begin writing your grant; and crucial to it all – time management strategies. Each talk will have a centered theme of the value of your mentoring team as you travel the path to independent investigator.

VI. Development of adaptive treatment strategies in the management of drug dependence: Lessons learned from clinical trials currently in the field

Chairs: Joy Schmitz and Charles Green

A core principle of drug addiction treatment states that no single treatment is appropriate for everyone; rather, treatments need to be adjusted based on patient characteristics and response in order to be maximally effective. Ideally, clinicians would identify a sequence of interventions that works best across different stages of treatment, from abstinence initiation to relapse prevention. Development of effective adaptive interventions calls for a shift in how we conduct randomized clinical trials (RCTs). The goal of this workshop is to highlight several real-world sequential, multiple assignment, randomized trials (SMART) currently in the field. Following brief introductory remarks on the role of adaptive experimental designs in addiction research, each speaker will describe how their trial is designed to answer questions of how and when to alter the course of treatment to improve patient outcome. By sharing insights and lessons learned from four diverse trials, the audience will gain practical knowledge in using SMARTs to address a broad range of problems related to substance use. Our discussant will review disadvantages and advantages of SMARTs relative to traditional fixed-intervention trial designs and describe future directions for adaptive intervention research.

WORKSHOPS

Monday, June 19

VII. Prescription monitoring programs – Issues and impact

Chairs: Beth Sproule and Suzanne Nielsen

Prescription monitoring programs (PMP) are designed to enhance patient care and assist in the safe use of controlled prescription drugs, to help reduce the harms resulting from the use of controlled prescription drugs, and to assist in reducing the diversion of controlled prescription drugs. However, interest in PMP research has increased only in recent years. The aims of this workshop are to describe the challenges in the development and implementation of PMPs, to delineate the practice implications for health care practitioners, to demonstrate how PMP data can be used to evaluate the impact of prescribing guidelines, and to review the evidence to date of the effectiveness of PMPs. The context for PMPs as an intervention strategy to address the problem of prescription drug abuse will be discussed. Future research needs will be identified.

VIII. 23rd Annual Contingency Management Working Group

Chairs: Diann Gaalema and August Holtyn

The Contingency Management (CM) Working Group, held annually during the CPDD convention, is an opportunity for the discussion and dissemination of current research regarding the use of CM interventions to promote behavior change and reduce drug use. CM is a behavioral treatment strategy that has demonstrated consistent success in promoting abstinence from a wide-range of drugs and across many different treatment populations. It is also being used to promote change in behaviors impacting the course of other chronic diseases (e.g., obesity, diabetes). At the 22nd annual meeting of the CM Working Group, junior and senior researchers will present preliminary data from ongoing studies involving CM. The goal for this working group is to provide an informal outlet for discussion of ongoing CM research, with an emphasis on developing or improving research strategies by seeking audience input, and providing opportunities for junior and senior researchers to interact.

Tuesday, June 20

IX. Writing workshop for emerging investigators: Profiting from peer review

Chairs: James Sorenson and Eric Strain

The addiction research field needs increasingly productive investigators who create high-quality scientific reports. Peer review (feedback from colleagues) is a traditional means of improving the quality of science. The peer review process, however, can be demoralizing. Building on a previous CPDD workshop, our aim is to help emerging investigators to profit from the comments and suggestions of peers, mentors, and formal reviews of research manuscripts. Presenters include both emerging and established investigators, as well as a current editor of an addiction research journal and an editorial liaison. All presenters suggest both conceptual and practical guidelines, and they provide several useful resources. While the workshop is aimed at young investigators, both junior and senior colleagues can benefit and provide their perspective.

WORKSHOPS

Tuesday, June 20

X. *Epidemiology and public health research methods*

Chairs: Jim Anthony and Howard Chilcoat

This workshop series on epidemiology and public health research methods aims to provide participants with an introduction to three topics: (1) an epidemiological 'mutoscope' developed at Michigan State University, with comparison to a 'constrained regression' approach to age-period-cohort research; (2) an adaptation to four-parameter Hill functional analysis for epidemiological estimates, as an alternative to logistic regression for complex sample data, developed at University of Kentucky; and (3) the multiphase optimization strategy (MOST) developed at Pennsylvania State University to guide the evaluation of research evidence, to develop optimized behavioral interventions, and to enhance Type I and Type II translation of research. The workshop will enable participants to apply these research approaches in their own studies. At minimum, they will have a better understanding of published evidence based on these approaches.

XI. *Advances in substance use disorder treatments for racial/ethnic minorities:*

Where do we go from here?

Chairs: Kathy Burlew and LaTrice Montgomery

A growing but compelling body of evidence suggests that interventions such as Motivational Interviewing (Montgomery et al., 2011), Cognitive Behavioral Therapy (Windsor et al., 2015) and Contingency Management (Montgomery et al., 2015) are inadequate for improving substance use disorder (SUD) outcomes for racial/ethnic minorities. One objective of the Minority Interest Group of NIDA's Drug Abuse Treatment Clinical Trials Network (CTN) is to identify effective SUD treatments for racial/ethnic minorities. Recent CTN research has identified promising directions for future treatments, such as the cultural adaptation of evidence-based treatments and the use of technology. The aim of this session is to provide recommendations from CTN research for improving SUD treatment outcomes across four racial/ethnic minority groups. Speakers will discuss the effectiveness of an exercise intervention for Hispanics; racial and ethnic differences in histories of sexual and physical abuse and implications for SUD treatment; a promising internet-based intervention for African American and Hispanic adults; adapting web-based interventions for American Indians/Alaska Natives; and a smart phone-based smoking intervention and the barriers for treatment among Asian Americans and Pacific Islanders. All speakers will address how their recent CTN research informs future directions for SUD treatment for racial/ethnic minorities.

WORKSHOPS

Tuesday, June 20

XII. NIDA medications development workshop: Addressing bad behavior in clinical trials

Chairs: David McCann and Tanya Ramey

This workshop will provide three brief presentations on topics related to research subject dishonesty/deception, including the description of important new procedures that can be implemented in clinical trials to address the problem. Specific aims are to familiarize attendees with 1) the results of survey research conducted on repeat clinical trial participants, many of whom have admitted to deceiving research investigators by withholding information (e.g., related to exclusionary medications or ongoing participation in another study), by exaggerating symptoms, or by pretending to have health problems that they do not have; 2) the availability of HIPPA-compliant clinical trial registries that can prevent the simultaneous enrollment of a subject in multiple clinical trials, or at multiple sites within a clinical trial; and 3) new medication adherence monitoring technologies, including smartphone-based remote observation with facial recognition software. Ample time will be provided for open discussion.

XIII. New NIH guidelines for reproducibility, rigor and transparency: Ethical and practical conundrums

Chairs: Michael Kuhar and Susan Weiss

A shocking finding has been that some scientific groups, including from Industry (Pharma) have been unable to replicate findings from key papers in their respective fields. This has led to a loss of public confidence in the scientific endeavor, and a major effort by the NIH and others to establish new guidelines to improve reproducibility. The guidelines for grant applications emphasize critical assessment of the scientific premise of a proposed project, and identifying strategies to improve the rigor and transparency of the work. These new guidelines are incorporated in the review of NIH grants and have also been endorsed by many journal editors; thus, they are receiving significant and well-deserved attention. The carrying out of rigorous, reproducible work with public funds is also an ethical issue. This workshop will address these topics by briefly describing the guidelines, presenting a realistic, but fictitious case, and then engaging the audience in discussion of how to best handle it. Topics to be covered include 1) evaluating the scientific premise -- assessing the quality of the scientific basis for a hypothesis, including in novel or developing areas of science; 2) ensuring rigorous methodology, with sufficient transparency for replication by other investigators; 3) investigator responsibilities for improving reproducibility, rigor, and transparency. The goal of this workshop is to help CPDD members understand these newer ethical requirements in concrete terms.

Acknowledgements

The following organizations and individuals have financially supported
the work of the CPDD organization during the past year

Altasciences Clinical Research

Gnatt Galloway

Apt Foundation

Grünenthal USA, Inc.

Patrick Beardsley

Margaret Haney

**Behavioral Pharmacology Research
Unit at Johns Hopkins Medical School**

Sarah H. Heil

Leonard Howell

Jack Bergman

Marc J. Kaufman

George Bigelow

Gundy Knos

Alan J. Budney

Dr. & Mrs. Donald Mees, Jr.

Kathleen M. Carroll

John Neeld

**Center for Substance Abuse Research,
Lewis Katz School of Medicine at
Temple University**

Charles O' Keeffe

Wallace Pickworth

Howard D. Chilcoat

William Stoops

**Theodore J. Cicero, Washington
University in St. Louis**

Jennifer Tidey

Timothy Condon

David Tompkins

Toby K. Eisenstein

Wendee Wechsberg

Loretta P. Finnegan

Mark Wentland

Funding for this conference was made possible (in part) by 5 R13 DA 013192 - 13 from the
National Institute on Drug Abuse

The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government

NOTES

NOTES

